{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "Fasttext_NLP.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "authorship_tag": "ABX9TyP5J3ON5HGJfrAmnknij8Jp",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/DataDoggo215/NLP_FastText/blob/main/Fasttext_NLP.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Purpose of this notebook is to experiment with FastText library with an application of Tika. I read an interesting article from [Usman Malik](https://stackabuse.com/python-for-nlp-working-with-facebook-fasttext-library/) and wanted to replicate this library applying it to a life science application. \n",
        "\n",
        "We will be using the Doctors without Borders 2016 Medical Guidelines and applying Facebook FastText Library to it. The PDF can be found here:\n",
        "https://samumsf.org/sites/default/files/2018-10/MSF%20Clinical%20Guideline%202016.pdf\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "lLsunrBcWN0D"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!wget \"https://samumsf.org/sites/default/files/2018-10/MSF%20Clinical%20Guideline%202016.pdf\""
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NANG2yyKbagn",
        "outputId": "cda87ec6-931c-4f34-f002-47343fa3fefd"
      },
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "--2022-08-16 04:31:07--  https://samumsf.org/sites/default/files/2018-10/MSF%20Clinical%20Guideline%202016.pdf\n",
            "Resolving samumsf.org (samumsf.org)... 64.225.102.238\n",
            "Connecting to samumsf.org (samumsf.org)|64.225.102.238|:443... connected.\n",
            "HTTP request sent, awaiting response... 200 OK\n",
            "Length: 4651560 (4.4M) [application/pdf]\n",
            "Saving to: ‘MSF Clinical Guideline 2016.pdf’\n",
            "\n",
            "MSF Clinical Guidel 100%[===================>]   4.44M  1.89MB/s    in 2.3s    \n",
            "\n",
            "2022-08-16 04:31:11 (1.89 MB/s) - ‘MSF Clinical Guideline 2016.pdf’ saved [4651560/4651560]\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "%%capture\n",
        "!pip install tika        #Tika is a Python Library to extract Text from Pdf\n",
        "!pip install fasttext"
      ],
      "metadata": {
        "id": "g3HYFmPySIbv"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%capture\n",
        "import nltk\n",
        "from pprint import pprint\n",
        "from gensim.models import FastText\n",
        "import fasttext\n",
        "nltk.download('punkt')\n",
        "from nltk import word_tokenize\n",
        "from pprint import pprint\n",
        "from tika import parser\n",
        "import string\n",
        "from sklearn.decomposition import PCA\n",
        "import matplotlib.pyplot as plt"
      ],
      "metadata": {
        "id": "Gj-9uCwKSq1a"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "rawText = parser.from_file(\"MSF Clinical Guideline 2016.pdf\")"
      ],
      "metadata": {
        "id": "V0RGo2KcbiZr",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "bb722c62-84d8-4cde-8fd9-6de3a3adac6c"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "INFO:tika.tika:Retrieving http://search.maven.org/remotecontent?filepath=org/apache/tika/tika-server/1.24/tika-server-1.24.jar to /tmp/tika-server.jar.\n",
            "INFO:tika.tika:Retrieving http://search.maven.org/remotecontent?filepath=org/apache/tika/tika-server/1.24/tika-server-1.24.jar.md5 to /tmp/tika-server.jar.md5.\n",
            "WARNING:tika.tika:Failed to see startup log message; retrying...\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(type(rawText))    #Tika parser returns a dictionary"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gvQ28moZSvbe",
        "outputId": "ee1b5384-757e-4066-b021-fb48943582fc"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<class 'dict'>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "rawList = rawText['content'].splitlines()                        \n",
        "rawList = [item.lower() for item in rawList if item.strip()]    \n",
        "print(len(rawList))   #About 15569 sentences in total\n",
        "print(rawList)   #sample sentence"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AmMGaUVKS2KQ",
        "outputId": "bfbf10b9-16f7-4bc9-a917-5ce567223e27"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "15569\n",
            "['clinical guidelines - 2016 (updated: 21 september 2017)', 'clinical guidelines', 'diagnosis and treatment manual', 'for curative programmes in hospitals and dispensaries', 'guidance for prescribing', '2016 edition', 'editorial committee', 'véronique grouzard, jean rigal, marianne sutton', 'with the participation of', 'p. albajar, s. balkan, p. barel, e. baron, t. baubet, m. biot, f. boillot, l. bonte, m.c. bottineau,', 'm.e. burny, v. captier, m. cereceda, f. charles, m.j de chazelles, d. chédorge, a.s. coutin,', 'c. danet, b. dehaye, k. dilworth, f. drogoul, f. fermon, b. graz, m. gueguen, b. guyard-boileau,', 'g. hanquet, g. harczi, m. van herp, l. hiffler, c. hook, v. ioos, k. de jong, r. kanapathipillai,', 's. lagrange, e. lasry, x. lassalle, b. laumont, d. laureillard, p. lechevalier, m. lekkerkerker,', 'd. martinez, j. menschik, d. mesia, a. minetti, r. murphy, r. petrucci, n. peyraud, s. pilon,', 'k. ritmeijer, l. shanks, m. de smet, s. seyfert, j. stassijns, j. thompson, f. varaine, b. vasset,', 'i. zuniga', 'we thank for their contributions to this guide s.c borkan, e. bottieau, o. bouchaud, m. boussinesq,', 'a. briend, e.c. briere, f. chappuis, j.p. chippaux, j. dupouy camet, f. delange, o. fontaine,', 'p.y. fournier, f. van gompel, m. goyffon, s. halperin, j. janin, b. lagardère, j.d. law-koune,', 'p. niaudet, f. nosten, g. potel, j.l. rey, m. rosenheim, j. ross, c.e. rupprecht, j. saló raïch,', 'p. pérez simarro, m. soriano, k. stille, g. tchernia, t. vallot, p. vigeral, m. warrell, a. weissman', 'and n. white.', 'translation', 'véronique grouzard and marianne sutton', 'design and layout', 'evelyne laissu', 'illustrations', 'germain péronne', 'published by', 'médecins sans frontières', '© médecins sans frontières, 2016', 'all rights reserved for all countries. no reproduction, translation and adaptation may be done', 'without the prior permission of the copyright owner.', 'médecins sans frontières. clinical guidelines - diagnosis and treatment manual. 2016 edition.', 'isbn 978-2-37585-001-5', 'foreword', 'this diagnostic and treatment manual is designed for use by medical professionals involved in', 'curative care at the dispensary and hospital levels.', 'we have tried to respond in the simplest and most practical way possible to the questions and', 'problems faced by field medical staff, using the accumulated field experience of médecins sans', 'frontières, the recommendations of reference organizations such as the world health', 'organization (who) and specialized works in each field.', 'this edition touches on the curative and, to a lesser extent, the preventive aspects of the main', 'diseases encountered in the field. the list is incomplete, but covers the essential needs.', 'this manual is used not only in programmes supported by médecins sans frontières, but also', 'in other programmes and in other contexts. it is notably an integral part of the who', 'emergency health kit.', 'médecins sans frontières has also issued french and spanish editions. editions in other', 'languages have also been produced in the field.', 'this manual is a collaborative effort of medical professionals from many disciplines, all with', 'field experience.', 'despite all efforts, it is possible that certain errors may have been overlooked in this manual.', 'please inform the authors of any errors detected. it is important to remember, that if in doubt,', 'it is the responsibility of the prescribing medical professional to ensure that the doses indicated', 'in this manual conform to the manufacturer ’s specifications.', 'the authors would be grateful for any comments or criticisms to ensure that this manual', 'continues to evolve and remains adapted to the reality of the field.', 'comments should be addressed to:', 'médecins sans frontières - guidelines', '8, rue st-sabin - 75011 paris', 'tel.: +33.(0)1.40.21.29.29', 'fax: +33.(0)1.48.06.68.68 ', 'e.mail: guide.clinical@msf.org', 'this manual is also available on the internet at www.refbooks.msf.org. as treatment protocols', 'for certain diseases are constantly changing, medical staff are encouraged to check this website', 'for updates of this edition.', '3', 'www.refbooks.msf.org', 'how to use this manual', 'organization', 'there are two easy ways to find information in this manual:', '– the table of contents at the beginning of the manual with the number and title of each', 'chapter, their subsections and page numbers;', '– an alphabetical index at the end of the manual with the names of the diseases and', 'symptoms.', 'names of drugs', 'the international non-proprietary name (inn) of drugs is used in this manual. a list of current', 'proprietary names can be found at the end of the manual.', 'abbreviations used', 'units administration route', 'kg = kilogram po = per os – oral', 'g = gram im = intramuscular', 'mg = milligram io = intraosseous', 'µg = microgram iv = intravenous', 'ui = international unit sc = subcutaneous', 'm = million', 'mmol = millimole', 'ml = millilitre', 'dl = decilitre', 'for certain drugs', 'nsaid =  nonsteroidal anti-inflammatory drug', 'smx + tmp =  sulfamethoxazole + trimethoprim = cotrimoxazole', 'expression of doses', '– doses of the combination sulfamethoxazole + trimethoprim (cotrimoxazole) are expressed as', 'smx + tmp, for example:', 'children: 30 mg smx + 6 mg tmp/kg/day', 'adults: 1600 mg smx + 320 mg tmp/day', '– doses of the combination amoxicillin + clavulanic acid (co-amoxiclav) are expressed in', 'amoxicillin.', '– doses of certain antimalarial drugs are expressed in base (and not in salts).', '– doses of iron are expressed in elemental iron (and not in ferrous salts).', '4', 'table of contents', 'introduction..................................................................................................................................9', 'chapter 1: a few symptoms and syndromes', 'shock...........................................................................................................................................15', 'seizures .......................................................................................................................................21', 'hypoglycaemia............................................................................................................................25', 'fever ...........................................................................................................................................27', 'pain .............................................................................................................................................30', 'anaemia ......................................................................................................................................38', 'severe acute malnutrition ..........................................................................................................41', 'chapter 2: respiratory diseases', 'acute upper airway obstruction .................................................................................................47', 'rhinitis and rhinopharyngitis (common cold).............................................................................49', 'acute sinusitis .............................................................................................................................50', 'acute pharyngitis ........................................................................................................................52', 'diphtheria ...................................................................................................................................55', 'other upper respiratory tract infections ....................................................................................58', 'laryngotracheitis and laryngotracheobronchitis (croup) .......................................................58', 'epiglottitis ..............................................................................................................................59', 'bacterial tracheitis .................................................................................................................60', 'otitis............................................................................................................................................62', 'acute otitis externa ................................................................................................................62', 'acute otitis media (aom) .......................................................................................................62', 'chronic suppurative otitis media (csom)...............................................................................64', 'whooping cough (pertussis) .......................................................................................................65', 'bronchitis ....................................................................................................................................67', 'acute bronchitis......................................................................................................................67', 'chronic bronchitis...................................................................................................................67', 'bronchiolitis ................................................................................................................................69', 'acute pneumonia........................................................................................................................71', 'pneumonia in children under 5 years of age ..........................................................................71', 'pneumonia in children over 5 years and adults......................................................................75', 'persistent pneumonia.............................................................................................................77', 'staphylococcal pneumonia .........................................................................................................78', 'asthma........................................................................................................................................80', 'asthma attack (acute asthma) ...............................................................................................80', 'chronic asthma ......................................................................................................................82', 'pulmonary tuberculosis ..............................................................................................................85', 'chapter 3: gastrointestinal disorders', 'acute diarrhoea ..........................................................................................................................89', 'shigellosis....................................................................................................................................92', 'amoebiasis..................................................................................................................................94', '5', 'disorders of the stomach and duodenum ..................................................................................95', 'gastro-oesophageal reflux .....................................................................................................95', 'gastric and duodenal ulcers in adults ....................................................................................95', 'dyspepsia ...............................................................................................................................97', 'stomatitis ....................................................................................................................................98', 'oral and oropharyngeal candidiasis.......................................................................................98', 'oral herpes .............................................................................................................................98', 'other infectious causes ..........................................................................................................99', 'stomatitis from scurvy (vitamin c deficiency) ......................................................................100', 'other lesions resulting from a nutritional deficiency ...........................................................100', 'chapter 4: skin diseases', 'dermatology .............................................................................................................................103', 'scabies ......................................................................................................................................104', 'lice (pediculosis) .......................................................................................................................107', 'superficial fungal infections......................................................................................................109', 'bacterial skin infections ............................................................................................................111', 'impetigo ...............................................................................................................................111', 'furuncles and carbuncles .....................................................................................................112', 'erysipelas and cellulitis.........................................................................................................113', 'cutaneous anthrax....................................................................................................................115', 'endemic treponematoses .........................................................................................................117', 'leprosy (hansen’s disease) .......................................................................................................119', 'herpes simplex and herpes zoster ............................................................................................122', 'herpes simplex .....................................................................................................................122', 'herpes zoster (shingles)........................................................................................................122', 'other skin disorders..................................................................................................................123', 'eczema (dermatitis)..............................................................................................................123', 'seborrheic dermatitis ...........................................................................................................123', 'urticaria ...............................................................................................................................124', 'pellagra ................................................................................................................................124', 'chapter 5: eye diseases', 'xerophthalmia (vitamin a deficiency).......................................................................................127', 'conjunctivitis ............................................................................................................................129', 'neonatal conjunctivitis.........................................................................................................130', 'viral epidemic keratoconjunctivitis ......................................................................................131', 'trachoma ..................................................................................................................................132', 'periorbital and orbital cellulitis.................................................................................................134', 'other pathologies .....................................................................................................................136', 'onchocerciasis......................................................................................................................136', 'loiasis ...................................................................................................................................136', 'pterygium .............................................................................................................................136', 'cataract................................................................................................................................137', 'chapter 6: parasitic diseases', 'protozoan infections', 'malaria ......................................................................................................................................141', 'human african trypanosomiasis ...............................................................................................148', 'american trypanosomiasis........................................................................................................151', '6', 'leishmaniases ...........................................................................................................................153', 'intestinal protozoan infections (parasitic diarrhoea) ...............................................................156', 'helminthic infections', 'flukes ........................................................................................................................................158', 'schistosomiases ........................................................................................................................159', 'cestodes....................................................................................................................................161', 'nematode infections ................................................................................................................163', 'filariasis ....................................................................................................................................166', 'onchocerciasis......................................................................................................................166', 'loiasis ...................................................................................................................................168', 'lymphatic filariasis (lf) ........................................................................................................170', 'chapter 7: bacterial diseases', 'bacterial meningitis ..................................................................................................................175', 'tetanus .....................................................................................................................................180', 'typhoid fever ............................................................................................................................186', 'brucellosis .................................................................................................................................188', 'plague .......................................................................................................................................190', 'leptospirosis .............................................................................................................................192', 'relapsing fever (borreliosis) .....................................................................................................194', 'louse-borne relapsing fever (lbrf) ......................................................................................194', 'tick-borne relapsing fever (tbrf).........................................................................................195', 'eruptive rickettsioses................................................................................................................197', 'chapter 8: viral diseases', 'measles .....................................................................................................................................201', 'poliomyelitis..............................................................................................................................204', 'rabies........................................................................................................................................506', 'viral hepatitis ............................................................................................................................210', 'dengue......................................................................................................................................213', 'viral haemorrhagic fevers.........................................................................................................220', 'hiv infection and aids ..............................................................................................................224', 'chapter 9: genito-urinary diseases', 'uro-nephrologic diseases', 'nephrotic syndrome in children ...............................................................................................239', 'urolithiasis ...............................................................................................................................243', 'acute cystitis .............................................................................................................................244', 'acute pyelonephritis.................................................................................................................246', 'acute prostatitis........................................................................................................................248', 'genital infections (gi) ..............................................................................................................249', 'urethral discharge ....................................................................................................................251', 'abnormal vaginal discharge......................................................................................................253', 'genital ulcers ............................................................................................................................256', 'lower abdominal pain in women .............................................................................................259', 'upper genital tract infections (ugti)........................................................................................260', 'veneral warts............................................................................................................................263', 'major genital infections (summary)..........................................................................................264', 'metrorrhagia.............................................................................................................................266', '7', 'chapter 10: medical and minor surgical procedures', 'dressings ...................................................................................................................................273', 'treatment of a simple wound...................................................................................................276', 'burns .........................................................................................................................................286', 'abscesses ..................................................................................................................................294', 'pyomyositis ...............................................................................................................................298', 'leg ulcers ..................................................................................................................................300', 'necrotising infections of the skin and soft tissues....................................................................302', 'venomous bites and stings .......................................................................................................304', 'dental infections.......................................................................................................................308', 'chapter 11: mental/psychical disorders in adults', 'anxiety ......................................................................................................................................311', 'insomnia ...................................................................................................................................312', 'agitation....................................................................................................................................313', 'mental confusion ......................................................................................................................314', 'post-traumatic stress disorder..................................................................................................315', 'depression ................................................................................................................................316', 'psychotic disorders ..................................................................................................................319', 'acute psychotic episode .......................................................................................................319', 'chronic psychoses ................................................................................................................319', 'bipolar disorder ....................................................................................................................321', 'chapter 12: other conditions', 'sickle cell disease ......................................................................................................................325', 'hypertension ............................................................................................................................331', 'heart failure in adults ...............................................................................................................335', 'endemic goitre and iodine deficiency.......................................................................................338', 'appendices', '1a. normal daily maintenance iv fluids in children > 1 month and adults ..............................343', '1b. 1.5 x daily maintenance iv fluids in children > 1 month and adults...................................344', '2. assessment and treatment of diarrhoea - the interagency emergency health kit,', 'annex 2 - who ...................................................................................................................345', '3. practical advice for writing medical certificates in the event of sexual violence....................352', 'main references .......................................................................................................................355', 'index .........................................................................................................................................356', '8', 'introduction', 'these clinical guidelines should be viewed as an aid in prescribing treatment. they do not go', 'into detail on public health measures like immunisation and nutrition programmes, or hygiene', 'and sanitation procedures, for managing the health of a population; these are covered in other', 'publications. they do, however, talk about preventive measures – such as vaccines – that', 'patients can be offered to protect them from disease.', 'objective', 'these guidelines’ primary objective is to cure an individual patient of his disease, and to', 'minimise the impact of that disease on both the patient and those around him (the risk of', 'transmission, for example).', 'but well-organised, carefully-followed treatments for high priority pathologies – such as', 'infectious diseases – also reduce mortality in the population. and if enough patients are', 'treated for endemic diseases like tuberculosis, transmission will be reduced.', 'strategy', 'curative activities should focus on priority targets, in terms of both diseases and particularly', 'vulnerable populations. all prescribers should be familiar with the epidemiological situation', 'around the medical facilities in which they practice (epidemic and endemic diseases, the', 'frequency of traumatic injuries, etc.), and with the demographics of the population they serve', '(proportion of children under five and pregnant women, as they are more vulnerable).', 'the treatment protocols and drugs that are used must be adapted to the epidemiological', 'circumstances; that is the aim of both this publication and essential drugs - practical guidelines.', 'these two sets of guidelines use a narrow list of drugs based on the world health', 'organization’s (who) model list of essential medicines. health ministries may, however, have', 'their own national list of essential drugs and treatment protocols that must be followed.', 'resources', 'the quality of prescribing relies on prescribers (health workers, physician’s assistants, nurses,', 'midwives and physicians) being properly trained. it will vary depending on the region and on', 'the level of both their training and the medical facility in which they work (health post, health', 'centre or hospital). as that level must often be evaluated to ensure that training is adequate,', 'this publication and the essential drugs factsheets can be used as a foundation.', 'introduction', '9', 'http://refbooks.msf.org/msf_docs/en/essential_drugs/ed_en.pdf', 'http://refbooks.msf.org/msf_docs/en/essential_drugs/ed_en.pdf', 'the drugs are chosen based on:', '– their efficacy and tolerance (few adverse effects); ', '– their ease of administration, duration of action, number of daily doses and ease of', 'adherence;', '– their stability at room temperature, availability, and cost.', 'the who model list of essential medicines is the basic tool for this selection, which should be', 'fine-tuned to the epidemiological profile of the region, the skills of the medical staff and the', 'possibility of referral to a higher-level medical facility.', 'the most important basic rule for a prescribing programme is standardised treatment', 'protocols. these is essential to the overall effectiveness of the treatments offered, health care', 'staff training and programme continuity during staff turnover.', 'the protocols in these guidelines were written according to the following principles:', '– all drugs are designated by their international non-proprietary name (inn).', '– selection is based on clinical and epidemiological reasoning, and on scientific evidence that', 'can be discussed and agreed upon by users.', '– selection facilitates treatment adherence: the shortest possible treatment with the fewest', 'daily doses; single dose treatments always given preference; the fewest possible drugs', 'prescribed. when efficacy is comparable, the oral route is preferred to reduce the risk of', 'contamination by injectables.', 'consultation', 'try to provide enough prescribers for the expected number of patients, so that each patient', 'gets at least 20 to 30 minutes per consultation.', 'the consultation area for diagnosis and treatment should be carefully arranged to ensure', 'privacy during the interview and patient comfort.', 'the quality and outcome of the treatment depends on more than just the protocol. treatment', 'adherence relies on the quality of the trust relationship established by the prescriber and the', 'respect he shows the patient.', 'the prescriber must know the local habits – for example, whether it is customary to have', 'gender-separate consultations, or if there is a rule that the examination must be done by a', 'prescriber of the same gender as the patient.', 'it is often necessary to use an interpreter, and interpreters should be trained in systematically', 'questioning the patient regarding his complaints and history. like the rest of the health care', 'staff, interpreters must be aware that they are also bound by the rules of confidentiality.', 'diagnosis rests primarily – and sometimes exclusively – on the clinical findings; hence the', 'importance of taking a careful history of the complaint and symptoms and doing a complete,', 'systematic exam. the data should be copied into the health record, admission note or register', 'so that the patient’s progress can be monitored.', 'introduction', '10', 'diagnostic aids', 'the equipment for ancillary testing depends on the level of the facility where the treatment', 'takes place.', 'when there is no laboratory available, either for outpatient or inpatient care, rapid diagnostic', 'tests may be made available (for malaria, hiv, hepatitis b and c, etc.).', 'a laboratory must be set up for certain diseases, such as tuberculosis, trypanosomiasis and', 'visceral leishmaniasis.', 'medical imaging (x-rays and ultrasound) may be nonexistent. in that case, patients who cannot', 'be diagnosed without imaging should be referred (trauma patients, in particular).', 'introduction', '11', 'chapter 1: ', 'a few symptoms and syndromes', 'shock', 'seizures', 'hypoglycaemia (new)', 'fever', 'pain', 'anaemia', 'severe acute malnutrition', '1', 'shock', 'acute circulatory failure leading to inadequate tissue perfusion which, if prolonged, results in', 'irreversible organ failure. mortality is high without early diagnosis and treatment.', 'aetiology and pathophysiology', 'hypovolaemic shock', 'absolute hypovolaemia due to significant intravascular fluid depletion:', '– internal or external haemorrhage: post-traumatic, peri or postoperative, obstetrical (ectopic', 'pregnancy, uterine rupture, etc.), blood loss due to an underlying condition (gastrointestinal', 'ulcer, etc.). a loss of greater than 30% of blood volume in adults will lead to haemorrhagic', 'shock.', '– dehydration: severe diarrhoea and vomiting, intestinal obstruction, diabetic ketoacidosis or', 'hyperosmolar coma, etc.', '– plasma leaks: extensive burns, crushed limbs, etc.', 'relative hypovolaemia due to vasodilation without concomitant increase in intravascular', 'volume:', '– anaphylactic reaction: allergic reaction to insect bites or stings; drugs, mainly neuromuscular', 'blockers, antibiotics, acetylsalicylic acid, colloid solutions (dextran, modified gelatin fluid);', 'equine sera; vaccines containing egg protein; food, etc.', '– acute haemolysis: severe malaria, drug poisoning (rare).', 'septic shock', 'by a complex mechanism, often including vasodilation, heart failure and absolute hypovolaemia.', 'cardiogenic shock', 'by decrease of cardiac output:', '– direct injury to the myocardium: infarction, contusion, trauma, poisoning.', '– indirect mechanism: arrhythmia, constrictive pericarditis, haemopericardium, pulmonary', 'embolism, tension pneumothorax, valvular disease, severe anaemia, beri beri, etc.', 'clinical features', 'signs common to most forms of shock', '– pallor, mottled skin, cold extremities, sweating and thirst.', '– rapid and weak pulse often only detected on major arteries (femoral or carotid).', '– low blood pressure (bp), narrow pulse pressure, bp sometimes undetectable.', '– capillary refill time (crt) > 2 seconds.', '– cyanosis, dyspnoea, tachypnoea are often present in varying degrees depending on the', 'mechanism.', '– consciousness usually maintained (more rapidly altered in children), but anxiety, confusion,', 'agitation or apathy are common.', '– oliguria or anuria.', 'a few symptoms and syndromes', '15', '1', 'signs specific to the mechanism of shock', 'hypovolaemic shock', 'the common signs of shock listed above are typical of hypovolaemic shock.', 'do not underestimate hypovolaemia. signs of shock may not become evident until a 50% loss', 'of blood volume in adults.', 'anaphylactic shock', '– significant and sudden drop in bp', '– tachycardia', '– frequent cutaneous signs: rash, urticaria, angioedema', '– respiratory signs: dyspnoea, bronchospasm', 'septic shock', '– high fever or hypothermia (< 36°c), rigors, confusion', '– bp may be initially maintained, but rapidly, same pattern as for hypovolaemic shock.', 'cardiogenic shock', '– respiratory signs of left ventricular failure (acute pulmonary oedema) are dominant:', 'tachypnoea, crepitations on auscultation.', '– signs of right ventricular failure: raised jugular venous pressure, hepatojugular reflux,', 'sometimes alone, more often associated with signs of left ventricular failure.', 'the aetiological diagnosis is oriented by:', '– the context: trauma, insect bite, ongoing medical treatment, etc.', '– the clinical examination:', '• fever', '• skin pinch consistent with dehydration', '• thoracic pain from a myocardial infarction or pulmonary embolus', '• abdominal pain or rigidity of the abdominal wall from peritonitis, abdominal distension', 'from intestinal obstruction', '• blood in stools, vomiting blood in intestinal haemorrhage', '• subcutaneous crepitations, likely anaerobic infection', 'management', 'symptomatic and aetiological treatment must take place simultaneously.', 'in all cases', '– emergency: immediate attention to the patient.', '– warm the patient, lay him flat, elevate legs (except in respiratory distress, acute pulmonary', 'oedema).', '– insert a peripheral iv line using a large calibre catheter (16g in adults). if no iv access, use', 'intraosseous route.', '– oxygen therapy, assisted ventilation in the event of respiratory distress.', '– assisted ventilation and external cardiac compression in the event of cardiac arrest.', '– intensive monitoring: consciousness, pulse, bp, crt, respiratory rate, hourly urinary output', '(insert a urinary catheter) and skin mottling.', 'management according to the cause', 'haemorrhage ', '– control bleeding (compression, tourniquet, surgical haemostasis).', '– determine blood group.', 'chapter 1', '16', '– priority: restore vascular volume as quickly as possible:', 'insert 2 peripheral iv lines (catheters 16g in adults).', 'ringer lactate or 0.9% sodium chloride: replace 3 times the estimated losses', 'and/or plasma substitute: replace 1.5 times the estimated losses', '– transfuse: classically once estimated blood loss represents approximately 30 to 40% of blood', 'volume (25% in children). the blood must be tested (hiv, hepatitis b and c, syphilis, etc.)', 'refer to the msf handbook, blood transfusion.', 'severe acute dehydration due to bacterial/viral gastroenteritis', '– urgently restore circulating volume using iv bolus therapy:', 'ringer lactate or 0.9% sodium chloride:', 'children < 2 months: 10 ml/kg over 15 minutes. repeat (up to 3 times) if signs of shock', 'persist.', 'children 2-59 months: 20 ml/kg over 15 minutes. repeat (up to 3 times) if signs of shock', 'persist.', 'children ≥ 5 years and adults: 30 mg/kg over 30 minutes. repeat once if signs of shock', 'persist.', '– then, replace the remaining volume deficit using continuous infusion until signs of', 'dehydration resolve (typically 70 ml/kg over 3 hours).', '– closely monitor the patient; be careful to avoid fluid overload in young children and elderly', 'patients).', 'note: in severely malnourished children the iv rate is different than those for healthy children', '(see severe acute malnutrition).', 'severe anaphylactic reaction', '– determine the causal agent and remove it, e.g. stop ongoing injections or infusions, but if in', 'place, maintain the iv line.', '– administer epinephrine (adrenaline) im, into the antero-lateral tight, in the event of', 'hypotension, pharyngolaryngeal oedema, or breathing difficulties:', 'use undiluted solution (1:1000 = 1 mg/ml) and a 1 ml syringe graduated in 0.01 ml: ', 'children under 6 years: 0.15 ml', 'children from 6 to 12 years: 0.3 ml', 'children over 12 years and adults: 0.5 ml', 'in children, if 1 ml syringe is not available, use a diluted solution, i.e. add 1 mg epinephrine to 9', 'ml of 0.9% sodium chloride to obtain a 0.1 mg/ml solution (1:10 000):', 'children under 6 years: 1.5 ml', 'children from 6 to 12 years: 3 ml', 'at the same time, administer rapidly ringer lactate or 0.9% sodium chloride: 1 litre in adults', '(maximum rate); 20 ml/kg in children, to be repeated if necessary.', 'if there is no clinical improvement, repeat im epinephrine every 5 to 15 minutes.', 'in shock persists after 3 im injections, administration of iv epinephrine at a constant rate by', 'a syringe pump is necessary:', 'use a diluted solution, i.e. add 1 mg epinephrine (1:1000) to 9 ml of 0.9% sodium chloride to', 'obtain a 0.1 mg/ml solution (1:10 000):', 'children: 0.1 to 1 microgram/kg/minute', 'adults: 0.05 to 0.5 microgram/kg/minute', 'if syringe pump is not available, see box page 20.', 'a few symptoms and syndromes', '17', '1', '– corticosteroids have no effect in the acute phase. however, they must be given once the', 'patient is stabilized to prevent recurrence in the short term:', 'hydrocortisone hemisuccinate iv or im', 'children: 1 to 5 mg/kg/24 hours in 2 or 3 injections', 'adults: 200 mg every 4 hours', '– in patients with bronchospasm, epinephrine is usually effective. if the spasm persists give', '10 puffs of inhaled salbutamol.', 'septic shock', '– vascular fluid replacement with ringer lactate or 0.9% sodium chloride or plasma substitute.', '– use of vasoconstrictors:', 'dopamine iv at a constant rate by syringe pump (see box page 20):', '10 to 20 micrograms/kg/minute', 'or, if not available', 'epinephrine iv at a constant rate by syringe pump:', 'use a diluted solution, i.e. add 1 mg epinephrine (1:1000) to 9 ml of 0.9% sodium chloride to', 'obtain a 0.1 mg/ml solution (1:10 000). start with 0.1 microgram/kg/minute. increase the', 'dose progressively until a clinical improvement is seen.', 'if syringe pump is not available, see box page 20.', '– look for the origin of the infection (abscess; ent, pulmonary, digestive, gynaecological or', 'urological infection etc.). antibiotic therapy according to the origin of infection:', 'ampicillin iv', 'children and adults: 150 to 200 mg/kg/day in 3 injections (every 8 hours)', 'cloxacillin iv infusion (60 minutes)', 'children over 1 month: 200 mg/kg/day in 4 divided doses (every 6 hours); max. 8 g/day', 'adults: 12 g/day in 4 divided doses (every 6 hours)', 'amoxicillin/clavulanic acid (co-amoxiclav) slow iv injection (3 minutes) or iv infusion (30 minutes)', 'children less than 3 months: 100 mg/kg/day in 2 divided doses (every 12 hours)', 'children ≥ 3 months and < 40 kg: 150 mg/kg/day in 3 divided doses (every 8 hours); max.', '6 g/day', 'children 40 kg and adults: 6 g/day in 3 divided doses (every 8 hours)', 'origin antibiotic therapy alternative', 'cutaneous', 'staphylococci, streptococci cloxacillin + gentamicin', 'pulmonary', 'pneumococci, haemophilus', 'influenzae', 'ampicillin or ceftriaxone', '+/- gentamicin', 'co-amoxiclav or ceftriaxone', '+ ciprofloxacin', 'intestinal or biliary', 'enterobacteria, anaerobic', 'bacteria, enterococci', 'co-amoxiclav + gentamicin ceftriaxone + gentamicin', '+ metronidazole', 'gynaecological', 'streptococci, gonococci,', 'anaerobic bacteria, e. coli', 'co-amoxiclav + gentamicin ceftriaxone + gentamicin', '+ metronidazole', 'urinary', 'enterobacteria, enterococci ampicillin + gentamicin ceftriaxone + ciprofloxacin', 'other or undetermined ampicillin + gentamicin ceftriaxone + ciprofloxacin', 'chapter 1', '18', 'ceftriaxone slow iva', 'children: 100 mg/kg as a single injection', 'adults: 2 g once daily', 'ciprofloxacin po (by nasogastric tube)', 'children: 15 to 30 mg/kg/day in 2 divided doses', 'adults: 1.5 g/day in 2 divided doses', 'gentamicin im or slow iv (3 minutes) or infusion (30 minutes)', 'children ≥ 1 month and adults: 6 mg/kg once daily', 'metronidazole iv infusion (30 minutes) ', 'children over 1 month: 30 mg/kg/day in 3 divided doses (every 8 hours); max. 1.5 g/day', 'adults: 1.5 g/day in 3 divided doses (every 8 hours)', '– corticosteroids: not recommended, the adverse effects outweigh the benefits.', 'cardiogenic shock', 'the objective is to restore efficient cardiac output. the treatment of cardiogenic shock', 'depends on its mechanism.', '– acute left heart failure with pulmonary oedema', 'acute pulmonary oedema (for treatment, see heart failure in adults, chapter 12).', 'in the event of worsening signs with vascular collapse, use a strong inotrope:', 'dopamine iv at a constant rate by syringe pump (see box page 20):', '3 to 10 micrograms/kg/minute', 'once the haemodynamic situation allows (normal bp, reduction in the signs of peripheral', 'circulatory failure), nitrates or morphine may be cautiously introduced.', 'digoxin should no longer be used for cardiogenic shock, except in the rare cases when a', 'supraventricular tachycardia has been diagnosed by ecg. correct hypoxia before using', 'digoxin.', 'digoxin slow iv', 'children: one injection of 0.010 mg/kg (10 micrograms/kg), to be repeated up to 4 times/', '24 hours if necessary', 'adults: one injection of 0.25 to 0.5 mg, then 0.25 mg 3 or 4 times/24 hours if necessary', '– cardiac tamponade: restricted cardiac filling as a result of haemopericardium or pericarditis.', 'requires immediate pericardial tap after restoration of circulating volume.', '– tension pneumothorax: drainage of the pneumothorax.', '– symptomatic pulmonary embolism: treat with an anticoagulant in a hospital setting.', 'a the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'a few symptoms and syndromes', '19', '1', 'administration of dopamine or epinephrine at a constant rate requires the following conditions:', '– close medical supervision in a hospital setting;', '– use of a dedicated vein (no other infusion/injection in this vein), avoid the antecubital', 'fossa if possible;', '– use of an electric syringe pump (or infusion pump);', '– progressive increase and adaptation of doses according to clinical response;', '– intensive monitoring of drug administration, particularly during syringe changes.', 'example:', 'dopamine: 10 micrograms/kg/minute in a patient weighing 60 kg', 'hourly dose: 10 (micrograms) x 60 (kg) x 60 (min) = 36 000 micrograms/hour = 36 mg/hour', 'in a 50 ml syringe, dilute one 200 mg-ampoule of dopamine with 0.9% sodium chloride to', 'obtain 50 ml of solution containing 4 mg of dopamine per ml.', 'for a dose of 36 mg/hour, administer the solution (4 mg/ml) at 9 ml/hour.', 'if there is no electric syringe pump, dilution in an infusion bag may be considered. however,', 'it is important to consider the risks related to this type of administration (accidental bolus or', 'insufficient dose). the infusion must be constantly monitored to prevent any, even small,', 'change from the prescribed rate of administration.', 'example for epinephrine:', '– in adults:', 'dilute 10 ampoules of 1 mg epinephrine (10 000 micrograms) in 1 litre of 5% glucose or 0.9%', 'sodium chloride to obtain a solution containing 10 micrograms of epinephrine per ml.', 'knowing that 1 ml = 20 drops, in an adult weighting 50 kg:', '• 0.1 microgram/kg/minute = 5 micrograms/minute = 10 drops/minute', '• 1 microgram/kg/minute = 50 micrograms/minute = 100 drops/minute, etc.', '– in children:', 'dilute 1 ampoule of 1 mg epinephrine (1000 micrograms) in 100 ml of 5% glucose or 0.9%', 'sodium chloride to obtain a solution containing 10 micrograms of epinephrine per ml.', 'for administration, use a paediatric infusion set; knowing that 1 ml = 60 drops, in a child', 'weighting 10 kg:', '• 0.1 microgram/kg/minute = 1 microgram/minute = 6 drops/minute', '• 0.2 microgram/kg/minute = 2 micrograms/minute = 12 drops/minute, etc.', 'note: account for all infused volumes when recording ins and outs.', 'chapter 1', '20', 'seizures', '– involuntary movements of cerebral origin (stiffness followed by clonic movements),', 'accompanied by a loss of consciousness, and often urinary incontinence (generalized tonic-', 'clonic seizures).', 'it is important to distinguish seizures from ‘pseudo-seizures’ (e.g. in hysteria or tetany)', 'during which consciousness may appear altered but is not lost.', '– 2 priorities: stop the seizures and determine the cause. in pregnant women, eclamptic', 'seizures require specific medical and obstetrical care (see special situation: seizures during', 'pregnancy).', 'initial treatment', 'during a seizure', '– protect from trauma, maintain airway, place patient in ‘recovery position’, loosen clothing.', '– most seizures are quickly self-limited. immediate administration of an anticonvulsant is not', 'systematic. if generalized seizure lasts more than 3 minutes, use diazepam to stop it:', 'diazepam:', 'children: 0.5 mg/kg preferably rectallya without exceeding 10 mg.', 'iv administration is possible (0.3 mg/kg over 2 or 3 minutes), only if means of ventilation are', 'available (ambu bag and mask).', 'adults: 10 mg rectally or slowly iv.', 'in all cases:', '• dilute 10 mg (2 ml) of diazepam in 8 ml of 5% glucose or 0.9% sodium chloride.', '• if convulsion continues, repeat dose once after 5 minutes.', '• in infants and elderly patients, monitor respiration and blood pressure.', '• if convulsion continues after the second dose, treat as status epilepticus.', 'the patient is no longer seizing', '– look for the cause of the seizure and evaluate the risk of recurrence.', '– keep diazepam and glucose available in case the patient starts seizing again.', 'status epilepticus', 'several distinct seizures without complete restoration of consciousness in between or an', 'uninterrupted seizure lasting more than 10 minutes.', '– protect from trauma, loosen clothing, maintain airway and administer oxygen as required.', '– insert an iv line.', '– administer 5 ml/kg of 10% glucose by iv (over 2 to 3 minutes) in children and 1 ml/kg of', '50% glucose by slow iv (over 3 to 5 minutes) in adults.', 'a for rectal administration, use a syringe without a needle, or better, cut a nasogastric tube, ch8, to a length of', '2-3 cm and attach it to the tip of the syringe.', 'a few symptoms and syndromes', '21', '1updated: april 2017', '– if diazepam (see above) has not stopped the seizure, continue with phenobarbital by iv', 'infusion:', 'children under 12 years: 20 mg/kg (max. 1 g) in 5 ml/kg of 0.9% sodium chloride or 5%', 'glucose for children < 20 kg and in 100 ml of 0.9% sodium chloride or 5% glucose for children', '≥ 20 kg, administered over 20 minutes minimum (never exceed 1 mg/kg/minute). if', 'necessary, a second dose of 10 mg/kg may be administered (as above) 15 to 30 minutes after', 'the first dose.', 'children over 12 years and adults: 10 mg/kg (max. 1 g) in 100 ml of 0.9% sodium chloride or', '5% glucose administered over 20 minutes minimum (never exceed 1 mg/kg/minute). if', 'necessary, a second dose of 5 to 10 mg/kg may be administered (as above) 15 to 30 minutes', 'after the first dose.', 'im route may be an alternative when an iv (or intraosseous) access cannot be obtained.', 'there is a high risk of respiratory depression and hypotension, especially in children and', 'elderly patients. never administer phenobarbital by rapid iv injection. monitor closely', 'respiration and blood pressure. ensure that respiratory support (ambu bag via face mask', 'or intubation) and iv solutions for fluid replacement are ready at hand.', 'further treatment', 'febrile seizures', '– determine the cause of the fever. give paracetamol (see fever), undress the patient, wrap in', 'damp cloth.', '– in children under 3 years, there is usually no risk of later complications after simple febrile', 'seizures and no treatment is required after the crisis. for further febrile episodes, give', 'paracetamol po.', 'infectious causes', 'severe malaria (chapter 6), meningitis (chapter 7), meningo-encephalitis, cerebral', 'toxoplasmosis (hiv infection and aids, pages 233-234, chapter 8), cysticercosis (cestodes,', 'chapter 6), etc.', 'metabolic causes', '– hypoglycaemia: administer glucose by slow iv injection (for administration, see previous', 'page) to all patients who do not regain consciousness, to patients with severe malaria and to', 'newborns and malnourished children. when possible, confirm hypoglycaemia (reagent strip', 'test).', 'iatrogenic causes', '– withdrawal of antiepileptic therapy in a patient being treated for epilepsy should be', 'managed over a period of 4-6 months with progressive reduction of the doses. an abrupt', 'stop of treatment may provoke severe recurrent seizures.', 'epilepsy', '– a first brief seizure does not need further protective treatment. only patients with chronic', 'repetitive seizures require further regular protective treatment with an antiepileptic drug,', 'usually over several years.', '– once a diagnosis is made, abstention from treatment may be recommended due to the risks', 'associated with treatment. however, these risks must be balanced with the risks of', 'aggravation of the epilepsy, ensuing seizure-induced cerebral damage and other injury if the', 'patient is not treated.', 'chapter 1', '22', '– it is always preferable to start with monotherapy. the effective dose must be reached', 'progressively and symptoms and drug tolerance evaluated every 15 to 20 days.', '– an abrupt interruption of treatment may provoke status epilepticus. the rate of dose', 'reduction varies according to the length of treatment; the longer the treatment period, the', 'longer the reduction period (see iatrogenic causes). in the same way, a change from one', 'antiepileptic drug to another must be made progressively with an overlap period of a few', 'weeks.', '– first line treatments for generalised tonic-clonic seizures in children under 2 years are', 'carbamazepine or phenobarbital, in older children and adults sodium valproate or', 'carbamazepine. for information:', 'sodium valproate po ', 'children over 20 kg: initial dose of 400 mg in 2 divided doses irrespective of weight; if', 'necessary, increase the dose progressively until the optimal dose for the individual has been', 'reached (usually 20 to 30 mg/kg/day in 2 divided doses).', 'adults: initial dose of 600 mg/day in 2 divided doses; increase by 200 mg/day every 3 days', 'until the optimal dose for the individual has been reached (usually 1 to 2 g/day in 2 divided', 'doses).', 'carbamazepine po', 'children: initial dose of 2 mg/kg/day in 1 or 2 divided doses; increase every week until the', 'optimal dose for the individual has been reached (usually 10 to 20 mg/kg/day in 2 to', '4 divided doses).', 'adults: initial dose of 200 mg/day in 1 or 2 divided doses; increase by 200 mg every week', 'until the optimal dose for the individual has been reached (usually 800 to 1200 mg/day in', '2 to 4 divided doses).', 'phenobarbital po ', 'children: initial dose of 3 to 4 mg/kg/day at night, increase the dose progressively to', '8 mg/kg/day if necessary', 'adults: initial dose of 2 mg/kg/day at night (without exceeding 100 mg per day), increase the', 'dose progressively to 6 mg/kg/day if necessary', 'special situation: seizures during pregnancy', 'eclampsia', 'seizures during the third trimester of pregnancy, most commonly in the context of pre-', 'eclampsia (hypertension, oedema and proteinuria on reagent-strip test).', '– symptomatic treatment of eclampsia:', 'treatment of choice is magnesium sulfate (5 g ampoule, 500 mg/ml, 10 ml) by iv infusion: 4 g', 'diluted in 0.9% sodium chloride to be administered over 15 minutes. then infuse 1 g/hour,', 'continue magnesium sulfate for 24 hours following delivery or the last seizure. if seizure', 'recurs, give another 2 g by slow iv injection (over 15 minutes).', 'monitor urine output. stop the treatment if urinary output is less than 30 ml/hour or', '100 ml/4 hours.', 'before each injection, verify the concentration written on the ampoules: it comes in', 'different concentrations.', 'always have calcium gluconate ready to reverse the effects of magnesium sulfate in the', 'event of toxicity.', 'monitor patellar tendon reflex every 15 minutes during the infusion. if the patient has', 'malaise, drowsiness, difficulty speaking or loss of patellar reflex: stop the magnesium sulfate', 'and inject 1 g of calcium gluconate by slow, direct iv injection (over 5 to 10 minutes).', 'a few symptoms and syndromes', '23', '1', 'only in the absence of magnesium sulfate, use diazepam: 10 mg slow iv followed by 40 mg in', '500 ml 5% glucose as a continuous infusion over 24 hours. if there is no venous access for', 'the loading dose, give 20 mg rectally. in the event of treatment failure after 10 minutes, give', 'a second dose of 10 mg.', 'for direct iv or rectal administration dilute diazepam in 5% glucose or 0.9% sodium chloride', 'to make a total volume of 10 ml.', '– oxygen: 4 to 6 litres/minute.', '– nursing, hydration.', '– urgent delivery within 12 hours.', '– treatment of hypertension: see hypertension (chapter 12).', 'other causes', 'during pregnancy, consider that seizures may also be caused by cerebral malaria or meningitis;', 'the incidence of these diseases is increased in pregnant women. see malaria (chapter 6) and', 'bacterial meningitis (chapter 7).', 'chapter 1', '24', 'hypoglycaemia', 'hypoglycaemia is an abnormally low concentration of blood glucose. severe hypoglycaemia', 'can be fatal or lead to irreversible neurological damage.', 'blood glucose levels should be measured whenever possible in patients presenting symptoms', 'of hypoglycaemia. if hypoglycaemia is suspected but blood glucose measurement is not', 'available, glucose (or another available sugar) should be given empirically.', 'always consider hypoglycaemia in patients presenting impaired consciousness (lethargy, coma)', 'or seizures.', 'for diagnosis and treatment of hypoglycaemia in neonates, see essential obstetric and', 'newborn care, msf.', 'clinical features', 'rapid onset of non-specific signs, mild to severe depending on the degree of the', 'hypoglycaemia: sensation of hunger and fatigue, tremors, tachycardia, pallor, sweats, anxiety,', 'blurred vision, difficulty speaking, confusion, convulsions, lethargy, coma.', 'diagnosis', 'capillary blood glucose concentration (reagent strip test):', '– non-diabetic patients:', '• hypoglycaemia: < 60 mg/dl (< 3.3 mmol/litre)', '• severe hypoglycaemia: < 40 mg/dl (< 2.2 mmol/litre)', '– diabetic patients on home treatment: ≤ 70 mg/dl (3.9 mmol/litre)', 'if blood glucose measurement is not available, diagnosis is confirmed when symptoms resolve', 'after the administration of sugar or glucose.', 'symptomatic treatment', '– conscious patients:', 'children: a teaspoon of powdered sugar in a few ml of water or 50 ml of fruit juice, maternal', 'or therapeutic milk or 10 ml/kg of 10% glucose by oral route or nasogastric tube.', 'adults: 15 to 20 g of sugar (3 or 4 cubes) or sugar water, fruit juice, soda, etc.', 'symptoms improve approximately 15 minutes after taking sugar by oral route.', '– patients with impaired consciousness or prolonged convulsions:', 'children: 5 ml/kg of 10% glucose by iv route (2 to 3 minutes) or infusion', 'adults: 1 ml/kg of 50% glucose by slow iv (3 to 5 minutes)', 'neurological symptoms improve a few minutes after the injection.', 'check blood glucose after 15 minutes. if it is still low, re-administer glucose by iv route or sugar', 'by oral route according to the patient’s clinical condition.', 'if there is no clinical improvement, differential diagnoses should be considered: e.g. serious', 'infection (severe malaria, meningitis, etc.), epilepsy.', 'a few symptoms and syndromes', '25', '1new: june 2017', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'in all cases, after stabilisation, give a meal or snack rich in complex carbohydrates and monitor', 'the patients for a few hours.', 'if patient does not return to full alertness after an episode of severe hypoglycaemia, monitor', 'blood glucose levels regularly.', 'treat the cause', '– other than diabetes:', '• treat severe malnutrition, neonatal sepsis, severe malaria, acute alcohol intoxication, etc.', '• end prolonged fast.', '• replace drugs inducing hypoglycaemia (e.g. quinine iv, pentamidine, ciprofloxacin,', 'enalapril, beta-blockers, high-dose aspirin, tramadol), or anticipate hypoglycaemia (e.g.', 'administer quinine iv in a glucose infusion).', '– in diabetic patients:', '• avoid missing meals, increase intake of carbohydrates if necessary.', '• adjust dosage of insulin according to blood glucose levels and physical activity (see', 'diabetes type 1, chapter 12).', '• adjust dosage of oral antidiabetics, taking into account possible drug interactions (see', 'diabetes type 2, chapter 12).', 'chapter 1', '26', 'new: june 2017', 'fever', '– fever is defined as a rectal temperature higher than or equal to 38°c.', '– in practice, axillary route is easier, more accepted and more hygienic. an axillary temperature', 'higher than or equal to 37.5°c is considered a fever. in a child under 3 years, if the axillary', 'temperature is ≥ 37.5°c, take the temperature rectally if possible.', 'record the temperature as measured and if taken using the rectal or axillary route. do', 'not add 0.5°c to the axillary temperature. use an electronic thermometer.', '– fever is frequently due to infection. in a febrile patient, first look for signs of serious illness', 'then, try to establish a diagnosis. there is an increased risk of severe bacterial infectiona if', 'the rectal temperature is ≥ 38°c in children 0 to 2 months; ≥ 38.5°c in children 2 months to', '3 years; ≥ 39°c in children older than 3 years and adults.', 'signs of severity', '– severe tachycardia, tachypnoea, respiratory distress, oxygen saturation ≤ 90%.', '– shock, altered mental status, petechial or purpuric rash, meningeal signs, seizures, heart', 'murmur, severe abdominal pain, dehydration, critically ill appearanceb; a bulging fontanel in', 'young children.', 'infectious causes of fever according to localizing symptoms', 'a malnourished or immune-depressed children may have a bacterial infection without a fever.', 'b critically ill appearing child: weak grunting or crying, drowsiness, difficult to arrouse, does not smile,', 'unconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'signs or symptoms possible aetiology', 'meningeal signs, seizures meningitis/meningoencephalitis/severe malaria', 'abdominal pain or peritoneal signs appendicitis/peritonitis/typhoid fever', 'diarrhoea, vomiting gastroenteritis/typhoid fever', 'jaundice, enlarged liver viral hepatitis', 'cough pneumonia/measles/tuberculosis if persistent', 'ear pain, red tympanic membrane otitis media', 'sore throat, enlarged lymph nodes streptococcal pharyngitis, diphtheria', 'dysuria, urinary frequency, back pain urinary tract infection', 'red, warm, painful skin erysipelas, cellulitis, abscess', 'limp, difficulty walking osteomyelitis/septic arthritis', 'rash measles/dengue/haemorrhagic fever/chikungunya', 'bleeding (petechiae, epistaxis, etc.) dengue/haemorrhagic fever', 'joint pain rheumatic fever/chikungunya/dengue', 'a few symptoms and syndromes', '27', '1', '– in endemic area, always consider malaria.', '– if the patient is ill appearingc and has a persistent fever, consider hiv infection and tuberculosis,', 'according to clinical presentation.', 'laboratory and other examinations', '– children less than 2 months with a rectal temperature ≥ 38°c without a focus:', '• urinary dipstick;', '• lumbar puncture (lp) if child less than 1 month or if any of the following: meningeal signs,', 'coma, seizures, critically ill appearancec, failure of prior antibiotic therapy, suspicion of', 'staphylococcal infection;', '• chest x-ray (if available) in case of signs of respiratory disease.', '– children 2 months to 3 years with a rectal temperature ≥ 38.5°c without a focus:', '• urine dipstick;', '• white blood cell count (wbc) if available;', '• lp if meningeal signs.', '– children over 3 years and adults with an axillary or rectal temperature ≥ 39°c:', 'according to clinical presentation.', 'treatment', '– treat according to the cause of fever.', '– for patients with sickle cell disease, see sickle cell disease, chapter 12.', '– if no source of infection is found, hospitalise and treat the following children with empiric', 'antibiotics:', '• children less than 1 month;', '• children 1 month to 3 years with wbc ≥ 15000 or ≤ 5000 cells/mm3;', '• all critically ill appearingc patients or those with signs of serious illness;', 'for antibiotic doses according to age, see acute pneumonia, chapter 2.', 'symptomatic treatment', '– undress the patient. do not wrap children in wet towels or cloths (not effective, increases', 'discomfort, risk of hypothermia).', '– antipyretics may increase the patient’s comfort but they do not prevent febrile convulsions.', 'do not treat for more than 3 days with antipyretics.', 'paracetamol po', 'children less than 1 month: 10 mg/kg/dose, 3 to 4 times daily as needed', 'children 1 month and over: 15 mg/kg/dose, 3 to 4 times daily as needed (max. 60 mg/kg/day)', 'adults: 1 g/dose, 3 to 4 times daily as needed (max. 4 g/day)', 'or', 'ibuprofen po', 'children over 3 months and < 40 kg: 10 mg/kg/dose, 3 times daily as needed (max. 1200 mg/day)', 'children ≥ 40 kg and adults: 400 mg/dose, 3 times daily as needed', 'or', 'acetylsalicylic acid (asa) po', 'children over 15 years and adults: 1 g/dose, 3 times daily as needed', 'c critically ill appearing child: weak grunting or crying, drowsiness, difficult to arrouse, does not smile,', 'unconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'chapter 1', '28', 'prevention of complications', '– encourage oral hydration. continue frequent breastfeeding in infants.', '– watch for signs of dehydration.', '– monitor urine output.', 'notes:', '– in pregnant or breast-feeding women use paracetamol only.', '– in case of haemorrhagic fever and dengue: acetylsalicylic acid and ibuprofen are contra-', 'indicated; use paracetamol with caution in the presence of hepatic dysfunction.', 'a few symptoms and syndromes', '29', '1', 'pain', 'pain results from a variety of pathological processes. it is expressed differently by each patient', 'depending on cultural background, age, etc. it is a highly subjective experience meaning that', 'only the individual is able to assess his/her level of pain. regular assessment of the intensity of', 'pain is indispensable in establishing effective treatment.', 'clinical features', 'pain assessment', '– intensity: use a simple verbal scale in children over 5 years and adults, and nfcs or flacc', 'scales in children less than 5 years (see pain rating scales on following page).', '– pattern: sudden, intermittent, chronic; at rest, at night, on movement, during care', 'procedures, etc.', '– character: burning, cramping, spasmodic, radiating, etc.', '– aggravating or relieving factors, etc.', 'clinical examination', '– of the organ or area where the pain is located.', '– specific signs of underlying disease (e.g. bone or osteoarticular pain may be caused by a', 'vitamin c deficiency) and review of all systems.', '– associated signs (fever, weight loss, etc.).', 'synthesis', 'the synthesis of information gathered during history taking and clinical examination allows', 'aetiological diagnosis and orients treatment. it is important to distinguish:', '– nociceptive pain: it presents most often as acute pain and the cause-effect relationship is', 'usually obvious (e.g. acute post-operative pain, burns, trauma, renal colic, etc.). the pain', 'may be present in different forms, but neurological exam is normal. treatment is relatively', 'well standardized.', '– neuropathic pain, due to a nerve lesion (section, stretching, ischaemia): most often chronic', 'pain. on a background of constant, more or less localized pain, such as paraesthesia or', 'burning, there are recurrent acute attacks such as electric shock-like pain, frequently', 'associated with disordered sensation (anaesthesia, hypo or hyperaesthesia). this type of', 'pain is linked to viral infections directly affecting the cns (herpes simplex, herpes zoster),', 'neural compression by tumors, post- amputation pain, paraplegia, etc.', '– mixed pain (cancer, hiv) for which management requires a broader approach.', 'chapter 1', '30', 'pain evaluation scales', 'self-evaluation scale - children over 5 years and adults', 'simple verbal scale (svs)', 'observational evaluation scale - children 2 months-5 years', 'flacc scale (face limb activity cry consolability)', 'each category is scored from 0 to 2, giving a final score between 0 and 10.', '0 to 3: mild pain, 4 to 7: moderate pain, 7 to 10: severe pain', 'observational evaluation scale - children under 2 months', 'nfcs scale (neonatal facial coding system)', 'a score of 2 or more signifies significant pain, requiring analgesic treatment.', 'intensity of pain no pain mild pain moderate pain severe pain', 'scoring 0 1 2 3', 'write down 0 + ++ +++', 'items', 'scoring', '0 1 2', 'face no particular expression or', 'smile', 'occasional grimace or', 'frown, withdrawn,', 'disinterested', 'frequent to constant', 'frown, clenched jaw,', 'quivering chin', 'legs normal position or relaxed uneasy, restless, tense kicking, or legs drawn up', 'activity lying quietly, normal', 'position, moves easily', 'squirming, shifting back', 'and forth, tense', 'arched, rigid or jerking', 'cry no cry (awake or asleep) moans or whimpers,', 'occasional complaint', 'crying steadily, screams or', 'sobs, frequent complaints', 'consolability content, relaxed reassured by occasional', 'touching, hugging or being', 'talked to, distractible', 'difficult to console or', 'comfort', 'items', 'scoring', '0 1', 'brow bulge no yes', 'eye squeeze no yes', 'nasolabial furrow no yes', 'open lips no yes', 'a few symptoms and syndromes', '31', '1', 'brow bulge', 'open lips', 'eye squeeze', 'nasolabial furrow', 'treatment', 'treatment depends on the type and intensity of the pain. it may be both aetiological and', 'symptomatic if a treatable cause is identified. treatment is symptomatic only in other cases (no', 'cause found, non-curable disease).', 'nociceptive pain', 'the who classifies analgesics used for this type of pain on a three-step ladder:', '– step 1: non-opioid analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs', '(nsaids).', '– step 2: weak opioid analgesics such as codeine and tramadol. their combination with one or', 'two step 1 analgesics is recommended.', '– step 3: strong opioid analgesics, first and foremost morphine. their combination with one or', 'two step 1 analgesics is recommended.', 'the treatment of pain is based on a few fundamental concepts:', '– pain can only be treated correctly if it is correctly evaluated. the only person who can', 'evaluate the intensity of pain is the patient himself. the use of pain assessment scales is', 'invaluable.', '– the pain evaluation observations should be recorded in the patient chart in the same fashion', 'as other vital signs.', '– treatment of pain should be as prompt as possible.', '– it is recommended to administer analgesics in advance when appropriate (e.g. before painful', 'care procedures).', '– analgesics should be prescribed and administered at fixed time intervals (not on demand).', '– oral forms should be used whenever possible.', '– the combination of different analgesic drugs (multimodal analgesia) is advantageous.', '– start with an analgesic from the level presumed most effective: e.g., in the event of a', 'fractured femur, start with a step 3 analgesic.', '– the treatment and dose chosen are guided by the assessment of pain intensity, but also by', 'the patient’s response which may vary significantly from one person to another.', 'treatment of acute pain', 'mild pain paracetamol + /- nsaid', 'moderate pain paracetamol + /- nsaid + tramadol or codeine', 'severe pain paracetamol + /- nsaid + morphine', 'chapter 1', '32', 'a few symptoms and syndromes', '33', '1', 'a', 'na', 'lg', 'es', 'ic', 's', 'ch', 'ild', 're', 'n', 'a', 'du', 'lt', 's ', '(e', 'xc', 'ep', 't p', 're', 'gn', 'an', 't/', 'br', 'ea', 'st', '-f', 'ee', 'di', 'ng', ' w', 'om', 'en', ')', 're', 'm', 'ar', 'ks', 'level 1', 'pa', 'ra', 'ce', 'ta', 'm', 'ol', 'p', 'o', '15', ' m', 'g/', 'kg', ' e', 've', 'ry', ' 6', ' h', 'o', 'u', 'rs', 'o', 'r', '10', ' m', 'g/', 'kg', ' e', 've', 'ry', ' 4', ' h', 'o', 'u', 'rs', '50', '0 ', 'm', 'g ', 'to', ' 1', ' g', ' e', 've', 'ry', ' 4', ' t', 'o', ' 6', ' h', 'o', 'u', 'rs', '(m', 'ax', '. 4', ' g', '/d', 'ay', ')', 'th', 'e ', 'ef', 'fi', 'ca', 'cy', ' o', 'f ', 'iv', ' p', 'ar', 'ac', 'et', 'am', 'o', 'l ', 'is', ' n', 'o', 't', 'su', 'p', 'e', 'ri', 'o', 'r ', 'to', 'th', 'e', 'e', 'ff', 'ic', 'a', 'cy', 'o', 'f ', 'o', 'ra', 'l', 'pa', 'ra', 'ce', 'ta', 'm', 'ol', ';t', 'h', 'e ', 'iv', ' r', 'o', 'u', 'te', ' is', ' r', 'es', 'tr', 'ic', 'te', 'd', 'to', ' s', 'it', 'ua', 'ti', 'on', 's ', 'w', 'he', 're', ' o', 'ra', 'l a', 'dm', 'in', 'is', 'tr', 'at', 'io', 'n', 'is', ' im', 'p', 'o', 'ss', 'ib', 'le', '.', 'pa', 'ra', 'ce', 'ta', 'm', 'ol', 'iv', '< ', '10', ' k', 'g:', ' 7', '.5', ' m', 'g/', 'kg', ' e', 've', 'ry', ' 6', ' h', 'o', 'ur', 's', '(m', 'ax', '. 3', '0 ', 'm', 'g/', 'kg', '/d', 'ay', ')', '> ', '10', ' k', 'g:', ' 1', '5 ', 'm', 'g/', 'kg', ' e', 've', 'ry', ' 6', ' h', 'o', 'ur', 's', '(m', 'ax', '. 6', '0 ', 'm', 'g/', 'kg', '/d', 'ay', ')', '≤ ', '50', ' k', 'g:', ' 1', '5 ', 'm', 'g/', 'kg', ' e', 've', 'ry', ' 6', ' h', 'o', 'ur', 's', '(m', 'ax', '. 6', '0 ', 'm', 'g/', 'kg', '/d', 'ay', ')', '> ', '50', ' k', 'g:', ' 1', ' g', ' e', 've', 'ry', ' 6', ' h', 'o', 'ur', 's', '(m', 'ax', '. 4', ' g', '/d', 'ay', ')', 'ac', 'et', 'yl', 'sa', 'lic', 'yl', 'ic', ' a', 'ci', 'd', '(a', 'sp', 'ir', 'in', ') ', 'p', 'o', '–', '30', '0 ', 'm', 'g ', 'to', ' 1', ' g', ' e', 've', 'ry', ' 4', ' t', 'o', ' 6', ' h', 'o', 'u', 'rs', '(m', 'ax', '. 4', ' g', '/d', 'ay', ')', 'a', 'vo', 'id', ' in', ' c', 'h', 'ild', 're', 'n', ' le', 'ss', ' t', 'h', 'an', ' 1', '6 ', 'ye', 'ar', 's.', 'di', 'cl', 'of', 'en', 'ac', 'im', '–', '75', ' m', 'g ', 'o', 'n', 'ce', ' d', 'ai', 'ly', 't', 're', 'a', 'tm', 'e', 'n', 't ', 'm', 'u', 'st', ' b', 'e', ' a', 's ', 'sh', 'o', 'rt', ' a', 's', 'p', 'o', 'ss', 'ib', 'le', '.', 'r', 'es', 'p', 'ec', 't ', 'co', 'n', 'tr', 'a-', 'in', 'd', 'ic', 'at', 'io', 'n', 's.', 'ib', 'up', 'ro', 'fe', 'n', 'p', 'o', '> ', '3 ', 'm', 'o', 'nt', 'hs', ': 3', '0 ', 'm', 'g/', 'kg', '/d', 'ay', ' in', ' 3', ' d', 'iv', 'id', 'ed', 'd', 'o', 'se', 's', '12', '00', ' t', 'o', ' 1', '80', '0 ', 'm', 'g/', 'da', 'y ', 'in', ' 3', ' t', 'o', ' 4', ' d', 'iv', 'id', 'ed', 'd', 'o', 'se', 's', 'level 2', 'co', 'de', 'in', 'e', 'p', 'o', '> ', '12', ' y', 'ea', 'rs', ': 3', '0 ', 'to', ' 6', '0 ', 'm', 'g ', 'ev', 'er', 'y ', '4 ', 'to', '6 ', 'h', 'o', 'u', 'rs', ' (', 'm', 'ax', '. 2', '40', ' m', 'g/', 'd', 'ay', ')', '30', ' t', 'o', ' 6', '0 ', 'm', 'g ', 'ev', 'er', 'y ', '4 ', 'to', ' 6', ' h', 'o', 'u', 'rs', '(m', 'ax', '. 2', '40', ' m', 'g/', 'd', 'ay', ')', 'a', 'dd', ' a', ' la', 'xa', 'ti', 've', ' if', ' t', 're', 'at', 'm', 'en', 't ', '> ', '48', ' h', 'o', 'ur', 's.', 'tr', 'am', 'ad', 'ol', 'p', 'o', '> ', '12', ' y', 'ea', 'rs', ': 5', '0 ', 'to', ' 1', '00', ' m', 'g ', 'ev', 'er', 'y ', '4 ', 'to', '6', 'ho', 'ur', 's ', '(m', 'ax', '. 4', '00', ' m', 'g/', 'da', 'y)', '50', ' t', 'o', ' 1', '00', ' m', 'g ', 'ev', 'er', 'y ', '4 ', 'to', ' 6', ' h', 'o', 'u', 'rs', '(m', 'ax', '. 4', '00', ' m', 'g/', 'd', 'ay', ')', '25', ' t', 'o', ' 5', '0 ', 'm', 'g ', 'ev', 'er', 'y ', '12', ' h', 'o', 'u', 'rs', ' in', ' e', 'ld', 'er', 'ly', 'p', 'at', 'ie', 'n', 'ts', ' a', 'n', 'd', ' i', 'n', ' p', 'at', 'ie', 'n', 'ts', ' w', 'it', 'h', ' s', 'ev', 'er', 'e', 're', 'n', 'al', ' o', 'r ', 'h', 'ep', 'at', 'ic', ' im', 'p', 'ai', 'rm', 'en', 't.', 'tr', 'am', 'ad', 'ol', 'im', ', s', 'lo', 'w', ' iv', 'o', 'r ', 'in', 'fu', 'si', 'o', 'n', '> ', '12', ' y', 'ea', 'rs', ': 5', '0 ', 'to', ' 1', '00', ' m', 'g ', 'ev', 'er', 'y ', '4 ', 'to', '6', 'ho', 'ur', 's ', '(m', 'ax', '. 6', '00', ' m', 'g/', 'da', 'y)', '50', ' t', 'o', ' 1', '00', ' m', 'g ', 'ev', 'er', 'y ', '4 ', 'to', ' 6', ' h', 'o', 'u', 'rs', '(m', 'ax', '. 6', '00', ' m', 'g/', 'd', 'ay', ')', 'updated: june 2017', 'chapter 1', '34', 'a', 'na', 'lg', 'es', 'ic', 's', 'ch', 'ild', 're', 'n', 'a', 'du', 'lt', 's ', '(e', 'xc', 'ep', 't p', 're', 'gn', 'an', 't/', 'br', 'ea', 'st', '-f', 'ee', 'di', 'ng', ' w', 'om', 'en', ')', 're', 'm', 'ar', 'ks', 'level 3', 'm', 'or', 'ph', 'in', 'e', 'p', 'o', 'im', 'm', 'ed', 'ia', 'te', ' r', 'el', 'ea', 'se', '(m', 'ir', ')', '> ', '6 ', 'm', 'o', 'n', 'th', 's:', ' 1', ' m', 'g/', 'kg', '/d', 'ay', ' in', ' 6', ' d', 'iv', 'id', 'ed', 'd', 'o', 'se', 's ', 'at', ' 4', ' h', 'o', 'u', 'r-', 'in', 'te', 'rv', 'al', 's,', ' t', 'o', ' b', 'e', 'aj', 'u', 'st', 'ed', ' in', ' r', 'el', 'at', 'io', 'n', ' t', 'o', ' p', 'ai', 'n', ' in', 'te', 'n', 'si', 'ty', '60', ' m', 'g/', 'd', 'ay', ' in', ' 6', ' d', 'iv', 'id', 'ed', ' d', 'o', 'se', 's ', 'at', '4 ', 'h', 'o', 'u', 'r-', 'in', 'te', 'rv', 'al', 's,', ' t', 'o', ' b', 'e ', 'aj', 'u', 'st', 'ed', ' in', 're', 'la', 'ti', 'o', 'n', ' t', 'o', ' p', 'ai', 'n', ' in', 'te', 'n', 'si', 'ty', '•', 'r', 'e', 'd', 'u', 'ce', ' t', 'h', 'e', ' d', 'o', 'se', ' (', '3', '0', ' m', 'g/', 'd', 'a', 'y)', ' i', 'n', 'el', 'd', 'er', 'ly', ' p', 'at', 'ie', 'n', 'ts', ' a', 'n', 'd', ' p', 'at', 'ie', 'n', 'ts', ' w', 'it', 'h', 're', 'na', 'l o', 'r ', 'he', 'pa', 'ti', 'c ', 'im', 'pa', 'ir', 'm', 'en', 't.', '•', 'a', 'd', 'd', ' a', ' la', 'xa', 'ti', 've', ' if', ' t', 're', 'at', 'm', 'en', 't', '> ', '48', ' h', 'o', 'u', 'rs', '.', 'm', 'or', 'ph', 'in', 'e', 'p', 'o', 'sl', 'o', 'w', ' r', 'el', 'ea', 'se', ' (', 'm', 'sr', ')', 'th', 'e ', 'ef', 'fe', 'ct', 'iv', 'e ', 'da', 'ily', ' d', 'o', 'se', ' is', ' d', 'et', 'er', 'm', 'in', 'ed', 'du', 'ri', 'ng', ' t', 'he', ' in', 'it', 'ia', 'l t', 're', 'at', 'm', 'en', 't ', 'w', 'it', 'h', 'im', 'm', 'ed', 'ia', 'te', ' r', 'el', 'ea', 'se', ' m', 'o', 'rp', 'hi', 'ne', ' (m', 'ir', ').', 'if', ' t', 're', 'at', 'm', 'en', 't ', 'is', ' in', 'it', 'ia', 'te', 'd ', 'di', 're', 'ct', 'ly', ' w', 'it', 'h', 'm', 'sr', ':', '> ', '6 ', 'm', 'o', 'nt', 'hs', ': 1', ' m', 'g/', 'kg', '/d', 'ay', ' in', ' 2', ' d', 'iv', 'id', 'ed', 'do', 'se', 's ', 'at', ' 1', '2 ', 'ho', 'ur', '-in', 'te', 'rv', 'al', 's,', ' t', 'o', ' b', 'e', 'aj', 'us', 'te', 'd ', 'in', ' r', 'el', 'at', 'io', 'n ', 'to', ' p', 'ai', 'n ', 'in', 'te', 'ns', 'it', 'y', 'th', 'e ', 'ef', 'fe', 'ct', 'iv', 'e ', 'da', 'ily', ' d', 'o', 'se', ' is', ' d', 'et', 'er', 'm', 'in', 'ed', 'du', 'ri', 'ng', ' t', 'he', ' in', 'it', 'ia', 'l t', 're', 'at', 'm', 'en', 't ', 'w', 'it', 'h', 'im', 'm', 'ed', 'ia', 'te', ' r', 'el', 'ea', 'se', ' m', 'o', 'rp', 'hi', 'ne', ' (m', 'ir', ').', 'if', ' t', 're', 'at', 'm', 'en', 't ', 'is', ' in', 'it', 'ia', 'te', 'd ', 'di', 're', 'ct', 'ly', ' w', 'it', 'h', 'm', 'sr', ':', '60', ' m', 'g/', 'da', 'y ', 'in', ' 2', ' d', 'iv', 'id', 'ed', ' d', 'o', 'se', 's ', 'at', '12', ' h', 'o', 'ur', '-in', 'te', 'rv', 'al', 's,', ' t', 'o', ' b', 'e ', 'aj', 'us', 'te', 'd ', 'in', 're', 'la', 'ti', 'o', 'n ', 'to', ' p', 'ai', 'n ', 'in', 'te', 'ns', 'it', 'y', '•', 'd', 'o', ' n', 'o', 't ', 'in', 'it', 'ia', 'te', ' t', 're', 'at', 'm', 'en', 't ', 'w', 'it', 'h', ' t', 'h', 'e', 'su', 'st', 'a', 'in', 'e', 'd', ' r', 'e', 'le', 'a', 'se', ' m', 'o', 'rp', 'h', 'in', 'e', ' i', 'n', 'el', 'de', 'rl', 'y ', 'pa', 'ti', 'en', 'ts', ' o', 'r ', 'th', 'o', 'se', ' w', 'it', 'h ', 're', 'na', 'l', 'o', 'r ', 'h', 'e', 'p', 'a', 'ti', 'c ', 'im', 'p', 'a', 'ir', 'm', 'e', 'n', 't.', 'b', 'e', 'g', 'in', 'tr', 'e', 'a', 'tm', 'e', 'n', 't ', 'w', 'it', 'h', ' t', 'h', 'e', ' i', 'm', 'm', 'e', 'd', 'ia', 'te', 're', 'le', 'as', 'e ', 'm', 'o', 'rp', 'hi', 'ne', ' (m', 'ir', ').', '•', 'a', 'd', 'd', ' a', ' la', 'xa', 'ti', 've', ' if', ' t', 're', 'at', 'm', 'en', 't', '> ', '48', ' h', 'o', 'u', 'rs', '.', 'm', 'or', 'ph', 'in', 'e', 'sc', ', i', 'm', '> ', '6 ', 'm', 'o', 'n', 'th', 's:', ' 0', '.1', ' t', 'o', ' 0', '.2', ' m', 'g/', 'kg', ' e', 've', 'ry', '4 ', 'h', 'o', 'u', 'rs', '0.', '1 ', 'to', ' 0', '.2', ' m', 'g/', 'kg', ' e', 've', 'ry', ' 4', ' h', 'o', 'u', 'rs', '•', 'in', ' e', 'ld', 'er', 'ly', ' p', 'at', 'ie', 'n', 'ts', ' a', 'n', 'd', ' i', 'n', ' p', 'at', 'ie', 'n', 'ts', 'w', 'it', 'h', 'se', 've', 're', 're', 'n', 'a', 'l ', 'o', 'r ', 'h', 'e', 'p', 'a', 'ti', 'c', 'im', 'p', 'ai', 'rm', 'en', 't:', ' r', 'ed', 'u', 'ce', ' d', 'o', 'se', 's ', 'b', 'y ', 'h', 'al', 'f', 'a', 'n', 'd', ' a', 'd', 'm', 'in', 'is', 'te', 'r ', 'le', 'ss', ' f', 're', 'q', 'u', 'e', 'n', 'tl', 'y,', 'ac', 'co', 'rd', 'in', 'g ', 'to', ' c', 'lin', 'ic', 'al', ' r', 'es', 'po', 'ns', 'e.', '•', 'a', 'd', 'd', ' a', ' la', 'xa', 'ti', 've', ' if', ' t', 're', 'at', 'm', 'en', 't', '> ', '48', ' h', 'o', 'u', 'rs', '.', 'm', 'or', 'ph', 'in', 'e', 'iv', '> ', '6 ', 'm', 'o', 'n', 'th', 's:', ' 0', '.1', ' m', 'g/', 'kg', ' a', 'd', 'm', 'in', 'is', 'te', 're', 'd', 'in', ' f', 'ra', 'ct', 'io', 'n', 'at', 'ed', ' d', 'o', 'se', 's ', '(0', '.0', '5 ', 'm', 'g/', 'kg', 'ev', 'er', 'y ', '10', ' m', 'in', 'u', 'te', 's)', ', t', 'o', ' b', 'e ', 're', 'p', 'ea', 'te', 'd', 'ev', 'er', 'y ', '4 ', 'h', 'o', 'u', 'rs', ' if', ' n', 'ec', 'es', 'sa', 'ry', '0.', '1 ', 'm', 'g/', 'kg', ' a', 'd', 'm', 'in', 'is', 'te', 're', 'd', ' in', 'fr', 'ac', 'ti', 'o', 'n', 'at', 'ed', ' d', 'o', 'se', 's ', '(0', '.0', '5 ', 'm', 'g/', 'kg', ' e', 've', 'ry', '10', ' m', 'in', 'u', 'te', 's)', ', t', 'o', ' b', 'e ', 're', 'p', 'ea', 'te', 'd', ' e', 've', 'ry', ' 4', 'h', 'o', 'u', 'rs', ' if', ' n', 'ec', 'es', 'sa', 'ry', 'notes on the use of morphine and derivatives:', '– morphine is an effective treatment for many types of severe pain. its analgesic effect is dose-', 'dependent. its adverse effects have often been exaggerated and should not be an obstacle', 'to its use.', '– the most serious adverse effect of morphine is respiratory depression, which may be fatal.', 'this adverse effect results from overdose. it is, therefore, important to increase doses', 'gradually. respiratory depression is preceded by drowsiness, which is a warning to monitor', 'respiratory rate (rr).', 'the rr should remain equal to or greater than the thresholds indicated below:', 'respiratory depression must be identified and treated quickly: verbal and physical', 'stimulation of the patient; administration of oxygen; respiratory support (bag and mask) if', 'necessary. if no improvement, administer naloxone (antagonist of morphine) in bolus of 1 to', '3 micrograms/kg as necessary until rr normalises and the excessive drowsiness resolves.', '– morphine and codeine always cause constipation. a laxative should be prescribed if the', 'opioid treatment continues more than 48 hours. lactulose po is the drug of choice: children', '< 1 year: 5 ml/day; children 1-6 years: 5 to 10 ml/day; children 7-14 years: 10 to 15 ml/day;', 'adults: 15 to 45 ml/day.', 'if the patient’s stools are soft, a stimulant laxative (bisacodyl po: children > 3 years: 5 to', '10 mg/day; adults: 10 to 15 mg/day) is preferred.', '– nausea and vomiting are common at the beginning of treatment.', 'adults: ', 'haloperidol po (2 mg/ml oral solution): 1 to 2 mg to be repeated up to 6 times daily', 'or metoclopramide po: 15 to 30 mg/day in 3 divided doses with an interval of at least 6 hours', 'between each dose', 'do not combine haloperidol and metoclopramide. ', 'children:', 'ondansetron po: 0.15 mg/kg to be repeated up to 3 times daily. do not exceed 4 mg/dose.', 'do not use metoclopramide in children.', '– for chronic pain in late stage disease (cancer, aids etc.), morphine po is the drug of choice.', 'it may be necessary to increase doses over time according to pain assessment. do not', 'hesitate to give sufficient and effective doses.', '– morphine, tramadol and codeine have similar modes of action and should not be combined.', '– buprenorphine, nalbuphine and pentazocine must not be combined with morphine,', 'pethidine, tramadol or codeine because they have competitive action.', 'neonate rr ≥ 35 respirations/min', 'children 1 to 12 months rr ≥ 25 respirations/min', 'children 1 to 2 years rr ≥ 20 respirations/min ', 'children 2 to 5 years rr ≥ 15 respirations/min', 'children > 5 years and adults rr ≥ 10 respirations/min', 'a few symptoms and syndromes', '35', '1', 'treatment of nociceptive pain in pregnant and breast-feeding women', 'neuropathic pain', 'commonly used analgesics are often ineffective in treating this type of pain.', 'treatment of neuropathic pain is based on a combination of two centrally acting drugs:', 'amitriptyline po', 'adults: start with a dose of 10 to 25 mg/day at night and increase progressively to reach an', 'effective dose, without exceeding 150 mg/day. reduce the dose by 1/2 in elderly patients.', 'carbamazepine po', 'adults: start with a dose of 200 mg once daily at night for one week, then 400 mg/day in', '2 divided doses (morning and night) for one week, then 600 mg/day in 3 divided doses.', 'given its teratogenic risk, carbamazepine should only be used in women of childbearing age', 'when covered by non-hormonal contraception (copper intrauterine device).', 'mixed pain', 'in mixed pain with a significant component of nociceptive pain, such as in cancer or aids,', 'morphine is combined with antidepressants and antiepileptics.', 'analgesics', 'pregnancy', 'breast-feeding', '0-5 months from 6th month', 'le', 've', 'l 1', 'paracetamol 1st choice 1st choice 1st choice', 'aspirin avoid contra-indicated avoid', 'ibuprofen avoid contra-indicated possible', 'le', 've', 'l 2', 'codeine possible the newborn infant may', 'develop withdrawal', 'symptoms, respiratory', 'depression and drowsiness', 'in the event of prolonged', 'administration of large', 'doses at the end of the', '3rd trimester. closely', 'monitor the newborn', 'infant.', 'use with caution, for a', 'short period (2-3 days), at', 'the lowest effective dose.', 'monitor the mother and', 'the child: in the event of', 'excessive drowsiness, stop', 'treatment.', 'tramadol possible the child may develop drowsiness when the mother', 'receives tramadol at the end of the 3rd trimester and', 'during breast-feeding. administer with caution, for a', 'short period, at the lowest effective dose, and monitor', 'the child.', 'le', 've', 'l 3', 'morphine possible the child may develop withdrawal symptoms,', 'respiratory depression and drowsiness when the mother', 'receives morphine at the end of the 3rd trimester and', 'during breast-feeding. administer with caution, for a', 'short period, at the lowest effective dose, and monitor', 'the child.', 'chapter 1', '36', 'chronic pain', 'in contrast to acute pain, medical treatment alone is not always sufficient in controlling chronic', 'pain. a multidisciplinary approach including medical treatment, physiotherapy, psychotherapy', 'and nursing is often necessary to allow good pain relief and encourage patient self-', 'management.', 'co-analgesics', 'the combination of certain drugs may be useful or even essential in the treatment of pain:', 'antispasmodics, muscle relaxants, anxiolytics, corticosteroids, local anaesthesia, etc.', 'a few symptoms and syndromes', '37', '1', 'anaemia', '– anaemia is defined as a haemoglobin level below reference valuesa. it is a frequent symptom', 'in tropical settings where 10 to 20% of the population present with hb levels less than', '10 g/dl.', '– anaemia is caused by:', '• decreased production of red blood cells: nutritional iron and/or folic acid deficiency,', 'depressed bone marrow function, some infections (hiv, visceral leishmaniasis etc.);', '• loss of red blood cells: acute or chronic haemorrhage (ancylostomiasis etc.);', '• increased destruction of red blood cells (haemolysis): malaria; infections or the intolerance', 'of certain drugs by patients with g6pd deficiency (primaquine, dapsone, cotrimoxazole,', 'nalidixic acid, nitrofuran derivatives etc.); haemoglobinopathies (sickle cell disease,', 'thalassaemias); certain bacterial and viral infections (hiv).', '– in tropical settings, the causes are often interlinked, the two most common causes are', 'nutritional deficiencies and malaria. the groups most at risk are children and young women,', 'particularly during pregnancy.', '– anaemia in itself is not an indication for transfusion. most anaemias are well tolerated and', 'can be corrected with simple aetiological treatment.', 'clinical features', '– common signs of anaemia: pallor of the conjunctivae, mucous membranes, palms of hands', 'and soles of feet; fatigue, dizziness, oedema in the lower limbs, dyspnoea, tachycardia, heart', 'murmur.', '– signs that anaemia may be immediately life threatening: sweating, thirst, cold extremities,', 'tachycardia, respiratory distress and shock.', '– look for signs of a specific pathology: cheilosis, nutritional deficiency glossitis, haemolytic', 'jaundice, signs of malaria (chapter 6), etc.', 'laboratory', '– haemoglobin level (or if haemoglobin is not available, haematocrit)', '– thick and thin blood films or rapid test if malaria is suspected', 'treatment', 'iron deficiency anaemia', '– elemental iron pob for 3 months', 'children under 2 years: 30 mg once daily = 1/2 tab/day', 'children from 2 to 12 years: 60 mg once daily = 1 tab/day', 'adults: 120 to 180 mg/day in 2 or 3 divided doses = 2 to 3 tab/day', 'or preferably, give a combination of elemental iron (65 mg) + folic acid (400 micrograms) po.', 'a normal values: > 13 g/dl in men; > 12 g/dl in women; > 11 g/dl in pregnant women; > 13.5 g/dl in newborns;', '> 9.5 g/dl in infants from 2 to 6 months; > 11 g/dl in children from 6 months to 6 years; > 11.5 g/dl in children', 'from 6 to 12 years.', 'b doses are calculated in elemental iron. tablets of 200 mg ferrous sulphate such as those of ferrous sulphate', '+ folic acid contain 65 mg of elemental iron. 300 mg tablets of ferrous gluconate contain 35 mg of elemental', 'iron.', 'chapter 1', '38', '– combine with an anthelminthic:', 'albendazole po (except during the first trimester of pregnancy)', 'children > 6 months and adults: 400 mg as a single dose', '(children > 6 months but < 10 kg: 200 mg as a single dose)', 'or', 'mebendazole po (except during the first trimester of pregnancy)', 'children > 6 months and adults: 200 mg/day in 2 divided doses for 3 days', '(children > 6 months but < 10 kg: 100 mg/day in 2 divided doses for 3 days)', 'folic acid deficiency anaemia (rarely isolated)', '– folic acid po', 'children under 1 year: 0.5 mg/kg once daily for 4 months', 'children over 1 year and adults: 5 mg once daily for 4 months', 'haemolytic anaemia', '– malaria: iron is ineffective except in patients with an associated iron deficiency. for the', 'treatment of malaria, see chapter 6.', '– g6pd deficiency: no specific treatment; early treatment of infections; stop any drugs', 'suspected to be causing a reaction.', 'immediately life threatening anaemia', '– oxygen, particularly for children.', '– transfusion after determination of blood group and type and screening for hiv, hepatitis b', 'and c, syphilis, malaria in endemic areas. to determine the blood volume required and the', 'rate of transfusion, see next page.', 'note: the prevalence of hiv infection makes screening of donors vital. if there is no', 'possibility of screening, it is up to the physician to weigh the transfusion risk with the life or', 'death risk of not transfusing the patient. all transfusions that are not strictly indicated are', 'strictly contra-indicated.', 'monitor vital signs (pulse, blood pressure, respiratory rate, temperature) and watch for', 'clinical signs of transfusion reactions.', 'adults', 'determine the volume of whole blood to be', 'transfused:', 'v = (haemoglobin required minus patient’s', 'haemoglobin) multiplied by 6 multiplied by', 'patient’s weight', 'example: haemoglobin required = 7 g/dl', 'patient’s haemoglobin = 4 g/dl', 'patient’s weight = 60 kg', 'volume in ml = (7 – 4) x 6 x 60 = 1080 ml', 'determine the transfusion rate:', '(1 ml of whole blood = 15 drops)', 'example: 1080 ml to be administered over 3 hours', '1080 (ml) ÷ 180 (minutes) = 6 ml/minute', '6 (ml) x 15 (drops) = 90 drops/minute', 'children', 'newborns and children under 1 year:', '15 ml/kg over 3 to 4 hours', 'children over 1 year:', '20 ml/kg over 3 to 4 hours', 'malnourished children:', '10 ml/kg over 3 hours', 'example: a malnourished child weighing 25 kg', '10 (ml) x 25 (kg) = 250 ml over 3 hours', '250 (ml) ÷ 180 (minutes) = 1.4 ml/minute', '1.4 (ml) x 15 (drops) = 21 drops/minute', 'a few symptoms and syndromes', '39', '1', 'in some cases, particularly in children suffering from severe malaria, anaemia may cause', 'heart failure which may be decompensated by transfusion. if signs of hypervolaemia are', 'seen:', 'furosemide slow, direct iv', '1 mg/kg without exceeding 20 mg/kg.', '– if present, treat any pulmonary or parasitic infection (malaria).', 'prevention', '– iron or folic acid deficiency:', '• drug supplements in pregnant woman:', 'elemental iron (65 mg) + folic acid (400 micrograms) po', '60 mg once daily = 1 tab/day', '• nutritional supplements if the basic diet is insufficient.', '– for sickle cell anaemia, see sickle cell disease (chapter 12).', '– early treatment of malaria, helminthic infections etc.', 'chapter 1', '40', 'severe acute malnutrition', 'severe acute malnutrition is caused by a significant imbalance between nutritional intake and', 'individual needs. it is most often caused by both quantitative (number of kilocalories/day) and', 'qualitative (vitamins and minerals, etc.) deficiencies.', 'children over 6 months of age', 'the two principal forms of severe malnutrition are:', '– marasmus: significant loss of muscle mass and subcutaneous fat, resulting in a skeletal', 'appearance.', '– kwashiorkor: bilateral oedema of the lower limbs/oedema of the face, often associated with', 'cutaneous signs (shiny or cracked skin, burn-like appearance; discoloured and brittle hair).', 'the two forms may be associated (marasmic-kwashiorkor).', 'in addition to these characteristic signs, severe acute malnutrition is accompanied by', 'significant physiopathological disorders (metabolic disturbances, anaemia, compromised', 'immunity, leading to susceptibility to infections often difficult to diagnose, etc.).', 'complications are frequent and potentially life-threatening.', 'mortality rates may be elevated in the absence of specific medical management.', 'admission and discharge criteria for treatment programmes for severe acute malnutrition are', 'both anthropometric and clinical:', '– mid-upper arm circumference (muac) is the circumference, measured in mid- position, of', 'the relaxed left upper arm, taken in children of 6 to 59 months (65 to 110 cm in height).', 'muac measures the degree of muscle wasting. a muac of < 115 mm indicates severe', 'malnutrition and significant mortality risk.', '– weight for height (w/h) index assesses the degree of weight loss by comparing the weight of', 'the malnourished child with non-malnourished children of the same height. severe', 'malnutrition is defined as a w/h index of < – 3z with reference to the new who child', 'growth standardsa.', '– the presence of bilateral oedema of the lower limbs (when other causes of oedema have', 'been ruled out) indicates severe malnutrition, regardless of the muac and w/h.', 'usual admission criteria are: muac < 115 mm (muac is not used as an admission criterion in', 'children older than 59 months or taller than 110 cm) or w/h < – 3za or presence of bilateral', 'oedema of the lower limbs. ', 'usual discharge (cure) criteria are: w/h > – 2 za and absence of bilateral oedema', '(2 consecutive assessments, one week apart) and absence of acute medical problems.', 'a some national programmes define anthropometric admission and discharge criteria with reference to nchs', 'growth standards, with thresholds expressed in percentage of the median.', 'a few symptoms and syndromes', '41', '1', 'medical management (hospitalisation or ambulatory care) is based on the presence or absence', 'of associated serious complications:', '– children exhibiting anorexia, or significant medical complications, such as severe anaemia,', 'severe dehydration or severe infection (complicated acute malnutrition) should be', 'hospitalisedb.', '– children without significant medical complications (uncomplicated acute malnutrition) may', 'undergo treatment on an ambulatory basis, with weekly medical follow-up.', 'treatment', '1) nutritional treatment', 'nutritional treatment is based on the use of therapeutic foods enriched with vitamins and', 'minerals:', '– therapeutic milks (for use exclusively in hospitalised patients):', '• f-75 therapeutic milk, low in protein, sodium and calories (0.9 g of protein and 75 kcal per', '100 ml) is used in the initial phase of treatment for patients suffering from complicated', 'acute malnutrition. it is used to cover basic needs while complications are being treated. it', 'is given in 8 daily meals.', '• f-100 therapeutic milk, in which the concentration of protein and calories is higher (2.9 g', 'of protein and 100 kcal per 100 ml), replaces f-75 after several days, once the patient is', 'stabilised (return of appetite, clinical improvement; disappearance or reduction of', 'oedema). the objective is to facilitate rapid weight gain. it can be given with, or be', 'replaced by, rutf.', '– rutf (ready-to-use therapeutic food), i.e. foods which are ready for consumption (for', 'example, peanut paste enriched with milk solids, such as plumpy’nut®), are used in children', 'treated in both hospital or ambulatory settings. the nutritional composition of rutf is', 'similar to f-100, but the iron content is higher. it is designed to promote rapid weight gain', '(approximately 500 kcal per 100 g). rutf are the only therapeutic foods which can be used', 'in ambulatory treatment.', 'furthermore, it is important to give drinking water, in addition to meals, especially if the', 'ambient temperature is high or the child has a fever.', 'breastfeeding should continue in children of the appropriate age.', '2) routine medical treatment', 'in the absence of specific medical complications, the following routine treatments should be', 'implemented in both ambulatory and hospital settings:', 'infections', '– measles vaccination on admission.', '– broad spectrum antibiotic therapy starting on day 1 (amoxicillin po: 70 to 100 mg/kg/day in', '2 divided doses for 5 days)c.', '– in endemic malaria areas: rapid test on d1, with treatment in accordance with results. if', 'testing is not available, give malaria treatment (malaria, chapter 6).', 'b as a rule, any malnourished child presenting with medical complications should initially be hospitalised, even if', 's/he suffers from moderate, rather than severe, malnutrition (w/h > – 3z).', 'c if specific signs of infection are present, the choice of treatment should be directed by the suspected focus.', 'chapter 1', '42', '– treatment for intestinal worms on d8:', 'albendazole po', 'children > 6 months: 400 mg as a single dose (200 mg in children > 6 months but < 10 kg)', 'micronutrient deficiencies', 'therapeutic foods correct most of these deficiencies.', '3) management of common complications', 'diarrhoea and dehydration', 'diarrhoea is common in malnourished children. therapeutic foods facilitate the recovery of', 'gastrointestinal mucosa and restore the production of gastric acid, digestive enzymes and bile.', 'amoxicillin, administered as part of routine treatment, is effective in reducing bacterial load.', 'diarrhoea generally resolves without any additional treatment.', 'watery diarrhoea is sometimes related to another pathology (otitis, pneumonia, malaria, etc.),', 'which should be considered.', 'if an aetiological treatment is necessary, see acute diarrhoea, chapter 3.', 'if a child has a significant diarrhoea (very frequent or abundant stools) but is not dehydrated,', 'administer specific oral rehydration solution (resomal, see below), after each watery stool, to', 'avoid dehydration, according to the who treatment plan a (appendix 2). ', 'however, if the child has no profuse diarrhoea, give plain water (not resomal) after each loose', 'stool.', 'dehydration is more difficult to assess in malnourished than healthy children (e.g., delay in', 'return of skin pinch and sunken eyes are present even without dehydration in children with', 'marasmus.).', 'the diagnosis is made on the basis of a history of watery diarrhoea of recent onset', 'accompanied by weight loss, corresponding to fluid losses since the onset of diarrhoea. chronic', 'and persistent diarrhoea does not require rapid rehydration.', 'in the event of dehydration:', '– in there is no hypovolaemic shock, rehydration is made by the oral route (if necessary using a', 'nasogastric tube), with specific oral rehydration solution (resomal)d, containing less sodium', 'and more potassium than standard solutions.', 'resomal is administered under medical supervision (clinical evaluation and weight every', 'hour). the dose is 20 ml/kg/hour for the first 2 hours, then 10 ml/kg/hour until the weight', 'loss (known or estimated) has been corrected. give resomal after each watery stool', 'according to the who treatment plan a (appendix 2).', 'in practice, it is useful to determine the target weight before starting rehydration. the', 'target weight is the weight before the onset of diarrhoea. if the child is improving and', 'showing no signs of fluid overload, rehydration is continued until the previous weight', 'is attained.', 'if the weight loss cannot be measured (e.g. in newly admitted child), it can be estimated at', '2 to 5% of the child’s current weight. the target weight should not exceed 5% of the current', 'weight (e.g., if the child weighs 5 kg before starting rehydration, the target weight should not', 'exceed 5.250 kg). regardless of the target weight, rehydration should be stopped if signs of', 'fluid overload appear.', 'd except for cholera, in which case standard oral rehydration solutions are used.', 'a few symptoms and syndromes', '43', '1', '– in case of hypovolaemic shock (weak and rapid or absent radial pulse, cold extremities, crt', '≥ 3 seconds, whether or not consciousness is altered) in a child with diarrhoea or', 'dehydration:', '• place an iv line and administer 10 ml/kg of 0.9% sodium chloride over 30 minutes, under', 'close medical supervision.', 'simultaneously: ', '• start broad spectrum antibiotic therapy:', 'ceftriaxone iv 100 mg/kg/day + cloxacillin iv 200 mg/kg/day', '• administer oxygen (2 litres minimum).', '• check blood glucose level or administer 5 ml/kg of 10% glucose by iv injection.', 'every 5 minutes, evaluate clinical response (recovery of consciousness, strong pulse, ctr', '< 3 seconds) and check for signs of over-hydration.', '- if the clinical condition has improved after 30 minutes, switch to the oral route with', 'resomal: 5 ml/kg every 30 minutes for 2 hours.', '- if the clinical condition has not improved, administer again 10 ml/kg of 0.9% sodium', 'chloride over 30 minutes then, when the clinical condition has improved, switch to the', 'oral route as above.', 'when switching to the oral route, stop the infusion but leave the catheter (capped) in', 'place to keep a venous access, for iv antibiotic therapy.', 'bacterial infections', 'lower respiratory infections, otitis, skin and urinary infections are common, but sometimes', 'difficult to identify (absence of fever and specific symptoms).', 'infection should be suspected in a drowsy or apathetic child.', 'severe infection should be suspected in the event of shock, hypothermia or hypoglycaemia.', 'since the infectious focus may be difficult to determine, a broad spectrum antibiotic therapy', '(cloxacilline + ceftriaxone) is recommended.', 'fever', 'avoid antipyretics. if absolutely necessary, paracetamol po:', '10 mg/kg/dose, up to 3 times per day maximum', 'do not wrap children in wet towels or cloths: not effective, increases disconfort, risk of', 'hypothermia.', 'hypothermia and hypoglycaemia', 'hypothermia (rectal temperature < 35.5°c or axillary < 35°c) is a frequent cause of death in the', 'first days of hospitalisation.', 'prevention measures include keeping the child close to the mother ’s body (kangaroo method)', 'and provision of blankets.', 'in case of hypothermia, warm the child as above, monitor the temperature, treat hypoglycaemia.', 'severe infection should be suspected in the event of hypothermia (see above).', 'in hypoglycaemia, suspected or confirmed (test strip < 3.3 mmol/l or 60 mg/dl), administer', 'glucose po if the child is able to drink (50 ml of sugar water [50 ml water + a teaspoon of sugar]', 'or 50 ml of milk); if the child is unconscious, 5 ml/kg of 10% glucose iv, to be repeated once if', 'necessary. treat possible underlying infection.', 'oral candidiasis', 'look routinely for oral candidiadis as it interferes with feeding; see treatment chapter 3,', 'stomatitis.', 'if the child fails to recover despite appropriate nutritional and medical treatment, consider', 'another pathology: tuberculosis, hiv infection, etc.', 'chapter 1', '44', 'updated: june 2017', 'adolescents and adults', 'clinical examination of the patient (sudden weight loss, loss of mobility from muscle wasting,', 'cachexia, bilateral lower limb oedema in the absence of other causes of oedema) is', 'indispensable for the diagnosis and adapted medical, nutritional and even social care of the', 'patient.', 'admission and discharge criteria, as a rough guide, are:', '– admission criteria:', 'adolescents: w/h according to nchs-cdc-who 1982 reference table or bilateral lower limb', 'oedema (grade 3 or more, having excluded other causes of oedema).', 'adults: muac < 160 mm or bilateral lower limb oedema or muac < 185 mm in poor general', 'condition (for example, inability to stand, evident dehydration).', 'as in children, any malnourished patient presenting with significant complications should', 'initially be hospitalised, regardless of the anthropometric criteria above.', '– discharge criteria: ', 'adolescents: as in children.', 'adults: weight gain of 10-15% over admission weight and oedema below grade 2 and good', 'general condition.', 'nutritional treatment follows the same principles as in children, but the calorie intake in', 'relation to body weight is lower.', 'routine treatment is similar to that in children, with the following exceptions:', '– measles vaccine is only administered to adolescents (up to age 15).', '– antibiotics are not routinely given, but infections should be considered, and treated or', 'excluded, in the assessment of the patient.', 'a few symptoms and syndromes', '45', '1', 'chapter 2: ', 'respiratory diseases', 'acute upper airway obstruction', 'rhinitis and rhinopharyngitis (common cold)', 'acute sinusitis', 'acute pharyngitis', 'diphtheria', 'other upper respiratory tract infections', 'laryngotracheitis and laryngotracheobronchitis (croup)', 'epiglottitis', 'bacterial tracheitis', 'otitis', 'acute otitis externa', 'acute otitis media (aom)', 'chronic suppurative otitis media (csom)', 'whooping cough (pertussis)', 'bronchitis', 'acute bronchitis', 'chronic bronchitis', 'bronchiolitis', 'acute pneumonia', 'pneumonia in children under 5 years of age', 'pneumonia in children over 5 years and adults', 'persistent pneumonia', 'staphylococcal pneumonia', 'asthma', 'asthma attack (acute asthma)', 'chronic asthma', 'pulmonary tuberculosis', '2', 'acute upper airway obstruction', 'acute upper airway obstruction can be caused by foreign body aspiration, viral or bacterial', 'infections (croup, epiglottitis, tracheitis), anaphylaxis, burns or trauma.', 'initially stable and partial obstruction may worsen and develop into a life-threatening', 'emergency, especially in young children.', 'clinical features', 'clinical signs of the severity of obstruction:', 'management in all cases', '– examine children in the position in which they are the most comfortable.', '– evaluate the severity of the obstruction according to the table above.', '– monitor oxygen saturation (sao2), except in mild obstruction.', '– administer oxygen (o2), continuously:', '• to maintain the o2 saturation between 94 and 98% if it is ≤ 90%a or if the patient has', 'cyanosis or respiratory distress;', '• if pulse oxymeter is not available: at least 5 litres/minute or to relieve the hypoxia and', 'improve respiration.', '– hospitalize (except if obstruction is mild), in intensive care if danger signs.', '– monitor mental status, heart and respiratory rate, sao2 and severity of obstruction.', '– maintain adequate hydration by mouth if possible, by iv if patient unable to drink.', 'a if possible it is better to treat all patients with a sao2 < 95% with oxygen.', 'obstruction signs', 'danger', 'signs', 'complete • respiratory distress followed by cardiac arrest', 'yes', 'imminent', 'complete', '• severe respiratory distress with cyanosis or saturation o2 < 90%', '• agitation or lethargy', '• tachycardia, capillary refill time > 2 seconds', 'severe • stridor (abnormal high pitched sound on inspiration) at rest', '• severe respiratory distress:', '– severe intercostal and subcostal retractions ', '– nasal flaring', '– substernal retractions (inward movement of the breastbone', 'during inspiration)', '– severe tachypnoea', 'moderate • stridor with agitation', '• moderate respiratory distress:', '– mild intercostal and subcostal retractions', '– moderate tachypnoea ', 'no', 'mild • cough, hoarse voice, no respiratory distress ', 'respiratory diseases', '47', '2', 'management of foreign body aspiration', 'acute airway obstruction (the foreign body either completely obstructs the pharynx or acts as a', 'valve on the laryngeal inlet), no warning signs, most frequently in a child 6 months to 5 years of', 'age playing with a small object or eating. conscience is initially maintained.', 'perform maneuvers to relieve obstruction only if the patient cannot speak or cough or emit', 'any sound:', '– children over 1 year and adults:', 'heimlich manoeuvre: stand behind the patient. place a closed fist in the pit of the stomach,', 'above the navel and below the ribs. place the other hand over fist and press hard into the', 'abdomen with a quick, upward thrust. perform one to five abdominal thrusts in order to', 'compress the lungs from the below and dislodge the foreign body.', '– children under 1 year:', 'place the infant face down across the forearm (resting the forearm on the leg) and support', 'the infant’s head with the hand. with the heel of the other hand, perform one to five slaps', 'on the back, between shoulder plates.', 'if unsuccessful, turn the infant on their back. perform five forceful sternal compressions as in', 'cardiopulmonary resuscitation: use 2 or 3 fingers in the center of the chest just below the', 'nipples. press down approximately one-third the depth of the chest (about 3 to 4 cm).', 'repeat until the foreign body is expelled and the patient resumes spontaneous breathing', '(coughing, crying, talking). if the patient loses consciousness ventilate and perform', 'cardiopulmonary rescucitation. tracheostomy if unable to ventilate.', 'differential diagnosis and management of airway obstructions of', 'infectious origin', '– croup, epiglottitis, and tracheitis: see other upper respiratory tract infections. ', '– abscess: refer for surgical drainage.', 'management of other causes', '– anaphylactic reaction (quincke’s oedema): see anaphylactic shock (chapter 1)', '– burns to the face or neck, smoke inhalation with airway oedema: see burns (chapter 10).', 'infections symptoms appearance timing ofsymptoms', 'viral croup stridor, cough and moderate', 'respiratory difficulty', 'prefers to sit progressive ', 'epiglottitis stridor, high fever and severe', 'respiratory distress', 'prefers to sit, drooling', '(cannot swallow their', 'own saliva)', 'rapid', 'bacterial', 'tracheitis', 'stridor, fever, purulent secretions', 'and severe respiratory distress', 'prefers to lie flat progressive ', 'retropharyngeal', 'or tonsillar', 'abscess', 'fever, sore throat and painful', 'swallowing, earache, trismus', 'and hot potato voice', 'prefers to sit, drooling progressive', 'chapter 2', '48', 'rhinitis and rhinopharyngitis (common cold)', 'rhinitis (inflammation of the nasal mucosa) and rhinopharyngitis (inflammation of the nasal', 'and pharyngeal mucosa) are generally benign, self-limited and most often of viral origin.', 'however, they may be an early sign of another infection (e.g. measles or influenza) or may be', 'complicated by a bacterial infection (e.g. otitis media or sinusitis).', 'clinical features', '– nasal discharge or obstruction, which may be accompanied by sore throat, fever, cough,', 'lacrimation, and diarrhoea in infants. purulent nasal discharge is not indicative of a', 'secondary bacterial infection.', '– in children under 5 years, routinely check the tympanic membranes to look for an associated', 'otitis media.', 'treatment', '– antibiotic treatment is not recommended: it does not promote recovery nor prevent', 'complications.', '– treatment is symptomatic:', '• clear the nose with 0.9% sodium chloridea.', '• fever, throat soreness: paracetamol po for 2 to 3 days (fever, chapter 1).', 'a for a child: place him on his back, head turned to the side, and instil 0.9% sodium chloride into each nostril.', 'respiratory diseases', '49', '2', 'acute sinusitis', 'acute sinusitis is an inflammation of one or more of the sinus cavities, caused by an infection or', 'allergy. ', 'most acute sinus infections are viral and resolve spontaneously in less than 10 days. treatment', 'is symptomatic. ', 'acute bacterial sinusitis may be a primary infection, a complication of viral sinusitis or of dental', 'origin. the principal causative organisms are streptococcus pneumoniae, haemophilus', 'influenzae and staphylococcus aureus.', 'it is essential to distinguish between bacterial sinusitis and common rhinopharyngitis (see', 'rhinitis and rhinopharyngitis). antibiotic therapy is required in case of bacterial sinusitis only. ', 'without treatment, severe sinusitis in children may cause serious complications due to the', 'spread of infection to the neighbouring bony structures, orbits or the meninges.', 'clinical features', 'sinusitis in adults', '– purulent unilateral or bilateral discharge, nasal obstruction', 'and', '– facial unilateral or bilateral pain that increases when bending over; painful pressure in', 'maxillary area or behind the forehead. ', '– fever is usually mild or absent.', 'sinusitis is likely if symptoms persist for longer than 10 to 14 days or worsen after 5 to 7 days', 'or are severe (severe pain, high fever, deterioration of the general condition).', 'sinusitis in children', '– same symptoms; in addition, irritability or lethargy or cough or vomiting may be present. ', '– in the event of severe infection: deterioration of the general condition, fever over 39°c, peri-', 'orbital or facial oedema.', 'treatment', 'symptomatic treatment', '– fever and pain (chapter 1).', '– clear the nose with 0.9% sodium chloridea.', 'antibiotic therapy', '– in adults:', 'antibiotic therapy is indicated if the patient meets the criteria of duration or severity of', 'symptoms. oral amoxicillin is the first-line treatment.', 'if the diagnosis is uncertain (moderate symptoms < 10 days) and the patient can be re-', 'examined in the next few days, start with a symptomatic treatment, as for rhinopharyngitis', 'or viral sinusitis.', 'a for a child: place him on his back, head turned to the side, and instil 0.9% sodium chloride into each nostril.', 'chapter 2', '50', '– in children:', 'antibiotic therapy is indicated if the child has severe symptoms or mild symptoms associated', 'with risk factors (e.g. immunosuppression, sickle cell disease, asthma). oral amoxicillin is the', 'first-line treatment.', 'amoxicillin po for 7 to 10 days: ', 'children: 80 to 100 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'in the event of failure to respond within 48 hours of therapy: ', 'amoxicillin/clavulanic acid po for 7 to 10 days (the dose is expressed in amoxicillin): ', 'children < 40 kg: 45 to 50 mg/kg/day in 2 divided doses (if using ratio 8:1 or 7:1) or in', '3 divided doses (if using ratio 4:1)', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', 'children ≥ 40 kg and adults: 1500 to 2000 mg/day depending on the formulation available:', 'ratio 8:1: 2000 mg/day = 2 tablets of 500/62.5 mg 2 times per day', 'ratio 7:1: 1750 mg/day = 1 tablet of 875/125 mg 2 times per day ', 'ratio 4:1: 1500 mg/day = 1 tablet of 500/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 375 mg/day.', 'in penicillin-allergic patients:', 'erythromycin po for 7 to 10 days:', 'children: 30 to 50 mg/kg/day in 2 to 3 divided doses', 'adults: 2 to 3 g/day in 2 to 3 divided doses', '– in infants with ethmoiditis, see periorbital and orbital cellulitis (chapter 5).', 'other treatments', '– for sinusitis secondary to dental infection: dental extraction while under antibiotic', 'treatment.', '– in the event of ophthalmologic complications (ophthalmoplegia, mydriasis, reduced visual', 'acuity, corneal anesthesia), refer for surgical drainage.', 'respiratory diseases', '51', '2', 'acute pharyngitis', '– acute inflammation of the tonsils and pharynx. the majority of cases are of viral origin and do not', 'require antibiotic treatment. group a streptococcus is the main bacterial cause, and mainly', 'affects children age 3 to 14 years. ', '– acute rheumatic fever, a serious late complication of group a streptococcal pharyngitis', '(gas), can be prevented with antibiotic therapy.', '– one of the main objectives in assessing acute pharyngitis is to identify patients requiring', 'antibiotic treatment.', 'clinical features', '– features common to all types of pharyngitis: throat pain and dysphagia (difficulty', 'swallowing), with or without fever.', '– specific features, depending on the cause:', 'common forms:', '• erythematous (red throat) or exudative (red throat and whitish exudate) pharyngitis: since', 'this appearance is common to both viral and gas pharyngitis, a clinical score that allows', 'identification of children at high risk for gas should be used. the joachim score diminishes', 'empiric antibiotic use in settings where rapid testing for gas is not available. ', 'joachim score', 'age', '≤ 35 months 1', '36 to 59 months 2', '≥ 60 months 3', 'bacterial', 'signs', 'one point for each total numberof bacterial signs', 'tender cervical node', 'headache', 'petechiae on the palate', 'abdominal pain', 'sudden onset (< 12 hours)', 'take age value (1, 2 or 3) and add it to the number of bacterial', 'signs above =', 'viral signs', 'one point for each total numberof viral signs', 'conjunctivitis', 'coryza (runny nose)', 'diarrhoea', 'subtract the number of viral signs to obtain the score =', 'chapter 2', '52', 'in patients over 14 years, the probability of gas pharyngitis is low. infectious mono -', 'nucleosis (im) due to the epstein-barr virus should be suspected in adolescents and young', 'adults with extreme fatigue, generalized adenopathy and often splenomegaly.', 'erythematous or exudative pharyngitis may also be associated with gonococcal or', \"primary hiv infection. in these cases, the diagnosis is mainly prompted by the patient's\", 'history.', '• pseudomembranous pharyngitis (red tonsils/pharynx covered with an adherent greyish', 'white false membrane): see diphtheria.', 'less common forms:', '• vesicular pharyngitis (clusters of tiny blisters or ulcers on the tonsils): always viral', '(coxsackie virus or primary herpetic infection).', '• ulcero-necrotic pharyngitis: hard and painless syphilitic chancre of the tonsil; tonsillar ulcer', 'soft on palpation in a patient with poor oral hygiene and malodorous breath (vincent', 'tonsillitis).', '– local complications:', 'peritonsillar abscess: fever, intense pain, hoarse voice, trismus (limitation of mouth', 'opening), unilateral deviation of the uvula.', 'treatment', '– in all cases: paracetamol po, see fever, chapter 1.', '– joachim score is ≤ 2: viral pharyngitis, which typically resolves within a few days (or weeks,', 'for im): no antibiotic therapy. ', '– joachim score is ≥ 3: administer antibiotic therapy for gas pharyngitis:', '• if single-use injection equipment is available, benzathine benzylpenicillin is the drug of', 'choice as streptococcus a resistance to penicillin remains rare; it is the only antibiotic', 'proven effective in reducing the incidence of rheumatic fever; and the treatment is', 'administered as a single dose.', 'benzathine benzylpenicillin im', 'children under 30 kg (or under 10 years): 600 000 iu as a single dose', 'children 30 kg and over (or 10 years and over) and adults: 1.2 miu as a single dose', '• penicillin v is the oral reference treatment, but poor adherence is predictable due to the', 'length of treatment.', 'phenoxymethylpenicillin (penicillin v) po for 10 days', 'children under 1 year: 250 mg/day in 2 divided doses', 'children from 1 to 5 years: 500 mg/day in 2 divided doses', 'children from 6 to 12 years: 1 g/day in 2 divided doses', 'adults: 2 g/day in 2 divided doses', '• amoxicillin is an alternative and the treatment has the advantage of being relatively short.', 'however, it can cause adverse skin reactions in patients with undiagnosed im and thus', 'should be avoided when im has not been excluded.', 'amoxicillin po for 6 days', 'children: 50 mg/kg/day in 2 divided doses', 'adults: 2 g/day in 2 divided doses', 'respiratory diseases', '53', '2', 'updated: october 2016', '• macrolides should be reserved for penicillin allergic patients as resistance to macrolides is', 'frequent and their efficacy in the prevention of rheumatic fever has not been studied.', 'poor adherence with erythromycin is predictable due to the length of treatment.', 'azithromycin treatment has the advantage of being short.', 'erythromycin po for 10 days', 'children: 30 to 50 mg/kg/day in 2 to 3 divided doses', 'adults: 2 to 3 g/day in 2 to 3 divided doses ', 'or', 'azithromycin po for 3 days', 'children: 20 mg/kg once daily without exceeding 500 mg/day', 'adults: 500 mg once daily', '– gonococcal or syphilitic pharyngitis: as for genital gonorrhoea (chapter 9, page 252) and', 'syphilis (chapter 9, page 257).', '– diphtherial pharyngitis: see diphtheria.', '– vincent tonsillitis: penicillin v or erythromycin as above.', '– peritonsillar abscess: refer for surgical drainage.', 'chapter 2', '54', 'diphtheria', '– bacterial infection due to corynebacterium diphtheriae, characterized by proliferation of the', 'bacteria in the upper respiratory tract and systemic diffusion of the diphtheria toxin through the', 'body.', '– the infection is spread by droplets (coughing, sneezing, speaking) from the upper respiratory', 'tract of a patient or carrier.', '– the disease does not confer sufficient immunity. immunisation protects against the effects of the', 'toxin but does not prevent individuals from becoming carriers.', 'clinical features', '– incubation period: 2 to 5 days.', '– signs related to the infection:', '• pseudomembranous tonsillitis (grey, tough and very sticky membranes) with dysphagia and', 'cervical adenitis, at times progressing to massive swelling of the neck;', '• airway obstruction and possible suffocation when the infection extends to the nasal passages,', 'the larynx, the trachea and the bronchi;', '• fever is generally low-grade.', '– generalised signs due to the toxin, they determine the prognosis:', '• cardiac dysfunction (gallop on auscultation, arrhythmias), myocarditis with severe heart', 'failure at times leading to cardiogenic shock;', '• neuropathies 1 to 3 months after the onset of the disease leading to difficulty with:', 'swallowing (paralysis of the soft palate), vision (ocular motor paralysis), breathing (paralysis of', 'respiratory muscles) and ambulation (limb paralysis);', '• oliguria, anuria and renal failure.', 'laboratory', 'confirmation is made by culturing a toxigenic strain of c. diphtheriae from a throat swab.', 'management of cases (in hospital)', '– careful examination of the throat.', '– strict isolation of patients; contact and droplet precautions for medical staff (gloves, gown,', 'masks and handwashing).', '– administration of diphtheria antitoxin derived from horse serum. do not wait for bacteriological', 'confirmation any delay can diminish efficacy. administer according to the besredka method to', 'assess possibility of allergy.', '• risk of an anaphylactic reaction, especially in patients with asthma. close monitoring', 'of the patient is essential, with immediate availability of equipment for manual', 'ventilation (ambu bag, face mask) and intubation, ringer lactate and epinephrine.', '• besredka method: inject 0.1 ml sc and wait 15 minutes. if there is no allergic reaction', '(no erythema at the injection site or a flat erythema of less than 0.5 in diameter,', 'inject a further 0.25 ml sc. if there is no reaction after 15 minutes, inject the rest of', 'the product im or iv depending on the volume to be administered.', 'respiratory diseases', '55', '2', 'doses are given as a function of the severity of illness, and the delay in treatment:', '– antibiotic treatment for 14 days (or according to length of treatment recommended by the', 'national protocol):', '• if the patient can swallow:', 'azithromycin po', 'children: 20 mg/kg once daily (max. 500 mg/day)', 'adults: 500 mg once daily', 'or', 'erythromycin po', 'children: 50 mg/kg/day in 2 divided doses (max. 2 g/day)', 'adults: 2 g/day in 2 divided doses ', 'or', 'phenoxymethylpenicillin (penicillin v) po', 'children under 1 year: 50 mg/kg/day in 4 divided doses (max. 500 mg/day)', 'children from 1 to 6 years: 500 mg/day in 4 divided doses ', 'children over 6 years and adults: 1 g/day in 4 divided doses ', '• if the patient cannot swallow:', 'benzylpenicillin im or slow iv (3 minutes)', 'children: 100 000 to 150 000 iu (60 to 90 mg)/kg/day in 4 divided doses (max. 4 miu', '(2.4 g)/day)', 'adults: 4 miu (2.4 g)/day in 4 divided doses ', 'in penicillin-allergic patients, use erythromycin iva.', 'as soon as the patient can drink, change to the oral route with one of the oral treatments', 'above, to complete 14 days of treatment.', '– urgent intervention to secure an airway (intubation, tracheotomy) may be necessary in the', 'event of laryngeal obstruction, cardiac or neurologic complications.', 'management of close contacts', 'close contacts include family members living under the same roof and people who were directly', 'exposed to nasopharyngeal secretions of the patient on a regular basis (e.g. children in the same', 'class, medical personnel).', '– throat culture; temperature and throat examination daily (7 days); exclusion from school or', 'work until 48 hours of antibiotics have been completed.', 'a erythromycin iv infusion (60 minutes)', 'children: 50 mg/kg/day in 4 divided doses (max. 2 g/day); adults: 2 g/day in 4 divided doses', 'erythromycin powder (1 g) should be reconstituted in 20 ml of water for injection only. then, dilute each dose', 'of erythromycin in 10 ml/kg of 0.9% sodium chloride in children less than 20 kg and in a bag of 250 ml of 0.9%', 'sodium chloride in children over 20 kg and in adults. do not dilute in glucose.', 'cllinical signs dose in units administration route', 'laryngitis or pharyngitis ', 'or duration < 48 hours 20 to 40 000', 'im or iv infusion in 250 ml of 0.9%', 'sodium chloride in 2 to 4 hours for', 'doses of more than 20 000 ui.', 'rhinopharyngitis 40 to 60 000', 'severe form, cervical oedema', 'or duration ≥ 48 hours 80 to 100 000', 'chapter 2', '56', 'updated: october 2016', '– antibiotic treatment:', '• benzathine benzylpenicillin im', 'children under 30 kg (or under 10 years): 600 000 iu as a single dose', 'children 30 kg and over (or 10 years and over) and adults: 1.2 miu as a single dose', 'benzathine benzylpenicillin should never be administered by iv route.', '• in penicillin-allergic patients, use azithromycin or erythromycin po as above for 7 days.', '– verify vaccination status:', '• less than 3 injections: complete with dtp, dt or td according to age;', '• 3 injections: if the last injection was given more than one year before, give a booster dose.', '– medical personnel in direct contact with patients: one dose of td (booster).', 'prevention', '– once the patient has recovered update their immunisations.', '– routine vaccination (epi), for information: dtp: 3 doses at one month intervals before the age of', '1 year, dtp booster one year later, and dt (diphtheria 30 iu/tetanus) at 6 years of age followed', 'by 3 more td (diphtheria 3 iu/tetanus) boosters at 10 year intervals.', '– mass vaccination (epidemic): update routine immunisations with dtp for children under 3 years', 'of age; dt for children from 3 to 6 years of age; td for children over 7 years of age and adults.', 'respiratory diseases', '57', '2', 'updated: october 2016', 'other upper respiratory tract infections', 'laryngotracheitis and laryngotracheobronchitis (croup)', 'viral infection in children aged 3 months to 4 years. ', 'clinical features', '– typical barking cough, hoarse voice or cry.', '– inspiratory stridor (abnormal high pitched sound on inspiration):', '• croup is considered mild or moderate if the stridor only occurs with agitation;', '• croup is considered severe if there is stridor at rest, especially when it is accompanied by', 'respiratory distress.', '– wheezing may also be present if the bronchi are involved.', 'treatment', '– in the absence of inspiratory stridor or retractions, treat symptomatically: ensure adequate', 'hydration, seek medical attention if symptoms worsen (e.g. respiratory difficulty, noisy', 'breathing and inability to tolerate oral fluids).', '– if stridor is only present with agitation (moderate croup):', '• hospitalize for treatment and observation (risk of worsening).', '• assure adequate hydration.', '• dexamethasonea po (use iv preparation flavoured with sugar water, 10% or 50% glucose', 'or juice) or im if child is vomiting: 0.6 mg/kg as a single dose (see table on the next page).', '– if danger signs are present (stridor at rest, respiratory distress), hospitalize in intensive care:', '• oxygen continuously: at least 5 litres/minute or to maintain the o2 saturation between', '94 and 98%.', '• insert a peripheral iv line and provide iv hydration.', '• epinephrine (adrenaline) via nebulizer (1 mg/ml, 1 ml ampoule): 0.5 mg/kg (max. 5 mg)', 'repeat every 20 minutes if danger signs persist.', 'monitor heart rate during nebulization (if heart rate greater than 200, stop the', 'nebulization).', '* add sufficient nacl 0.9% to obtain a total volume of 4 to 4.5 ml in the nebulizing chamber.', 'epinephrine is intended exclusively for nebulized administration and should not be', 'given iv or im in croup.', 'a administer orally if possible in order to avoid causing agitation in the child as this may worsen symptoms.', 'age 3 months 4-6 months 7-9 months 10-11 months 1-4 years', 'weight 6 kg 7 kg 8 kg 9 kg 10-17 kg', 'dose in mg 3 mg 3.5 mg 4 mg 4.5 mg 5 mg', 'dose in ml 3 ml 3.5 ml 4 ml 4.5 ml 5 ml', 'nacl 0.9%* 1 ml 1 ml – – –', 'chapter 2', '58', '• dexamethasoneb (4 mg/ml, 1 ml ampoule) im or iv: 0.6 mg/kg single dose ', 'suspect bacterial tracheitis in a critically ill appearing childc with croup who does not', 'improve with the above treatment.', '– if wheezing is present:', 'salbutamol aerosol (using a spacer): 2 to 3 puffs every 20 to 30 minutes as needed', '– if the patient has a complete airway obstruction, intubation if possible or emergency', 'tracheotomy.', 'epiglottitis', 'bacterial infection of the epiglottis in young children caused by haemophilus influenzae, it is', 'rare when hib vaccine coverage is high. it can be caused by other bacteria and occur in adults. ', 'clinical features', '– rapid (less than 12-24 hours) onset of high fever.', '– typical “tripod or sniffing” position, preferring to sit, leaning forward with an open mouth,', 'anxious appearing.', '– difficulty swallowing, drooling, and respiratory distress.', '– stridor may be present (as opposed to croup, hoarse voice and cough are usually absent).', '– critically ill appearingc.', 'allow the child to sit in a comfortable position or on the parent’s lap. do not force them', 'to lie down (may precipitate airway obstruction). avoid any examination that will upset', 'the child including examination of the mouth and throat.', 'treatment', '– in case of imminent airway obstruction, emergency intubation or tracheotomy is indicated.', 'the intubation is technically difficult and should be performed under anaesthesia by a', 'physician familiar with the procedure. be prepared to perform a tracheotomy if intubation is', 'unsuccessful.', '– in all cases:', '• insert a peripheral iv line and provide intravenous hydration.', 'b administer orally if possible in order to avoid causing agitation in the child as this may worsen symptoms.', 'c critically ill appearing child: weak grunting or crying, drowsiness, difficult to arrouse, does not smile,', 'unconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'age 3-11 months 1-2 years 3-4 years', 'weight 6-9 kg 10-13 kg 14-17 kg', 'dose in mg 4 mg 8 mg 10 mg', 'dose in ml 1 ml 2 ml 2.5 ml', 'respiratory diseases', '59', '2', '• antibiotic therapy:', 'ceftriaxone slow ivd (3 minutes) or iv infusion (30 minutes). avoid im (may agitate the', 'child and precipitate a respiratory arrest).', 'children: 50 mg/kg once daily', 'adults: 1 g once daily', 'the iv treatment is administered for at least 5 days then, if the clinical condition has', 'improvede and oral treatment can be tolerated, change to:', 'amoxicillin/clavulanic acid (co-amoxiclav) po to complete a total of 7 to 10 days of', 'treatment. the dose is expressed in amoxicillin:', 'children < 40 kg: 80 to 100 mg/kg/day in 2 or 3 divided doses (use formulations in a ratio', 'of 8:1 or 7:1 exclusively)f. ', 'children ≥ 40 kg and adults:', 'ratio 8:1: 3000 mg/day (= 2 tablets of 500/62.5 mg 3 times per day)', 'ratio 7:1: 2625 mg/day (= 1 tablet of 875/125 mg 3 times per day) ', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day. ', 'bacterial tracheitis', 'bacterial infection of the trachea in children, occurring as a complication of a previous viral', 'infection (croup, influenza, measles, etc.). ', 'clinical features', '– fever in a critically ill appearing childg.', '– stridor, cough and respiratory distress.', '– copious purulent secretions.', '– as opposed to epiglottitis the onset of symptoms is gradual and the child prefers to lie flat.', '– in severe cases there is a risk of complete airway obstruction, especially in very young', 'children.', 'treatment', '– suction purulent secretions.', '– insert a peripheral iv line and provide iv hydration.', '– antibiotic therapy:', 'ceftriaxone slow ivd (3 minutes) or iv infusion (30 minutes), avoid im (may agitate the child', 'and precipitate a respiratory arrest).', 'children: 50 mg/kg once daily', 'adults: 1 g once daily', 'd for administration by iv route, ceftriaxone powder should to be reconstituted in water for injection only. for', 'administration by iv infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose', 'in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg', 'and in adults.', 'e improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'f if the only formulation of co-amoxiclav available is 4:1, the dose is 50 mg/kg/day.', 'g critically ill appearing child: weak grunting or crying, drowsiness, difficult to arrouse, does not smile,', 'unconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'chapter 2', '60', '+', 'cloxacillin iv infusion (60 minutes)', 'children less than 12 years: 100 to 200 mg/kg/day in 4 divided doses', 'children over 12 years and adults: 8 to 12 g/day in 4 divided doses', 'the iv treatment is administered for at least 5 days then, if the clinical condition has', 'improvedh and oral treatment can be tolerated, change to :', 'amoxicillin/clavulanic acid (co-amoxiclav) po to complete 7 to 10 days of treatment, as in', 'epiglottitis.', '– if the patient has a complete airway obstruction, intubation if possible or emergency', 'tracheotomy.', 'h improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'respiratory diseases', '61', '2', 'otitis', 'acute otitis externa', 'diffuse inflammation of the external ear canal, due to bacterial or fungal infection. common', 'precipitants of otitis externa are maceration, trauma of the ear canal or presence of a foreign', 'body or dermatologic diseases (such as eczema, psoriasis).', 'clinical features', '– ear canal pruritus or ear pain, often severe and exacerbated by motion of the pinna; feeling', 'of fullness in the ear; clear or purulent ear discharge or no discharge', '– otoscopy: ', '• diffuse erythema and edema, or infected eczema, of the ear canal', '• look for a foreign body', '• if visible, the tympanic membrane is normal (swelling, pain or secretions very often', 'prevent adequate visualization of the tympanic membrane)', 'treatment ', '– remove a foreign body, if present.', '– treatment of pain: paracetamol and/or ibuprofen po (chapter 1, pain, page 31).', '– local treatment (usually 5 to 7 days):', 'remove skin debris and secretions from the auditory canal by gentle dry mopping (use a dry', 'cotton bud or a small piece of dry cotton wool). in addition, 0.5% gentian violet can be', 'applied once a day, using a cotton bud.', 'consider ear irrigation (0.9% sodium chloride, using a syringe) only if the tympanic', 'membrane can be fully visualised and is intact (no perforation). otherwise, ear irrigation is', 'contra-indicated.', 'acute otitis media (aom)', 'acute inflammation of the middle ear, due to viral or bacterial infection, very common in', 'children under 3 years, but uncommon in adults.', 'the principal causative organisms of bacterial otitis media are streptococcus pneumoniae,', 'haemophilus influenzae, moraxella catarrhalis and in older children, streptococcus pyogenes.', 'clinical features', '– rapid onset of ear pain (in infants: crying, irritability, sleeplessness, reluctance to nurse) and', 'ear discharge (otorrhoea) or fever.', '– other signs such as rhinorrhoea, cough, diarrhoea or vomiting are frequently associated, and', 'may confuse the diagnosis, hence the necessity of examining the tympanic membranes.', '– otoscopy: bright red tympanic membrane (or yellowish if rupture is imminent) and presence', 'of pus, either externalised (drainage in ear canal if the tympanic membrane is ruptured) or', 'internalised (opaque or bulging tympanic membrane). the combination of these signs with ear', 'pain or fever confirms the diagnosis of aom.', 'chapter 2', '62', 'note:', 'the following otoscopic findings are not sufficient to make the diagnosis of aom:', '• a red tympanic membrane alone, with no evidence of bulging or perforation, is suggestive', 'of viral otitis in a context of upper respiratory tract infection, or may be due to prolonged', 'crying in children or high fever.', '• the presence of air bubbles or fluid behind an intact tympanic membrane, in the absence', 'of signs and symptoms of acute infection, is suggestive of otitis media with effusion', '(ome).', '– complications, particularly in high-risk children (malnutrition, immunodeficiency, ear', 'malformation) include chronic suppurative otitis media, and rarely, mastoiditis, brain abscess', 'or meningitis.', 'treatment', '– in all cases:', '• treatment of fever and pain: paracetamol po (chapter 1).', '• ear irrigation is contra-indicated if the tympanic membrane is ruptured, or when the', 'tympanic membrane cannot be fully visualised. ear drops are not indicated.', '– indications for antibiotic therapy:', '• antibiotics are prescribed in children less than 2 years, children whose assessment', 'suggests severe infection (vomiting, fever > 39°c, severe pain) and children at risk of', 'unfavourable outcome (malnutrition, immunodeficiency, ear malformation).', '• for other children:', '1) if the child can be re-examined within 48 to 72 hours: it is preferable to delay antibiotic', 'prescription. spontaneous resolution is probable and a short symptomatic treatment of', 'fever and pain may be sufficient. antibiotics are prescribed if there is no improvement', 'or worsening of symptoms after 48 to 72 hours.', '2) if the child cannot be re-examined: antibiotics are prescribed.', '• for children treated with antibiotics: advise the mother to bring the child back if fever and', 'pain persist after 48 hours.', '– choice of antibiotic therapy:', '• amoxicillin is the first-line treatment:', 'amoxicillin po', 'children: 80 to 100 mg/kg/day in 3 divided doses for 5 days', 'adults: 3 g/day in 3 divided doses for 5 days', '• amoxicillin/clavulanic acid is used as second-line treatment, in the case of treatment', 'failure. treatment failure is defined as persistence of fever and/or ear pain after 48 hours', 'of antibiotic treatment.', 'amoxicillin/clavulanic acid (co-amoxiclav) po for 5 days', 'the dose is expressed in amoxicillin:', 'children < 40 kg: 45 to 50 mg/kg/day in 2 divided doses (if using ratio 8:1 or 7:1) or in', '3 divided doses (if using ratio 4:1)', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', 'children ≥ 40 kg and adults: 1500 to 2000 mg/day depending on the formulation available:', 'ratio 8:1: 2000 mg/day = 2 tablets of 500/62.5 mg 2 times per day', 'ratio 7:1: 1750 mg/day = 1 tablet of 875/125 mg 2 times per day', 'ratio 4:1: 1500 mg/day = 1 tablet of 500/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 375 mg/day', 'respiratory diseases', '63', '2', 'persistence of a ear drainage alone, without fever and pain, in a child who has otherwise', 'improved (reduction in systemic symptoms and local inflammation) does not warrant a', 'change in antibiotic therapy. clean ear canal by gentle dry mopping until no more drainage is', 'obtained.', '• azithromycin or erythromycin should be reserved for very rare penicillin-allergic patients,', 'as treatment failure (resistance to macrolides) is frequent.', 'azithromycin po', 'children over 6 months: 10 mg/kg once daily for 3 days', 'erythromycin po ', '30 to 50 mg/kg/day in 2 to 3 divided doses for 10 days', 'chronic suppurative otitis media (csom)', 'chronic bacterial infection of the middle ear with persistent purulent discharge through a', 'perforated tympanic membrane.', 'the principal causative organisms are pseudomonas aeruginosa, proteus spp, staphylococcus,', 'other gram negatives and anaerobes.', 'clinical features', '– purulent discharge for more than 2 weeks, often associated with hearing loss or even', 'deafness; absence of pain and fever', '– otoscopy: perforation of the tympanic membrane and purulent exudate', '– complications:', '• consider a superinfection (aom) in the case of new onset of fever with ear pain, and treat', 'accordingly.', '• consider mastoiditis in the case of new onset of high fever, severe ear pain and/or tender', 'swelling behind the ear, in a patient who appears significantly unwell.', '• consider brain abscess or meningitis in the case of impaired consciousness, neck stiffness', 'and focal neurological signs (e.g. facial nerve paralysis).', 'treatment', '– remove secretions from the auditory canal by gentle dry mopping (use a dry cotton bud or a', 'small piece of dry cotton wool) then apply ciprofloxacin (ear drops): 2 drops twice daily, until', 'no more drainage is obtained (max. 4 weeks).', '– complications:', '• chronic mastoiditis is a medical emergency that requires prompt hospitalisation,', 'prolonged antibiotic treatment that covers the causative organisms of csom (ceftriaxone', 'im 10 days + ciprofloxacin po for 14 days), atraumatic cleaning of the ear canal; surgical', 'treatment may be required. before transfer to hospital, if the patient needs to be', 'transferred, administer the first dose of antibiotics.', '• meningitis (chapter 7).', 'chapter 2', '64', 'whooping cough (pertussis)', 'whooping cough is a highly contagious bacterial infection of the lower respiratory tract, of', 'prolonged duration, due to bordetella pertussis.', 'b. pertussis is transmitted through inhalation of droplets spread by infected individuals', '(coughing, sneezing).', 'the majority of cases arise in non-vaccinated or incompletely vaccinated individuals. whooping', 'cough affects all age groups. signs and symptoms are usually minor in adolescents and adults.', 'as a result the infection may be ignored, thus contributing to the spread of b. pertussis and', 'infection in infants and young children, in whom the illness is severe.', 'clinical features', 'after an incubation period of 7 to 10 days, the illness evolves in 3 phases:', '– catarrhal phase (1 to 2 weeks): coryza and cough. at this stage, the illness is indistinguishable', 'from a minor upper respiratory infection.', '– paroxysmal phase (1 to 6 weeks):', '• typical presentation: cough of at least 2 weeks duration, occurring in characteristic bouts', '(paroxysms), followed by a laboured inspiration causing a distinctive sound (whoop), or', 'vomiting. fever is absent or moderate, and the clinical exam is normal between coughing', 'bouts; however, the patient becomes more and more fatigued.', '• atypical presentations:', '- infants under 6 months: paroxysms are poorly tolerated, with apnoea, cyanosis;', 'coughing bouts and whoop may be absent.', '- adults: prolonged cough, often without other symptoms.', '• complications: ', '- major: in infants, secondary bacterial pneumonia (new-onset fever is an indicator);', 'malnutrition and dehydration triggered by poor feeding due to cough and vomiting; rarely,', 'seizures, encephalopathy; sudden death.', '- minor: subconjunctival haemorrhage, petechiae, hernias, rectal prolapse.', '– convalescent phase: symptoms gradually resolve over weeks or months.', 'management and treatment', 'suspect cases', '– routinely hospitalise infants less than 3 months, as well as children with severe cases.', 'infants under 3 months must be monitored 24 hours per day due to the risk of apnoea.', '– when children are treated as outpatients, educate the parents about signs that should lead', 'to re-consultation (fever, deterioration in general condition, dehydration, malutrition,', 'apnoea, cyanosis).', '– respiratory isolation (until the patient has received 5 days of antibiotic treatment):', '• at home: avoid contact with non-vaccinated or incompletely vaccinated infants;', '• in congregate settings: exclusion of suspect cases;', '• in hospital: single room or grouping together of cases away from other patients', '(cohorting).', 'respiratory diseases', '65', '2', '– hydration and nutrition: ensure children < 5 years are well hydrated; breastfeeding should', 'continue. advise mothers to feed the child frequently in small quantities after coughing', 'bouts and the vomiting which follows. monitor the weight of the child during the course of', 'the illness, and consider food supplements for several weeks after recovery.', '– antibiotic therapy:', 'antibiotic treatment is indicated in the first 3 weeks after onset of cough. infectivity is', 'virtually nil after 5 days of antibiotic treatment. ', '– for hospitalised children:', '• place the child in a semi-reclining position (± 30°).', '• oro-pharyngeal suction if needed.', 'post-exposure prophylaxis', '– antibiotic prophylaxis (same treatment as for suspect cases) is recommended for', 'unvaccinated or incompletely vaccinated infants of less than 6 months, who have had', 'contact with a suspect case.', '– isolation of contacts is not necessary.', 'note: pertussis vaccination should be updated in all cases (suspects and contacts). if the', 'primary series has been interrupted, it should be completed, rather than restarted from the', 'beginning.', 'prevention', 'routine vaccination with polyvalent vaccines containing pertussis antigens (e.g. dtp, or dtp', '+ hep b, or dtp + hib + hep b) from the age of 6 weeks or according to national protocol.', 'neither vaccination nor natural disease confers lasting immunity. booster doses are necessary', 'to reinforce immunity and reduce the risk of developing disease and transmitting it to young', 'children.', 'antibiotic children adults', 'fi', 'rs', 't l', 'in', 'e', 'azithromycin po', 'once daily,', 'for 5 days', '10 mg/kg/day (max. 500 mg/day) d1 500 mg', 'd2-d5 250 mg/day', 'a', 'lt', 'er', 'na', 'ti', 've', 's', 'erythromycin po', 'in 3 divided doses/day,', 'for 7 days', '50 mg/kg/day', '(avoid in infant < 1 month of age)', '1 g/day', 'cotrimoxazole po', 'in 2 divided doses/day,', 'for 14 days', '40 mg/kg/day smx', '+ 8 mg/kg/day tmp', '(avoid in infant < 1 month of age,', 'and last month of pregnancy)', '1600 mg/day smx', '+ 320 mg/day tmp', 'chapter 2', '66', 'bronchitis', 'acute bronchitis', 'an acute inflammation of the bronchial mucosa, most commonly of viral origin. in older', 'children it can be caused by mycoplasma pneumoniae. in children over 2 years of age with', 'repetitive acute bronchitis or ‘wheezing’ bronchitis, consider asthma (see asthma). in children', 'under 2 years of age, consider bronchiolitis (see bronchiolitis).', 'clinical features', 'often begins with a rhinopharyngitis that descends progressively: pharyngitis, laryngitis,', 'tracheitis.', '– heavy cough, dry at the beginning then becoming productive', '– low-grade fever', '– no tachypnoea, no dyspnoea', '– on pulmonary auscultation: bronchial wheezing', 'treatment', '– fever: paracetamol po (chapter 1).', '– keep the patient hydrated, humidify air (with a bowl of water or a wet towel).', '– children: nasal irrigation with 0.9% sodium chloride or ringer lactate, 4 to 6 times/day to', 'clear the airway.', '– antibiotic treatment is not useful for patients in good overall condition with rhinopharyngitis', 'or influenza.', '– antibiotic treatment is indicated only if:', '• the patient is in poor general condition: malnutrition, measles, rickets, severe anaemia,', 'cardiac disease, elderly patient etc.', '• if the patient has dyspnoea, fever greater than 38.5°c and purulent expectorations: a', 'secondary infection with haemophilus influenzae or with pneumococcus is probable.', 'amoxicillin po', 'children: 100 mg/kg/day in 3 divided doses for 5 days', 'adults: 3 g/day in 3 divided doses for 5 days', 'chronic bronchitis', 'a chronic inflammation of the bronchial mucosa due to irritation (tobacco, pollution), allergy', '(asthma) or infection (repetitive acute bronchitis). it may develop into chronic obstructive', 'pulmonary disease.', 'clinical features', '– productive cough for 3 consecutive months per year for 2 successive years.', '– no dyspnoea at onset. dyspnoea develops after several years, first on exertion, then', 'becoming persistent.', '– on pulmonary auscultation: bronchial wheeze (always exclude tuberculosis).', 'respiratory diseases', '67', '2', 'a patient with an acute exacerbation of chronic bronchitis presents with:', '– onset or increase of dyspnoea.', '– increased volume of sputum.', '– purulent sputum.', 'treatment', '– antibiotic treatment is not useful in treating simple chronic bronchitis.', '– antibiotic treatment may be useful, for patients in a poor general condition only, for acute', 'exacerbations of chronic bronchitis (see acute bronchitis).', '– discourage smoking and other irritating factors.', 'chapter 2', '68', 'bronchiolitis', 'bronchiolitis is an epidemic and seasonal viral infection of the lower respiratory tract in', 'children less than 2 years of age, characterised by bronchiolar obstruction.', 'respiratory syncytial virus (rsv) is responsible for 70% of cases of bronchiolitis. transmission of', 'rsv is direct, through inhalation of droplets (coughing, sneezing), and indirect, through contact', 'with hands or materials contaminated by infected secretions.', 'in the majority of cases, bronchiolitis is benign, resolves spontaneously (relapses are possible),', 'and can be treated on an outpatient basis.', 'severe cases may occur, which put the child at risk due to exhaustion or secondary bacterial', 'infection. hospitalisation is necessary when signs/criteria of severity are present (10 to 20% of', 'cases).', 'clinical features', '– tachypnoea, dyspnoea, wheezing, cough; profuse, frothy, obstructive secretions.', '– on auscultation: prolonged expiration with diffuse, bilateral wheezes; sometimes diffuse', 'fine, end-inspiratory crackles.', 'rhinopharyngitis, with dry cough, precedes these features by 24 to 72 hours; fever is absent or', 'moderate.', '– signs of severity:', '• significant deterioration in general condition, toxic appearance (pallor, greyish', 'colouration)', '• apnoea, cyanosis (check lips, buccal mucosa, fingernails)', '• respiratory distress (nasal flaring, sternal and chest wall indrawing) ', '• anxiety and agitation (hypoxia), altered level of consciousness', '• respiratory rate > 60/min', '• decreased respiratory distress and slow respirations (< 30/min below the age of 1 year', 'and < 20/min below the age of 3 years, exhaustion). exercise caution in interpreting these', 'signs as indicators of clinical improvement.', '• sweats, tachycardia at rest and in the absence of fever', '• silence on auscultation (severe bronchospasm)', '• difficulty drinking or sucking (reduced tolerance for exertion)', 'treatment', 'treatment is symptomatic. obstructive signs and symptoms last for about 10 days; cough may', 'persist for 2 weeks longer.', 'hospitalise children with one of the following criteria:', '– presence of any sign of severity', '– pre-existing pathology (cardiac or pulmonary disease, malnutrition, hiv, etc.)', 'consider hospitalisation on a case-by-case basis in the following situations:', '– associated acute pathology (viral gastro-enteritis, bacterial infection, etc.)', '– age less than 3 months', 'in all other cases, the child may be treated at home, provided the parents are taught how to', 'carry out treatment, and what signs of severity should lead to re-consultation.', 'respiratory diseases', '69', '2', 'outpatient treatment', '– nasal irrigation with 0.9% nacl before each feeding (demonstrate the technique to the', 'mother)a.', '– small, frequent feedings to reduce vomiting triggered by bouts of coughing.', '– increased fluids if fever and/or significant secretions are present.', '– treat fever (chapter 1).', '– handle the patient the patient as little as possible and avoid unnecessary procedures.', 'hospitalisation', '– in all cases:', '• place the infant in a semi-reclining position (± 30°).', '• nasal irrigation, small, frequent feeds, treatment of fever: as for outpatient treatment.', '• gentle oro-pharyngeal suction if needed.', '• monitor fluid intake: normal requirements are 80 to 100 ml/kg/day + 20 to 25 ml/kg/day', 'with high fever or very profuse secretions.', '– according to symptoms:', '• humidified nasal oxygen (1 to 2 litres/min). ', '• when there is vomiting or significant fatigue when sucking, fluid requirements may be', 'administered by nasogastric tube (small volumes on a frequent basis) or the iv route, for', 'the shortest possible time. avoid breastfeeding or oral feeds in children with severe', 'tachypnoea, but do not prolong ng feeds (respiratory compromise) or iv infusions any', 'longer than necessary.', '• bronchodilator therapy: this therapy may be considered after a trial treatment has been', 'given (salbutamol inhaler, 100 micrograms/puff: 2 to 3 puffs with spacer, repeated twice at', 'an interval of 30 minutes). if inhaled salbutamol appears effective in relieving symptoms,', 'the treatment is continued (2 to 3 puffs every 6 hours in the acute phase, then gradual', 'reduction as recovery takes place). if the trial is ineffective, the treatment is discontinued.', '• antibiotics are not indicated unless there is concern about complications such as', 'secondary bacterial pneumonia. ', 'prevention and control', 'the risk of transmission of the virus is increased in hospital settings:', '– children with bronchiolitis should be grouped together, away from other children', '(cohorting). ', '– as infection is most commonly transmitted by the hands, the most important prevention', 'measure is hand-washing after any contact with patients, and objects or surfaces in contact', 'with patients on which the virus may survive for several hours.', '– in addition, staff should wear gowns, gloves and surgical masks when in contact with', 'patients.', 'a lie the child on his back, head turned to the side and instil 0.9% nacl into the nose, one nostril at a time.', 'chapter 2', '70', 'acute pneumonia', 'acute pneumonia is a viral, bacterial (pneumococcus, haemophilus influenzae, staphylococcus,', 'atypical bacteria) or parasitic (pneumocystosis) infection of the pulmonary alveoli.', 'pneumonia in children under 5 years of age', 'the most common causes are viruses, pneumococcus and haemophilus influenzae.', 'clinical examination must be done on a calm child in order to correctly count the respiratory', 'rate and look for signs of serious illness.', 'clinical features', 'pneumonia should be suspected in a child who presents with cough or difficulty breathing.', 'fever is often high (> 39°c), but the child may present with low-grade fever or may have no', 'fever (often a sign of serious illness).', 'the respiratory rate (rr) should be measured over 1 minute. a child has tachypnoea (increased', 'respiratory rate) if:', 'rr ≥ 60 breaths/minute in children under 2 months', 'rr ≥ 50 breaths/minute in children from 2 to 11 months', 'rr ≥ 40 breaths/minute in children from 12 months to 5 years', 'on pulmonary auscultation: dullness with diminished vesicular breath sounds, crepitations and', 'sometimes bronchial breathing or normal pulmonary auscultation.', 'signs of serious illness (severe pneumonia) include:', '– chest indrawing: the inferior thoracic wall depresses on inspiration as the superior abdomen', 'expands', '– cyanosis (lips, oral mucosa, fingernails) or o2 saturation < 90%', '– nasal flaring', '– altered consciousness (child is abnormally sleepy or difficult to wake)', '– stridor (hoarse noise on inspiration)', '– grunting (a short repetitive noise produced by a partial closure of the vocal cords) on', 'expiration', '– refusal to drink or feed', '– children under 2 months', '– severe malnutrition', 'notes: ', '– in malnourished children, the rr thresholds should be decreased by 5 breaths/minute from', 'those listed above.', '– chest indrawing is significant if it is clearly visible and present at all times. if it is observed', 'when a child is upset or feeding and is not visible when the child is resting, there is no chest', 'indrawing.', '– in children under 2 months of age, moderate chest indrawing is normal as the thoracic wall is', 'flexible.', '– if only the soft tissues between the ribs or above the clavicles depress, there is no chest', 'indrawing.', 'respiratory diseases', '71', '2', 'consider also:', '– malaria in endemic areas, as it may also cause cough and tachypnoea. ', '– staphylococcal pneumonia in patients with empyema or painful abdominal swelling and', 'diarrhoea.', '– pneumocystosis in patients with confirmed or suspected hiv infection (see hiv infection and', 'aids, page 230, chapter 8).', '– tuberculosis:', '• in a child with cough, fever and poor weight gain and a history of close contact with a', 'tuberculous patienta. for the diagnosis, refer to the msf handbook, tuberculosis.', '• in the event of pneumonia complicated with empyema (pus in the pleural space).', 'diagnosis of pneumonia in children under 5 presenting with cough or difficulty breathing:', 'chest indrawing present?', 'with ou without other', 'signs of serious illness', 'increased rr? severe pneumonia', 'cough pneumonia', 'upper respiratory tract infections', 'a contact is defined as living in the same household, or in close and regular contact with any known or suspected', 'tb case within the last 12 months.', 'children from 2 to 11 months rr ≥\\u200850 breaths/minute', 'children from 12 to 59 months rr ≥\\u200840 breaths/minute', 'children under 2 months rr ≥\\u200860 breaths/minute', 'chapter 2', '72', 'no yes', 'yesno', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'treatment', 'severe pneumonia (inpatient treatment)', 'infants under 2 months of age', 'the first line treatment is the combination ampicillin slow iv (3 minutes) for 10 days + gentamicin', 'slow iv (3 minutes) or im for 5 days:', 'for ampicillin, iv route is preferred but im route may be an alternative.', 'benzylpenicillin procain im, 50 000 iu/kg once daily (50 mg/kg once daily) for 10 days', '(combined with gentamicin im as above), may be an alternative to ampicillin in contexts where', 'ampicillin cannot be properly administered. however ampicillin remains the drug of choice.', 'benzylpenicillin procain must never be administered by iv route.', 'if penicillins are not available, alternatives may be cefotaxime slow iv (3 minutes) or infusion', '(20 minutes) or im for 10 days (for doses, see meningitis, chapter 7), or, as a last resort:', 'ceftriaxone slow ivb (3 minutes) or infusion (30 minutes; 60 minutes in neonates) or im:', '50 mg/kg once daily for 10 days.', \"if the child's condition does not improvec after 48 hours of well administered treatment, add\", 'cloxacillin iv for 10 to 14 days:', 'children from 2 months to 5 years of age', 'the first line treatment is:', 'ceftriaxone im or slow ivb (3 minutes): 50 mg/kg once daily', 'or', 'ampicillin slow iv (3 minutes) or im: 200 mg/kg/day in 3 to 4 divided doses', '+ gentamicin slow iv (3 minutes) or im: 6 mg/kg once daily', 'ampicillin is preferably administered in 4 divided doses. if the context does not permit it, the', 'daily dose must be divided in at least 3 injections.', 'b the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'c improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'children 0 - 7 days', '< 2 kg cloxacillin 100 mg/kg/day in 2 divided doses', '≥ 2 kg cloxacillin 150 mg/kg/day in 3 divided doses', 'children > 7 days', '< 2 kg cloxacillin 150 mg/kg/day in 3 divided doses', '≥ 2 kg cloxacillin 200 mg/kg/day in 4 divided doses', 'children', '0 - 7 days', '< 2 kg', 'ampicillin 100 mg/kg/day in 2 divided doses', '+ gentamicin 3 mg/kg once daily', '≥ 2 kg', 'ampicillin 150 mg/kg/day in 3 divided doses', '+ gentamicin 5 mg/kg once daily', 'children', '8 days - < 1 month', 'ampicillin 150 mg/kg/day in 3 divided doses', '+ gentamicin 5 mg/kg once daily', 'children', '1 month - < 2 months', 'ampicillin 200 mg/kg/day in 3 or 4 divided doses', '+ gentamicin 6 mg/kg once daily', 'respiratory diseases', '73', '2', 'the treatment is administered by parenteral route for at least 3 days then, if the clinical', 'condition has improvedd and oral treatment can be tolerated, switch to the oral route with', 'amoxicillin po: 100 mg/kg/day in 3 divided doses, to complete 10 days of treatment.', \"if the child's condition deteriorates or does not improve after 48 hours of correct administration,\", 'add cloxacillin iv: 100 to 200 mg/kg/day in 4 divided doses. after clinical improvement and 3 days', 'with no fever, switch to the oral route with amoxicillin/clavulanic acid (co-amoxiclav) po to', 'complete 10 to 14 days of treatment:', 'the dose is expressed in amoxicillin: 100 mg/kg/day in 2 divided doses (if using formulations in', 'a ratio of 8:1 or 7:1)e.', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', \"if the child's condition does not improve after 48 hours with ceftriaxone + cloxacillin, consider\", 'tuberculosis. for the diagnosis, refer to the msf handbook, tuberculosis.', 'if tuberculosis is unlikely, continue with ceftriaxone + cloxacillin and add azithromycin (see', 'atypical pneumonia).', 'notes:', '– for malnourished children, refer to specific protocol.', '– in the event of moderate-large empyema, assess if drainage is required. administer', 'antibiotics active against pneumococci and staphylococci (see staphylococcal pneumonia).', 'adjuvant therapy', '– fever: paracetamol po (chapter 1).', '– infants: keep warm.', '– install on an incline (head elevated) or in semi-sitting position.', '– clear the airway (nasal irrigation with 0.9% sodium chloride if needed).', '– oxygen at the flow rate required to maintain spo2 ≥ 90% or, if pulse oxymeter is not', 'available, minimum 1 litre/minute.', '– maintain adequate hydration and nutrition:', '• in children with severe respiratory difficulty: place an iv line and give 70% of normal', 'maintenance fluids. resume oral feeding as soon as possible (no severe respiratory', 'difficulty, ability to eat normally).', 'use a nasogastric tube only if an iv line cannot be established: children under 12 months:', '5 ml/kg/hour; children over 12 months: 3 to 4 ml/kg/hour; alternate milk and water.', 'resume normal oral feeding as soon as possible.', '• in the absence of severe respiratory difficulty: breastfeed on demand; milk/food and', 'water by spoon on demand.', '• ors when required (appendix 2). ', 'pneumonia with no signs of serious illness', 'infant under 2 months of age', 'admit the child for inpatient care and treat for severe pneumonia.', 'children from 2 months to 5 years of age (outpatients, except young infants)', 'amoxicillin po: 100 mg/kg/day in 3 divided doses for 5 days', 'd improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'e if the only formulations of co-amoxiclav available are those with a 4:1 ratio, the dose is: 50 mg/kg/day.', 'chapter 2', '74', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'follow-up in 48 to 72 hours or sooner if the child’s condition deteriorates:', '– if the condition is improvingf: continue with the same antibiotic to complete treatment.', '– if there is no improvement after 3 days of correct administration: add azithromycin (see', 'atypical pneumonia).', '– if the condition is deteriorating: hospitalise and treat as severe pneumonia.', 'pneumonia in children over 5 years and adults', 'the most common causes are viruses, pneumococcus, and mycoplasma pneumoniae.', 'clinical features', '– cough, with or without purulent sputum, fever, thoracic pain, tachypnoea', '– on pulmonary auscultation: decreased vesicular breath sounds, dullness, localised foci of', 'crepitations, sometimes bronchial wheeze.', 'sudden onset with high fever (higher than 39°c), thoracic pain and oral herpes are suggestive', 'of pneumococcal infection. symptoms may be confusing, particularly in children with', 'abdominal pain, meningeal syndrome, etc.', 'signs of serious illness (severe pneumonia) include:', '– cyanosis (lips, oral mucosa, fingernails)', '– nasal flaring', '– iintercostal or subclavial indrawing', '– rr > 30 breaths/minute', '– heart rate > 125 beats/minute', '– altered level of consciousness (drowsiness, confusion)', 'patients at risk include the elderly, patients suffering from heart failure, sickle cell disease or', 'severe chronic bronchitis; immunocompromised patients (severe malnutrition, hiv infection', 'with cd4 < 200).', 'treatment', 'severe pneumonia (inpatient treatment)', 'benzylpenicillin procaine im', 'children: 50 000 iu/kg once daily', 'adults: 1.5 miu once daily', 'benzylpenicillin procain must never be administered by iv route.', 'the treatment is given by parenteral route for at least 3 days then, if the clinical condition has', 'improvedf and oral treatment can be tolerated, switch to the oral route with amoxicillin po to', 'complete 7 to 10 days of treatment:', 'children: 100 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'f improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'respiratory diseases', '75', '2', 'or', 'ceftriaxone im or slow ivg (3 minutes)', 'children: 50 mg/kg once daily', 'adults: 1 g once daily', 'the treatment is given by parenteral route for at least 3 days then, if the clinical condition has', 'improvedh and oral treatment can be tolerated, switch to the oral route with amoxicillin po as', 'above, to complete 7 to 10 days of treatment.', 'or', 'ampicillin slow iv (3 minutes) or im', 'children: 200 mg/kg/day in 3 to 4 divided doses', 'adults: 3 to 4 g/day in 3 to 4 divided doses', 'ampicillin is preferably administered in 4 divided doses. if the context does not permit it, the', 'daily dose must be divided in at least 3 injections.', 'the treatment is given by parenteral route for at least 3 days then, if the clinical condition has', 'improvedh and oral treatment can be tolerated, switch to the oral route with amoxicillin po as', 'above, to complete 7 to 10 days of treatment.', 'if the clinical condition deteriorates or does not improve after 48 hours of correct administration,', 'administer ceftriaxone as above + cloxacillin iv:', 'children: 100 to 200 mg/kg/day in 4 divided doses', 'adults: 8 g/day in 4 divided doses', 'after clinical improvement and 3 days with no fever, switch to the oral route with amoxicillin/', 'clavulanic acid (co-amoxiclav) po to complete 10 to 14 days of treatment:', 'the dose is expressed in amoxicillin:', 'children: 100 mg/kg/day in 2 divided doses (if using formulations in a ratio of 8:1 or 7:1)i', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', 'adults: 2.5 to 3 g/day in 3 divided doses. depending on the formulation of co-amoxiclav', 'available:', 'ratio 8:1: 3000 mg/day = 2 tablets of 500/62.5 mg 3 times per day', 'ratio 7:1: 2625 mg/day = 1 tablet of 875/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 375 mg/day.', 'if the clinical condition does not improve after 48 hours with ceftriaxone + cloxacillin, consider', 'tuberculosis. for the diagnosis, refer to the msf handbook, tuberculosis.', 'if tuberculosis is unlikely, continue with ceftriaxone + cloxacillin and add azithromycin (see', 'atypical pneumonia).', 'adjuvant therapy', '– fever: paracetamol po (chapter 1).', '– clear the airway (nasal irrigation with 0.9% sodium chloride if needed).', '– oxygen at the flow rate required to maintain spo2 ≥ 90% or, if pulse oxymeter is not', 'available, minimum 1 litre/minute.', '– maintain adequate hydration and nutrition.', 'g the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'h improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'i if the only formulations of co-amoxiclav available are those with a 4:1 ratio, the dose is: 50 mg/kg/day.', 'chapter 2', '76', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'pneumonia without signs of serious illness (outpatient treatment)', 'amoxicillin po', 'children: 100 mg/kg/day in 3 divided doses for 5 days', 'adults: 3 g/day in 3 divided doses for 5 days', 'follow-up in 48 to 72 hours or sooner if the child’s condition deteriorates:', '– if the condition is improvingj: continue with the same antibiotic to complete treatment.', '– if there is no improvement after 3 days of correct administration: add azithromycin (see', 'atypical pneumonia).', '– if the condition is deteriorating: hospitalise and treat as severe pneumonia.', 'persistent pneumonia', 'in patients not responding to therapy, consider atypical pneumonia, tuberculosis, pneumocystosis', '(hiv infection and aids, page 230, chapter 8).', 'bacteria responsible for atypical pneumonia are mainly mycoplasma pneumoniae and', 'chlamydophila pneumoniae. if suspected, one of the following antibiotics may be used:', 'first choice, azithromycin po', 'children: 10 mg/kg once daily (max. 500 mg/day) for 5 days', 'adults: 500 mg on d1 then, 250 mg once daily from d2 to d5', 'if not available,', 'erythromycin po ', 'children: 30 to 40 mg/kg/day in 4 divided doses for 10 to 14 days', 'adults: 2 g/day in 4 divided doses for 10 to 14 days', 'or', 'doxycycline po (except in children under 8 years and pregnant or lactating women)', 'children: 4 mg/kg/day (max. 200 mg/day) in 2 divided doses for 10 to 14 days', 'adults: 200 mg/day in 2 divided doses for 10 to 14 days', 'j improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'respiratory diseases', '77', '2', 'staphylococcal pneumonia', 'pneumonia due to staphylococcus aureus affecting young children, often those in a poor general', 'condition (malnutrition, skin lesions, etc.). staphylococcal pneumonia is a classic complication of', 'measles.', 'clinical features', '– general signs: change in overall condition, pallor, high fever or hypothermia, frequently signs', 'of shock; presence of skin lesions (point of bacterial entry), however, skin lesions may be', 'absent.', '– gastrointestinal signs: nausea, vomiting, diarrhoea, painful abdominal distention.', '– respiratory signs: dry cough, tachypnoea, signs of distress (nasal flaring, chest indrawing).', 'pulmonary auscultation is often normal; sometimes dullness indicating pleural effusion.', 'if possible, take a chest x-ray: the presence of bullae confirms the diagnosis. pleural effusion,', 'often unilateral, may also be seen.', 'treatment', 'treatment is urgent as patients deteriorate quickly: hospitalise.', '– antibiotic treatment: if staphylococcal aetiology cannot be confirmed or while waiting for', 'confirmation, a broad spectrum antibiotic therapy is recommended:', 'ceftriaxone im or slow iva (at least 3 minutes): 50 mg/kg once daily', '+ cloxacillin iv infusion (60 minutes)b', 'neonates 0 to 7 days (< 2 kg): 100 mg/kg/day in 2 divided doses', 'neonates 0 to 7 days (≥ 2 kg): 150 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (< 2 kg): 150 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (≥ 2 kg): 200 mg/kg/day in 4 divided doses', 'children 1 month and over: 100 to 200 mg/kg/day in 4 divided doses (max. 8 g/day)', 'after clinical improvementc, 3 days with no fever, and drain removal if any, switch to the oral', 'route with amoxicillin/clavulanic acid po to complete 10 to 14 days:', 'the dose is expressed in amoxicillin:', '100 mg/kg/day in 2 divided doses (if using formulations in a ratio of 8:1 or 7:1)d', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', 'a the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'b cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. then dilute each dose of', 'cloxacillin in 5 ml/kg of 0.9% sodium chloride or 5 % glucose in children less than 20 kg and in a bag of 100 ml of', '0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'c improvement criteria include: fever reduction, diminished respiratory distress, improved o2 saturation,', 'improved appetite and/or activity.', 'd if the only formulations of co-amoxiclav available are those with a 4:1 ratio, the dose is: 50 mg/kg/day.', 'chapter 2', '78', 'in the event of large empyema: same treatment but switch to the oral route after 7 days', 'with no fever and treat for 3 weeks.', 'clindamycin iv may be an alternative to cloxacillin: 30 mg/kg/day in 3 divided injections then', 'switch to clindamycin po at the same dose, according to the criteria above.', '– fever: paracetamol (chapter 1).', '– hydration by oral route or infusion or nasogastric tube depending on clinical condition (see', 'page 73).', '– oxygen at the flow rate required to maintain spo2 ≥ 90% or, if pulse oxymeter is not', 'available, minimum 1 litre/minute.', '– local disinfection of skin lesions.', '– if there is significant pleural effusion: pleural tap with drainage (for pyopneumothorax; insert', '2 drains, one anterior and one posterior) or without drainage (for suppurative pleurisy, make', 'repetitive taps with an iv catheter).', 'clinical evolution', '– there is a serious risk of decompensation from pneumothorax or suppurative pleurisy or', 'pyopneumothorax.', '– on a paediatric ward, adequate equipment for urgent pleural drainage should always be', 'available.', 'respiratory diseases', '79', '2', 'asthma', 'asthma is a chronic inflammatory disorder of the airways associated with airway hyper-', 'responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness', 'and coughing. these episodes are usually associated with airflow obstruction within the lung,', 'often reversible, either spontaneously or with treatment.', 'factors that precipitate/aggravate asthma include: allergens, infection, exercise, drugs', '(aspirin), tobacco, etc.', 'in young children, most initial episodes of asthma-like symptoms are associated with a', 'respiratory tract infection, with no symptoms between infections. wheezing episodes usually', 'become less frequent with time; most of these children do not develop asthma.', 'asthma attack (acute asthma)', 'asthma attack is a substantial worsening of asthma symptoms. the severity and duration of', 'attacks are variable and unpredictable.', 'assessment of the severity of asthma attack', 'the severity of the asthma attack must be rapidly evaluated by the following clinical criteria.', 'not all signs are necessarily present.', 'assessment of severity in children under 2 years and adults', 'mild to moderate attack severe attack life threatening attack', 'able to talk in sentences', 'respiratory rate (rr)', 'children 2-5 years ≤ 40/min', 'children > 5 years ≤ 30/min', 'pulse', 'children 2-5 years ≤ 140/min', 'children > 5 years ≤ 125/min', 'and', 'no criteria of severity', 'cannot complete sentences in', 'one breath', 'or', 'too breathless to talk or feed', 'rr', 'children 2-5 years > 40/min', 'children > 5 years > 30/min', 'adults ≥ 25/min', 'pulse', 'children 2-5 years > 140/min', 'children > 5 years > 125/min', 'adults ≥ 110/min', 'o2 saturation ≥ 92%', 'altered level of consciousness', '(drowsiness, confusion, coma)', 'exhaustion', 'silent chest', 'paradoxical thoracoabdominal', 'movement', 'cyanosis', 'collapse', 'bradycardia in children or', 'arrhythmia/hypotension in', 'adults', 'o2 saturation ≥ 92%', 'chapter 2', '80', 'treatment', 'treatment and follow-up depend on the severity of the attack and the patient’s response:', 'mild to moderate attack', '– reassure the patient; place him in a 1/2 sitting position.', '– administer:', '• salbutamol (aerosol): 2 to 4 puffs every 20 to 30 minutes, up to 10 puffs if necessary during', 'the first hour. in children, use a spacera to ease administration (use face mask in children', 'under 3 years). single puffs should be given one at a time, let the child breathe 4 to', '5 times from the spacer before repeating the procedure.', '• prednisolone po: one dose of 1 to 2 mg/kg', '– if the attack is completely resolved: observe the patient for 1 hour (4 hours if he lives far', 'from the health centre) then give outpatient treatment: salbutamol for 24 to 48 hours', '(2 to 4 puffs every 4 to 6 hours depending on clinical evolution) and prednisolone po', '(1 to 2 mg/kg once daily) to complete 3 days of treatment.', '– if the attack is only partially resolved: continue with 2 to 4 puffs of salbutamol every 3 to', '4 hours if the attack is mild; 6 puffs every 1 to 2 hours if the attack is moderate, until', 'symptoms subside, then when the attack is completely resolved, proceed as above.', '– if symptoms worsen or do not improve, treat as severe attack.', 'severe attack', '– hospitalise the patient; place him in a 1/2 sitting position.', '– administer:', '• oxygen continuously, at least 5 litres/minute or maintain the o2 saturation between', '94 and 98%.', '• salbutamol (aerosol): 2 to 4 puffs every 20 to 30 minutes, up to 10 puffs if necessary in', 'children under 5 years, up to 20 puffs in children over 5 years and adults. use a spacer to', 'increase effectiveness, irrespective of age.', 'or salbutamol (solution for nebulisation), see following page.', '• prednisolone po: one dose of 1 to 2 mg/kg', 'in the case of vomiting, use hydrocortisone iv every 6 hours (children: 5 mg/kg/injection, adults:', '100 mg/injection) until the patient can tolerate oral prednisolone.', '– if the attack is completely resolved, observe the patient for at least 4 hours. continue the', 'treatment with salbutamol for 24 to 48 hours (2 to 4 puffs every 4 hours) and prednisolone', 'po (1 to 2 mg/kg once daily) to complete 3 days of treatment.', 'reassess after 10 days: consider long-term treatment if the asthma attacks have been', 'occurring for several months. if the patient is already receiving long-term treatment,', 'reassess the severity of the asthma (see table page 83) and review compliance and correct', 'use of medication and adjust treatment if necessary.', '– if symptoms worsen or do not improve, see life-threatening attack next page.', 'a if a conventional spacer is not available, use a 500 ml plastic bottle: insert the mouthpiece of the inhaler into a', 'hole made in the bottom of the bottle (the seal should be as tight as possible). the child breathes from the', 'mouth of the bottle in the same way as he would with a spacer. the use of a plastic cup instead of a spacer is', 'not recommended (ineffective).', 'respiratory diseases', '81', '2', 'life-threatening attack (intensive care)', '– insert an iv line.', '– administer:', '• oxygen continuously, at least 5 litres/minute or maintain the o2 saturation between', '94 and 98%.', '• salbutamol + ipratropium, solutions for nebulisation:', 'the two solutions can be mixed in the nebuliser reservoir. the solutions must be', 'administered via an oxygen-driven nebuliser.', '• corticosteriods (prednisolone po or hydrocortisone iv) as for severe attack.', '– if the attack is resolved after one hour: switch to salbutamol aerosol and continue', 'prednisolone po as for severe attack.', '– if symptoms do not improve after one hour:', '• administer a single dose of magnesium sulfate by iv infusion in 0.9% sodium chloride over', '20 minutes, monitoring blood pressure:', 'children over 2 years: 40 mg/kg', 'adults: 1 to 2 g', '• continue salbutamol by nebulisation and corticosteriods, as above.', 'notes: ', '– in pregnant women, treatment is the same as for adults. in mild or moderate asthma', 'attacks, administering oxygen reduces the risk of foetal hypoxia.', '– for all patients, irrespective of the severity of the asthma attack, look for underlying lung', 'infection and treat accordingly.', 'chronic asthma', 'clinical features', '– asthma should be suspected in patients with episodic respiratory symptoms (wheezing,', 'chest tightness, shortness of breath and/or cough) of variable frequency, severity and', 'duration, disturbing sleep, and causing the patient to sit up to breathe. these symptoms may', 'appear during or after exercise.', '– chest auscultation may be normal or demonstrate diffuse sibilant wheezes.', '– atopic disorders or a personal or family history of atopy (eczema, allergic rhinitis/', 'conjunctivitis) or a family history of asthma increases probability of asthma but their absence', 'does not exclude asthma.', 'patients with typical symptoms of asthma and a history of disease that is characteristic of', 'asthma should be considered as having asthma after exclusion of other diagnoses.', 'the assessment of the frequency of daytime and nigthtime symptoms and limitations of', 'physical activity determines whether asthma is intermittent or persistent.', 'children 1 month', 'to < 5 years', 'salbutamol 2.5 mg + ipratropium 0.25 mg', 'every 20 to 30 minutes', 'children 5 to < 12 years', 'salbutamol 2.5 to 5 mg + ipratropium 0.25 mg', 'every 20 to 30 minutes', 'children 12 years and over', 'and adults', 'salbutamol 5 mg + ipratropium 0.5 mg', 'every 20 to 30 minutes', 'chapter 2', '82', 'updated: february 2017', 'treatment', 'only patients with persistent asthma need long-term treatment. the mainstay of treatment is', 'inhaled corticosteroids. treatment is started at the step most appropriate to initial severity', 'then, re-evaluated and adjusted according to clinical response. it aims to abolish symptoms', 'with the lowest possible dose of inhaled corticosteroids. an intervening severe exacerbation or', 'loss of control necessitates reassessment to re-evaluate treatment.', 'long-term treatment does not mean treatment for life. asthma attacks may occur over months or', 'years, with intervening asymptomatic intervals when long-term treatment is not required.', 'long-term treatment of asthma according to severity', 'inhaled corticosteroid treatment: beclometasone dose varies according to the severity of', 'asthma. find the minimum dose necessary to both control the symptoms and avoid local and', 'systemic adverse effects:', 'children: 50 to 100 micrograms twice daily depending on the severity. increase to', '200 micrograms twice daily if the symptoms are not controlled. in patients with severe chronic', 'asthma the dosage may be as high as 800 micrograms/day.', 'adults: start with 250 to 500 micrograms twice daily depending on to the severity. if a total', 'dosage of 1000 micrograms/day (in 2 to 4 divided doses) is ineffective, the dosage may be', 'increased to 1500 micrograms/day, but the benefits are limited.', 'the number of puffs of beclometasone depends on its concentration in the inhaled', 'aerosol: 50, 100 or 250 micrograms/puff.', 'categories treatment', 'intermittent asthma', '• intermittent symptoms (< once/week)', '• night time symptoms < twice/month', '• normal physical activity', 'no long term treatment', 'inhaled salbutamol when symptomatic', 'mild persistent asthma', '• symptoms > once/week, but < once/day', '• night time symptoms > twice/month', '• symptoms may affect activity', 'continuous treatment with inhaled beclometasone', '+', 'inhaled salbutamol when symptomatic', 'moderate persistent asthma', '• daily symptoms', '• symptoms affect activity', '• night time symptoms > once/week', '• daily use of salbutamol', 'continuous treatment with inhaled beclometasone', '+', 'inhaled salbutamol (1 puff 4 times/day)', 'severe persistent asthma', '• daily symptoms', '• frequent night time symptoms', '• physical activity limited by symptoms', 'continuous treatment with inhaled beclometasone', '+', 'inhaled salbutamol (1-2 puff/s 4 to 6 times/day)', 'respiratory diseases', '83', '2', 'do not restrict exercise. if exercise is a trigger for asthma attacks, administer 1 or 2 puffs of', 'salbutamol 10 minutes beforehand.', 'in pregnant women, poorly controlled asthma increases the risk of pre-eclampsia, eclampsia,', 'haemorrhage, in utero growth retardation, premature delivery, neonatal hypoxia and perinatal', 'mortality. long-term treatment remains inhaled salbutamol and beclometasone at the usual', 'dosage for adults. whenever possible, avoid oral corticosteroids.', 'if symptoms are not well controlled during a period of at least 3 months, check the inhalation', 'technique and adherence before changing to a stronger treatment.', 'if symptoms are well controlled for a period of at least 3 months (the patient is asymptomatic', 'or the asthma has become intermittent): try a step-wise reduction in medication, finally', 'discontinuing treatment, if it seems possible. provide patients with a salbutamol inhaler for any', 'possible attacks. evaluate after 2 weeks. if the results are satisfactory, continue for 3 months', 'and then re-evaluate. if the patient has redeveloped chronic asthma, restart long-term', 'treatment, adjusting doses, as required.', 'chapter 2', '84', 'pulmonary tuberculosis', 'pulmonary tuberculosis is a bacterial infection due to mycobacterium tuberculosis, spread by', 'airborne route. after contamination, m. tuberculosis multiplies slowly in the lungs: this', 'represents the primary infection.', 'in immunocompetent patients, the pulmonary lesion heals in 90% of cases, but in 10%,', 'patients develop active tuberculosis.', 'tuberculosis may also be extrapulmonary: tuberculous meningitis, disseminated tuberculosis,', 'lymph node tuberculosis, spinal tuberculosis, etc.', 'patients with hiv infection have an increased risk of developing active tuberculosis.', 'tuberculosis is the opportunistic disease that most commonly reveals aids. in certain', 'countries, up to 70% of patients with tuberculosis are co-infected with hiv.', 'clinical features', 'prolonged cough (> two weeks), sputum production, chest pain, weight loss, anorexia, fatigue,', 'moderate fever, and night sweats.', 'the most characteristic sign is haemoptysis (presence of blood in sputum), however it is not', 'always present and haemoptysis is not always due to tuberculosis. if sputum is smear-negative,', 'consider pulmonary distomatosis (flukes, chapter 6), melioidosis (southeast asia), profound', 'mycosis or bronchial carcinoma.', 'in an endemic area, the diagnosis of tuberculosis is to be considered, in practice, for all patients', 'consulting for respiratory symptoms for over two weeks who do not respond to non-specific', 'antibacterial treatment.', 'diagnosis', '– sputum smear microscopy; culture.', '– chest x-rays are useful for the diagnosis of smear negative tuberculosis and tuberculosis in', 'children.', 'treatment', 'the treatment is a combination of several of the following antituberculous drugs [isoniazid (h),', 'rifampicin (r), pyrazinamide (z), ethambutol (e), streptomycin (s)]. the regimen is standardised', 'and organized into 2 phases (initial phase and continuation phase).', 'the treatment of drug-sensitive tuberculosis lasts a minimum of 6 months.', 'it takes significant investment to cure a tb patient, both from the patient and the medical', 'team. only uninterrupted treatment for several months may lead to cure and prevent the', 'development of resistance, which complicates later treatment. it is essential that the patient', 'understands the importance of treatment adherence and that he has access to correct case', 'management until treatment is completed.', 'respiratory diseases', '85', '2', 'prevention', 'when bcg is correctly carried out, it confers protection that is not insignificant (probably over', '50%). it has been proven that bcg protects against severe forms of the disease, in particular', 'tuberculous meningitis and miliary tuberculosis.', 'bcg vaccination does not diminish transmission of tuberculosis.', 'for more information on the diagnosis, treatment and prevention of tuberculosis, and on the', 'follow-up of tuberculosis patients, refer to the msf handbook, tuberculosis.', 'chapter 2', '86', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'chapter 3: ', 'gastrointestinal disorders', 'acute diarrhoea', 'shigellosis', 'amoebiasis', 'disorders of the stomach and duodenum', 'gastro-oesophageal reflux', 'gastric and duodenal ulcers in adults', 'dyspepsia', 'stomatitis', 'oral and oropharyngeal candidiasis', 'oral herpes', 'other infectious causes', 'stomatitis from scurvy (vitamin c deficiency)', 'other lesions resulting from a nutritional deficiency', '3', 'acute diarrhoea', '– acute diarrhoea is defined as at least 3 liquid stools per day for less than 2 weeks.', '– there are 2 clinical types of acute diarrhoea:', '• simple diarrhoea without blood, caused by viruses in 60% of cases (rotavirus, enterovirus),', 'bacteria (vibrio cholerae, enterotoxigenic escherichia coli, non-typhi salmonella, yersinia', 'enterocolitica) or parasites (giardiasis). diseases, such as malaria, acute otitis media, upper', 'and lower respiratory tract infections, etc. can be accompanied by this type of diarrhoea.', '• dysentery  or bloody  diarrhoea ,  caused by bacteria (shigella in 50% of cases,', 'campylobacter jejuni, enteroinvasive or enterohaemorrhagic escherichia coli, salmonella)', 'or parasites (intestinal amoebiasis).', '– infectious diarrhoeas are transmitted by direct (dirty hands) or indirect (ingestion of', 'contaminated water or food) contact.', '– the high mortality rate from diarrhoeal diseases, even benign, is due to acute dehydration', 'and malnutrition. this can be prevented by adequate rehydration and nutrition.', 'clinical features', '– first assess for signs of dehydration. see assessment of diarrhoeal patients for dehydration,', 'who (appendix 2).', '– then look for other signs:', '• profuse watery diarrhoea (cholera, enterotoxigenic e. coli),', '• repeated vomiting (cholera),', '• fever (salmonella, viral diarrhoea),', '• presence of red blood in stools: see shigellosis and amoebiasis.', '– in a patient over 5 years with severe and rapid onset of dehydration, suspect cholera.', 'treatment', 'general principles:', '– prevent or treat dehydration: rehydration consists of prompt replacement of fluid and', 'electrolyte losses as required, until the diarrhoea stops.', '– administer zinc sulfate to children under 5 years.', '– prevent malnutrition.', '– do not systematically administer antimicrobials: only certain diarrhoeas require antibiotics', '(see antimicrobial treatment).', '– do not administer anti-diarrhoeal drugs or antiemetics.', '– treat the underlying condition if any (malaria, otitis, respiratory infection, etc.).', 'gastrointestinal disorders', '89', '3', 'prevention of dehydration (outpatient)', 'follow treatment plan a to treat diarrhoea at home, who (appendix 2).', 'treatment of dehydration', '1st case: moderate dehydration (at dispensary level)', 'follow treatment plan b to treat dehydration, who (appendix 2).', '2nd case: severe dehydration (at hospital level)', 'follow treatment plan c to treat severe dehydration quickly, who (appendix 2).', '– in the event of hypovolaemic shock or if there is no improvement after one hour: increase', 'the infusion rate.', '– check for signs of fluid overload: palpebral oedema is the first sign of overhydration. stop', 'rehydration until oedema disappear.', '– if there are signs of acute pulmonary oedema (laryngeal crackles, dyspnoea and increased', 'respiration rate, coughing with or without frothy sputum, distress, bilateral lung crepitations,', 'tachycardia etc.), administer iv furosemide immediately and repeat after one to 2 hours if', 'required:', 'children: 1 mg/kg/injection', 'adults: 40 mg/injection', 'special situations', '– cholera', 'in the event of severe dehydration, an adult may require up to 10 to 15 litres of ringer', 'lactate (rl) on the first day. rl potassium content is low. there is a risk of symptomatic', 'hypokalaemia in patients exclusively rehydrated by iv route. thus, start oral rehydration', 'solution (sro) as soon as possible in patients under infusion.', '– oral rehydration and severe malnutrition', 'use standard rehydration salts (sro) in cholera patients only. in all other cases, use resomal', '(see severe acute malnutrition, chapter 1).', 'zinc supplementation (in children under 5 years)', 'zinc sulfate is given in combination with oral rehydration solution in order to reduce the', 'duration and severity of diarrhoea, as well as to prevent further occurrences in the 2 to', '3 months after treatment:', 'zinc sulfate po', 'children under 6 months: 10 mg once daily (1/2 tablet once daily) for 10 days', 'children from 6 months to 5 years: 20 mg once daily (1 tablet once daily) for 10 days', 'place the half-tablet or full tablet in a teaspoon, add a bit of water to dissolve it, and give the', 'entire spoonful to the child.', 'do not administer this treatment if the child receives ready-to-use therapeutic food (rutf)', 'which already contains zinc.', 'prevention of malnutrition', 'follow treatment plan a to treat diarrhoea at home, who (appendix 2).', 'chapter 3', '90', 'antimicrobial treatment', 'diarrhoea without blood', 'most acute diarrhoeas are caused by viruses unresponsive to antimicrobials. antimicrobials can', 'be beneficial in the event of cholera or giardiasis.', '– cholera: the most important part of treatment is rehydration. in the absence of resistance', '(perform antibiotic-sensitivity testing), antibiotic treatment shortens the duration of', 'diarrhoea:', 'doxycycline po', 'children: 4 mg/kg as a single dose', 'adults: 300 mg as a single dose', 'or', 'azithromycin po', 'children: 20 mg/kg as a single dose', 'adults: 1 g as a single dose', 'note: doxycycline is usually contraindicated in pregnant women and children under 8 years.', 'however, for treating cholera, the administration of a single dose should not provoke any', 'adverse effects. check national recommendations.', '– giardiasis: tinidazole or metronidazole (see intestinal protozoan infections, chapter 6).', 'bloody diarrhoea (dysentery)', '– shigellosis is the most frequent cause of dysentery (amoebic dysentery is much less', 'common). if there is no laboratory diagnosis to confirm the presence of amoebae, first line', 'treatment is for shigellosis.', '– amoebiasis: antiparasitic treatment only if motile e. histolytica amoebae are found in stools', 'or if a correct shigellosis treatment has been ineffective (see amoebiasis).', 'prevention', '– breastfeeding reduces infant morbidity and mortality from diarrhoea and the severity of', 'diarrhoea episodes.', '– when the child is weaned preparation and storage of food are associated with the risk of', 'contamination by faecal micro-organisms: discourage bottle-feeding; food must be cooked', 'well; milk or porridge must never be stored at room temperature.', '– access to sufficient amounts of clean water and personal hygiene (washing hands with soap', 'and water before food preparation and before eating, after defecation etc.) are effective', 'methods of reducing the spread of diarrhoea.', 'gastrointestinal disorders', '91', '3', 'shigellosis', '– there are 4 serogroups of shigella: s. flexneri, s. boydii, s. sonnei and s. dysenteriae. shigella', 'dysenteriae type 1 (sd1) is the only strain that causes large scale epidemics. of the', '4 serogroups it has the highest case fatality rate (up to 10%). ', '– ciprofloxacin is currently the only effective treatment for shigellosis. it is therefore essential', 'to prevent the development of resistances.', 'clinical features', 'bloody diarrhoea with or without fever, abdominal pain and tenesmus, which is often intense. ', 'patients with at least one of the following criteria have an increased risk of death:', '– signs of serious illness:', '• fever > 38.5°c', '• malnutrition (< 80% of the median)', '• severe dehydration', '• confusion, seizures or coma', '– age groups at risk:', '• children under 5 years', '• adults over 50 years', 'treatment', '– antibiotic treatment:', '• ciprofloxacin po is the first line treatment', 'children: 30 mg/kg/day in 2 divided doses for 3 days', 'adults: 1 g/day in 2 divided doses for 3 days', '• in pregnant women, ciprofloxacin is contra-indicated in principle, use ceftriaxone im: 1 g', 'once daily for 3 to 5 days', 'amoxicillin is ineffective in vivo. the use of nalidixic acid favours the development of', 'ciprofloxacin resistance.', '– for pain:', 'hyoscine butylbromide po ', 'children from 6 to 12 years: 10 mg, to be repeated every 8 hours if necessary', 'adults: 10 to 20 mg, to be repeated every 8 hours if necessary', 'all opioid analgesics are contra-indicated as they slow peristalsis.', '– supportive therapy:', '• nutrition: all patients with dysentery should receive nutritional supplements.', '2500 kcal/day during hospitalisation', '1000 kcal/day as outpatients', 'children already in nutritional centres should be isolated.', '• rehydration: systematic administration of ors  (follow the who protocols, appendix 2). ', '– never give loperamide or any other antidiarrhoeal.', 'chapter 3', '92', '– complications of shigellosis due to sd1:', '• septicaemia: see antibiotic treatment of septic shock (shock ,page 18, chapter 1)', '• acute abdomen: see antibiotic treatment of septic shock (shock, page 18, chapter 1) and', 'laparotomy', '• seizures: diazepam (seizures, chapter 1) and fluid restriction', '• moderate to severe haemolytic uraemic syndrome, may require transfusion and/or', 'haemodialysis.', 'shigellosis in an epidemic context (sd1)', '– antibiotic resistance develops rapidly (sometimes during the course of an epidemic). after', 'confirming the causal agent, antimicrobial susceptibility should be monitored monthly by', 'culture and sensitivity tests.', '– patients presenting with signs of serious illness or with risk factors are hospitalised for the', 'duration of treatment and are monitored daily (clinically and for compliance).', '– patients with neither signs of serious illness nor risk factors are treated as outpatients.', 'organise home visits for daily monitoring (clinically and for compliance); hospitalise if the', 'patient develops signs of serious illness.', '– hygiene measures: isolate patients as for cholera, individual and collective hygiene.', 'shigellosis is an extremely contagious disease (the ingestion of 10 bacteria is infective).', 'note: over the past few years, sd1 epidemics of smaller scale and with lower case fatality rates', '(less than 1%) have been observed.', 'gastrointestinal disorders', '93', '3', 'amoebiasis', 'amoebiasis is a parasitic infection due to the intestinal protozoa entamoeba histolytica.', 'transmission is faecal-oral, by ingestion of amoebic cysts from food or water contaminated', 'with faeces. usually, ingested cysts release non-pathogenic amoebae and 90% of carriers are', 'asymptomatic.', 'in 10% of infected patients, pathogenic amoebae penetrate the mucous of the colon: this is the', 'intestinal amoebiasis (amoebic dysentery). the clinical picture is similar to that of shigellosis,', 'which is the principal cause of dysentery.', 'occasionally, the pathogenic amoebae migrate via the blood stream and form peripheral', 'abscesses. amoebic liver abscess is the most common form of extra-intestinal amoebiasis.', 'clinical features', '– amoebic dysentery', '• diarrhoea containing red blood and mucus', '• abdominal pain, tenesmus', '• no fever or moderate fever', '• possibly signs of dehydration', '– amoebic liver abscess', '• painful hepatomegaly; mild jaundice may be present', '• anorexia, weight loss, nausea, vomiting', '• intermittent fever, sweating, chills; change in overall condition', 'laboratory', '– amoebic dysentery: identification of mobile trophozoites (e. histolytica histolytica) in fresh', 'stool samples', '– amoebic liver abscess: indirect haemoagglutination and elisa', 'treatment', '– amoebic dysentery', '• the presence of cysts alone should not lead to the treatment of amoebiasis.', '• amoebiasis confirmed with a parasitological stool examination:', 'tinidazole po', 'children: 50 mg/kg once daily for 3 days (without exceeding 2 g/day)', 'adults: 2 g once daily for 3 days', 'or metronidazole po', 'children: 45 mg/kg/day in 3 divided doses for 5 days', 'adults: 1.5 g/day in 3 divided doses for 5 days', '• if there is no laboratory, first line treatment for dysentery is for shigellosis. treat for', 'amoebiasis if correct treatment for shigellosis has been ineffective.', '• oral rehydration salts (ors) if there is risk of, or if there are signs of dehydration (follow the', 'who protocols, appendix 2).', '– amoebic liver abscess', '• tinidazole po: same treatment for 5 days', '• metronidazole po: same treatment for 5 to 10 days', 'chapter 3', '94', 'disorders of the stomach and duodenum', 'gastro-oesophageal reflux', 'clinical features', 'burning stomachache or heartburn, generally relieved by antacids; acid regurgitation (often', 'postural: while sitting forward or lying down). in the absence of dysphagia (oesophageal', 'stenosis), these signs are benign.', 'treatment', '– first instance, encourage the patient to avoid alcohol and tobacco use.', 'give aluminium hydroxide poa: 1.5 to 3 g/day in 3 divided doses one hour after meals or', 'instruct the patient to take 500 mg at the time of a painful attack.', '– if antacids are insufficient:', 'omeprazole po: 20 mg once daily in the morning for 3 days', 'or, if not available:', 'cimetidine po: 400 mg once daily at bedtime for 3 days', '– in small children: no drug treatment, rest and sleep on an incline (30° to 45°).', 'gastric and duodenal ulcers in adults', 'clinical features', 'burning epigastric pain or epigastric cramps between meals, that wake the patient at night.', 'they are most characteristic when they occur as episodes of a few days and when accompanied', 'by nausea and even vomiting.', 'the most common complications are perforation and bleeding.', 'treatment of non-complicated ulcers', '– for an isolated episode:', '• identify patients taking nsaid or acetylsalicylic acid; stop treatment;', '• encourage patients to avoid alcohol and tobacco use;', '• omeprazole po: 20 mg once daily in the morning for 7 to 10 days', 'or, if not available:', 'cimetidine po: 800 mg once daily at bedtime for 7 to 10 days', '– if the patient has frequent recurrences, unrelated to nsaid use, that require repeated', 'treatment with antiulcer drugs: see eradication of helicobacter pylori, next page.', 'a aluminium hydroxide may decrease absorption of drugs taken at the same time, leave an interval of at least', '2 hours between taking aluminium hydroxide and other drugs.', 'gastrointestinal disorders', '95', '3', 'treatment of complicated ulcers', 'perforation', 'perforation should be considered in patients presenting with sudden onset intense epigastric', 'pain, particularly if there is rigidity of the abdominal wall. the risk of peritonitis is increased if', 'the perforation occurs on a full stomach.', '– to start:', '• place the patient on a strict fast (npo); insert a nasogastric tube and aspirate if possible;', '• place an intravenous line and hydrate (alternate between 5% glucose and ringer lactate);', '• hyoscine butylbromide iv or im: 10 to 20 mg, to be repeated every 8 hours if necessary;', '• omeprazole iv infusion:  40 mg/day over 20 to 30 minutes', 'or, if not available, cimetidine continuous iv infusion: 1600 mg over 24 hours', '– refer to a surgeon if the patient has eaten during the 6 hours prior to the onset of pain or if', 'there is no improvement within 12 hours despite medical treatment.', '– continue treatment for 3 days then restart oral feeding if the perforation occurred on an', 'empty stomach and if the patient improved during the first 12 hours of treatment. then start', 'po treatment to eradicate helicobacter pylori (see further).', 'gastrointestinal bleeding', 'passing of black stool (maelena) and/or vomiting blood (haematemesis). in 80% of cases the', 'bleeding stops spontaneously.', '– insert a nasogastric tube for aspiration and insert an iv line (16g).', 'if the haemodynamic state is stable (pulse and blood pressure are normal):', '– hydrate (ringer lactate), monitor, keep npo for 12 hours.', '– if there is no active haemorrhage, restart oral feeding after 12 hours.', 'gastric lavage with cold water is not essential, but may help evaluate persistence of', 'bleeding.', 'if the haemorrhage continues (haematemesis) and/or if the haemodynamic state deteriorates', '(pulse increases, bp drops):', '– intensive care and transfusion according to the severity of the bleeding (see haemorrhagic', 'shock, page 16, chapter 1).', '– emergency surgical intervention.', 'most peptic ulcers are caused by helicobacter pylori infection. if a diagnosis of ulcer is', 'probable, and the patient has frequent attacks requiring repeated treatment with antiulcer', 'drugs or, in cases of complicated ulcers (perforation or gastrointestinal bleeding) treatment to', 'eradicate h. pylori should be considered to prevent relapses.', 'once the acute phase has passed, prescribe one of the following treatments:', 'b metronidazole po can be replaced with tinidazole po: 1 g/day in 2 divided doses.', 'treatment of choice', '(10 days)', 'alternative', '(14 days)', 'metronidazole pob', '1 g/day in 2 divided doses', '+ amoxicillin po', '2 g/day in 2 divided doses', '+ omeprazole po', '40 mg/day in 2 divided doses', 'metronidazole pob', '1 g/day in 2 divided doses', '+ amoxicillin po', '2 g/day in 2 divided doses', '+ cimetidine po', '1600 mg/day in 2 divided doses', 'chapter 3', '96', 'notes: ', '– acetylsalicylic acid (aspirin) and nsaid (indometacin, ibuprofen, diclofenac etc) are contra-', 'indicated in patients suffering from or with a history of ulcers.', '– omeprazole is as effective po as iv.', 'dyspepsia', 'clinical features', 'epigastric pain or discomfort following meals, often accompanied by bloating, sensation of', 'fullness and nausea. dyspepsia is most commonly functional, linked with stress and not linked', 'to the quantity of gastric acid (antiacids and antiulcer drugs are ineffective). resolution is', 'usually spontaneous.', 'treatment', 'if the symptoms persist, short term symptomatic treatment may be considered.', 'in adults:', '– metoclopramide po (30 mg/day in 3 divided doses given 6 hours apart, 1/2 hour before', 'meals, for 2 to 3 days) may be helpful in cases of nausea, vomiting, bloating, etc.', '– hyoscine butylbromide po (30 mg/day in 3 divided doses, 1/2 hour before meals, for 2 to', '3 days) may be helpful in cases of spasmodic pain.', 'note: consider and treat possible intestinal parasites (taeniasis, ascariasis, ancylostomiasis,', 'giardiasis, amoebiasis).', 'gastrointestinal disorders', '97', '3', 'stomatitis', 'stomatitis is an inflammation of the mucous membranes of the mouth caused by a fungal, viral', 'or bacterial infection, a vitamin deficiency, an injury, etc.', 'prolonged or painful stomatitis may contribute to dehydration or may cause loss of appetite', 'with denutrition, particularly in children.', 'in infants, examine routinely the mouth in the event of breast refusal or difficulties in sucking.', 'in all cases:', '– maintain adequate hydration and feeding; offer foods that will not irritate the mucosa (soft,', 'non-acidic). use a nasogastric tube for a few days if pain is preventing the patient from eating.', '– keep the mouth clean to prevent complications and recurrence.', 'oral and oropharyngeal candidiasis', 'infection due to candida albicans, common in infants, immunocompromised or diabetic', 'patients. other risk factors include treatment with oral antibiotics or high-dose inhaled', 'corticosteroids.', 'clinical features', 'white patches on the tongue, inside the cheeks, that may spread to the pharynx.', 'in patients with frequent recurrences or extensive forms invading the esophagus (swallowing', 'difficulty and pain), consider hiv infection.', 'treatment', 'to be taken between meals:', 'nystatin lozenge to be sucked or oral suspension: 400 000 iu/day i.e. i lozenge to be sucked or', '1 ml of the oral suspension (100 000 iu) 4 times/day', 'or miconazole oral gel', 'children 6 months to 2 years: 1.25 ml 4 times/day', 'children over 2 years and adults: 2.5 ml 4 times/day', 'the oral suspension of nystatin or the oral gel of miconazole should be kept in the mouth for', '2 to 3 minutes and then swallowed, or, in young children, applied to the tongue and inside of', 'each cheek.', 'show the mother how to treat since, in most cases, candidiasis will be treated at home.', 'in immunocompromised patients: see hiv infection and aids, page 229, chapter 8.', 'oral herpes', 'infection due to the herpes simplex virus. primary infection typically occurs in children aged', '6 months-5 years and may cause acute gingivostomatitis, sometimes severe. after primary', 'infection, the virus remains in the body and causes in some individuals periodic recurrences', 'which are usually benign (herpes labialis).', 'chapter 3', '98', 'updated: september 2016', 'clinical features', '– primary herpetic gingivostomatitis', 'multiple vesicles on the oral mucosa and lips which rupture to form painful, yellowish, at', 'times extensive ulcers. local lesions are usually associated with general malaise, regional', 'lymphadenopathy and fever.', '– recurrent herpes labialis', 'clusters of vesicles at the junction between the lip and the skin.', 'in patients with frequent recurrences or extensive forms, consider hiv infection (see page 229,', 'chapter 8).', 'treatment', 'primary herpetic gingivostomatitis', '– treat pain: paracetamol or ibuprofen po (chapter 1)', '– in the event of severe lesions, inability to drink and significant pain:', '• admit the child to hospital (high risk of dehydration).', '• if the child presents within the first 96 hours of symptoms onset, aciclovir po for 5 to', '7 days: ', 'children under 2 years: 200 mg 5 times per day', 'children over 2 years: 400 mg 5 times per day', '– in the event of secondary bacterial infection: amoxicillin po 7 days.', 'in immunocompromised patients: see hiv infection and aids, page 229, chapter 8.', 'recurrent herpes labialis', 'spontaneous resolution within 7 to 10 days. an antiseptic (chlorhexidine or polyvidone iodine)', 'may be applied; paracetamol po if necessary.', 'both forms of herpes are contagious: do not touch lesions (or wash hands afterwards); avoid', 'oral contact.', 'other infectious causes', 'see pharyngitis (chapter 2), diphtheria (chapter 2), measles (chapter 8).', 'for scarlet fever (strawberry tongue associated with a skin rash):', 'phenoxymethylpenicillin (pencillin v) po for 10 days', 'children under 1 year: 250 mg/day in 2 divided doses', 'children from 1 to 5 years: 500 mg/day in 2 divided doses', 'children from 6 to 12 years: 1 g/day in 2 divided doses', 'adults: 2 g/day in 2 divided doses', 'gastrointestinal disorders', '99', '3', 'stomatitis from scurvy (vitamin c deficiency)', 'clinical features', 'bleeding gums, associated in infants with lower limb pain caused by subperiosteal', 'haemorrhage. it is common in contexts of poor food quality or in populations completely', 'dependent on food aid (refugee camps).', 'treatment', 'ascorbic acid (vitamin c) po', 'children: 150 to 200 mg/day in 3 or 4 divided doses', 'adults: 500 to 750 mg/day in 3 or 4 divided doses', 'the treatment is continued until symptoms improve (1 to 2 weeks), then a preventive', 'treatment (children and adults: 25 to 50 mg/day) is given as long as the situation requires.', 'other lesions resulting from a nutritional deficiency', 'other vitamin deficiencies may provoke mouth lesions: angular stomatitis of the lips and', 'glossitis from vitamin b2 (riboflavin), niacin (see pellagra, chapter 4) or vitamin b6 (pyridoxine)', 'deficiencies.', 'iron deficiency may also provoke angular stomatitis (see anaemia, chapter 1).', 'give the corresponding vitamins at curative doses. multivitamins are insufficient to treat true', 'vitamin deficiencies.', 'chapter 3', '100', 'chapter 4: ', 'skin diseases', 'dermatology', 'scabies', 'lice (pediculosis)', 'superficial fungal infections', 'bacterial skin infections', 'impetigo', 'furuncles and carbuncles', 'erysipelas and cellulitis', 'cutaneous anthrax', 'endemic treponematoses', 'leprosy (hansen’s disease)', 'herpes simplex and herpes zoster', 'herpes simplex', 'herpes zoster (shingles)', 'other skin disorders', 'eczema (dermatitis)', 'seborrheic dermatitis', 'urticaria', 'pellagra', '4', 'dermatology', 'skin diseases, particularly infectious skin diseases, are very common. they must be treated', 'individually or collectively, but must also be considered as indicators of the sanitary condition', 'of a population. a high prevalence of infectious skin diseases may reflect a problem of', 'insufficient water quantity and lack of hygiene in a population.', 'dermatological examination', '– observe the type of lesion:', '• macule: flat, non palpable lesion that is different in colour than the surrounding skin', '• papule: small (< 1 cm) slightly elevated, circumscribed, solid lesion', '• vesicle (< 1 cm), bulla (> 1 cm): clear fluid-filled blisters', '• pustule: vesicle containing pus', '• nodule: firm, elevated palpable lesion (> 1 cm) that extend into the dermis or subcutaneous', 'tissue', '• erosion: loss of the epidermis that heals without leaving a scar', '• excoriation: erosion caused by scratching', '• ulcer: loss of the epidermis and at least part of the dermis that leaves a scar', '• scale: flake of epidermis that detaches from the skin surface', '• crust: dried serum, blood, or pus on the skin surface', '• atrophy: thinning of the skin', '• lichenification: thickening of the skin with accentuation of normal skin markings', '– look at the distribution of the lesions over the body; observe their arrangement: isolated,', 'clustered, linear, annular (in a ring). ask if the lesions are itchy.', '– look for a possible cause: insect bites; scabies, lice, other parasitic skin infections; contact', 'with plants, animals, jewellery, detergents, etc.', '– ask about any ongoing treatment: topical, oral or parenteral.', '– look for local or regional signs (secondary infection, lymphangitis, adenopathy, erysipelas)', 'and/or systemic signs (fever, septicaemia, distant infectious focus).', '– consider the sanitary condition of the family, particularly for contagious skin diseases', '(scabies, scalp ringworm, lice).', '– check tetanus vaccination status.', 'patients with skin disease often present late. at this stage, primary lesions and specific signs', 'may be masked by secondary infection. in these cases, it is necessary to re-examine the', 'patient, after treating the secondary infection, in order to identify and treat the underlying skin', 'disease..', 'skin diseases', '103', '4', 'scabies', 'scabies is a cutaneous parasitosis due to the presence of the mite sarcoptes scabiei hominis', 'within the epidermis. it exists in two forms: ordinary scabies, relatively benign and moderately', 'contagious; and crusted scabies, favoured by immune deficiency, extremely contagious and', 'refractory to conventional treatment. person to person transmission takes place chiefly', 'through direct skin contact, and sometimes by indirect contact (sharing clothing, bedding). the', 'challenge in management is that it must include simultaneous treatment of both the patient', 'and close contacts, and at the same time, decontamination of clothing and bedding of all', 'persons undergoing treatment, in order to break the transmission cycle.', 'clinical features', 'ordinary scabies', 'in older children and adults', '– itching, worse at night, very suggestive of scabies if close contacts have the same symptom', 'and', '– typical skin lesions:', '• scabies burrows (common): fine wavy lines of 5 to 15 mm, corresponding to the tunnels', 'made by the parasite within the skin. burrows are most often seen in the interdigital', 'spaces of the hand and flexor aspect of the wrist, but may be present on the areolae,', 'buttocks, elbows, axillae. the back and the face are spared. burrows may be associated', 'with vesicles, corresponding to the entry point of the parasite in the skin.', '• scabies nodules (less common): reddish-brown nodules, measuring 2 to 20 mm, on the', 'genitals in men, persisting after effective treatment (they are not necessarily indicative of', 'active infection).', 'and/or', '– secondary skin lesions: resulting from scratching (excoriations, crusts) or super-infection', '(impetigo).', 'typical lesions and secondary lesions may co-exist, or specific lesions may be entirely masked', 'by secondary lesions.', 'in infants and young children', '– vesicular eruption; often involving palms and soles, back, face, and limbs. secondary', 'infection or eczematisation is frequent. isolated scabies nodules in the axillae may be the', 'only manifestation.', '– examination of the mother’s hands may support the diagnosis.', 'crusted (norwegian) scabies', 'thick, scaly, erythematous plaques, generalised or localised, resembling psoriasis, with or', 'without itching (50% of cases). delay in diagnosis may lead to a scabies epidemic.', 'chapter 4', '104', 'treatment', 'in all cases', '– close contacts of the patient are treated simultaneously, even in the absence of symptoms.', '– clothing and bedding (including that of contacts) are changed after each treatment. they are', 'washed at ≥ 60°c then dried in the sun, or exposed to sunlight for 72 hours, or sealed in a', 'plastic bag for 72 hours.', 'ordinary scabies', 'topical treatment', 'topical scabicides are applied over the entire body (including the scalp, post-auricular areas,', 'umbilicus, palms and soles), avoiding mucous membranes and face, and the breasts in', 'breastfeeding women. particular attention should be paid to common infestation sites. the', 'recommended contact time should not be shortened or exceeded; the patient must not wash', 'his hands while the product is in use (or the product should be reapplied if the hands are', 'washed). in infants, the hands must be wrapped to prevent accidental ingestion of the product.', 'topical scabicides should not be applied to broken or inflamed skin. treatment of secondary', 'bacterial infection, if present, should be initiated 24 to 48 hours before use of topical', 'scabicides (see impetigo). ', 'the preferred treatment is 5% permethrin (lotion or cream):', 'child > 2 months and adult: one application, with a contact time of 8 hours, then rinse off.', 'permethrin is easier to use (no dilution required), and preferred over benzyl benzoate in', 'children, and pregnant/lactating women. one application may be sufficient, but a second', 'application 7 days later reduces the risk of treatment failure.', 'or, if not available, benzyl benzoate 25% lotion:', 'a second application of benzyl benzoate (e.g. after 24 hours, with a rinse between the', '2 applications; or two successive applications, 10 minutes apart, when the first application has', 'dried, with a rinse after 24 hours) reduces the risk of treatment failure.', 'second applications are not recommended in pregnant women and children < 2 years', 'oral treatment', 'treatment with ivermectin po (200 micrograms as a single dose) is an alternative: it is more', 'practical than topical treatment (e.g. in the case of an epidemic or for treating contacts) and', 'can be started right away in the case of secondary infection. a single dose may be sufficient; a', 'second dose 7 days later reduces the risk of treatment failure.', 'children < 2 years children 2-12 years children > 12 yearsand adults', 'dilution', 'lotion must be diluted before use:', 'use undiluted 25% lotion1 part 25% lotion', '+ 3 parts water', '1 part 25% lotion', '+ 1 part water', 'contact', 'time', '12 hours (6 hours for infants', '< 6 months), then rinse off', '24 hours, then rinse off 24 hours, then rinse off', 'skin diseases', '105', '4', 'ivermectin is not recommended for children < 15 kg or pregnant women (safety not', 'established)a.', 'administration of ivermectin to patients with loiasis carries a risk of severe neurological', 'complications when significant loa loa microfilaraemia is present (see filariasis, chapter 6)b.', 'treatment effectiveness is judged on clinical grounds. itching may persist for 1 to 3 weeks after', 'elimination of the parasite.', 'persistence of typical burrows beyond 3 weeks should lead to suspicion of treatment failure', '(insufficient treatment, e.g. the scalp was not included in topical treatment or the patient', 'washed his hands during the treatment period), or early re-infestation (contacts and', 'environment not treated). in these cases, patient and contacts should be retreated.', 'persistent itching may be due to another condition, initially masked by scabies.', 'crusted scabies', 'treatment combines simultaneous administration of oral ivermectin and topical scabicide at', 'regular intervals, e.g. every week for 2 to 3 weeks or more, according to severity and clinical', 'response.', 'crusts should be softened (salicylic acid ointment) and removed before applying local', 'treatment (otherwise, local treatment is ineffective).', 'as exfoliated skin scales may spread the parasite, the patient should be isolated during the', 'treatment, staff should use protection (gloves, gowns and hand washing after contact), and', 'environment (bedding, floors and surfaces) should be decontaminated.', 'a treatment with ivermectin in these patients is reserved for severe cases for which no alternative exists (see', 'crusted scabies).', 'b in areas where loiasis is endemic, certain precautions are recommended before administering ivermectin: e.g.', 'measure the loa loa microfilaraemia, if possible, or ensure that the patient has no history of loiasis (migration', 'of an adult worm under the conjunctiva or transient « calabar » swellings), nor history of severe adverse', 'reactions following a previous treatment with ivermectin, or if in doubt, use topical treatment in preference to', 'oral.', 'weight 15 to 24 kg 25 to 35 kg 36 to 50 kg 51 to 65 kg', 'ivermectin 3 mg tab 1 tab 2 tab 3 tab 4 tab', 'ivermectin 6 mg tab 1/2 tab 1 tab 11/2 tab 2 tab', 'chapter 4', '106', 'lice (pediculosis)', 'pediculosis is a benign contagious parasitic infection due to 3 species of lice specific to humans:', 'head lice, body lice and pubic lice. transmission from person to person occurs through direct or', 'indirect contact.', 'body lice are potential vectors of relapsing fever (chapter 7), typhus (eruptive rickettsioses,', 'chapter 7) and trench fever.', 'clinical features', '– head lice mainly affect children: itching and scratch marks (nape of neck and around the', 'ears), which may become secondarily infected (impetigo) in prolonged infestation; presence', 'of live lice and/or live (shiny, grey) nits attached to the hair shaft within 5 mm of the scalp.', '– body lice mainly affect populations living under poor conditions (refugees, prisoners, the', 'homeless): itching and scratch marks (back, belt line and armpits), often inflamed and', 'infected; presence of lice and nits in the clothing (parasites are not found on the body).', '– pubic lice are considered to be a sexually transmitted infection (sti): itching and scratch', 'marks (pubic and perianal area), but other hairy areas may also be affected (armpits, thighs,', 'eyelashes); lice and nits at the base of the hair shaft, rarely visible.', '– examine contacts; check for associated systemic infection (body lice) or sti (pubic lice).', 'treatment', 'head lice', 'apply to dry hair 1% permethrin lotion (leave on for 10 min) or 0.5% malathion lotion (leave on', 'for 12 hours; 8 hours in children 6 months-2 years). do not reduce or exceed the', 'recommended duration of treatment. rinse thoroughly. decontaminate combs, headwear and', 'bedding (wash ≥ 60°c/30 min, iron or dry in the sun or, if not feasible, seal in a plastic bag for', '2 weeks). treat those contacts with lice and/or live nits, not those with dead nits alone (dull,', 'white, > 1 cm from scalp) as above. it is recommended to repeat the application after 10 days.', 'body lice', 'mass treatment (outbreakk)', 'apply 30 to 60 g (2 to 4 heaped soup spoons) of 0.5% permethrin powder to the inside of', 'the clothes and underclothes in contact with the skin (front and back, neck and waistline,', 'sleeves and socks) in a fully clothed patient, then rub in the powder by hand. leave for 12 to', '24 hours.', 'treat other clothing (including headwear) and bedding in a plastic bag with 0.5% permethrin', 'powder. repeat in 8 to 10 days if the infestation persists. ', 'individual treatment', 'disinfection of clothing and bedding as above or as for head lice.', 'skin diseases', '107', '4', 'pubic lice', 'shave and/or apply 1% permethrin lotion to hairy areas (as for head lice). treat the partner at', 'the same time. decontaminate clothing and bedding (as for head lice). repeat the application', 'after 7 days.', 'treatment of secondary bacterial infection, if present, should begin 24 to 48 hours before local', 'antiparasitic treatment (see impetigo); local treatment is applied later when tolerated.', 'chapter 4', '108', 'superficial fungal infections', 'superficial fungal infections are benign infections of the skin, scalp and nails caused by candida', 'albicans or dermatophytes.', 'clinical features and treatment', 'candidiasis', 'candidal diaper dermatitis', 'erythema of the perianal area with peripheral desquamation and sometimes pustules.', 'secondary infection may develop.', '– buttocks must be kept clean (ordinary soap and water) and dry.', '– avoid humidity: according to the context, expose the buttocks to air or change diapers more', 'frequently; remove plastic pants.', '– protect the skin with zinc oxide ointment if diarrhoea is present.', '– if diaper dermatitis is severe and persistent despite these measures, consider an intestinal', 'infection (nystatin po: 400 000 iu/day in 4 divided doses for 20 days).', 'other candidiasis', '– candidiasis of skin folds: miconazole 2% cream, twice daily for 2 to 4 weeks', '– oral candidiasis: see stomatitis, chapter 3.', '– vulvovaginal candidiasis: see abnormal vaginal discharge, chapter 9.', 'dermatophytoses', 'dermatophytes cause various clinical lesions, depending on the anatomic site involved: scalp,', 'glabrous (hairless) skin, folds or nails. see following page.', 'skin diseases', '109', '4', 'dermatophytoses', 'a dermatophytosis may affect the nails (tinea unguium, onychomycosis). treatment is prolonged (12 to 18 months with griseofulvin) thus, in practice, difficult. failures and', 'relapses are frequent.', 'b in candidal intertrigo, lesions are usually located in the 1st and 2nd interdigital spaces..', 'c', 'h', 'ap', 'ter 4', '110', 'anatomic sitea clinical features treatment', 'scalp', 'scalp ringworm', 'tinea capitis', 'common in children.', 'depending on the species:', '• one or more round, scaly, erythematous', 'plaques with the ends of broken hairs.', '• inflammation, suppuration, crusting and', 'peripheral lymphadenopathy (kerion).', '• permanent hair loss (favus).', 'some scalp ringworms are contagious:', 'simultaneously examine (and treat) symptomatic', 'contacts.', '• shave or cut hair short on and around the lesions.', '• local treatment: 2 times/day, clean with soap and water, dry and apply miconazole 2%', 'cream or whitfield’s ointment for 2 weeks or longer if necessary.', '• administer systemic treatment as local treatment alone does not cure scalp', 'ringworm:', 'griseofulvin po for 6 weeks (up to 8 to 12 weeks)', 'children ≤ 12 years: 10 to 20 mg/kg/day in 1 or 2 divided doses (max. 500 mg/d)', 'children > 12 years and adults: 500 mg to 1 g/day in 1 or 2 divided doses', 'or itraconazole po', 'children: 3 to 5 mg/kg once daily for 4 weeks (max. 200 mg/d)', 'adults: 200 mg once daily for 2 to 4 weeks', '• suppurative lesions: treat superinfection (see impetigo) before applying local antifungal', 'treatment.', '• for painful kerion: paracetamol po.', 'in pregnant lactating/breastfeeding women: oral antifungals are contraindicated. apply', 'a topical treatment (miconazole 2% cream or whitfield’s ointment) to limit the spread', 'of infection until it is possible to treat orally.', 'glabrous skin', 'ringworm of the', 'body', 'tinea corporis', 'erythematous, scaly, pruritic macule with a well-', 'demarcated, raised, vesicular border and central', 'healing.', '• for non widespread, localised tinea:', 'local treatment: 2 times/day, clean with soap and water, dry and apply miconazole 2%', 'cream or whitfield’s ointment for 2 to 4 weeks or for 2 weeks after clinical resolution.', '• reserve oral antifungals for particularly extensive lesions: griseofulvin po for 4 to 6', 'weeks or itraconazole for 15 days.', 'folds', 'tinea pedis', '(athlete’s foot)', 'tinea cruris', '• interdigital spaces (tinea pedis):', 'pruritus, fissure and whitish scales in the 3rd', 'and/or 4th interdigital spacesb.', '• groin (tinea cruris):', 'circumscribed, pruritic, erythematous plaque,', 'with a pale centre surrounded by vesiculo-', 'pustules, extending outward from the groin.', 'topical treatment as above. if oozing lesions, use miconazole 2% cream only (do not use', 'whitfield’s ointment).', 'bacterial skin infections', 'impetigo', '– impetigo is a benign, contagious infection of the epidermis due to group a ß-haemolytic', 'streptococcus and staphylococcus aureus. co-infection is common. transmission is by direct', 'contact. lack of water, and poor hygiene, increase spread.', '– primary infections are most common in children. secondary infections complicating pre-', 'existing pruritic dermatoses (lice, scabies, eczema, herpes, chickenpox, etc.) are more', 'common in adults.', 'clinical features', '– non bullous impetigo (classic form): flaccid vesicle on erythematous skin which becomes', 'pustular and forms a yellowish crust. different stages o the infection may be present', 'simultaneously. the lesion does not leave a scar. the most common sites of infection are', 'around the nose and mouth, on the limbs or on the scalp.', '– bullous impetigo: large flaccid bullae and erosions of the skin in the ano-genital region in', 'newborns and infants.', '– ecthyma: an ulcerative form of impetigo that leaves scars. this form is most common in the', 'immunocompromised (e.g. hiv infection, malnutrition), diabetics and alcoholics.', '– regardless of the type of impetigo: absence of fever or systemic signs.', '– possible complications:', '• abscess, pyodermitis, cellulitis, lymphangitis, osteomyelitis, septicaemia;', '• acute glomerulonephritis (routinely look for signs of glomerulonephritis).', 'treatment', '– localised non bullous impetigo (less than 5 lesions in a single skin area):', '• clean with soap and water and dry before applying mupirocin.', '• apply 2% mupirocin ointment 3 times per day for 7 days. reassess after 3 days. if there is', 'no response, switch to oral antibiotic therapy (see below).', '• keep fingernails short. avoid touching the lesions, keep them covered with gauze if possible.', '– extensive non bullous impetigo (more than 5 lesions or impetigo involving more than one skin', 'area), bullous impetigo, ecthyma, impetigo with abscess; immunocompromised patient; topical', 'treatment failure:', '• clean with soap and water and dry 2 to 3 times per day.', '• keep fingernails short. avoid touching the lesions, keep them covered with gauze if possible.', '• incise abscesses if present.', '• administer oral antibiotic therapya:', 'cefalexin po for 7 days', 'neonates under 7 days: 50 mg/kg/day in 2 divided doses', 'neonates 7 to 28 days: 75 mg/kg/day in 3 divided doses', 'children 1 month to 12 years: 25 to 50 mg/kg/day in 2 divided doses', 'children over 12 years and adults: 2 g/day in 2 divided doses', 'a in penicillin-allergic patients only (résistance to macrolides is common):', 'azithromycin po for 3 days (children: 10 mg/kg once daily; adults: 500 mg once daily)', 'or erythromycin po for 7 days (children: 30 to 50 mg/kg/day in 2 or 3 divided doses; adults: 3 g/day in', '3 divided doses)', 'skin diseases', '111', '4', 'or cloxacillin po for 7 days', 'children over 10 years: 50 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'note: in newborns with lesions located around the umbilicus, administer cloxacilllin iv (see', 'table page 178, chapter 7).', '– for all patients:', '• quarantine from school (children can return to school after 24 to 48 hours of antibiotic', 'therapy).', '• look for and treat any underlying dermatosis: lice, scabies, eczema, herpes, scalp', 'ringworm, or an ent infection.', '• trace and treat contacts.', '• check for proteinuria (use urine dipstick) 3 weeks after the infection.', 'furuncles and carbuncles', 'necrotising perifollicular infection, usually due to staphylococcus aureus. risk factors include:', 'nasal carriage of s. aureus, maceration, breaks in the skin, poor hygiene; diabetes mellitus,', 'malnutrition, iron deficiency or immunodeficiency.', 'clinical features', '– furuncle: red, warm, painful nodule with a central pustule, usually around a hair follicle. it', 'becomes fluctuant, discharges a core of purulent exudate, and leaves a depressed scar. it occurs', 'most frequently on the thighs, groin, buttocks, armpits, neck and back. there is no fever.', '– carbuncle: a cluster of interconnected furuncles, sometimes with fever and peripheral', 'lymphadenopathy. it leaves a depressed scar.', 'treatment', '– single furuncle:', '• clean with soap and water 2 times/day and cover with a dry dressing.', '• apply warm moist compresses to the furuncle in order to encourage it to drain.', '• after drainage, clean and apply a dry dressing until the lesion has healed.', '– furuncle on the face, multiple furuncles, carbuncles or in immunocompromised patients:', '• same local care.', '• add systematically an antibiotic for 7 daysb:', 'cefalexin po', 'neonates under 7 days: 50 mg/kg/day in 2 divided doses', 'neonates 7 to 28 days: 75 mg/kg/day in 3 divided doses', 'children 1 month to 12 years: 25 to 50 mg/kg/day in 2 divided doses', 'children over 12 years and adults: 2 g/day in 2 divided doses', 'b for penicillin-allergic patients:', 'clindamycin po (children: 30 mg/kg/day in 3 divided doses; adults: 1800 mg/day in 3 divided doses)', 'chapter 4', '112', 'or amoxicillin/clavulanic acid (co-amoxiclav) po', 'the dose is expressed in amoxicillin:', 'children < 40 kg: 45 to 50 mg/kg/day in 2 divided doses (if using formulations in a ratio of', '8:1 or 7:1) or in 3 divided doses (if using formulations in a ratio of 4:1)', 'children ≥ 40 kg and adults: 1500 to 2000 mg/day depending on the formulation available:', '8:1 ratio: 2000 mg/day = 2 tablets of 500/62.5 mg 2 times per day ', '7:1 ratio: 1750 mg/day = 1 tablet of 875/125 mg 2 times per day ', '4:1 ratio: 1500 mg/day = 1 tablet of 500/125 mg 3 times per day ', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', '– in all cases: wash hand frequently, wash bedding.', 'erysipelas and cellulitis', 'acute skin infections, most often due to group a beta-haemolytic streptococcus, and at times', 'staphylococcus aureus (including methicillin resistant s. aureus–mrsa). recurrence is common', 'in adults.', 'clinical signs', '– skin erythema, oedema with well demarcated margins, warmth, pain, usually on the lower', 'limbs and at times the face.', '– often with fever, lymphadenopathy and lymphangitis.', '– look for a portal of entry (bite, ulcer, wound, intertrigo, eczema, fungal infection, etc.). ', '– rarely progression to necrotising fasciitis (chapter 10).', '– rare systemic complications: septicaemia, acute glomerulonephritis.', 'treatment', '– in all cases:', '• outline the area of erythema with a pen in order to follow the infectionc.', '• bed rest with leg elevated, treatment of pain (chapter 1).', '• administer antibiotics: either orally or iv depending on severity.', '• treat portal of entry.', '• non-steroidal anti-inflammatory drugs are contra-indicated (risk of necrotizing fasciitis).', '• test for proteinuria by urine dipstick, 3 weeks after infection in order to detect', 'glomerulonephritis. ', '• tetanus immunisation: see tetanus (chapter 7).', '– hospitalize for the following: children younger than 3 months, critically ill appearing', 'patientd, local complications, debilitated patient (chronic conditions, the elderly) or if there', 'is a risk of non-compliance with or failure of -outpatient treatment. treat other patients as', 'outpatients. ', 'c the erythema will regress if the treatment is effective. if the erythema spreads consider a treatment failure', '(mrsa or a necrotizing infection).', 'd critically ill appearing child: weak grunting or crying, drowsy and difficult to arouse, does not smile,', 'disconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'skin diseases', '113', '4', '– outpatient antibiotic therapye:', 'cefalexin po for 7 to 10 days', 'children 1 month to 12 years: 25 to 50 mg/kg/day in 2 divided doses', 'children over 12 years and adults: 2 g/day in 2 divided doses', 'or', 'amoxicillin/clavulanic acid (co-amoxiclav) po for 7 to 10 days. the dose is expressed in', 'amoxicillin:', 'children < 40 kg: 45 to 50 mg/kg/day in 2 divided doses (if using formulations in a ratio of 8:1', 'or 7:1) or in 3 divided doses (if using formulations in a ratio of 4:1).', 'children ≥ 40 kg and adults: 1500 to 2000 mg/day depending on the formulation available:', '8:1 ratio: 2000 mg/day = 2 tablets of 500/62.5 mg 2 times per day', '7:1 ratio: 1750 mg/day = 1 tablet of 875/125 mg 2 times per day', '4:1 ratio: 1500 mg/day = 1 tablet of 500/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', '– inpatient antibiotic therapyf:', '• first line therapy:', 'cloxacillin iv infusion over 60 minutesg', 'children 1 month to 12 years: 50 to 100 mg/kg/day in 4 divided doses', 'children over 12 years and adults: 4 g/day in 4 divided doses', 'or', 'amoxicillin/clavulanic acid (co-amoxiclav) by slow iv injection (3 minutes) or infusion', '(30 minutes). the dose is expressed in amoxicillin:', 'children: 80 to 100 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'if there is clinical improvement after 48 hours (afebrile and erythema and oedema have', 'improved) switch to cefalexin or amoxicillin/clavulanic acid po at the doses indicated', 'above to complete 7 to 10 days of treatment.', '• if there is no clinical improvement after 48 hours, consider mrsa:', 'clindamycin iv infusion over 30 minutesh', 'children 1 month and over: 30 mg/kg/day in 3 divided doses', 'adults: 1800 mg/day in 3 divided doses', 'after 48 hours, change to clindamycin po at the doses indicated above to complete 7 to', '10 days of treatment.', '• in case of necrotizing fasciitis: urgent transfer to a surgical centre, initiate antibiotic therapy', 'while awaiting transfer.', 'e for penicillin-allergic patients, clindamycin po for 7 to 10 days:', 'children: 30 mg/kg/day in 3 divided doses; adults: 1800 mg/day in 3 divided doses', 'f for penicillin-allergic patients, clindamycin iv infusion (doses as above).', 'g cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. then dilute each dose of', 'cloxacillin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of 100 ml of', '0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'h dilute each dose of clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg', 'and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'chapter 4', '114', 'cutaneous anthrax', '– anthrax is caused by the bacterium bacillus anthracis that primarily affects herbivores', '(sheep, goats, cows, camels, horses, etc.). humans may become infected through contact of', 'broken skin with a dead or sick animal. people at risk include livestock farmers and those', 'that manipulate skins, wool or carcasses of infected animals.', '– the disease is found in eastern europe, central asia, the mediterranean basin, africa and', 'south america.', '– pulmonary (acquired by inhalation) and intestinal (acquired by eating infected meat) forms', 'also exist.', 'clinical features', '– papule, then pruritic vesicle on uncovered skin surfaces (face, neck, arms, legs). the vesicle', 'ulcerates and becomes a painless black eschar surrounded by oedema, often associated with', 'with lymphangitis and regional lymphadenopathy.', '– the following are criteria of severity:', '• lesion located on the head or neck, or', '• presence of systemic symptoms (fever, malaise, headache, tachycardia, tachypnoea,', 'hypotension, hyper/hypothermia), or ', '• presence of extensive oedema, or', '• multiple, extensive or bullous lesions.', 'laboratory', '– from vesicular fluida: culture and susceptibility testing (rarely available) or gram stain for', 'microscopic examination.', '– pcr testing (reference laboratory).', 'treatment', 'cutaneous anthrax without severity criteria', '– do not excise the eschar; daily dry dressings.', '– antibiotic therapy for 7 to 10 days:', '• if drug susceptibility is not known:', 'ciprofloxacin po is first-line treatment for all patients including pregnant women and children:', 'children: 30 mg/kg/day in 2 divided doses (max. 1 g/day)', 'adults: 1 g/day in 2 divided doses', 'alternatives include:', 'doxycycline po (except in pregnant or lactating women and children less than 8 years)', 'children 8 to 12 years: 100 mg/day in 2 divided doses ', 'children over 12 years and adults: 200 mg/day in 2 divided doses', 'or', 'clindamycin po (e.g. in pregnant or lactating women and children less than 8 years)', 'children: 30 mg/kg/day in 3 divided doses (max. 1800 mg/day)', 'adults: 1800 mg/day in 3 divided doses', 'a samples can be stored (including transport time) for 7 days max. in cold chain (if not available, at a temperature', '< 30°c).', 'skin diseases', '115', '4', '• if penicillins are effective (documented susceptibility): ', 'amoxicillin po', 'children: 100 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'severe cutaneous anthrax', '– combination antibiotic therapy for 14 days:', 'whatever the protocol used, do not mix the two drugs in the same infusion bag', '(incompatibility).', '• if drug susceptibility is not known:', 'ciprofloxacin iv infusion over 60 minutesb', 'children: 30 mg/kg/day in 3 divided doses', 'adults: 1200 mg/ day in 3 divided doses', '+', 'clindamycin iv infusion over 30 minutesb', 'children 1 month and over: 40 mg/kg/day in 3 divided doses (max. 2700 mg/day)', 'adults: 2700 mg/day in 3 divided doses', '• if penicillins are effective (documented susceptibility): ', 'ampicillin iv', 'children 1 month and over: 200 mg/kg/day in 3 divided doses', 'adults: 12 g/day in 3 divided doses', '+ ', 'clindamycin iv infusion as above.', 'change to oral treatment as soon as possible to complete 14 days of treatment with', 'ciprofloxacin + clindamycin or amoxicillin + clindamycin as for cutaneous anthrax without', 'severity criteria.', '– intensive care: symptomatic treatment of shock (see shock, chapter 1); tracheostomy and', 'ventilatory support may be necessary.', 'prevention', '– antibiotic prophylaxis in case of known skin exposure: treat for 10 days po as for cutaneous', 'anthrax without severity criteria.', '– livestock vaccination; burial or burning of animal carcasses. ', 'b dilute each dose of ciprofloxacin or clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children', 'less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children above 20 kg and in', 'adults. administer ciprofloxacin more slowly than clindamycin.', 'chapter 4', '116', 'endemic treponematoses', 'endemic treponematoses are bacterial infections caused by 3 different types of treponema', '(other than treponema pallidum). human-to-human transmission may be direct or indirect.', 'the 3 endemic treponematoses result in positive syphilis serology (tpha-vdrl), but these tests', 'are not necessary as diagnosis is clinical. there is no laboratory test that can distinguish', 'between the different treponematoses.', 'for the diagnosis and treatment of syphilis, see genital infections, chapter 9.', 'clinical features', 'see table following page.', 'treatment', 'yaws', 'azithromycin po', 'children and adults: 30 mg/kg as a single dose (maximum 2 g)', 'or', 'benzathine benzylpenicillin im', 'children under 30 kg (or under 10 years): 600 000 iu as a single dose', 'children 30 kg and over (or 10 years and over) and adults: 1.2 miu as a single dose', 'pinta and bejel', 'benzathine benzylpenicillin im', 'children under 30 kg (or under 10 years): 600 000 iu as a single dose', 'children 30 kg and over (or 10 years and over) and adults: 1.2 miu as a single dose', 'for patients allergic to penicillin:', 'erythromycin po', 'children: 50 mg/kg/day in 2 or 3 divided doses for 14 days', 'adults: 2 to 3 g/day in 2 or 3 divided doses for 14 days', 'or', 'doxycycline po (except for children under 8 years and pregnant and lactating women)', 'children over 8 years: 100 to 200 mg once daily or in 2 divided doses for 14 days', 'adults: 200 mg once daily or in 2 divided doses for 14 days', 'notes:', '– antibiotic treatment will cure early stage cases and may relieve the pain of osteitis. it may be', 'ineffective for late stage infections.', '– syphilis serology will remain positive despite clinical cure.', 'treatment of contacts and latent cases', 'the same treatment should be administered to all symptomatic and asymptomatic contacts', 'and to all latent cases (asymptomatic individuals with positive serologic test for syphilis) in', 'endemic zones.', 'skin diseases', '117', '4', 'updated: october 2016', 'c', 'h', 'ap', 'ter 4', '118', 'yaws pinta bejel', 'pathogen treponema pertenue treponema carateum treponema pallidum type m', 'geographic', 'distribution', 'tropical and humid forests tropical zones of latin america arid areas, semi-desert', 'of the middle east and africa', 'population children between 4 and 14\\u2008years children and adults nomadic populations, particularly children', 'first stage yaws chancre: skin coloured lesion, non-', 'indurated, itchy, on the lower limbs in 95% of', 'cases, with peripheral adenopathy. ', 'spontaneous healing or development of a', 'large yaw surrounded by smaller yaws.', 'annular, erythematous, scaly plaques, usually', 'on uncovered body parts (face, extremities),', 'resemble dermatophytes. lesions heal sponta -', 'neously leaving scars.', 'discrete chancre: moist papule, most', 'commonly on the mucous membranes or in', 'dermal folds, with peripheral adenopathy.', 'second stage lesions appear 3 weeks after the initial chancre,', 'occur in crops and heal spontaneously:', '• frambesioma (papillomatous lesion, vegetal,', 'very contagious)', '• isolated or associated with yaws (round,', 'squamous papules, not very contagious)', '• osteoperiostitis of the long bones (phalanges,', 'nasal process of the maxilla, tibia)', 'pintids: plaques of various colours (bluish,', 'reddish, whitish). may occur anywhere on', 'the body.', '• mucous patches of the mouth common:', 'very contagious ulcerated, round in form,', 'indurated, with white coating, bleed easily,', 'usually occur on the inside of the lips,', 'cheek and tongue or labial folds', '• condyloma in the anogenital region (rare)', '• cutaneous lesions are rare: vegetal aspect,', 'in dermal folds', '• bone destruction identical to that of yaws,', 'in the legs and forearms', 'late stage after some years of latency:', '• periostitis; painful, debilitating osteitis', '• ulcerating and disfiguring rhinopharyngitis', '• juxta-articular nodules', 'symmetrical white patches on the limbs.\\u2008the', 'depigmentation is permanent, remaining after', 'treatment.', 'after several years of latency:', '• gummatous lesions of skin and long bones', '• plantar and palmar keratosis', '• juxta-articular nodules', '• hyper- and hypo-pigmented patches (as in', 'pinta)', 'leprosy (hansen’s disease)', 'an endemic, chronic bacterial infection due to mycobacterium leprae. humans are the only', 'reservoir of proven significance. leprosy is not very contagious with transmission through', 'prolonged, close, direct contact, particularly between household members. children are most', 'at risk of contracting the disease.', 'clinical features', 'leprosy should be considered in any patient presenting with hypopigmented skin lesions or', 'peripheral neuropathy. in suspect cases, conduct a thorough clinical examination:', '– skin and mucous membranes (patient must be undressed),', '– neurological examination: sensitivity to light touch, pinprick and temperature (hot-cold test),', '– palpation of the peripheral nerves.', 'different clinical forms and classification of leprosy exist.', 'the ridley-jopling classification differentiates 5 forms based on several factors, including the', 'bacteriological index.', 'the who clinical classification is simplified to include only 3 forms (see next page).', 'the ridley-jopling classification of leprosy', 'tuberculoid leprosy', '– the primary characteristic is peripheral nerve involvement: tender, infiltrated and thickened', 'nerves; loss of thermal, then tactile and pain sensation. this may lead to trophic ulcers and', 'mutilations of the extremities.', '– lesions are single or few in number:', '• plaque with a well-demarcated raised border and an atrophic, clear centre,', 'or', '• erythematous macule on pale skin, hypopigmented macule on dark skin.', '– nerve involvement develops late in the disease.', 'lepromatous leprosy', '– the primary characteristic is multiple muco-cutaneous lesions:', '• macules, papules or infiltrated nodules on the face, ear lobes and the upper and lower', 'limbs. lesions are bilateral, symmetrical, pigmented. initially, there is no sensory loss;', '• involvement of the nasal mucosa with crusting and nose bleeds;', '• oedema of the lower limbs.', '– nerve involvement develops late in the disease.', 'paucibacillary forms multibacillary forms', '(least contagious forms) (most contagious forms))', 'tuberculoid borderline borderline borderline lepromatous', 'tuberculoid lepromatous', 't.t. b.t. b.b. b.l. l.l.', 'skin diseases', '119', '4', 'borderline leprosy', 'forms between tuberculoid and lepromatous.', 'indeterminate leprosy (i)', 'form that does not fall in the ridley-jopling classification, frequent in children: a single well-', 'demarcated macule, hypopigmented on dark skin, slightly erythematous on pale skin. absence', 'of sweat and hair, and loss of sensation are inconstant.', 'lesion heals spontaneously or the disease evolves towards tuberculoid or lepromatous leprosy.', 'lepra reactions', '– reversal reactions: occur in patients with borderline leprosy, during treatment, when', 'evolving towards tuberculoid leprosy. skin lesions become swollen and painful with a risk of', 'necrosis and ulceration. acute painful neuritis (ulnar nerve) requires urgent treatment (see', 'next page) as there is a risk of permanent sequelae.', '– downgrading reactions: occur in untreated patients with borderline leprosy, when the', 'disease evolves towards lepromatous leprosy. these reactions are difficult to distinguish', 'from reversal reactions.', '– erythema nodosum leprosum: crops of tender subcutaneous nodules, purplish-red, then', 'yellowish in colour. this reaction is seen exclusively in patients with lepromatous leprosy', 'during the first year of treatment.', 'in order to simplify diagnosis and to promote rapid implementation of treatment, the who', 'simplified clinical classification of leprosy and differentiates only 3 forms:', '– multibacillary leprosy: more than 5 skin lesions', '– paucibacillary leprosy: 2 to 5 skin lesions', '– single skin lesion paucibacillary leprosy', 'laboratory', 'demonstration of acid-fast bacilli in a ziehl-neelsen stained smear:', '– nasal smear,', '– skin-split smear taken from the ear lobe or from a skin lesion.', 'in tuberculoid leprosy, bacilli are usually not found.', 'treatment', 'treatment of leprosy', '– leprosy is a curable disease. early antibiotic treatment prevents functional sequelae and', 'transmission of the disease.', '– in countries where leprosy is endemic, it is important to be informed about national control', 'programmes.', '– the high rates of resistance and of recurrences after single drug therapy have led to the use', 'of effective multi-drug therapy regimens which are easy to administer in the field and for', 'which no resistance has been reported.', '– teach the patient to recognise and quickly report a lepra reaction or relapse in order to', 'modify or restart treatment.', 'chapter 4', '120', 'treatment recommended by the who, based on the simplified clinical classification of leprosy', 'treatment of leprosy reactions', '– reversal or downgrading reactions', 'prednisolone (or prednisone) po: 1 mg/kg/day for 3 to 5 days then progressively decrease', 'the dosage (reduce the dosage by 10% each week).', '– erythema nodosum leprosum', 'clofazimine po: 100 to 300 mg/day associated with an nsaid (do not administer dosages', 'equal to or greater than 300 mg/day for more than 3 months).', 'multibacillary leprosy', '(more than 5 skin lesions)', 'paucibacillary leprosy', '(2 to 5 skin lesions)', 'paucibacillary leprosy', '(single skin lesion)', 'children under', '10 years', 'dapsone po: 25 mg once', 'daily, self-administered', '+ rifampicin po: 300 mg', 'once monthly, under', 'supervision', '+ clofazimine po: 100 mg', 'once monthly, under', 'supervision', 'and 50 mg 2\\u2008times', 'weekly, self-administered', 'dapsone po: 25 mg once', 'daily, self-administered', '+ rifampicin po: 300 mg', 'once monthly, under', 'supervision', 'children between', '10 and 14\\u2008years', 'dapsone po: 50 mg once', 'daily, self-administered', '+ rifampicin po: 450 mg', 'once monthly, under', 'supervision', '+ clofazimine po: 150 mg', 'once monthly, under', 'supervision', 'and 50 mg on alternate', 'days, self-administered', 'dapsone po: 50 mg once', 'daily, self-administered', '+ rifampicin po: 450 mg', 'once monthly, under', 'supervision', 'adults dapsone po: 100 mg once', 'daily, self-administered', '+ rifampicin po: 600 mg', 'once monthly, under', 'supervision', '+ clofazimine po: 300 mg', 'once monthly, under', 'supervision', 'and 50 mg once daily,', 'self-administered', 'dapsone po: 100 mg once', 'daily, self-administered', '+ rifampicin po: 600 mg', 'once monthly, under', 'supervision', 'rifampicin po: 600 mg', '+ ofloxacin po: 400 mg', '+ minocycline po: 100 mg', 'duration 12 months 6 months single dose', 'skin diseases', '121', '4', 'herpes simplex and herpes zoster', 'herpes simplex', 'recurrent viral infection of the skin and mucous membranes due to the herpes simplex virus.', 'recurrent lesions have a different presentation than primary infection.', 'clinical features', '– recurrent herpes labialis: tingling feeling followed by an eruption of vesicles on an', 'erythematous base, located on the lips (‘fever blisters’) and around the mouth, they may', 'extend onto the face. recurrence corresponds to a reactivation of the latent virus after a', 'primary infection. no associated malaise, adenopathy or fever.', '– carefully consider other sites: buccal (stomatitis, chapter 3), genital (genital ulcers, chapter 9),', 'ophthalmic, and secondary bacterial infections.', 'treatment', '– clean with soap and water 2 times/day until the lesions have healed.', '– for patients with secondary bacterial infections: antibiotic treatment as for impetigo.', 'herpes zoster (shingles)', 'acute viral infection due to the varicella-zoster virus. chickenpox is the primary infection and', 'herpes zoster the reactivation of the latent virus.', 'clinical features', '– unilateral neuralgic pain followed by an eruption of vesicles on a erythematous base, that', 'follow the distribution of a nerve pathway.', '– lesions most commonly occur on the thorax, but herpes zoster may also develop on the face', 'with a risk of ophthalmic complications.', '– herpes zoster is more common in adults than in children.', 'treatment', '– similar to that of herpes simplex, with the addition of systematic analgesics: paracetamol po', '(see pain, chapter 1).', '– aciclovir po given within the first 48 hours after the eruption of lesions is only indicated for', 'severe forms: necrotic or extensive lesions or lesion on the face which may spread to the', 'eyes (see hiv infection and aids, page 232, chapter 8).', 'chapter 4', '122', 'other skin disorders', 'eczema (dermatitis)', '– acute eczema: erythematous plaque, pruritic, vesicular, oozing, with poorly demarcated and', 'crumbly borders.', '– chronic eczema: erythematous plaque, scaly, dry, poorly demarcated and pruritic.', '– look for a cause (contact allergic dermatitis, fungal or bacterial infection with a distant focus,', 'malnutrition) and ask about family history.', 'treatment', '– clean with soap and water 2 times/day.', '– then apply:', '• for acute eczema: calamine lotion 2 times/day', '• for chronic eczema: zinc oxide ointment 2 times/day', '– look for and treat any pre-existing skin disease (scabies, lice etc.).', '– for patients with secondary infections: treat as impetigo.', '– for patients with intense pruritus, antihistamines (chlorphenamine or promethazine po at', 'the dosages indicated following page) for a few days.', 'seborrheic dermatitis', 'seborrheic dermatitis is an inflammatory chronic dermatosis that can be localized on rich areas', 'rich with sebaceous glands. this dermatosis is more common in infected patients with hiv.', 'clinical features', '– erythematous plaques covered by greasy yellow scales that can be localized on the scalp,', 'the face (nose wings, eyebrows, edge of the eyelids), sternum, spine, perineum, and skin', 'folds.', 'treatment', '– clean with soap and water 2 times /day; shampooing the scalp.', '– hydrocortisone 1%: 1 to 2 applications/day in a thin layer, for 7 days maximum', '– do not apply if pre-existing bacterial infection; treat first the infection (see impetigo).', 'skin diseases', '123', '4', 'urticaria', '– papules: transient, erythematous, oedematous, pruritic, resembling nettle stings.', '– look for a cause: food or drug (particularly antibiotic) allergy, insect bites; the invasive', 'stage of a bacterial or parasitic infection (ascariasis, strongylodiasis, ancylostomiasis,', 'schistosomiasis, loiasis), viral infection (hepatitis b or c); generalised disease (cancer, lupus,', 'dysthyroidism, vasculitis).', 'treatment', '– if the pruritus is intense, antihistamines:', 'chlorphenamine po', 'children from 1 to 2 years: 1 mg 2 times daily', 'children from 2 to 6 years: 1 mg 4 to 6 times daily (max. 6 mg/day)', 'children from 6 to 12 years: 2 mg 4 to 6 times daily (max. 12 mg/day)', 'children over 12 years and adults: 4 mg 4 to 6 times daily (max. 24 mg/day)', 'or, if not available,', 'promethazine po', 'adults: 75 mg/day in 3 divided doses', '– in the event of anaphylactic reaction, see shock (chapter 1).', 'pellagra', 'pellagra is a dermatitis resulting from niacin and/or tryptophane deficiency (in persons whose', 'staple food is sorghum; patients with malabsorption, or during famine).', 'clinical features', 'classically, disease of the ‘three ds’: dermatitis, diarrhoea and dementia.', '– dark red plaques, well demarcated, symmetric, located on exposed areas of the body', '(forehead, neck, forearms, legs). the skin becomes very scaly, pigmented, sometimes with', 'haemorrhagic bullae.', '– gastrointestinal (glossitis, stomatitis and diarrhoea) and neuropsychiatric symptoms are seen', 'in more serious forms.', 'treatment', '– nicotinamide (vitamin pp) po', 'children and adults: 300 to 500 mg/day in 2 divided doses, give with a diet rich in protein', 'until the patient is fully cured.', '– in the event of an epidemic of pellagra, for example in a refugee camp, it is vital that the', 'food ration be modified (add groundnuts or dry vegetables) in order to meet the daily', 'requirements (approximately 15 mg/day for adults).', 'chapter 4', '124', 'updated: september 2017', 'chapter 5: ', 'eye diseases', 'xerophthalmia (vitamin a deficiency)', 'conjunctivitis', 'neonatal conjunctivitis', 'viral epidemic keratoconjunctivitis', 'trachoma', 'periorbital and orbital cellulitis', 'other pathologies', 'onchocerciasis', 'loiasis', 'pterygium', 'cataract', '5', 'xerophthalmia (vitamin a deficiency)', 'the term xerophthalmia covers all the ocular manifestations of vitamin a deficiency.', 'xerophthalmia can progress to irreversible blindness if left untreated.', 'in endemic areas, vitamin a deficiency and xerophthalmia affect mainly children (particularly', 'those suffering from malnutrition or measles) and pregnant women.', 'disorders due to vitamin a deficiency can be prevented by the routine administration of', 'retinol.', 'clinical features', '– the first sign is hemeralopia (crepuscular blindness): the child cannot see in dim light, may', 'bump into objects and/or show decreased mobility.', '– then, other signs appear gradually:', '• conjunctival xerosis: bulbar conjunctiva appears dry, dull, thick, wrinkled and insensitive', '• bitot’s spots: greyish foamy patches on the bulbar conjunctiva, usually in both eyes', '(specific sign, however not always present).', '• corneal xerosis: cornea appears dry and dull', '• corneal ulcerations', '• keratomalacia (the last and most severe sign of xerophthalmia): softening of the cornea,', 'followed by perforation of the eyeball and blindness (extreme care must be taken during', 'ophthalmic examination due to risk of rupturing cornea).', 'treatment', 'it is essential to recognise and treat early symptoms to avoid the development of severe', 'complications. vision can be saved provided that ulcerations affect less than a third of the', 'cornea and the pupil is spared. even if deficiency has already led to keratomalacia and', 'irreversible loss of sight, it is imperative to administer treatment, in order to save the other eye', 'and the life of the patient.', '– retinol (vitamin a) po', 'regardless of the clinical stage:', 'children from 6 to 12 months (or under 8 kg): 100 000 iu once daily on d1, d2 and d8', 'children over 1 year (or over 8 kg): 200 000 iu once daily on d1, d2 and d8', 'adults (except pregnant women): 200 000 iu once daily on d1, d2 and d8', 'vitamin a deficiency is rare in breast fed infants under 6 months, if needed: 50 000 iu once', 'daily on d1, d2 and d8.', 'in pregnant women, treatment varies according to the stage of illness:', \"• hemeralopia or bitot's spots: 10 000 iu once daily or 25 000 iu once weekly for at least 4 weeks.\", 'do not exceed indicated doses (risk of foetal malformations).', '• if the cornea is affected, risk of blindness outweighs teratogenic risk. administer 200 000 iu once', 'daily on d1, d2 and d8.', 'eye diseases', '127', '5', '– corneal lesions are a medical emergency. in addition to the immediate administration of', 'retinol, treat or prevent secondary bacterial infections: apply 1% tetracycline eye ointment', 'twice daily (do not apply eye drops containing corticosteroids) and protect the eye with an', 'eye-pad after each application.', 'prevention', '– systematically administer retinol po to children suffering from measles (one dose on d1 and', 'd2).', '– in areas where vitamin a deficiency is common, routine supplementation of retinol po: ', 'children under 6 months: 50 000 iu as a single dose', 'children from 6 to 12 months: 100 000 iu as a single dose every 4 to 6 months', 'children from 1 to 5 years: 200 000 iu as a single dose every 4 to 6 months', 'mothers after giving birth: 200 000 iu as a single dose immediately after delivery or within', '8 weeks of delivery', 'note: to avoid excessive dosage, record any doses administered on the health/ immunisation', 'card and do not exceed indicated doses. vitamin a overdose may cause raised intracranial', 'pressure (bulging fontanelle in infants; headache, nausea, vomiting) and, in severe cases,', 'impaired consciousness and convulsions. these adverse effects are transient; they require', 'medical surveillance and symptomatic treatment if needed.', 'chapter 5', '128', 'conjunctivitis', 'conjunctivitis is an acute inflammation of the conjunctiva due to a bacterial or viral infection,', 'allergy, or irritation. endemic or epidemic, conjunctivitis may be associated with measles or', 'rhinopharyngitis in children. in the absence of hygiene and effective treatment, secondary', 'bacterial infections may develop, affecting the cornea (keratitis) and leading to blindness.', 'clinical features', '– clinical signs of all conjuctivites include: redness of the eye and irritation. visual acuity is not', 'affected.', '– depending on the cause:', '• abundant and purulent secretions, eyelids stuck together on waking, unilateral infection at', 'onset: bacterial conjunctivitis;', '• watery (serous) secretions, no itching: viral conjunctivitis;', '• excessive lacrimation, eyelid oedema, intense itching: allergic conjunctivitis.', '– in endemic areas, turn both upper eyelids up to check for signs of trachoma (see trachoma).', '– suspect keratitis if patient reports intense pain (more than is usually associated with', 'conjunctivitis) and photophobia. instill one drop of 0.5% fluorescein to check for possible', 'ulcerations.', '– always check for foreign bodies (subconjunctival or corneal) and remove after administering', '0.4% oxybuprocaine anaesthetic eye drops. never give bottle of eye drops to the patient.', 'treatment', 'bacterial conjunctivitis', '– clean eyes 4 to 6 times/day with boiled water or 0.9% sodium chloride.', '– apply 1% tetracycline eye ointment 2 times/day into both eyes for 7 days.', '– never use corticosteroid drops or ointment.', 'viral conjunctivitis', '– clean eyes 4 to 6 times/day with boiled water or 0.9% sodium chloride.', '– apply local antibiotics if there is a (risk of) secondary bacterial infection (see above).', 'allergic conjunctivitis', '– local treatment as for viral conjunctivitis.', '– antihistamines for one to 3 days: chlorphenamine or promethazine po (see urticaria,', 'chapter 4).', 'note: in the event of a foreign body, check tetanus immunisation status.', 'eye diseases', '129', '5', 'updated: august 2016', 'neonatal conjunctivitis', 'conjunctivitis due to neisseria gonorrhoeae and/or chlamydia trachomatis in children born to', 'infected mothers.', 'clinical features', '– purulent conjunctivitis within the first 28 days of life.', '– gonococcal conjunctivitis usually occurs 2 to 7 days after birth. the infection is bilateral in', '50% of cases, highly contagious and may rapidly lead to severe corneal lesions and blindness.', '– chlamydial conjunctivitis usually occurs 5 to 14 days after birth. the infection is often', 'unilateral.', 'prevention', 'immediately at birth:', '– clean eyelids with sterile 0.9% sodium chloride.', '– then, apply 1% tetracycline eye ointment once into both eyes.', 'note:', 'in case of maternal herpes simplex virus infection at delivery: clean eyelids with sterile 0.9%', 'sodium chloride then, apply 3% aciclovir eye ointment once into both eyes, then wait 12 hours', 'and apply tetracycline.', 'treatment', 'at dispensary level', 'treatment is urgent and the child should be referred. when immediate hospitalisation is not', 'possible, clean and apply 1% tetracycline eye ointment into both eyes every hour, until systemic', 'treatment is available.', 'at hospital level', '– if possible isolate the newborn for 24 to 48 hours.', '– treatment of choice is ceftriaxone im: 50 mg/kg as a single dose (without exceeding 125 mg)', 'if only the eyes are infected.', 'if ceftriaxone is not available or contraindicated, use cefotaxime im: 100 mg/kg as a single', 'dose.', '– clean eyes with an isotonic sterile solution (0.9% sodium chloride or ringer lactate) to', 'prevent secretions from adhering, and apply 1% tetracycline eye ointment 4 times/day.', '– if systemic treatment is not immediately available, apply 1% tetracycline eye ointment into', 'both eyes every hour until the treatment is available.', '– treat mother and partner (genital infections, chapter 9).', 'chapter 5', '130', '– if symptoms persist 48 hours after the injection of ceftriaxone or appear after 7 days of life,', 'add erythromycin po: 25 to 50 mg/kg/day in 4 divided doses for 14 days.', 'azithromycin po, 20 mg/kg once daily for 3 days, may be an alternative if treatment with', 'erythromycin is difficult to achieve.', 'viral epidemic keratoconjunctivitis', '(corneal and conjunctival lesions)', '– treat as viral conjunctivitis. if possible, refer to an ophthalmologist.', '– protect the eye with a compress as long as photophobia lasts. remove as soon as possible.', '– if necessary, administer a preventive dose of vitamin a (see page 128).', 'eye diseases', '131', '5', 'trachoma', 'trachoma is a highly contagious keratoconjunctivitis due to chlamydia trachomatis. the', 'disease is endemic in the poorest rural areas of africa, asia, central and south america and the', 'middle east.', 'infection is usually first contracted early in childhood by direct or indirect contact (dirty hands,', 'contaminated towels, flies). in the absence of hygiene and effective treatment, the', 'inflammation intensifies with successive infections, causing scars and deformities on the upper', 'tarsal conjunctiva. the resulting ingrowing eyelashes (trichiasis) cause corneal lesions followed', 'by permanent blindness, usually in adulthood.', 'the who classifies trachoma into 5 stages. early diagnosis and treatment of first stages is', 'essential to avoid the development of trichiasis and associated complications.', 'clinical features', 'several stages can occur simultaneously:', '– stage i: trachomatous inflammation - follicular (tf)', 'presence of five or more follicles in the upper tarsal conjunctiva. follicles are whitish, grey or', 'yellow elevations, paler than the surrounding conjunctiva.', '– stage ii: trachomatous inflammation - intense (ti)', 'the upper tarsal conjunctiva is red, rough and thickened. the blood vessels, normally visible,', 'are masked by a diffuse inflammatory infiltration or follicles.', '– stage iii: trachomatous scarring (ts)', 'follicles disappear, leaving scars: scars are white lines, bands or patches in the tarsal', 'conjunctiva.', '– stage iv: trachomatous trichiasis (tt)', 'due to multiple scars, the margin of the eyelid turns inwards (entropion); the eyelashes rub', 'the cornea and cause ulcerations and chronic inflammation.', '– stage v: corneal opacity (co)', 'cornea gradually loses its transparency, leading to visual impairment and blindness.', 'treatment', '– stages i and ii:', '• clean eyes and face several times per day.', '• antibiotic therapy:', 'the treatment of choice is azithromycin po:', 'children over 6 months or over 6 kg: 20 mg/kg as a single dose', 'adults: 1 g as a single dose', 'failing the above, apply 1% tetracycline eye ointment: 2 times/day for 6 weeks', 'in children under 6 months or 6 kg: erythromycin po (40 mg/kg/day in 2 divided doses for', '14 days)', 'chapter 5', '132', '– stage iii: no treatment', '– stage iv: surgical treatment', 'while waiting for surgery, if regular patient follow-up is possible, taping eyelashes to the', 'eyelid is a palliative measure that can help protect the cornea. in certain cases, this may lead', 'to permanent correction of the trichiasis within a few months.', 'the method consists in sticking the ingrowing eyelashes to the external eyelid with thin strip', 'of sticking-plaster, making sure that the eyelid can open and close perfectly. replace the', 'plaster when it starts to peel off (usually once a week); continue treatment for 3 months.', 'note: epilation of ingrowing eyelashes is not recommended since it offers only temporary', 'relief and regrowing eyelashes are more abrasive to the cornea.', '– stage v: no treatment', 'prevention', 'cleaning of the eyes, face and hands with clean water reduces direct transmission and the', 'development of secondary bacterial infections.', 'eye diseases', '133', '5', 'periorbital and orbital cellulitis', '– periorbital cellulitis is a common, usually benign, bacterial infection of the eyelids. it arises', 'principally following trauma to the eyelids (insect bite or abrasion).', '– orbital cellulitis is a serious infection involving the contents of the orbit (fat and ocular', 'muscles) that may lead to loss of vision or a brain abscess. it usually arises secondary to', 'spread from sinusitis (e.g. as a complication of ethmoid sinusitis).', '– periorbital and orbital cellulitis are more common in children than in adults.', '– the most common organisms causing periorbital and orbital cellulitis are staphylococcus', 'aureus, streptococcus pneumoniae and other streptococci, as well as haemophilus influenzae', 'type b in children living in countries where rates of immunisation with hib remain low.', 'clinical features', '– signs common to both periorbital and orbital cellulitis: acute eyelid erythema and oedema; the', 'oedema has a violaceous hue if secondary to h. influenzae.', '– in case of orbital cellulitis only:', '• pain with eye movements;', '• ophthalmoplegia (paralysis of eye movements) often with diplopia (double vision);', '• protrusion of the eye;', '• high fever, systemic signs.', 'treatment', '– hospitalize for the following: orbital cellulitis, children younger than 3 months, critically ill', 'appearing patienta, local complications, debilitated patient (chronic conditions, the elderly),', 'if there is a risk of non-compliance with or failure of outpatient treatment. treat the other', 'patients as outpatients.', '– outpatient antibiotic therapyb:', 'cefalexin po for 7 to 10 days', 'neonates 0 to 7 days: 50 mg/kg/day in 2 divided doses', 'neonates 8 days to 1 month: 75 mg/kg/day in 3 divided doses', 'children over 1 month: 25 to 50 mg/kg/day in 2 divided doses (max. 2 g/day)', 'children ≥ 40 kg and adults: 2 g/day in 2 divided doses', 'or', 'amoxicillin/clavulanic acid (co-amoxiclav) po for 7 to 10 days', 'the dose is expressed in amoxicillin: ', 'children < 40 kg: 80 to 100 mg/kg/day in 2 or 3 divided doses (use formulations in a ratio of', '8:1 or 7:1 exclusively)c.', 'a critically ill appearing child: weak grunting or crying, drowsy and difficult to arrouse, does not smile,', 'disconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'b for penicillin-allergic patients, clindamycin po for 7 to 10 days:', 'children: 30 mg/kg/day in 3 divided doses; adults: 1800 mg/day in 3 divided doses', 'c if the only formulation of co-amoxiclav available is 4:1, the dose is 50 mg/kg/day in 3 divided doses. ', 'chapter 5', '134', 'children ≥ 40 kg and adults:', 'ratio 8:1: 3000 mg/day (= 2 tab of 500/62.5 mg 3 times per day)', 'ratio 7:1: 2625 mg/day (= 1 tab of 875/125 mg 3 times per day) ', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day. ', '– inpatient antibiotic therapyd:', 'ceftriaxone slow ive (3 minutes) or iv infusion (30 minutes; 60 minutes in neonates) for at', 'least 5 days', 'children: 100 mg/kg/day as a single dose on the first day, then 100 mg/kg/day in 2 divided', 'doses', 'adults: 1 to 2 g once daily', '+', 'cloxacillin iv infusion (60 minutes)f', 'neonates 0 to 7 days (< 2 kg): 100 mg/kg/day in 2 divided doses', 'neonates 0 to 7 days (≥ 2 kg): 150 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (< 2 kg): 150 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (≥ 2 kg): 200 mg/kg/day in 4 divided doses', 'children 1 month and over: 100 to 200 mg/kg/day in 4 divided doses (max. 8 g/day)', 'children ≥ 40 kg and adults: 8 g/day in 4 divided doses', 'if there is clinical improvement (patient afebrile and erythema and oedema have improved)', 'after 5 days, change to amoxicillin/clavulanic acid po at the doses indicated above to', 'complete 7 to 10 days of treatment.', 'if there is no improvement in the first 48 hours (suspicion of methicillin resistant s. aureus),', 'replace cloxacillin with:', 'clindamycin iv infusion (30 minutes)g', 'neonates 0 to 7 days (< 2 kg): 10 mg/kg/day in 2 divided doses', 'neonates 0 to 7 days (≥ 2 kg): 15 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (< 2 kg): 15 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (≥ 2 kg): 30 mg/kg/day in 3 divided doses', 'children 1 month and over: 30 mg/kg/day in 3 divided doses (max. 1800 mg/day)', 'adults: 1800 mg/day in 3 divided doses', 'after 5 days, change to clindamycin po at the same doses to complete 7 to 10 days of', 'treatment.', '– if orbital cellulitis is unresponsive to iv antibiotics, consider an abscess. transfer patient to a', 'surgical centre for drainage.', 'd for penicillin-allergic patients, clindamycin iv infusion (doses as above).', 'e for administration by iv route, ceftriaxone powder should to be reconstituted in water for injection only. for', 'administration by iv infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose', 'in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg', 'and in adults.', 'f cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. then dilute each dose of', 'cloxacillin in 5 ml/kg of 0.9% sodium chloride or 5 % glucose in children less than 20 kg and in a bag of 100 ml of', '0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'g dilute each dose of clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg', 'and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'eye diseases', '135', '5', 'other pathologies', 'onchocerciasis', '(river blindness)', 'ocular lesions result from the invasion of the eye by microfilariae. they generally develop in', 'adults and progress to blindness in the absence of early treatment.', 'clinical features and treatment', 'ocular lesions are always associated with onchocercal skin lesions (see onchocerciasis, chapter 6). ', '– pruritus, hemeralopia (crepuscular blindness), decrease in visual acuity, narrowing of the', 'visual field, awareness of microfilariae in the visual field (the patient sees “little wiggling', 'worms before his eyes”).', '– lesions of the cornea (punctuate, then sclerosing, keratitis), iris (iridocyclitis) or posterior', 'segment (chorioretinopathy and optic atrophy); microfilariae within the anterior chamber or', 'vitreous humor (slit lamp).', 'for treatment, see onchocerciasis, chapter 6. ivermectin treatment may improve anterior', 'segment lesions (sclerosing keratitis, iridocyclitis) and visual acuity. severe lesions', '(chorioretinal lesions, optic atrophy) continue to progress despite treatment.', 'loiasis', 'clinical features and treatment', 'migration of an adult worm under the palpebral or bulbar conjunctiva (white, filiform worm,', 'measuring 4 to 7 cm in length, mobile) and ocular pruritus, lacrimation, photophobia or eyelid', 'oedema.', 'for treatment, see loiais, chapter 6. the migration of the worm is often of very brief duration.', 'do not attempt to extract it, or administer anaesthetic drops; simply reassure the patient, the', 'event is harmless. surgical removal is likewise futile if the worm is dead/calcified.', 'pterygium', 'a whitish, triangular growth of fibrovascular tissue extending slowly from the conjunctiva to', 'the cornea. it occurs most frequently in patients who are exposed to wind, dust, or arid', 'climates and never disappears spontaneously.', 'chapter 5', '136', 'clinical features and treatment', 'two stages:', '– benign pterygium develops slowly, does not reach the pupil: no treatment.', '– progressive vascularized pterygium: red and inflamed growth covers the pupil and may', 'impair vision:', '• clean eye with sterile water or 0.9% sodium chloride.', '• surgical removal if facilities are available.', 'cataract', 'opacity of the lens that causes a progressive loss of visual acuity. cataract is common in the', 'tropics and can occur at a younger age than in europe. the presence of cataract in both eyes', 'leads to blindness. surgery is the only treatment.', 'eye diseases', '137', '5', 'chapter 6: ', 'parasitic diseases', 'protozoan infections', 'malaria', 'human african trypanosomiasis', 'american trypanosomiasis', 'leishmaniases', 'intestinal protozoan infections (parasitic diarrhoea)', 'helminthic infections', 'flukes', 'schistosomiases', 'cestodes', 'nematode infections', 'filariasis', 'onchocerciasis', 'loiasis', 'lymphatic filariasis (lf)', '6', 'malaria', 'malaria is a parasitic infection due to protozoa of the genus plasmodium, transmitted to', 'humans by the bite of anopheles mosquitoes. transmission by transfusion of parasite infected', 'blood and transplacental transmission are also possible.', 'most infections are due to 5 species: p. falciparum, p. vivax, p. ovale, p. malariae and p. knowlesi.', 'all species may cause uncomplicated malaria; severe malaria (defined by the presence of', 'complications) is almost always due to p. falciparum.', 'clinical suspicion of malaria should be confirmed whenever possible by a parasitological', 'diagnosis. however, treatment of suspected malaria should not be delayed when confirmatory', 'testing is not available: uncomplicated malaria can progress rapidly to severe malaria, and', 'severe malaria may cause death within a few hours if left untreated.', 'clinical features', 'malaria should always be considered in a patient living in or coming from an endemic area,', 'who presents with fever (or history of fever in the previous 48 hours).', 'uncomplicated malaria', 'fever is frequently associated with chills, sweating, headache, muscular ache, malaise,', 'anorexia or nausea. in children, fever may be associated with abdominal pain, diarrhoea and', 'vomiting. anaemia is frequent in children and pregnant women.', 'severe malaria', 'in addition to the above, the patient presents with one or more of the following complications:', '– impaired consciousness, delirium or coma.', '– seizures, generalised or focal (e.g. abnormal eye movements).', '– prostration (extreme weakness; in children: inability to sit or drink/suck).', '– respiratory distress: rapid and laboured breathing or slow, deep breathing.', '– circulatory collapse (shock): cold extremities, weak or absent pulse, slow capillary refill time', '(> 2 seconds), cyanosis.', '– jaundice (check mucosal surfaces of the mouth, conjunctivae and palms).', '– haemoglobinuria: dark red urine.', '– abnormal bleeding: skin (petechiae), conjunctivae, nose, gums; blood in stools.', '– acute renal failure: urine output < 12 ml/kg/day in children and < 400 ml/day in adults,', 'despite adequate hydration.', 'patients presenting with any of the above features or with severe anaemia (anaemia, chapter 1)', 'must be hospitalised immediately.', 'laboratory', 'parasitological diagnosis', 'microscopiy', 'thin and thick blood films enable parasite detection, species identification, quantification and', 'monitoring of parasitaemia.', 'note: blood films may be negative due to sequestration of the parasitized erythrocytes in', 'peripheral capillaries in severe malaria, as well as in placental vessels in pregnant women.', 'parasitic diseases', '141', '6', 'rapid diagnostic tests (rdts)a', 'rapid tests detect parasite antigens. they give only a qualitative result (positive or negative)', 'and may remain positive several days or weeks following effective treatment.', 'note: even with positive diagnostic results, rule out other causes of fever.', 'additional examinations', 'haemoglobin (hb) level', 'to be measured routinely in all patients with clinical anaemia, and in all patients with severe', 'malaria.', 'blood glucose level', 'to be measured routinely to detect hypoglycaemia (< 3.3 mmol/l or < 60 mg/dl) in patients', 'with severe malaria and those with malnutrition.', 'treatment of malaria due to p. vivaxb, p. ovale, p. malariae, p. knowlesi', 'chloroquine (cq) po', 'children and adults: 10 mg base/kg once daily on d1, d2', '5 mg base/kg on d3', 'p. vivax and p. ovale can cause relapses due to activation of dormant parasites in the liver. a', 'treatment with primaquinec can be given to eliminate these parasites, after the initial', 'treatment with cq. however, this treatment is reserved for patients living in areas where re-', 'infection is unlikely, i.e. non-endemic or low transmission areas.', 'treatment of uncomplicated falciparum malaria', 'antimalarial treatment ', 'during pregnancy, see antimalarial treatment in pregnant women.', 'the treatment is an artemisinin-based combination therapy (act)d given by the oral route for', '3 days. the first-line act is chosen according to therapeutic efficacy in the area under', 'consideration. coformulations (2 antimalarials combined in the same tablet) are preferred over', 'coblisters (2 distinct antimalarials presented in the same blister). for dosing information, see', 'table next page.', 'if vomiting precludes oral therapy, treatment is started using iv or im artesunate or', 'im artemether or rectal artesunate, depending on availability, until the patient can tolerate a', 'complete 3-day oral treatment with an act.', 'a most rapid tests detect the following antigens alone or in combination: hrp2 protein specific to p. falciparum;', 'an enzyme (pf pldh) specific to p. falciparum; an enzyme (pan pldh) common to all 4 plasmodium species.', 'hrp2 may continue to be detectable for 2 to 3 weeks or more after parasite clearance; pldh remains', 'detectable for several days (up to 2 weeks) after parasite clearance.', 'b in general, p. vivax remains sensitive to cq but resistance is found in papua new guinea, the solomon islands,', 'burma, india, indonesia and east timor. in these regions, follow national recommendations.', 'c primaquine po for 14 days: 0.25 to 0.5 mg/kg once daily in children > 4 years; 15 mg once daily in adults.', 'primaquine is contra-indicated in individuals with g6pd deficiency. if g6pd deficiency cannot be tested', 'individually, the decision to prescribe primaquine must take into account the prevalence of deficiency in the', 'population.', 'd act: a combination of artemisinin or one of its derivatives (e.g. artesunate, artemether) with another', 'antimalarial of a different class.', 'chapter 6', '142', 'updated: june 2017', 'treatment of uncomplicated falciparum malaria', 'parasitic diseases', '143', '6', 'act presentation dosage', 'ar', 'te', 'm', 'et', 'he', 'r/', 'lu', 'm', 'ef', 'an', 'tr', 'in', 'e', '(a', 'l)', 'coformulated tablets of 20 mg artemether/', '120 mg lumefantrine', 'blister child 5 to < 15 kg, 6 tab/blister', 'blister child 15 to < 25 kg, 12 tab/blister', 'blister child 25 to < 35 kg, 18 tab/blister', 'blister child ≥ 35 kg and adult, 24 tab/blister', 'on d1, the first dose is given at 0 hour and the 2nd dose at', '8-12 hours. subsequent doses on d2 and d3 are given', 'twice daily (morning and evening).', '==> 1 tab twice daily on d1, d2, d3', '==> 2 tab twice daily on d1, d2, d3', '==> 3 tab twice daily on d1, d2, d3', '==> 4 tab twice daily on d1, d2, d3', 'ar', 'te', 'su', 'na', 'te', '/a', 'm', 'od', 'ia', 'qu', 'in', 'e', '(a', 's', '/a', 'q', ')', 'coformulated tablets', 'blister child 4.5 to < 9 kg,', 'tab of as 25 mg/aq base 67.5 mg, 3 tab/blister', 'blister child 9 to < 18 kg,', 'tab of as 50 mg/aq base 135 mg, 3 tab/blister', 'blister child 18 to < 35 kg,', 'tab of as 100 mg/aq base 270 mg, 3 tab/blister', 'blister child ≥ 36 kg and adult,', 'tab of as 100 mg/aq base 270 mg, 6 tab/blister', '==> 1 tab once daily on d1, d2, d3', '==> 1 tab once daily on d1, d2, d3', '==> 1 tab once daily on d1, d2, d3', '==> 2 tab once daily on d1, d2, d3', 'ar', 'te', 'su', 'na', 'te', '-', 'su', 'lfa', 'do', 'xi', 'ne', '/p', 'yr', 'am', 'et', 'ha', 'm', 'in', 'e', '(a', 's', '-s', 'p', ')', 'co-blister', 'coblister child ≤ 25 kg,', '3 tab of as 50 mg + 1 tab of sp 500/25 mg', 'coblister child 25 to < 50 kg,', '6 tab of as 50 mg + 2 tab of sp 500/25 mg', 'coblister child ≥ 50 kg and adult,', '12 tab of as 50 mg + 3 tab of sp 500/25 mg', 'coblister child ≥ 50 kg and adult,', '6 tab of as 100 mg + 3 tab of sp 500/25 mg', '5 to < 10 kg ==> ½ tab as once daily on d1, d2, d3', '+ ½ tab sp as a single dose on d1', '10 to < 25 kg ==> 1 tab as once daily on d1, d2, d3', '+ 1 tab sp as a single dose on d1', '==> 2 tab as once daily on d1, d2, d3 + 2 tab sp as a', 'single dose on d1', '==> 4 tab as once daily on d1, d2, d3 + 3 tab sp as a', 'single dose on d1', '==> 2 tab as once daily on d1, d2, d3 + 3 tab sp as a', 'single dose on d1', 'ar', 'te', 'su', 'na', 'te', '/m', 'ef', 'lo', 'qu', 'in', 'e', '(a', 's', '/m', 'q', ')', 'coformulated tablets', 'blister child 5 to < 8 kg,', 'tab of as 25 mg/mq 55 mg, 3 tab/blister', 'blister child 8 to < 17 kg,', 'tab of as 25 mg/mq 55 mg, 6 tab/blister', 'blister child 17 to < 30 kg,', 'tab of as 100 mg/mq 220 mg, 3 tab/blister', 'blister child ≥ 30 kg and adult,', 'tab of as 100 mg/mq 220 mg, 6 tab/blister', '==> 1 tab once daily on d1, d2, d3', '==> 2 tab once daily on d1, d2, d3', '==> 1 tab once daily on d1, d2, d3', '==> 2 tab once daily on d1, d2, d3', 'di', 'hy', 'dr', 'oa', 'rt', 'em', 'is', 'in', 'in', 'e/', 'pi', 'pe', 'ra', 'qu', 'in', 'e', '(d', 'h', 'a', '/p', 'p', 'q', ')', 'coformulated tablets', 'blister children,', 'tab of 20 mg dha/160 mg ppq, 3 tab/blister', 'blister children,', 'tab of 40 mg dha/320 mg ppq, 3 tab/blister', 'blister children,', 'tab of 40 mg dha/320 mg ppq, 6 tab/blister', 'blister adolescents-adults,', 'tab of 40 mg dha/320 mg ppq, 9 tab/blister', 'blister adolescents-adults,', 'tab of 40 mg dha/320 mg ppq, 12 tab/blister', '5 to < 8 kg: 1 tab 20/160 mg once daily on d1, d2, d3', '8 to < 11 kg: 1½ tab 20/160 mg once daily on d1, d2, d3', '11 to < 17 kg: 1 tab 40/320 mg once daily on d1, d2, d3', '17 to < 25 kg: 1½ tab  40/320 mg once daily on d1, d2, d3', '25 to < 36 kg: 2 tab 40/320 mg once daily on d1, d2, d3', '36 to < 60 kg: 3 tab 40/320 mg once daily on d1, d2, d3', '60 to < 80 kg: 4 tab 40/320 mg once daily on d1, d2, d3', '≥ 80 kg: 5 tab 40/320 mg once daily on d1, d2, d3', 'notes:', 'in infants below the age/weight mentioned in the table above, there is little data on efficacy', 'and safety of acts.', 'the combinations al, as/aq and dha/ppq can be used. the dose should be calculated so as to', 'correspond to 10-16 mg/kg/dose of lumefantrine; 10 mg/kg/day of amodiaquine; 20 mg/kg/day of', 'piperaquine).', 'the combination as-sp should not be used during the first weeks of life.', 'clinical condition of young children can deteriorate rapidly; it may be preferable to start', 'parenteral treatment straight away (see next page).', 'in the event of failure of correctly administered treatment with a first line act, use another', 'act.', 'quinine po is still recommended in some national protocols:', 'quinine po d1 to d7', 'children and adults < 50 kg: 30 mg/kg/day in 3 divided doses at 8-hour intervals', 'adults ≥ 50 kg: 1800 mg/day in 3 divided doses at 8-hour intervals', 'reduced susceptibility to quinine has been observed in south-east asia and amazon region.', 'note: p. falciparum is resistant to chloroquine (cq) in africa, south america, south-east asia', 'and oceania but appears to remain sensitive to cq in haiti and the dominican republic. in', 'these regions, cq remains the first line treatment (see non-falciparum malaria).', 'symptomatic treatment', 'paracetamol po in the event of high fever only (fever, chapter 1). ', 'treatment of severe malaria', 'the patient must be hospitalised.', 'antimalarial treatment', 'during pregnancy, see antimalarial treatment in pregnant women.', 'at dispensary level', 'before transfer, administer the first dose of artesunate or artemether im (loading dose, see', 'below) or one dose of rectal artesunate in children less than 6 years:', '10 mg/kg as a single dose i.e.:', 'children 3 to < 6 kg: 1 suppository 50 mg', 'children 6 to < 11 kg: 2 suppositories 50 mg', 'children 11 to 20 kg: 1 suppository 200 mg', 'at hospital level', 'the drugs of choice is artesunate iv or im; if artesunate is not available, use artemether im.', 'for patients in shock: use artesunate iv or, if not available, quinine iv. the im route is not', 'appropriate.', 'artesunate slow iv injection (3 to 5 minutes) or, if not possible, slow im injection, into the', 'anterior thigh', 'children less than 20 kg: 3 mg/kg/dose', 'children 20 kg and over and adults: 2.4 mg/kg/dose', '– one dose on admission (h0)', '– one dose 12 hours after admission (h12)', '– one dose 24 hours after admission (h24)', '– then one dose once daily', 'chapter 6', '144', 'administer at least 3 doses, then, if the patient can tolerate oral route, change to an act.', 'or artemether im (anterior thigh)', 'children and adults: 3.2 mg/kg on admission (d1) then 1.6 mg/kg once daily.', 'as soon as the patient can tolerate oral route, change to an act.', 'for completion of therapy by oral route:', '– if the duration of parenteral treatment was less than 7 days: treat 3 days with an acte (see', 'treatment of uncomplicated falciparum malaria).', '– if the duration of parenteral treatment was 7 days: to not give additional oral treatment.', 'quinine iv is still recommended in some national protocols. the dose is expressed in quinine', 'salt:', '– loading dose: 20 mg/kg to be administered over 4 hours, then, keep the vein open with an', 'infusion of 5% glucose over 4 hours; then', '– maintenance dose: 8 hours after the start of the loading dose, 10 mg/kg every 8 hours', '(alternate quinine over 4 hours and 5% glucose over 4 hours).', 'for adults, administer each dose of quinine in 250 ml of glucose. for children under 20 kg,', 'administer each dose of quinine in a volume of 10 ml/kg of glucose.', 'do not administer a loading dose to patients who have received oral quinine, mefloquine', 'within the previous 24 hours: start with maintenance dose.', 'as soon as the patient can tolerate oral treatment, administer either a 3-day course of acte or', 'oral quinine to complete 7 days of treatment.', 'if the combination as-mq is used as oral completion treatment following iv quinine, an interval', 'of 12 hours should elapse between the last dose of quinine and the administration of mq.', 'symptomatic treatment and management of complications', 'hydration', 'maintain adequate hydration. as a guide, volume to be administered per 24 hours by oral or iv', 'route, see appendix 1a.', 'adjust the volume according to clinical condition in order to avoid dehydration or fluid', 'overload (risk of pulmonary oedema).', 'fever', 'paracetamol in the event of high fever only (fever, chapter 1). ', 'severe anaemia', '– blood transfusion is indicated:', '• in children with hb < 4 g/dl (or between 4 and 6 g/dl with signs of decompensationf).', '• in pregnant women with hb < 7 g/dl (before 36 weeks) or hb < 8 g/dl (at 36 weeks or', 'later).', '– in other patients with hb < 7 g/dl, monitor clinical status and hb level and consider', 'transfusion on a case-by-case basis.', 'hypoglycaemia', '– if the patient is able to swallow:', '50 ml of 10% glucose', 'or 40 ml of water + 10 ml of 50% glucose', 'or 50 ml of water + 5 g (1 teaspoon) of granulated sugar', 'or 50 ml of milk', 'e do not use as-mq if the patient developed neurological signs during the acute phase.', 'f clinical signs of decompensation may include: shock, impaired consciousness or respiratory distress (acidosis).', 'parasitic diseases', '145', '6', '– in an unconscious patient:', 'children: 5 ml/kg of 10% glucoseg by iv injection (2 to 3 minutes) or infusion', 'adults: 1 ml/kg of 50% glucose by slow iv injection (3 to 5 minutes)', '– check blood glucose level after 15 minutes. if blood glucose level remains < 3.3 mmol/l or', '< 60 mg/dl, administer another dose or give glucose by oral route, according to the patient’s', 'clinical condition. hypoglycaemia may recur: maintain regular sugar intake (5% glucose, milk,', 'according to circumstances) and continue to monitor for several hours.', 'notes: ', '– in an unconscious or prostrated patient, in case of emergency or when venous access is', 'unavailable or awaited, use granulated sugar by the sublingual route to correct hypoglycaemia.h', '– the risk of hypoglycaemia is higher in patients receiving iv quinine.', 'coma', 'check/ensure the airway is clear, measure blood glucose level and assess level of', 'consciousness (blantyre or glasgow coma scale).', 'in the event of hypoglycaemia or if blood glucose level cannot be measured, administer glucose.', 'if the patient does not respond to administration of glucose, or if hypoglycaemia is not detected:', '– exclude meningitis (lumbar puncture) or proceed directly to administration of an antibiotic', '(see meningitis, chapter 7). ', '– insert a urinary catheter; place the patient in the recovery position.', '– reposition the patient every 2 hours; ensure eyes and mouth are kept clean and moist, etc.', '– monitor vital signs, blood glucose level, level of consciousness, urine output, hourly until', 'stable, then every 4 hours.', '– monitor fluid balance.', 'seizures', 'see chapter 1. address possible causes (e.g. hypoglycaemia; fever in children).', 'respiratory distress', '– rapid laboured breathing:', 'check for pulmonary oedema, which may occur with or without fluid overload: reduce iv', 'infusion rate if the patient is receiving iv therapy, nurse semi-sitting, oxygen, furosemide iv:', '1 mg/kg in children, 40 mg in adults. repeat after 1 to 2 hours if necessary.', 'associated pneumonia should also be considered (see acute pneumonia, chapter 2).', '– slow, deep breathing (acidosis):', 'look for dehydration (and correct if present), decompensated anaemia (and transfuse if', 'present).', 'oliguria and acute renal failure', 'look first for dehydration (appendix 2), especially due to inadequate fluid intake or excessive', 'fluid losses (high fever, vomiting, diarrhoea). treat dehydration if present. be aware of the risk', 'of fluid overload and acute pulmonary oedema. monitor for the return of urine output.', 'acute renal failure (arf) is found almost exclusively in adults and is more common in asia than', 'africa. arf should be suspected if urine output remains < 400 ml/day or < 20 ml/hour', '(< 12 ml/kg/day in children) despite adequate rehydration. insert a urinary catheter, measure', 'output. restrict fluids to 1 litre/day (30 ml/kg/day in children), plus additional volume equal to', 'urine output. renal dialysis is often necessary.', 'g in children, if ready-made g10% solution is not available: add 10 ml of g50% solution per 100 ml of g5%', 'solution to obtain a g10% solution.', 'h place a level teaspoon of sugar, moistened with a few drops of water, under the tongue, then place the patient', 'in the recovery position. repeat after 15 min if the patient has not regained consciousness. as with other', 'methods for treating hypoglycaemia, maintain regular sugar intake, and monitor.', 'chapter 6', '146', 'updated: june 2017', 'antimalarial treatment in pregnant women', 'uncomplicated falciparum malaria', 'act are recommended in all trimesters. however, the combination as/sp is contra-indicated in', 'hiv-infected pregnant women taking cotrimoxazole preventive therapy.', 'quinine po (± clindamycin) may be an alternative to act.', 'severe malaria', 'artesunate iv or im or artemether im are recommended in all trimesters. quinine iv is still', 'recommended in some national protocols.', 'preventioni', '– in areas with high risk of infection with p. falciparum, pregnant women should be tested for', 'malaria at regular interval during antenatal clinic visits. all women with a positive test should', 'receive a 3 day-course of act. women with negative(s) test(s) should receive sp (as a single', 'dose) for its preventive effect, according to a specific schedule (refer to the msf handbook,', 'essential obstetric and newborn care), but only in regions where sp still has sufficient', 'efficacy.', '– in areas with seasonal malaria transmission, seasonal malaria chemoprevention in children', '< 5 years reduces mortality: administration once monthly of a combination such as', 'amodiaquine + sp.', '– in malaria endemic zones and in epidemic-prone contexts, all in-patient facilities (including', 'hiv treatment centres and feeding centres), should be furnished with long-lasting', 'insecticidal nets (llins).', 'i see specialised literature for information regarding anti-vector measures and prevention in travellers.', 'parasitic diseases', '147', '6', 'updated: june 2017', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'human african trypanosomiasis', '(sleeping sickness)', 'human african trypanosomiasis (hat) is a zoonosis caused by protozoa (trypanosomes),', 'transmitted to humans through the bite of a tsetse fly (glossina). transmission by', 'contaminated blood transfusion and transplacental transmission are also possible.', 'the disease is found only in sub-saharan africa. there are two forms: trypanosoma brucei', 'gambiense hat in western and central africa and trypanosoma brucei rhodesiense hat in', 'eastern and southern africa.', 'clinical features', 'inoculation may be followed by an immediate local reaction (trypanosomal chancre). this', 'chancre arises in about 50% of all rhodesiense but rarely in gambiense.', 'gambiense hat', '– incubation lasts from a few days to several years.', '– the first stage (haemolymphatic stage) corresponds to the haematogenous and lymphatic', 'dissemination of the parasite. signs include intermittent fever, joint pain, lymphadenopathy', '(firm, mobile, painless lymph nodes, mainly cervical), hepatosplenomegaly and skin signs', '(facial oedema, pruritus).', '– the second stage (meningoencephalitic stage) corresponds to the invasion of the central', 'nervous system. signs of the haemolymphatic stage recede or disappear and varying', 'neurological signs progressively develop: sensory disturbances (deep hyperaesthesia),', 'psychiatric disorders (apathy or agitation), disturbance of the sleep cycle (with daytime', 'somnolence alternating with insomnia at night), impaired motor functions (paralysis,', 'seizures, tics) and neuroendocrine disorders (amenorrhoea, impotence).', '– in the absence of treatment: cachexia, lethargy, coma and death.', 'rhodesiense hat', 'the first stage is the same as above, but the incubation period is shorter (< 3 weeks), the', 'disease evolves more rapidly and symptoms are more severe. patients often die of myocarditis', 'in 3 to 6 months without having developed signs of the meningo- encephalitic stage.', 'in practice, gambiense and rhodesiense hat can be difficult to differentiate: e.g., there exist', 'cases of acute gambiense infection and others of chronic rhodesiense infection.', 'laboratory', '– diagnosis involves 3 steps for gambiense hat (screening test, diagnostic confirmation and', 'stage determination) and 2 steps for rhodesiense hat (diagnostic confirmation and stage', 'determination).', '– the recommended screening test for t.b. gambiense infection is the catt (card', 'agglutination test for trypanosomiasis). it detects the presence of specific antibodies in the', 'patient’s blood or serum.', 'chapter 6', '148', '– diagnostic confirmation: presence of trypanosomes in lymph node aspirates or in blood', 'using concentration techniques: capillary tube centrifugation technique (woo test),', 'quantitative buffy coat (qbc), mini-anion exchange centrifugation technique (maec).', '– stage determination: detection of trypanosomes (after centrifugation) and white cell count', 'in the cerebrospinal fluid (lumbar puncture):', '• haemolymphatic stage: no trypanosomes and ≤ 5 white cells/mm3', '• meningoencephalitic stage: evidence of trypanosomes or > 5 white cells/mm3', 'treatment (except in pregnant women)', '– due to the toxicity of trypanocides, detection of the parasite is essential before initiating', 'treatment. in the absence of parasitological confirmation, treatment may nevertheless be', 'justified in certain cases: very strong clinical suspicion, patients in life-threatening condition,', 'strong serological suspicion (catt 1:16 positive) in a population where the disease is highly', 'prevalent (> 2%).', '– several treatment regimens exist. check national recommendations and local resistance', 'levels.', '– treatment must be administered under close medical supervision. patients receiving', 'pentamidine can be treated as outpatients but those receiving suramin, eflornithine (with or', 'without nifurtimox) or melarsoprol should be hospitalised.', '– after treatment, patients should be checked every 6 months (clinical examination, lumbar', 'puncture and examination for trypanosomes) over 24 months, to look for relapse.', 'haemolymphatic stage (stage i)', 'gambiense hat', 'pentamidine isetionate deep im', 'children and adults: 4 mg/kg once daily for 7 to 10 days', 'patients should receive a source of glucose (meal, sweet tea) one hour before injection (risk of', 'hypoglycaemia); they should remain supine during administration and one hour after injection', '(risk of hypotension).', 'rhodesiense hat', 'suramin slow iv', 'children and adults: d1: test dose of 4 to 5 mg/kg', 'd3, d10, d17, d24, d31: 20 mg/kg without exceeding 1 g/injection', 'suramin may cause anaphylactic reactions, a test dose is recommended prior to starting', 'treatment. in the event of an anaphylactic reaction after the test dose, the patients must not be', 'given suramin again.', 'meningoencephalitic stage (stage ii)', 'before administrating trypanocides, the priority is to improve the patient’s general condition', '(rehydration, treatment of malaria, intestinal worms, malnutrition, bacterial infections). it is', 'nonetheless recommended not to postpone the trypanocidal treatment for more than 10 days.', 'gambiense hat', '– first choice: nifurtimox-eflornithine combination therapy (nect)', 'nifurtimox po', 'children and adults: 15 mg/kg/day in 3 divided doses for 10 days', '+ eflornithine iv infusion over 2 hours', 'children and adults: 400 mg/kg/day in 2 divided infusions (every 12 hours) for 7 days', 'parasitic diseases', '149', '6', 'the catheter must be handled with great attention to avoid local or general bacterial', 'infections: thoroughly disinfect the insertion site, ensure secure catheter fixation, protect', 'the insertion site with a sterile dressing, systematically change the catheter every 48 hours', 'or earlier in case of signs of phlebitis.', '– second choice:', 'eflornithine iv infusion over 2 hours', 'children under 12 years: 600 mg/kg/day in 4 divided infusions (every 6 hours) for 14 days', 'adults: 400 mg/kg/day in 4 divided infusions (every 6 hours) for 14 days', '– in the event of a relapse after nect or eflornithine:', 'melarsoprol slow iv', 'children and adults: 2.2 mg/kg once daily for 10 days', 'melarsoprol is highly toxic: reactive encephalopathy (coma, or recurrent or prolonged', 'seizures) in 5 to 10% of treated patients, fatal in around 50% of cases; peripheral', 'neuropathy, invasive diarrhoea, severe skin rash, phlebitis, etc.', 'prednisolone po (1 mg/kg once daily) is frequently combined throughout the duration of', 'treatment.', 'rhodesiense hat', 'melarsoprol slow iv', 'children and adults: 2.2 mg/kg once daily for 10 days', 'prednisolone po (1 mg/kg once daily) is frequently combined throughout the duration of', 'treatment.', 'treatment in pregnant women', 'all trypanocides are potentially toxic for the mother and the foetus (risk of miscarriage,', 'malformation, etc.). however, due to the life-threatening risk for the mother and the risk of', 'mother-to-child transmission, treatment must be initiated as follows:', 'haemolymphatic stage:', 'pentamidine for gambiense hat as of the second trimester and suramin for rhodesiense hat.', 'meningoencephalitic stage:', \"treatment depends on the mother's condition:\", '– if in immediately life-threatening condition: treatment with nect or eflornithine cannot be', 'deferred until after delivery.', '– if not immediately life-threatening condition: pentamidine for gambiense hat and suramin', 'for rhodesiense hat. treatment with nect or eflornithine is to be administered after', 'delivery.', 'prevention and control', '– individual protection against tsetse fly bites: long sleeves and trousers, repellents, keeping', 'away from risk areas (e.g. near rivers).', '– disease control: mass screening and treatment of patients (t.b. gambiense), trypanocide', 'treatment of cattle (t.b. rhodesiense), vector control using tsetse fly traps or insecticides.', 'chapter 6', '150', 'american trypanosomiasis', '(chagas’ disease)', 'chagas’ disease is a zoonosis due to the flagellated protozoan parasite trypanosoma cruzi,', 'transmitted to man by triatomine bugs (reduviidae) through a break in the skin or mucous', 'membranes. transmission by contaminated blood transfusion and transplacental transmission', 'are also possible.', 'the disease is only found on the american continent in the area between the south of mexico', 'and the south of argentina.', 'clinical features', 'acute phase', '– depending on the inoculation site, the first sign is a skin chancre or unilateral purplish orbital', \"oedema (romaña's sign) with local lymphadenopathy and fever (38°c, higher in children)\", 'over several weeks.', '– this is followed by multiple lymphadenopathies, hepatosplenomegaly, myocarditis (chest', 'pain, heart failure), sometimes meningoencephalitis (seizures, paralysis).', '– acute phase may be asymptomatic or subclinical.', 'the transition from the acute to chronic phase does not always occur.', 'chronic phase', '– follows a long latent period after the acute phase: cardiac lesions (arrhythmia and', 'conduction disorders, cardiomyopathy, heart failure, chest pain, thromboembolism) and', 'gastrointestinal lesions (megaoesophagus and megacolon).', '– most patients are asymptomatic.', 'laboratory', 'acute phase', '– thin or thick film: detection of the parasite in blood or lymph nodes.', '– serologic tests: detection of anti-trypanosoma cruzi antibodies.', \"– xenodiagnosis: examination of the faeces of uninfected triatomine bug fed with the patient's\", 'blood.', 'chronic phase', '– serologic tests: detection of anti-trypanosoma cruzi antibodies.', 'treatment', 'phase aiguë', 'nifurtimox po (contra-indicated in the first trimester of pregnancy, breast-feeding or in patients', 'with history of mental disorders or seizures):', 'patient under 40 kg: 10 to 12 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'patient over 40 kg: 8 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'parasitic diseases', '151', '6', 'the adverse effects of nifurtimox (anorexia, nausea, gastric pain, agitation, sleeping disorders,', 'seizures) occur in less than 20% of cases and must not result in treatment discontinuation.', 'avoid alcohol during treatment.', 'or', 'benznidazole po (contra-indicated in the first trimester of pregnancy and breast-feeding):', 'patient under 40 kg: 7.5 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'patient over 40 kg: 5 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'the minor adverse effects of benznidazole (nausea, skin rash) occur in about 50% of patients.', 'in the event of purpura with fever, paraesthesia or peripheral polyneuritis, stop treament.', 'chronic phase in children under 12 years', 'benznidazole po ', 'children under 40 kg: 7.5 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'children over 40 kg: 5 mg/kg/day in 2 to 3 divided doses for 30 to 60 days', 'chronic phase in children over 12 years and adults', 'do not treat in the event of pregnancy, breast-feeding, hepatic or renal failure, or a severe', 'intercurrent pathology.', 'nifurtimox po', '8 to 10 mg/kg/day in 2 to 3 divided doses for 60 to 90 days ', 'or', 'benznidazole po', '5 mg/kg/day in 2 to 3 divided doses for 60 days', 'symptomatic treatment', 'see seizures (chapter 1), pain (chapter 1) and heart failure (chapter 12).', 'prevention', '– improvement of housing and vector control: plastered walls and cement floors, corrugated-', 'iron roofs, insecticide spraying.', '– blood transfusions: screening donor blood for t. cruzi infection.', 'chapter 6', '152', 'leishmaniases', 'the leishmaniases are a group of parasitic diseases caused by protozoa of the genus', 'leishmania, transmitted by the bite of a sandfly. over 20 species cause disease in man.', '– cutaneous leishmaniasis is endemic in more than 70 countries in south and central america,', 'middle east, central asia, and africa.', '– mucocutaneous leishmaniasis occurs in latin america and, more rarely, in africa (ethiopia,', 'sudan).', '– visceral leishmaniasis occurs in more than 60 countries in east and north africa, south and', 'central asia, southern europe, and south and central america.', 'clinical features', 'cutaneous and mucocutaneous leishmaniasis', '– single or multiple lesions on the uncovered parts of the body: an erythematous papule', 'begins at the sandfly bite, enlarges to a nodule and extends in surface and depth to form a', 'scabbed ulcer. ulcers are painless, unless there is secondary bacterial or fungal infection.', 'usually, lesions heal spontaneously, leaving a scar, and result in lifelong protection from', 'disease.', '– lesions may also spread to the mucosa (mouth, nose, conjunctiva) giving rise to the', 'mucocutaneous form, which may cause severe disfigurement.', 'visceral leishmaniasis', 'visceral leishmaniasis (kala azar) is a systemic disease, resulting in pancytopenia, immuno -', 'suppression, and death if left untreated.', '– prolonged (> 2 weeks) irregular fever, splenomegaly, and weight loss are the main signs.', '– other signs include: anaemia, diarrhoea, epistaxis, lymphadenopathy, moderate hepatomegaly.', '– bacterial diarrhoea, pneumonia, and tuberculosis may develop due to immunosuppression.', 'post-kala azar dermal leishmaniasis', 'macular, nodular or papular skin rash of unknown aetiology, particularly on the face, and typically', 'occurring after apparent cure of visceral leishmaniasis.', 'laboratory', 'cutaneous and mucocutaneous leishmaniasis', '– parasitological diagnosis: identification of giemsa-stained parasites in smears of tissue', 'biopsy from the edge of the ulcer.', '– no useful serological tests.', 'parasitic diseases', '153', '6', 'visceral leishmaniasis', '– parasitological diagnosis: identification of giemsa-stained parasites in smears of splenic,', 'bone marrow, or lymph node aspiration-biopsy. splenic aspiration is the most sensitive', 'technique but carries a theoretical risk of potentially fatal haemorrhage.', '– serological diagnosis: rk39 dipstick test and direct agglutination test (dat) can be used for', 'diagnosis of primary visceral leishmaniasis in clinically suspect cases. diagnosis of relapse is', 'only by parasitological confirmation.', 'treatment', 'the various species of leishmania respond differently to drugs. follow national recommendations.', 'for information:', 'cutaneous and mucocutaneous leishmaniasis', '– cutaneous lesions generally heal spontaneously in 3 to 6 months. treatment is only', 'indicated if lesions are persistent (> 6 months), disfiguring, ulcerating, or disseminated.', '– forms with a single lesion or few lesions: start with local treatment with a pentavalent', 'antimonial: sodium stibogluconate or meglumine antimoniate, 1 to 2 m 6 infiltrated into the', 'lesion if it is a nodule and into the edges and base around the crust if it is an ulcer.', 'it should be repeated every 3 to 7 days for 2 to 4 weeks. once healing begins, the treatment', 'can be stopped and healing will continue.', '– im treatment with a pentavalant antimonial (20 mg/kg/day for 10 to 20 days) is restricted to', 'severe cases and must be administered under close medical supervision.', '– miltefosine po (as for visceral leishmaniasis) for 28 days is effective in many forms of', 'cutaneous leishmaniasis.', '– ulcers are often secondarily infected with streptococci and staphylococci: administer', 'suitable antibiotics.', '– mucocutaneous forms: as for visceral leishmaniasis.', 'visceral leishmaniasis', 'visceral leishmaniasis in east africa', '– first-line treatment:', 'a pentavalent antimonial im or slow iv: 20 mg/kg/day for 17 days', '+ paromomycin im: 15 mg (11 mg base)/kg/day for 17 days', '– second-line treatment for relapse and for specific vulnerable groups: severe disease,', 'pregnant women, patients over 45 years:', 'liposomal amphotericin b iv infusion: 3 to 5 mg/kg/day for 6 to 10 days up to a total dose of', '30 mg/kg', '– treatment in hiv co-infected patients:', 'liposomal amphotericin b iv infusion: 3 to 5 mg/kg/day for 6 to 10 days up to a total dose of', '30 mg/kg', '+ miltefosine po for 28 days:', 'children 2 to 11 years: 2.5 mg/kg/day', 'children > 11 years and < 25 kg: 50 mg/day', 'children and adults 25 to 50 kg: 100 mg/day', 'adults > 50 kg: 150 mg/day', 'chapter 6', '154', 'visceral leishmaniasis in south asia', '– first-line treatment:', 'liposomal amphotericin b iv infusion: 3 to 5 mg/kg/day for 3 to 5 days up to a total dose of', '15 mg/kg', 'or', 'liposomal amphotericin b iv infusion: 10 mg/kg as a single dose', '– second-line treatment for relapse:', 'liposomal amphotericin b iv infusion: 3 to 5 mg/kg/day for 5 to 8 days up to a total dose of', '25 mg/kg', 'for all patients with visceral leishmaniasis, hydration, nutritional support and treatment of', 'intercurrent infections (malaria, dysentery, pneumonia, etc.) are essential.', 'tuberculosis and/or hiv infection may also be present and should be suspected if relapse', 'occurs more than once or in the event of treatment failure.', 'post-kala azar dermal leishmaniasis (pkdl)', 'only patients with severe or disfiguring disease or with lesions remaining for > 6 months, and', 'young children with oral lesions that interfere with feeding, are treated.', 'pkdl in east africa', 'a pentavalent antimonial im or slow iv: 20 mg/kg/day for 17 to 60 days', '+ paromomycin im: 15 mg (11 mg base)/kg/day for 17 days', 'or', 'liposomal amphotericin b iv infusion: 2.5 mg/kg/day for 20 days', 'or', 'miltefosine po for 28 days (as for visceral leishmaniasis) may be beneficial in hiv co-infected', 'patients', 'pkdl in south asia', 'liposomal amphotericin b iv infusion: 5 mg/kg/day twice weekly up to a total dose of 30 mg/kg', 'prevention', '– insecticide-treated mosquito nets.', '– vector control and elimination of animal reservoir hosts..', 'parasitic diseases', '155', '6', 'intestinal protozoan infections ', '(parasitic diarrhoea)', 'the most important intestinal protozoan infections are amoebiasis (entamoeba histolytica),', 'giardiasis (giardia lamblia), cryptosporidiosis (cryptosporidium sp), cyclosporiasis (cyclospora', 'cayetanensis) and isosporiasis (isospora belli).', 'intestinal protozoa are transmitted by the faecal-oral route (soiled hands, ingestion of food or', 'water contaminated with faeces) and may cause both individual cases of diarrhoea and', 'epidemic diarrhoea outbreaks.', 'clinical features', '– amoebiasis gives rise to bloody diarrhoea (see amoebiasis, chapter 3).', '– clinical presentation of giardiasis, cryptosporidiosis, cyclosporiasis and isosporiasis is very', 'similar:', '• diarrhoea is usually mild and self-limiting, except in children and patients with advanced', 'hiv disease (cd4 < 200). these patients are likely to develop severe, intermittent or', 'chronic diarrhoea that may be complicated by malabsorption with significant wasting (or', 'failure to gain weight in children) or severe dehydration.', '• stools are usually watery, but steatorrhoea (pale, bulky, fatty stools) may be found in the', 'event of secondary fat malabsorption; stools may contain mucus.', '• diarrhoea is usually associated with non-specific gastrointestinal symptoms (abdominal', 'distension and cramps, flatulence, nausea, anorexia), but patients have low-grade fever or', 'no fever.', 'laboratory', 'definitive diagnosis relies on parasite identification in stool specimens (trophozoites and cysts', 'for giardia; oocysts for cryptosporidium, cyclospora, isospora). two to three samples, collected', '2 to 3 days apart are necessary, as pathogens are shed intermittently.', 'treatment', '– correct dehydration if present (for clinical features and management, see appendix 2).', 'chapter 6', '156', '– if the causal agent has been identified in the stool:', '– if reliable stool examination cannot be carried out: parasitic diarrhoeas cannot be', 'differentiated on clinical grounds, nor is it possible to distinguish these from non- parasitic', 'diarrhoeas. an empirical treatment (using tinidazole or metronidazole and cotrimoxazole as', 'above, together or in succession) may be tried in the case of prolonged diarrhoea or', 'steatorrhoea. in patients with hiv infection, see empirical treatment (hiv infections and', 'aids, page 228, chapter 8).', '– in patients with advanced hiv disease, cryptosporidiosis, cyclosporiasis and isosporiasis are', 'opportunistic infections; the most effective intervention is the treatment of the underlying', 'hiv infection with antiretrovirals. patients remain at high risk for dehydration/death until', 'immunity is restored.', 'giardiasis tinidazole po as a single dose or metronidazole po for 3 days', 'children: 50 mg/kg (max.2 g) children: 30 mg/kg once daily', 'adults: 2 g adults: 2 g once daily', 'cryptosporidiosis in immunocompetent patients, no aetiological treatment; spontaneous', 'resolution in 1 to 2 weeks.', 'cyclosporiasis co-trimoxazole po for 7 days', 'children: 50 mg smx + 10 mg tmp/kg/day in 2 divided doses', 'adults: 1600 mg smx + 320 mg tmp/day in 2 divided doses', 'in immunocompetent patients, symptoms usually resolve spontaneous in', '1 to 3 weeks. treatment is given in case of severe or prolonged symptoms.', 'isoporiasis co-trimoxazole po for 7 to 10 days', 'adults: 1600 to 3200 mg smx + 320 to 640 mg tmp/ day in 2 divided doses', 'in immunocompetent patients, symptoms usually resolve spontaneous in', '2 to 3 weeks. treatment is given in case of severe prolonged symptoms.', 'parasitic diseases', '157', '6', 'c', 'h', 'ap', 'ter 6', '158 flukes', 'infection/epidemiology clinical features/diagnosis treatment', 'lung flukes', 'paragonimus sp', 'distribution: south-east asia, china,', 'parts of cameroon, nigeria, gabon,', 'congo, colombia, peru', 'transmission: eating raw freshwater', 'crustaceans', 'the two most prominent symptoms are prolonged (> 2 weeks) productive cough and', 'intermittent haemoptysis (rusty-brown sputum). in endemic areas, paragonimosis', 'should be considered whenever pulmonary tuberculosis is suspected as the clinical', 'and radiological features overlap. paragonimosis is confirmed when eggs are', 'detected in sputum (or possibly in stools).', 'praziquantel po', 'children > 2 years and adults:', '75 mg/kg/day in 3 divided', 'doses for 2 to 3 days', 'hepatobiliary flukes', 'fasciola hepatica and gigantica', 'distribution: worldwide, in areas where', 'sheep and cattle are raised', 'transmission: eating uncooked aquatic', 'plants', 'opisthorchis felineus', '(asia, eastern europe)', 'opisthorchis viverrini', '(cambodia, laos, vietnam, thailand)', 'clonorchis sinensis', '(china, koera, vietnam)', 'transmission: eating raw/undercooked', 'freshwater fish', 'during migration phase: asthenia, prolonged fever, myalgia, right upper quadrant', 'pain, mid hepatomegaly; sometimes, allergic signs (e.g. pruritus). at this stage, the', 'diagnosis is rarely considered and can only be confirmed through serology;', 'parasitological examination of stools is always negative.', 'once adult flukes are present in the biliary tract: presentation resembles', 'cholelithiasis: right upper quadrant pain, recurrent episodes of obstructive jaundice/', 'febrile cholangitis. the diagnosis is confirmed when parasite eggs are detected in', 'stools (or flukes are seen in the biliary tract with sonography).', 'abdominal pain and diarrhoea. with heavy infection, hepatobiliary symptoms:', 'hepatomegaly, right upper quadrant pain, jaundice or episodes of febrile cholangitis.', 'the diagnosis is confirmed when parasite eggs are detected in stools.', 'triclabendazole po', 'children and adults:', '10 mg/kg as a single dose', 'may repeat in 24 hours in the', 'event of severe infection', 'praziquantel po', 'children > 2 years and adults:', '75 mg/kg/day in 3 divided', 'doses for 1 or 2 days', 'intestinal flukes', 'fasciolopsis buski', '(india, bangladesh, south-east asia)', 'heterophyes heterophyes', '(south-east asia, nile delta)', 'metagonimus yokogawai', '(siberia, china, korea)', 'transmission: eating uncooked aquatic', 'plants (f. buski), raw/undercooked fish', '(other species)', 'symptoms are limited to diarrhoea and epigastric or abdominal pain.', 'with massive infection, f. buski can cause oedematous allergic reactions (including', 'ascites, anasarca).', 'the diagnosis is confirmed when parasite eggs are detected in stools.', 'praziquantel po', 'children > 2 years and adults:', '75 mg/kg/day in 3 divided', 'doses for 1 day', 'schistosomiases', 'schistosomiases are acute or chronic visceral parasitic diseases due to 5 species of trematodes', '(schistosomes).', 'the three main species infecting humans are schistosoma haematobium, schistosoma mansoni', 'and schistosoma japonicum. schistosoma mekongi and schistosoma intercalatum have a more', 'limited distribution (see table next page).', 'humans are infected while wading/bathing in fresh water infested with schistosome larvae.', 'symptoms occurring during the phases of parasite invasion (transient localized itching as larvae', 'penetrate the skin) and migration (allergic manifestations and gastrointestinal symptoms', 'during migration of schistosomules) are frequently overlooked. in general, schistosomiasis is', 'suspected when symptoms of established infection become evident (see table next page).', 'each species gives rise to a specific clinical form: genito-urinary schistosomiasis due to', 's. haematobium, intestinal schistosomiasis due s. mansoni, s. japonicum, s. mekongi and', 's. intercalatum.', 'the severity of the disease depends on the parasite load. heavily infected patients are prone to', 'visceral lesions with potentially irreversible sequelae.', 'children aged 5 to 15 years are particularly at risk: prevalence and parasite load are highest in', 'this age group.', 'an antiparasitic treatment should be administered to reduce the risk of severe lesions, even if', 'there is a likelihood of re-infection.', 'geographic distribution of schistosomiasis in africa (who)', 'parasitic diseases', '159', '6', 'c', 'h', 'ap', 'ter 6', '160', 'a for the treatment of schistosomiasis, praziquantel may me administered to pregnant women.', 'parasite/epidemiology clinical features/diagnosis (established infection) treatment', 'g', 'en', 'it', 'o-', 'ur', 'in', 'ar', 'y ', 'sc', 'hi', 'st', 'os', 'om', 'ia', 'si', 's', 's. haematobium', 'distribution: africa, madagascar', 'and the arabian peninsula', '• urinary manifestations:', '– in endemic areas, urinary schistosomiasis should be suspected in any patients', 'who complain of macroscopic haematuria (red coloured urine throughout, or at', 'the end of, micturition). haematuria is frequently associated with polyuria/', 'dysuria (frequent and painful micturition).', '– in patients, especially children and adolescents, with urinary symptoms, visual', 'inspection of the urine (and dipstick test for microscopic haematuria if the urine', 'appears grossly normal) is indispensible.', '– presumptive treatment is recommended in the presence of macro- or', 'microscopic haematuria, when parasitological confirmation (parasite eggs', 'detected in urine) cannot be obtained.', '• genital manifestations:', 'in women, symptoms of genital infection (white-yellow or bloody vaginal', 'discharge, itching, lower abdominal pain, dyspareunia) or vaginal lesions resembling', 'genital warts or ulcerative lesions on the cervix; in men, haematospermia (blood', 'in the semen).', '• if left untreated: risk of recurrent urinary tract infections, fibrosis/calcification of', 'the bladder and ureters, bladder cancer; increased susceptibility to sexually', 'transmitted infections and risk of infertility.', '• in endemic areas, genito-urinary schistosomiasis may be a differential diagnosis', 'to the genito-urinary tuberculosis, and in women, to the sexually transmitted', 'infections (especially in women with an history of haematuria).', 'the same antiparasitic', 'treatment is used for all', 'species:', 'praziquantel po', 'children > 2 years and adultsa:', '40 mg/kg as a single dose', 'in', 'te', 'st', 'in', 'al', ' s', 'ch', 'is', 'to', 'so', 'm', 'ia', 'si', 's', 's. mansoni', 'distribution: tropical africa,', 'madagascar, the arabian peninsula,', 'south america (especially brazil)', 's. japonicum', 'distribution: china, indonesia, the', 'philippines', 's. mekongi', 'distribution: parts of lao pdr,', 'cambodia (along the mekong river)', 's. intercalatum', 'distribution: parts of drc, congo,', 'gabon, cameroon, chad', '• non-specific digestive symptoms (abdominal pain; diarrhoea, intermittent or', 'chronic, with or without blood) and hepatomegaly.', '• for s. intercalatum: digestive symptoms only (rectal pain, tenesmus, rectal', 'prolapse, bloody diarrhoea).', '• if left untreated: risk of hepatic fibrosis, portal hypertension, cirrhosis,', 'gastrointestinal haemorrhage (hematemesis, melanea, etc.), except with', 's. intercalatum (less pathogenic than other intestinal schistosomes, no severe', 'hepatic lesions).', '• the diagnosis is confirmed when parasite eggs are detected in stools.', '• in the absence of reliable parasitological diagnosis: in areas where intestinal', 'schistosomiasis is common, diarrhoea (especially bloody diarrhoea) with abdominal', 'pain and/or hepatomegaly may be a basis for presumptive diagnosis and', 'treatment.', 'p', 'arasitic d', 'iseases', '161', '6', 'cestodes (adult forms)', 'a praziquantel may be administered to pregnant women with t. solium taeniasis. for the other indications, treatment can usually be deferred until after delivery.', 'parasites clinical features/laboratory treatment transmission/prevention', 'taeniasis', 'taenia saginata', 'taenia solium', '(worldwide)', 'often asymptomatic', 'segments expelled in the stools,', 'sometimes gastrointestinal', 'disturbances (epigastric or abdo -', 'minal pain, nausea, diarrhoea)', 'laboratory: eggs in stools or', 'collected from perianal skin (scotch', 'tape method), segments in stools', 'praziquantel poa', 'children over 4 years and adults:', '5 to 10 mg/kg as a single dose', 'or', 'niclosamide po', 'children: 50 mg/kg as a single dose', 'adults: 2 g as a single dose', 'thoroughly chew the tablets before swallowing and', 'wash down with as little water as possible.', 'transmission by eating raw or under -', 'cooked meat:', '• beef for t. saginata', '• pork for t. solium', 'prevention:', '• individual: cook meat thoroughly', '• collective: slaughterhouse moni -', 'toring', 'diphyllobothriasis', 'diphyllobothrium latum', '(temperate or cold lake', 'areas)', 'often asymptomatic', 'in the event of heavy infection:', 'mild gastrointestinal disturbances,', 'anaemia due to vitamin b12', 'deficiency associated with (rare)', 'neurological sequelae', 'laboratory: eggs in stools', 'praziquantel poa', 'children over 4 years and adults:', '10 to 25 mg/kg as a single dose', 'or', 'niclosamide po', 'echildren: 50 mg/kg as a single dose', 'adults: 2 g as a single dose', 'thoroughly chew the tablets before swallowing and', 'wash down with as little water as possible.', 'if anaemia: vitamin b12 + folic acid', 'transmission by eating raw or under -', ' cooked freshwater fish', 'prevention:', '• individual: cook fish thoroughly', 'hymenolepiasis', 'hymenolepis nana', '(worldwide)', 'often asymptomatic', 'in the event of heavy infection:', 'gastrointestinal disturbances', '(epigastric pain)', 'laboratory: eggs in stools', 'praziquantel poa', 'children over 4 years and adults:', '15 to 25 mg/kg as a single dose', 'or', 'niclosamide po', 'adults: 2 g as a single dose on d1, then 1 g/day for', '6 days', 'thoroughly chew the tablets before swallowing and', 'wash down with as little water as possible.', 'transmission by faecal-oral route or', 'auto-infection', 'prevention:', '• individual: hand washing, nail', 'cutting', '• collective: hygiene and sanitation', '(water, latrines, etc.)', 'c', 'h', 'ap', 'ter 6', '162 cestodes (larvae)', '-', 'b albendazole is contra-indicated during the first trimester of pregnancy.', 'parasites clinical features/laboratory treatment transmission/prevention', 'cysticercosis', 'taenia solium', '(worldwide)', '• muscular: asymptomatic or', 'myalgia', '• subcutaneous: nodules', '• neurological (neurocysticercosis)', 'headache, convulsions, coma, etc.', '• ocular: exophthalmia, strabismus,', 'iritis, etc.', 'laboratory: hypereosinophilia in', 'blood and cerebrospinal fluid', 'neurological and ocular cysticercosis should be managed', 'in specialized facilities.', 'antiparasitic treatment without diagnosis of location by', 'computerirsed tomography and/or magnetic resonance', 'imaging can worsen the symptoms even threat the life.', 'neurosurgical treatment can be required.', 'transmission by eating food', 'contaminated with t. solium eggs or', 'auto-infection', 'prevention:', '• individual: treat t. solium carriers,', 'hygiene, cook meat thoroughly', 'hydatid cyst', 'echinococcus granulosus', '(south america, north,', 'east and south africa,', 'western europe)', 'cysts located in the liver (60% of', 'cases); lungs (30% of cases), and,', 'less frequently, in other sites', 'including the brain.', 'long asymptomatic period. the', 'cyst becomes symptomatic when', 'complications develop (biliary', 'obstruction; anaphylactic shock in', 'the event of rupture into peritoneal', 'cavity, vessels or an organ; febrile', 'painful jaundice in the event of', 'rupture into the biliary tree, etc.).', 'first-line treatment: surgical excision', 'albendazole pob is useful in addition to, or instead of,', 'surgery:', 'children over 2 years and adults under 60 kg:', '15 mg/kg/day in 2 divided doses', 'adults over 60 kg:', '800 mg/day in 2 divided doses', 'treatment duration:', 'in addition to surgery (pre-operatively or post-', 'operatively): continuous course of minimum 2 months', 'or at least two 28-day courses with a drug-free interval', 'of 14 days.', 'inoperable cases: 28-day courses with drug-free', 'intervals of 14 days, for 3 to 6 months (on average),', 'possibly up to 1 year.', 'transmission:', '• direct: contact with dogs', '• indirect: water and food', 'contaminated by dog faeces', 'prevention:', '• individual: avoid contact with dogs', '• collective: eliminate stray dogs,', 'monitor slaughterhouses', 'p', 'arasitic d', 'iseases', '163', '6', 'nematode infections', 'a roundworms, whipworms and hookworms frequently co-infect the same host. this should be taken into account when prescribing antihelminthic treatment.', 'infection/epidemiology clinical features/diagnosis treatment', 'ascariasis (roundworms)a', 'ascaris lumbricoides', 'distribution: worldwide,', 'mainly in tropical and', 'subtropical', 'transmission: ingestion of', 'ascaris eggs', '• during larval migration', 'loeffler ’s syndrome: transient pulmonary symptoms (dry cough, dyspnoea, wheezing)', 'and mild fever.', '• once adult worms are present in the intestine', 'abdominal pain and distension. in general, the diagnosis is made when adult worms are', 'expelled from the anus (or occasionally from the mouth). ascaris are large (15-30 cm),', 'cylindrical worms, pinkish-white, with slightly tapered ends.', '• complications', 'ascariasis is usually benign, but massive infestation may cause intestinal obstruction', '(abdominal pain, vomiting, constipation), especially in children < 5 years. worms may', 'accidentally migrate to gall bladder, liver or peritoneum, causing jaundice, liver abscess, or', 'peritonitis.', '• ascaris eggs may be detected through parasitological examination of stools.', 'albendazole po as a single dose', 'children > 6 months and adults:', '400 mg', '(200 mg in children > 6 months', 'but < 10 kg)', 'or', 'mebendazole po for 3 days', 'children > 6 months and adults:', '200 mg/day in 2 divided doses', '(100 mg/day in 2 divided doses in', 'children > 6 months but < 10 kg)', 'trichuriasis (whipworms)a', 'trichuris trichiura', 'distribution and transmission:', 'as for a. lumbricoides', '• in heavy infection: abdominal pain and diarrhoea.', '• in massive infection: chronic bloody diarrhea, tenesmus, rectal prolapse due to', 'frequent attempts to defecate, especially in children.', 'worms may sometimes be seen on the rectal mucosa when prolapsed: these are', 'grayish-white, 3-5 cm in length, in the shape of a whip, with a thickened body and a', 'long, threadlike extremity.', '• trichuris eggs may be detected through parasitological examination of stools.', 'albendazole po for 3 days', 'children > 6 months and adults:', '400 mg once daily ', '(200 mg once daily in children', '> 6 months but < 10 kg)', 'or', 'mebendazole po po for 3 days, as', 'for ascariasis.', 'a single dose of albendazole or', 'mebendazole is often insufficient.', 'ankylostomiasea', 'ancylostoma duodenale', 'necator americanus', 'distribution: tropical and', 'subtropical regions', 'transmission: larval skin', 'penetration following', 'contact (feet, hands) with', 'contaminated soil', '• during larval penetration/migration', 'cutaneous signs (pruritic papulo-vesicular rash at the site of penetration, usually the feet)', 'and pulmonary symptoms (similar to ascariasis).', '• once adult worms are present in the intestine', 'mild abdominal pain. attachment of the parasite to the mucosa leads to chronic blood', 'loss and anaemia (in endemic areas, antihelminthic treatment is recommended for', 'patients with iron-deficiency anaemia).', '• hookworm eggs may be detected through parasitological examination of stools.', 'albendazole as a single dose (as for', 'ascariasis) is much more effective', 'than mebendazole as a single dose.', 'when using mebendazole, a 3-day', 'treatment (as for ascariasis) is', 'recommended.', 'treatment of anaemia (chapter 1).', 'c', 'h', 'ap', 'ter 6', '164', 'b the migrating larvae of ancylostoma braziliense and caninum (hookworms of cats and dogs) also present as a pruritic, inflammatory, creeping eruption in humans', '(cutaneous larva migrans) but with a slower rate of progression and a longer duration (several weeks or months). treatment is with albendazole (400 mg as a single dose or', 'once daily for 3 days in children > 6 months and adults; 200 mg in children > 6 months but < 10 kg) or ivermectin (200 micrograms/kg as a single dose).', 'infection/epidemiology clinical features/diagnosis treatment', 'strongyloidiasis', 'strongyloides stercoralis', 'distribution: humid tropical', 'regions', 'transmission: larval skin', 'penetration and auto-', 'infection', '• acute strongyloidiasis', '– during larval penetration/migration: cutaneous signs (erythema and pruritus at the site', 'of penetration, which may persist several weeks) and pulmonary symptoms (similar to', 'ascariasis).', '– once larvae are present in the intestine: gastrointestinal symptoms (bloating,', 'abdominal and epigastric pain, vomiting, diarrhoea).', '• chronic strongyloidiasis', 'intestinal larvae may re-infect their host (auto-infection) by penetrating through the', 'intestinal wall or by migrating transcutaneously from perianal skin. chronic infections', 'result in prolonged or recurrent pulmonary and gastrointestinal symptoms.', 'transcutaneous migration of intestinal larvae gives rise to a typical rash (larva currens),', 'mainly in the anal region and on the trunk: sinuous, raised, linear, migrating lesion,', 'intensely pruritic, moving rapidly (5 to 10 cm/hour) and lasting several hours or daysb.', '• complications', 'hyperinfection (massive infestation) results in exacerbation of pulmonary and', 'gastrointestinal symptoms, and possible dissemination of larvae to atypical locations,', '(cns, heart, etc.). this form occurs mainly in patients receiving immunosuppressive', 'therapy (e.g. corticosteroids).', '• strongyloides larvae may be detected through parasitological examination of stools.', 'first line treatment is:', 'ivermectin pob as a single dose', 'children > 15 kg and adults:', '200 micrograms/kg, on an empty', 'stomach', 'while less effective, a 3-day', 'treatment with albendazole po (as', 'for trichuriasis) may be an', 'alternative.', 'hyperinfections are refractory to', 'conventional therapy. prolonged or', 'intermittent multiple-dose regimens', 'are required.', 'enterobiasis (pinworms)', 'enterobius vermicularis', 'distribution: worldwide', 'transmission: faecal-oral', 'route or auto-infection', '• anal pruritus, more intense at night, vulvovaginitis in girls (rare). in practice, the', 'diagnosis is most often made when worms are seen on the perianal skin (or in the stool', 'in heavy infestation). pinworms are small (1 cm), mobile, white, cylindrical worms with', 'slightly tapered ends.', '• pinworm eggs may be collected from the anal area (scotch tape method) and detected', 'under the microscope.', 'albendazole po as a single dose, as', 'for ascariasis', 'or', 'mebendazole po as a single dose', 'children > 6 months and adults:', '100 mg', '(50 mg in children > 6 months but', '< 10 kg)', 'a second dose may be given after', '2 to 4 weeks.', 'p', 'arasitic d', 'iseases', '165', '6', 'infection/epidemiology clinical features/diagnosis treatment', 'trichinellosis ', 'trichinella sp', 'distribution: worldwide,', 'particularly frequent in asia', '(thailand, laos, china, etc.', 'transmission: consumption of', 'raw or undercooked meat', 'containing trichinella larvae', '(pork, wart-hog, bear, dog,', 'etc.)', '• enteric phase (1 to 2 days after ingestion of infected meat)', 'self-limited episode of diarrhoea and abdominal pain lasting several days.', '• muscular phase (about 1 week after ingestion)', 'high fever; muscular pain (ocular [pain on eye movement], masseters [limitation of mouth', 'opening], throat and neck [pain with swallowing and speech], trunk and limbs); facial or', 'bilateral peri-orbital oedema; conjunctival haemorrhage, subungual haemorrhage;', 'headache. typical features are not always present and the patient may present with a', 'non-specific flu-like syndrome.', 'other features, such as dietary habits (consuming pork/raw meat), suggestive symptoms', '(fever > 39°c and myalgia and facial oedema) in several individuals who have shared the', 'same meal (e.g. ceremony) or hypereosinophilia > 1000/mm3, reinforce the clinical', 'suspicion.', '• definitive diagnosis: muscle biopsy; serology (elisa, western blot).', 'albendazole po for 10 to 15 days', 'children > 2 years: ', '10 mg/kg/day in 2 divided doses', 'adults:', '800 mg/day in 2 divided doses', 'or', 'mebendazole po for 10 to 15 days', 'children > 2 years: ', '5 mg/kg/day in 2 divided doses', 'adults:', '400 mg/day in 2 divided doses', 'plus, regardless of which anti -', 'helminthic is chosen:', 'prednisolone po', '0.5 to 1 mg/kg/day for the duration', 'of treatment', 'filariasis', 'filariases are helminthiases due to tissue-dwelling nematode worms (filariae). human to', 'human transmission takes place through the bite of an insect vector.', 'the most important pathogens are outlined in the table below. mixed infections are common', 'in co-endemic regions.', 'each filarial species is found in 2 principal developmental stages: macrofilariae (adult worms)', 'and microfilariae (larval offspring). the treatment depends on the pathogenic stage of the', 'species considered and targets microfilariae for o. volvulus and macrofilariae for the other', 'species.', 'classical antifilarial agents include diethylcarbamazine (dec), ivermectin and albendazole.', 'doxycycline is used solely in the treatment of o. volvulus and lymphatic filarial worms, which', 'harbour an endosymbiotic bacterium (wolbachia) sensitive to doxycycline.', 'onchocerciasis', '(river blindness)', 'the distribution of onchocerciasis is linked to that of its vector (simulium), which reproduces', 'near rapidly flowing rivers in intertropical africa (99% of cases), latin america (guatemala,', 'mexico, ecuador, colombia, venezuela, brazil) and yemen.', 'clinical features', 'in endemic areas, the following signs, alone or in combination, are suggestive of onchocerciasis:', '– onchocercomas: painless subcutaneous nodules containing adult worms, usually found over', 'a bony prominence (iliac crest, trochanters, sacrum, rib cage, skull, etc.), measuring several', 'mm or cm in size, firm, smooth, round or oval, mobile or adherent to underlying tissue;', 'single, or multiple and clustered', '– acute papular onchodermatitis: papular rash, sometimes diffuse but often confined to the', 'buttocks or lower extremities, intensely itchy, associated with scratch marks, often', 'superinfected (« filarial scabies »)a. this arises from dermal invasion by microfilariae.', 'a differential diagnosis is sarcoptic scabies (scabies, chapter 4).', 'species/infections location ofmacrofilariae', 'location of', 'microfilariae', 'pathogenic', 'stage', 'presence of', 'wolbachia', 'onchocerca volvulus', '(onchocerciasis)', 'subcutaneous', 'nodules skin and eye microfilariae yes', 'loa loa', '(loiasis)', 'subcutaneous', 'tissue blood macrofilariae no', 'wuchereria bancrofti,', 'brugia malayi and', 'brugia timori', '(lymphatic filariasis)', 'lymph vessels blood macrofilariae yes', 'chapter 6', '166', '– late chronic skin lesions: patchy depigmentation on the shins (« leopard skin »), skin atrophy', 'or areas of dry, thickened, peeling skin (lichenification; “lizard skin”).', '– visual disturbances and ocular lesions: see onchocerciasis, chapter 5.', 'laboratory', '– detection of the microfilariae in the skin (skin snip biopsy, iliac crest).', '– if the skin biopsy is positive, look for loiasis in regions where loiasis is co-endemic (mainly in', 'central africa).', 'treatment', 'antiparasitic treatment', '– diethylcarbamazine is contra-indicated (risk of severe ocular lesions).', '– doxycycline po (200 mg/day for 4 weeks; if possible 6 weeks) kills a significant percentage of', 'adult worms and progressively reduces the number of o. volvulus microfilariaeb. it is contra-', 'indicated in children < 8 years and pregnant or breast- feeding women.', '– ivermectin po is the drug of choice: 150 micrograms/kg as a single dose; a 2nd dose should be', 'administered after 3 months if clinical signs persist. repeat the treatment every 6 or 12 months', 'to maintain the parasite load below the threshold at which clinical signs appearc. ivermectin is', 'not recommended in children < 5 years or < 15 kg and pregnant women.', '– in case of co-infection with loa loa or in regions where loiasis is co-endemic, ivermectin', 'should be administered with caution (risk of severe adverse reactions in patients with high', 'l. loa microfilarial load):', '• if it is possible to test for loa loa (thick blood film):', 'confirm and quantify the microfilaraemia. administer the appropriate treatment', 'according to the microfilarial load (see loiasis, next page).', '• if it is not possible to perform a thick film examination, take a history from the patient:', 'if the patient has received a previous treatment with ivermectin without developing', 'serious adverse reactions (see page 169)), administer the treatment.', 'if the patient has never received ivermectin nor developed signs of loiasis (migration of an', 'adult worm under the conjunctiva, or « calabar » swellings), administer the treatment.', 'if the patient already has developed signs of loiaisis and if onchocerciasis has a significant', 'clinical impact, administer ivermectin under close supervision (see loiasis, next page) or', 'use an alternative (doxycycline, as above).', '– in the case of concomitant lymphatic filariasis: administer ivermectin first then start', 'treatment for lymphatic filariasis with doxycycline po (see lymphatic filariasis) one week', 'later.', 'nodulectomy (surgical removal of onchocercomas)', 'nodules are benign, often deep, and their ablation does not treat onchocerciasis. thus,', 'nodulectomy is reserved for cranial nodules (their proximity to the eye is a risk factor for visual', 'compromise) or nodules which are cosmetically unacceptable. in other cases, refrain from', 'nodulectomy. nodulectomy is performed under local anaesthesia, in an appropriately equipped', 'facility.', 'b elimination of wolbachia reduces the longevity and fertility of the macrofilariae, and thus the production of', 'new microfilariae within the organism.', 'c ivermectin kills microfilariae and disrupts production of microfilariae by adult worms. however the treatment', 'must be administered at regular intervals since it does not kill adult worms.', 'parasitic diseases', '167', '6', 'loiasis', 'the distribution of loiasis is linked to that of its vector (chrysops) in forests or savannah with', 'gallery forests in west or central africa (limits west: benin; east: uganda; north: sudan and', 'south: angola).', 'clinical features', '– the subconjunctival migration of an adult worm is pathognomonic of loa loa infection.', '– localised subcutaneous swellings, allergic in origin, transient (several hours or days),', 'painless, non-pitting, appearing anywhere on the body, frequently the upper extremities and', 'face, often associated with localised or generalised pruritus (« calabar swellings »).', '– onset of pruritus, in the absence of other signs.', '– subcutaneous migration of an adult worm: pruritic, palpable red cord-like linear lesion,', 'sinuous, advancing (1 cm/hour), disappearing rapidly with no traced. such migration', 'generally arises following treatment with diethylcarbamazine, rarely spontaneously.', 'laboratory', '– detection of microfilariae in the peripheral blood (thick film, stained with giemsa). blood', 'specimens should be collected between 10 am and 5 pm. quantify microfilaraemia even if', 'the diagnosis is certain, since treatment is determined by the intensity of the parasite load.', '– if the thick film is positive, look for onchocerciasis in regions where onchocerciasis is co-', 'endemic (mainly in central africa).', 'treatment', 'antiparasitic treatment', '– diethylcarbamazine (dec) is the only macrofilaricide available but is contra- indicated in:', '• patients with microfilaraemia > 2000 mf/ml (risk of severe encephalopathy, with poor', 'prognosis).', '• patients co-infected with o. volvulus (risk of severe eye lesions).', '• pregnant women, infants, and patients in poor general condition.', '– ivermectin (and possibly albendazole) is used to reduce microfilaraemia before', 'administration of dec; however, ivermectin administration may trigger encephalopathy in', 'patients with very high loa loa microfilaraemia (> 30 000 mf/ml).', '– doxycycline is not indicated since loa loa does not harbour wolbachia.', 'd for differential diagnosis, see cutaneous larva migrans, page 164.', 'chapter 6', '168', '– management:', '1) l. loa microfilaraemia is < 1,000-2,000 mf/ml', 'a 28-day treatment of dec may be started using small doses of 3 to 6 mg/day, i.e. 1/32 or', '1/16 of a 100 mg tablet, administered in 2 divided doses.', 'double the dose every day up to 400 mg/day in 2 divided doses in adults (3 mg/kg/day in', 'children).', 'if microfilaraemia or symptoms persist, a second treatment is given 4 weeks later.', 'if dec is contra-indicated due to possible or confirmed co-infection with o. volvulus,', 'ivermectin (150 micrograms/kg as a single dose) treats onchocerciasis, and reduces', 'pruritus and frequency of calabar swellings.', 'the treatment may be repeated every month or every 3 months.', '2) l. loa microfilaraemia is between 2,000 and 8,000 mf/ml', 'reduce microfilaraemia with ivermectin (150 micrograms/kg as a single dose); repeat', 'the treatment every month if necessary; administer dec when the microfilaraemia is', '< 2000 mf/ml.', '3) l. loa microfilaraemia is between 8,000 and 30,000 mf/ml', 'treatment with ivermectin (150 micrograms/kg as a single dose) may cause marked', 'functional impairment for several days. close supervision and support from family', 'member(s) are necessarye. prescribe paracetamol as well for 7 days.', '4) l. loa microfilaraemia is > 30,000 mf/ml', '• if the loiasis is well tolerated, it is preferable to refrain from treatment: the disease is', 'benign and treatment with ivermectin may cause very severe adverse reactions', '(encephalopathy), albeit rarely.', '• if loiasis has a significant clinical impact and/or the patient presents with symptomatic', 'onchocerciasis requiring treatment, ivermectin (150 micrograms/kg as a single dose) is', 'administered for 5 days under supervision in hospitalf. an attempt to first reduce l. loa', 'microfilaraemia using albendazole (400 mg/day in 2 divided doses for 3 weeks) is an', 'option. when l. loa microfilaraemia is < 30 000 mf/ml, treat with ivermectin under close', 'supervision and support, then dec when the microfilaraemia is < 2000 mf/ml.', 'extraction of macrofilariae', 'subcutaneous migration of a microfilaria usually results from treatment with dec; the worm', 'will die beneath the skin and extracting it serves no purpose.', 'removal of an adult worm from the conjunctiva: see loiasis, chapter 5.', 'e patients may present with various pain syndromes, be unable to move without help or unable to move at all.', 'monitoring is necessary to determine whether the patient can manage activities of daily living, and provide', 'assistance if necessary. if the patient remains bedridden for several days, ensure pressure sores do not develop', '(mobilisation, repositioning).', 'f a severe reaction may occur on d2-d3. it is usually preceded by haemorrhages of the palpebral conjunctiva on', 'd1-d2. routinely check for this sign by turning back the eyelids. symptoms of post-ivermectin encephalopathy', 'are reversible and the prognosis favourable, if the patient is correctly managed; the treatment is symptomatic', 'until symptoms resolve. avoid the use of steroids due to adverse effects.', 'parasitic diseases', '169', '6', 'lymphatic filariasis (lf)', 'the distribution of lf is linked to that of its mosquito vectors (anopheles, culex, aedes, etc.):', '– w. bancrofti: sub-saharan africa, madagascar, egypt, india, south east asia, pacific region,', 'south america, the caribbean', '– b. malayi: south east asia, china, india, sri lanka', '– b. timori: timor', '90% of lf is due to w. bancrofti and 10% to brugia spp.', 'clinical features', '– acute recurrent inflammatory manifestations', '• adenolymphangitis: lymph node(s) and red, warm, tender oedema along the length of a', 'lymphatic channel, with or without systemic signs (e.g. fever, nausea, vomiting). the', 'inflammation may involve the lower limbs, external genitalia and breast.', '• in men: acute inflammation of the spermatic cord (funiculitis), epididymis and testicle', '(epididymo-orchitis).', 'attacks resolve spontaneously within a week and recur regularly in patients with chronic', 'disease.', '– chronic manifestations', '• lymphoedema: oedema of the lower extremity or external genitalia or breast, secondary', 'to obstruction of the lymphatics by macrofilariae. the oedema is reversible initially but', 'then becomes chronic and increasingly severe: hypertrophy of the area affected,', 'progressive thickening of the skin (fibrous thickening with formation of creases, initially', 'superficial, but then deep, and verrucous lesions). the final stage of lymphoedema is', 'elephantiasis.', '• in men: increase in volume of fluid due to accumulation within the tunica vaginalis', '(hydrocoele, lymphocoele, chylocoele); chronic epididymo-orchitis.', '• chyluria: milky or rice-water urine (disruption of a lymphatic vessel in the urinary tract).', 'in patients parasitized by brugia spp, genital lesions and chyluria are rare: lymphoedema is', 'usually confined to below the knee.', 'laboratory', '– detection of microfilariae in the peripheral blood (thick film)g; blood specimens should be', 'collected between 9 pm and 3 am.', '– in regions where loiasis and/or onchocerciasis are co-endemic, check for co-infection if the', 'lf diagnosis is positive.', 'treatment', 'antiparasitic treatment', '– treatment is not administered during an acute attack.', 'g when test results are negative in a clinically suspect case, consider detection of antigens (ict rapid test) and/or', 'ultrasound of the inguinal area in search of the « filarial dance sign ».', 'chapter 6', '170', '– doxycycline po, when administered as a prolonged treatment, eliminates the majority of', 'macrofilariae and reduces lymphoedema: 200 mg/day for 4 weeks minimum. it is contra-', 'indicated in children < 8 years and pregnant or breast-feeding women.', '– diethylcarbamazine po as a single dose (400 mg in adults; 3 mg/kg in children) may be an', 'alternative but eliminates a variable proportion of adult worms (up to 40%) and does not', 'relieve symptoms; a prolonged treatment is no more effective than single dose therapy. in', 'addition, dec is contra-indicated in patients with onchocerciasis or loa loa microfilarial load', '> 2000 mf/ml and in pregnant and breast-feeding women.', '– ivermectin (weak or absent macrofilaricidal effect) and albendazole should not be used for', 'the treatment of individual cases (no effect on symptoms).', '– in the case of confirmed or probable co-infection with o. volvulus: treat onchocerciasis first,', 'then administer doxycycline.', 'control/prevention of inflammatory manifestations and infectious complications', '– acute attacks: bed rest, elevation of the affected limb without bandaging, cooling of the', 'affected limb (wet cloth, cold bath) and analgesics; antibacterial or antifungal cream if', 'necessary; antipyretics if fever (paracetamol) and hydration.', '– prevention of episodes of lymphangitis and lymphoedema: hygiene of the affected', 'extremityh, comfortable footwear, immediate attention to secondary bacterial/fungal', 'infections and wounds.', '– established lymphoedema: bandaging of the affected limb by day, elevation of the affected', 'extremity (after removal of the bandage) when at rest, simple exercises (flexion-extension of', 'the feet when recumbent or upright, rotation of the ankles); skin hygiene, as above.', 'surgery', 'may be indicated in the treatment of chronic manifestations: advanced lymphoedema', '(diversion-reconstruction), hydrocoele and its complications, chyluria.', 'h wash at least once daily (soap and water at room temperature), paying special attention to folds and', 'interdigital areas; rinse thoroughly and dry with a clean cloth; nail care.', 'parasitic diseases', '171', '6', 'chapter 7: ', 'bacterial diseases', 'bacterial meningitis', 'tetanus', 'typhoid fever', 'brucellosis', 'plague', 'leptospirosis', 'relapsing fever (borreliosis)', 'louse-borne relapsing fever (lbrf)', 'tick-borne relapsing fever (tbrf)', 'eruptive rickettsioses 7', 'bacterial meningitis', 'meningitis is an acute bacterial infection of the meninges, which may affect the brain and lead', 'to irreversible neurological damage and auditory impairment.', 'bacterial meningitis is a medical emergency. the treatment is based on early parenteral', 'administration of antibiotics that penetrates well into the cerebrospinal fluid. empiric antibiotic', 'therapy is administered if the pathogen cannot be identified or while waiting for laboratory', 'results.', 'the main bacteria responsible vary depending on age and/or context:', '– meningitis in a non-epidemic context:', '• children 0 to 3 months:', 'children ≤ 7 days: gram-negative bacilli (klebsiella spp, e. coli, s. marscesens, pseudomona spp,', 'salmonella spp) and group b streptococcus', 'children > 7 days: s. pneumoniae accounts for 50% of all bacterial meningitis', 'l. monocytogenes is occasionally responsible for meningitis during this period.', '• children 3 months-5 years: s. pneumoniae, h. influenza b and n. meningitidis', '• children > 5 years and adults: s. pneumoniae and n. meningitidis', 'special conditions:', '• immunodepressed patients (hiv, malnourished): high percentage of gram- negative bacilli', '(specially salmonella spp) and also m. tuberculosis.', '• sickle cell anaemia: salmonella spp and staphylococcus aureus are frequent causes.', '• meningitis may be related to s. aureus when associated with skin infection or skull', 'fracture.', '– meningitis in an epidemic context:', 'in the sahelian regiona during the dry season, epidemics of meningococcal meningitis', '(neisseria meningitidis a or c or w135) affect children from 6 months of age, adolescents', 'and adults. in these regions, whether during epidemics or not, all the above pathogens can', 'be found, especially in young children.', 'clinical features', \"the clinical presentation depends on the patient's age.\", 'children over 1 year and adults', '– fever, severe headache, photophobia, neck stiffness', \"– brudzinski's sign (neck flexion in a supine patient results in involuntary flexion of the knees)\", \"and kernig's sign (attempts to extend the knee from the flexed-thigh position are met with\", 'strong passive resistance).', '– petechial or ecchymotic purpura (usually in meningococcal infections)', '– in severe forms: coma, seizures, focal signs, purpura fulminans', 'a but not exclusively, e.g. rwanda, angola, brazil.', 'bacterial diseases', '175', '7', 'children under 1 year', 'the classic signs of meningitis are usually absent.', '– the child is irritable, appears sick with fever or hypothermia, poor feeding or vomiting.', '– other features include: seizures, apnoea, altered consciousness, bulging fontanelle (when', 'not crying); occasionally, neck stiffness and purpuric rash.', 'laboratory', '– lumbar puncture (lp):', '• macroscopic examination of the cerebrospinal fluid (csf): antibiotic therapy should be', 'initiated immediately if the lp yields a turbid csf.', '• microscopic examination: gram stain (but a negative examination does not exclude the', 'diagnosis) and white blood cell count (wbc).', '• in an epidemic context, once the meningococcal aetiology has been confirmed, there is no', 'need for routine lp for new cases.', '– rapid test for detection of bacterial antigens.', 'note: in an endemic area, it is essential to test for severe malaria (rapid test or thin/thick films).', 'pressure aspect wbc', '(leucocytes/mm3)', 'protein other tests', 'normal csf clear < 5 pandy –', '< 40 mg/dl', '–', 'bacterial', 'meningitis ++++', 'cloudy,', 'turbid', '100-20 000', 'mainly neutrophiles', 'in neonates:', '> 20', 'in', 'immunocompromised,', 'the wbc may be < 100', 'pandy +', '100-500 mg/dl', 'gram stain +', 'viral', 'meningitis', 'normal', 'to +', 'clear', '10-700', 'mainly lymphocytes', 'pandy – –', 'tb', 'meningitis +++', 'clear or', 'yellowish', '< 500', 'mainly lymphocytes', 'pandy + afb', 'cryptococcal', 'meningitis ++++ clear', '< 800', 'mainly lymphocytes', 'pandy – india ink', 'chapter 7', '176', 'treatment in a non-epidemic context', 'antibiotic therapy', 'for the choice of antibiotic therapy and dosages according to age, see table next page.', 'duration of antibiotic therapy:', '1) according to the pathogen:', '• haemophilus influenzae: 7 days', '• streptococcus pneumonia: 10-14 days', '• group b streptococcus and listeria: 14-21 days', '• gram-negative bacilli: 21 days', '• neisseria meningitidis: see antibiotic therapy in an epidemic context', '2) if the pathogen is unknown:', 'children < 3 months: 2 weeks beyond the first sterile csf culture or 21 days', 'children > 3 months and adults: 10 days. consider extending treatment or alternative', 'diagnoses if fever persists beyond 10 days. on the other hand, a 7-day course of ceftriaxone', 'is sufficient in patients who are making an uncomplicated recovery.', 'additional treatment', '– dexamethasone reduces the risk of hearing loss in patients with h. influenzae or', 's. pneumoniae.', 'early administration in indicated in meningitis caused by these pathogens or when the', 'pathogen is unknown, except in neonates (and in presumed meningococcal meningitis in an', 'epidemic context).', 'dexamethasone iv', 'children > 1 month and adults: 0.15 mg/kg (max. 10 mg) every 6 hours for 2 days', 'the treatment should be started before or with the first dose of antibiotic, otherwise, the', 'treatment offers no benefit.', '– ensure that the patient is well fed and well hydrated (infusions or nasogastric tube if', 'necessary).', '– seizures (chapter 1).', '– coma: prevention of bed sores, care of the mouth and eyes, etc.', 'bacterial diseases', '177', '7', 'c', 'h', 'ap', 'ter 7', '178', 'no associated skin infection associated skin infection (including umbilical cord infection)', 'first line alternative first line alternative', '0 ', 'to', '7 ', 'd', 'ay', 's', '< ', '2 ', 'kg', 'ampicillin iv', '200 mg/kg/day in 2 divided doses', '+', 'cefotaxime iv', '100 mg/kg/day in 2 divided doses', 'ampicillin iv', '200 mg/kg/day in 2 divided doses', '+', 'gentamicin iv', '3 mg/kg once daily', 'cloxacillin iv', '100 mg/kg/day in 2 divided doses', '+', 'cefotaxime iv', '100 mg/kg/day in 2 divided doses', 'cloxacillin iv', '100 mg/kg/day in 2 divided doses', '+', 'gentamicin iv', '3 mg/kg once daily', '0 ', 'to', ' 7', ' d', 'ay', 's', '≥ ', '2 ', 'kg', 'ampicillin iv', '300 mg/kg/day in 3 divided doses', '+', 'cefotaxime iv', '150 mg/kg/day in 3 divided doses', 'ampicillin iv', '300 mg/kg/day in 3 divided doses', '+', 'gentamicin iv', '5 mg/kg once daily', 'cloxacillin iv', '150 mg/kg/day in 3 divided doses', '+', 'cefotaxime iv', '150 mg/kg/day in 3 divided doses', 'cloxacillin iv', '150 mg/kg/day in 3 divided doses', '+', 'gentamicin iv', '5 mg/kg once daily', '8 ', 'd', 'ay', 's ', 'to', ' <', ' 1', ' m', 'o', 'n', 'th', '≥ ', '2 ', 'kg', 'ampicillin iv', '300 mg/kg/day in 3 divided doses', '+', 'cefotaxime iv', '150 mg/kg/day in 3 divided doses', 'ampicillin iv', '300 mg/kg/day in 3 divided doses', '+', 'gentamicin iv', '5 mg/kg once daily', 'cloxacillin iv', '200 mg/kg/day in 4 divided doses', '+', 'cefotaxime iv', '150 mg/kg/day in 3 divided doses', 'cloxacillin iv', '200 mg/kg/day in 4 divided doses', '+', 'gentamicin iv', '5 mg/kg once daily', '1 ', 'to', ' 3', ' m', 'o', 'n', 'th', 's ', 'ampicillin iv', '300 mg/kg/day in 4 divided doses', '+', 'ceftriaxone iv', '100 mg/kg on d1', 'then 100 mg/kg/day starting on', 'd2 in 1 or 2 divided doses', 'ampicillin iv', '300 mg/kg/day in 4 divided doses', '+', 'gentamicin iv', '7.5 mg/kg/day in 3 divided doses', 'cloxacillin iv', '200 mg/kg/day in 4 divided doses', '+', 'ceftriaxone iv', '100 mg/kg on d1', 'then 100 mg/kg/day starting on', 'd2 in 1 or 2 divided doses', 'cloxacillin iv', '200 mg/kg/day in 4 divided doses', '+', 'gentamicin iv', '7.5 mg/kg/day in 3 divided doses', '> ', '3 ', 'm', 'o', 'n', 'th', 's', 'an', 'd', ' a', 'd', 'u', 'lt', 's', 'ceftriaxone iv', 'children < 20 kg: 100 mg/kg on d1 then 100 mg/kg/day starting on d2', 'in 1 or 2 divided doses', 'children ≥ 20 kg and adults: 2 g/day', 'cloxacillin iv', 'children < 40 kg: 200 mg/kg/day in 4 divided doses', 'children ≥ 40 kg and adults: 8 to 12 g/day in 4 divided doses', '+', 'ceftriaxone iv', 'children < 20 kg: 100 mg/kg on d1 then 100 mg/kg/day starting on d2', 'in 1 or 2 divided doses', 'children ≥ 20 kg and adults: 2 g/day', 'treatment in an epidemic context', 'antibiotic therapy', 'in this context, n. meningitidis is the most likely pathogen.', 'children under 2 months', 'ceftriaxone ivb or imc for 7 days', '100 mg/kg once daily', 'children over 2 months and adults', 'ceftriaxone ivb or imc for 5 days', 'children 2 months to < 5 years: 100 mg/kg once daily (max. 2 g/day)', 'children ≥ 5 years and adults: 2 g once daily', 'note:', 'a short treatment with a single dose of ceftriaxone im can be used in children 2 years and older,', 'and in adults, if during a meningococcal meningitis epidemic confirmed by a reliable laboratory,', 'the number of cases exceeds management capacities with the 5-day treatment. check national', 'recommendations. nevertheless, it is essential to ensure a monitoring of cases after 24 hours.', 'ceftriaxone imc', 'children 2 to < 12 years: 100 mg/kg as a single dose', 'children ≥ 12 years and adults: 4 g as a single dose', 'if there is no clinical improvement (fever > 38.5°c, repeated seizures, appearance or aggravation', 'of a reduced level of consciousness or of neurological signs) 24 hours after the injection,', 'continue the treatment with ceftriaxone for 5 days.', 'additional treatment', '– ensure that the patient is well fed and well hydrated (infusions or nasogastric tube if', 'necessary).', '– seizures (chapter 1).', '– coma: prevention of bed sores, care of the mouth and eyes, etc.', '– dexamethasone in not indicated.', 'b the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'c for im administration, divide the dose into 2 injections if needed, half-dose in each buttock.', 'bacterial diseases', '179', '7', 'tetanus', 'tetanus is a severe infection due to the bacillus clostridium tetani, which is found in soil, and', 'human and animal waste. the infection is noncontagious. c. tetani is introduced into the body', 'through a wound and produces a toxin whose action on the central nervous system is', 'responsible for the symptoms of tetanus.', 'tetanus is entirely preventable by immunisation. it occurs in people who have not been fully', 'immunized before exposure or have not received adequate post-exposure prophylaxis. in these', 'individuals, most breaks in the skin or mucous membranes carry a risk of tetanus, but the', 'wounds with the greatest risk are: the stump of the umbilical cord in neonates, puncture', 'wounds, wounds with tissue loss or contamination with foreign material or soil, avulsion and', 'crush injuries, sites of non-sterile injections, chronic wounds (e.g. lower extremity ulcers),', 'burns and bites. surgical or obstetrical procedures performed under non-sterile conditions also', 'carry a risk of tetanus.', 'clinical features', 'generalised tetanus is the most frequent and severe form of the infection. it presents as', 'muscular rigidity, which progresses rapidly to involve the entire body, and muscle spasms,', 'which are very painful. level of consciousness is not altered. ', 'children and adults', '– average time from exposure to onset of symptoms is 7 days (3 to 21 days).', '– muscular rigidity begins in the jaw muscles (difficulty with then inability to open mouth', '[trismus] preventing the patient from speaking, eating), spreading to the face (fixed smile),', 'neck (difficulty with swallowing), to the trunk (restriction of respiratory muscles;', 'hyperextension of spine [opisthotonus]), to the abdomen (guarding) and to the limbs (flexion', 'of the upper limbs and extension of the lower limbs).', '– muscle spasms, which are very painful, appear at the onset or when muscular rigidity', 'becomes generalised. they are triggered by stimuli (noise, light, touch) or arise', 'spontaneously. spasms of the thoracic and laryngeal muscles may cause respiratory distress', 'or aspiration.', 'neonates', '– in 90% of cases, initial symptoms appear within 3 to 14 days of birth.', '– the first signs are significant irritability and difficulty sucking (rigidity of the lips, trismus)', 'then rigidity becomes generalised, as in adults. any neonate, who initially sucked and cried', 'normally, presenting with irritability and difficulty sucking 3 to 28 days after birth and', 'demonstrating rigidity and muscle spasms should be assumed to have neonatal tetanus.', 'treatment', 'hospitalisation is needed and usually lasts 3 to 4 weeks. correct management can reduce', 'mortality even in hospitals with limited resources.', 'chapter 7', '180', 'general measures', '– ensure intensive nursing care.', '– the patient should be in a dark, quiet room. blindfold infants with a cloth bandage.', '– handle the patient carefully, while sedated and as little as possible; change position every', '3 to 4 hours to avoid bedsores.', '– teach family the danger signs and instruct them to call the nurse for the slightest respiratory', 'symptom (cough, difficulty breathing, apnoea, excessive secretions, cyanosis, etc.).', '– establish iv access for hydration, iv injections.', '– gentle suction of secretions (mouth, oropharynx).', '– insert a nasogastric tube for hydration, feeding and administration of oral medications.', '– provide hydration and nutrition in feeds divided over 24 hours. in neonates, give expressed', 'breast milk every 3 hours (risk of hypoglycaemia).', 'neutralisation of toxin', 'human tetanus immunoglobulin im', 'neonates, children and adults: 500 iu as a single dose, injected into 2 separate sites', 'inhibition of toxin production', 'metronidazolea iv infusion (30 minutes; 60 minutes in neonates) for 7 days', 'neonates:', '• 0 to 7 days: 15 mg/kg on d1 then, after 24 hours, 15 mg/kg/day in 2 divided doses', '• 8 days to < 1 month (< 2 kg): same doses', '• 8 days to < 1 month (≥ 2 kg): 30 mg/kg/day in 2 divided doses', 'children 1 month and over: 30 mg/kg/day in 3 divided doses (max. 1.5 g/day)', 'adults: 1.5 g/day in 3 divided doses', 'control of rigidity and spasms, and sedation of the patient', 'diazepam should decrease the frequency and intensity of spams without causing respiratory', 'depression. the dose and frequency of administration depend on the patient’s clinical', 'response and tolerance.', '– there is a high risk of respiratory depression and hypotension when using diazepam,', 'especially in children and elderly patients. constant and close monitoring of the patient‘s', 'respiratory rate (rr) and oxygen saturation (sao2) is essential, with immediate', 'availability of equipment for manual ventilation (ambu bag, face mask) and intubation,', 'suction (electric if possible) and ringer lactate.', '– a continuous iv infusion of diazepam requires the use of a dedicated vein (no other', 'infusion/injection in this vein); avoid the antecubital fossa if possible.', '– do not stop treatment abruptly; an abrupt stop can cause tetanic spasms.', 'a clindamycin iv for 7 days is an alternative (for doses, see periorbital and orbital cellulitis, chapter 5).', 'bacterial diseases', '181', '7', 'count the volume of the infusion of diazepam as part of the patient’s daily fluid intake.', 'b administer the first dose rectally if an iv cannot be placed immediately.', 'n', 'eo', 'na', 'te', 's', 'diazepam emulsion for injection (10 mg vial, 5 mg/ml, 2 ml)', '• 0.1 to 0.3 mg/kg by slow iv injection (3 to 5 minutes) every 1 to 4 hours depending', 'on the severity and the persistence of the spasms as long as the rr is ≥ 30. ', '• if despite hourly diazepam the spasms persist, start a continuous infusion of', 'diazepam with an electric syringe: 0.1 to 0.5 mg/kg/hour (2.4 to 12 mg/kg every', '24 hours). start with 0.1 mg/kg/hour and if symptoms persist, increase by', '0.1 mg/kg/hour as long as rr is ≥ 30.', '• if in spite of 0.5 mg/kg/hour symptoms persist, the dose can be increased up to', '0.8 mg/kg/hour as long as the rr ≥ 30.', '• diluted diazepam emulsion does not keep for more than 6 hours.', 'example:', 'neonate weighing 3 kg (administration by electric syringe)', '0.1 mg/kg/hour x 3 kg = 0.3 mg/hour', 'dilute one 10 mg vial of diazepam emulsion for injection in 50 ml of 10% glucose to', 'obtain a solution containing 0.2 mg of diazepam per ml.', 'administer 1.5 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour i.e.', '0.3 (mg/hour) ÷ 0.2 (mg/ml) = 1.5 ml/hour].', 'if an electric syringe is not available, diluting the diazepam emulsion in an infusion bag', 'for continuous infusion may be considered. weigh the risks associated with this mode', 'of administration (accidental bolus or insufficient dose). the infusion should be', 'monitored closely to avoid any change, however small, of the prescribed rate.', 'ch', 'ild', 're', 'n ', '> ', '1m', 'on', 'th', ' a', 'nd', ' a', 'du', 'lt', 's', 'same doses and protocol as in neonates but:', '• use diazepam solution for injection 5 mg/ml: (10 mg vial, 5 mg/ml, 2 ml)b.', '• these doses can be administered as long as the rr is:', '≥ 30 in children under 1 year ', '≥ 25 in children 1 to 4 years', '≥ 20 in children 5 to 12 years ', '≥ 14 in children over 12 years', '≥ 12 in adults', 'examples:', '• child weighing 6 kg (continuous iv infusion using a pediatric infusion set; 1 ml =', '60 drops)', '0.1 mg/kg/hour x 6 kg = 0.6 mg/hour', 'dilute one 10 mg vial of diazepam solution for injection in 50 ml of 5% glucose (10%', 'glucose if child < 3 months) to obtain a solution containing 0.2 mg of diazepam per ml.', 'administer 3 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour i.e.', '0.6 (mg/hour) ÷ 0.2 (mg/ml) = 3 ml/hour] or 3 drops/minute (in a paediatric infusion', 'set ml/hour = drops/minute).', '• adult weighing 60 kg (standard adult infusion set, 1 ml = 20 drops)', '0.1 mg/kg/hour x 60 kg = 6 mg/hour', 'dilute 5 vials of 10 mg of diazepam solution (50 mg) in 250 ml of 0.9% sodium', 'chloride or 5% glucose to obtain a solution containing 0.2 mg of diazepam per ml.', 'administer 30 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour', 'e.g. 6 (mg/hour) ÷ 0.5 (mg/ml) = 30 ml/hour] or 10 drops/minute.', 'chapter 7', '182', 'when the frequency and severity of the spasms have decreased, start weaning the diazepam', '(gradually decrease the rate of infusion):', '– calculate the total daily dose of iv diazepam and administer it orally in 4 divided doses,', '6 hours apart, via nasogastric (ng)c tube.', '– give first ng dose and decrease rate of iv infusion by 50%.', '– give second ng dose and stop iv diazepam infusion.', '– if withdrawal signsd appear, wean more slowly.', '– once on oral diazepam, wean by 10 to 20% of the original dose daily, until at a dose of', '0.05 mg/kg every 6 hours.', '– then increase the interval from every 6 hours to every 8 hours for 24 hours as tolerated', '(wean more slowly if withdrawal signs appear).', '– continue to increase the interval between the doses from every 8 hours to every 12 hours', 'and then to every 24 hours before stopping the diazepam. ', '– each step should be for 24 hours or more if withdrawal signs appear.', 'notes:', '– it is often at these smaller doses that it is difficult to wean diazepam. if this is the case, slow', 'the wean further: dropping the % wean (e.g. 5% wean every 24 hours instead of 10% wean)', 'or increasing the interval between weans (e.g. going from every 24 hours to every 48 hours).', '– if the patient is also receiving morphine, wean diazepam first then, wean morphine.', '– non-pharmacological measures to reduce withdrawal: reduce environmental stimuli;', 'swaddle infants, frequent feedings.', '– infants who have had tetanus remain hypertonic, even when they are no longer having', 'spams.', 'treatment of pain', 'morphine po (via ng tube) if necessary (see pain, chapter 1).', 'when morphine is administered with diazepam the risk of respiratory depression is increased,', 'thus closer monitoring is required. when morphine is no longer required, wean the same way', 'as diazepam.', 'treatment of the point of entry', '– search systematically the entry wound. provide local treatment under sedation: cleansing and', 'for deep wounds, irrigation and debridement.', '– cord infection: do not excise or debride; treat bacterial omphalitis and sepsis, add to', 'metronidazole iv: cloxacillin iv + cefotaxime iv or cloxacillin iv + gentamicin iv (for doses, see', 'bacterial meningitis).', 'tetanus vaccination', 'as tetanus does not confer immunity, immunisation against tetanus must be administered', 'once the patient has recovered.', 'in case of neonatal tetanus, initiate the immunisation of the mother.', 'c administration of oral diazepam tablets to infants: calculate the exact dose of diazepam, e.g. to obtain 0.5 mg', 'of diazepam, cut a scored diazepam 2 mg tablet in half along scoring then split in half again. crush quarter', 'tablet and dissolve in expressed breast milk or infant formula.', 'd withdrawal signs: excessive irritability, tremors, increased muscle tone, frequent yawning, poor feeding,', 'watery stools and sweating.', 'bacterial diseases', '183', '7', 'prevention', 'of critical importance, given the difficulty of treating tetanus once established.', '1) post-exposure prophylaxis', '– in all cases:', '• cleansing and disinfection of the wound, and removal of any foreign body. ', '• antibiotics are not prescribed routinely for prophylaxis. the decision to administer an', 'antibiotic (metronidazole or penicillin) is made on a case-by-case basis, according to the', 'patient’s clinical status.', '– depending on pre-exposure vaccination status: ', '• tetanus vaccine (tv)e and immunoglobulin: see indications below. ', 'tetanus vaccine im', 'children and adults: 0.5 ml/injection', 'if no immunisation or unknown immunisation status: administer at least 2 doses at an', 'interval of 4 weeks.', 'if incomplete immunisation: administer one dose.', 'then, to ensure long-lasting protection, administer additional doses to complete a total of', '5 doses, as indicated in the table on next page.', 'human anti-tetanus immunoglobulin im', 'children and adults: 250 iu as a single dose; 500 iu for wounds more than 24 hours old.', 'inject the vaccine and the immunoglobulin in 2 different sites, using a separate syringe for', 'each.', '2) routine immunisation (pre-exposure prophylaxis)', '– children: 5 doses in total: a first series of 3 doses of dtp or dtp + hepb or dtp + hib + hepb', 'before the age of 1 year, administered at an interval of 1 month (e.g. at the age of 6, 10 and', '14 weeks), then a 4th dose of a vaccine containing tetanus toxoid between the ages of 4 to', '7 years, then a 5th dose between 12 and 15 years.', '– women of childbearing age: 5 doses during the reproductive years: a series of 3 doses (dt or', 'tt) with an interval of at least one month between the 1st and 2nd dose and an interval of at', 'least 6 months between the 2nd and 3rd dose, then two other doses, each at minimum', 'interval of one year, e.g. during pregnancies (see table on next page).', 'e tetanus-containing vaccine, such as tt or dt or dt or dtp or dtp + hepb or dtp + hib + hepb according to', 'availability and patient’s age.', 'risk', 'complete immunisation (3 or more doses)', 'time since administration of latest dose:', '< 5 years 5-10 years > 10 years', 'incomplete immunisation', '(less than 3 doses)', 'or no immunisation', 'or unknown status', 'minor', 'clean', 'wound', 'none none', 'tv', 'one booster', 'dose', 'initiate or complete tv', 'all other', 'wounds none', 'tv', 'one booster', 'dose', 'tv', 'one booster', 'dose', 'initiate or complete tv and', 'administer tetanus immunoglobulin', 'chapter 7', '184', '– pregnant women: if a woman has never been immunized or if her immunisation status is', 'unknown: 2 doses of dt or tt during the pregnancy to reduce the risk of tetanus in mother', 'and newborn: the first as soon as possible during the pregnancy and the second at least', '4 weeks later and at least 2 weeks before delivery. this immunisation schedule protects', 'more than 80% of newborns from neonatal tetanus. a single dose offers no protection', 'dose vaccination schedule in adults degree and duration of protection', 'tv1 on first contact with the health care system', 'or as soon as possible during pregnancy', 'no protection', 'tv2 at least 4 weeks after tv1 80%', '1 to 3 years', 'tv3 6 months to 1 year after tv2', 'or during the following pregnancy', '95%', '5 years', 'tv4 1 to 5 years after tv3', 'or during the following pregnancy', '99%', '10 years', 'tv5 1 to 10 years after tv4', 'or during the following pregnancy', '99%', 'throughout the reproductive years', 'bacterial diseases', '185', '7', 'typhoid fever', 'systemic infection due to salmonella typhi. the organism enters the body via the gastrointestinal', 'tract and gains access to the bloodstream via the lymphatic system. typhoid fever is acquired', 'by ingestion of contaminated water and food or by direct contact (dirty hands).', 'clinical features', '– sustained fever (lasting more than one week), headache, asthenia, insomnia, anorexia,', 'epistaxis.', '– abdominal pain or tenderness, diarrhoea or constipation, gurgles.', '– toxic confusional state, prostration.', '– moderate splenomegaly, relative bradycardia (normal pulse despite fever).', '– differential diagnosis may be difficult as symptoms resemble those of lower respiratory tract', 'infections, urinary infections, and malaria or dengue fever in endemic areas.', '– complications can occur during the active phase or during convalescence (even during', 'treatment): intestinal perforation or haemorrhage, peritonitis, myocarditis, encephalitis,', 'coma.', 'laboratory', '– relative leukopenia (normal white blood cell count despite septicaemia).', '– isolation of s. typhi from blood cultures (take at least 10 ml of blood) and stool cultures', 'during the first 2 weeks.', \"– widal's agglutination reaction is not used (both sensitivity and specificity are poor).\", 'treatment (at hospital level)', '– isolate the patient.', '– keep under close surveillance, hydrate, treat fever (chapter 1).', '– antibiotic therapy: case-fatality rates of 10% can be reduced to less than 1% with early', 'antibiotic treatment based on the findings of blood cultures. the oral route is more effective', 'than the parenteral route. if the patient cannot take oral treatment, start by injectable route', 'and change to oral route as soon as possible.', '• antibiotic treatment (except during pregnancy or breast-feeding)', '- the treatment of choice is:', 'ciprofloxacin po for 5 to 7 days', 'children: 30 mg/kg/day in 2 divided doses (usually not recommended in children under', '15 years, however, the life-threatening risk of typhoid outweighs the risk of adverse', 'effects)', 'adults: 1 g/day in 2 divided doses', 'cefixime po for 7 days may be an alternative to ciprofloxacin in children under 15 years:', 'children over 3 months: 20 mg/kg/day in 2 divided doses', 'chapter 7', '186', 'failing that, and in the absence of resistance:', 'amoxicillin po for 14 days', 'children: 75 to 100 mg/kg/day in 3 divided doses', 'adults: 3 g/day in 3 divided doses', 'or', 'chloramphenicol po for 10 to 14 days depending on severity', 'children from 1 year to less than 13 years: 100 mg/kg/day in 3 divided doses', 'children ≥ 13 years and adults: 3 g/day in 3 divided doses', '- s. typhi is rapidly developing resistance to quinolones. in this event, use:', 'ceftriaxonea,b im or slow iv (3 minutes) or infusion (30 minutes) for 10 to 14 days', 'depending on severity', 'children: 75 mg/kg once daily', 'adults: 2 to 4 g once daily', '• antibiotic treatment in pregnant or breast-feeding women', 'in pregnant women, typhoid carries a major risk of maternal complications (intestinal', 'perforation, peritonitis, septicaemia) and foetal complications (miscarriage, premature', 'delivery, intrauterine death).', '- in the absence of resistance:', 'amoxicillin po: 3 g/day in 3 divided doses for 14 days', '- if resistance:', 'ceftriaxone as above for 10 to 14 days', 'failing that, use ciprofloxacin po (usually not recommended for pregnant or breast-', 'feeding women. however, the life-threatening risk of typhoid outweighs the risk of', 'adverse effects). for dosage, see above.', 'note: fever persists for 4 to 5 days after the start of treatment, even if the antibiotic is', 'effective. it is essential to treat the fever and to check for possible maternal or foetal', 'complications.', '– in patients presenting severe typhoid, with toxic confusional state (hallucinations, altered', 'consciousness) or intestinal haemorrhage:', 'dexamethasone iv: loading dose 3 mg/kg and then 1 mg/kg every 6 hours for 2 days', 'prevention', '– disinfection of faeces with 2% chlorine solution.', '– individual (hand washing) and collective hygiene (safe water supply, sanitation).', '– the possibility of vaccination must be considered: it can be useful in some situations (high-', 'risk age group, hyperendemic zone), but its effectiveness remains controversial.', 'a the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'b doses of ceftriaxone greater than 1 g im should be administered in 2 equally divided injections (one in each', 'buttock). doses greater than 2 g should be administered by iv infusion only.', 'bacterial diseases', '187', '7', 'brucellosis', '– a zoonosis that mainly affects domestic animals. it is occasionally transmitted to man by', 'ingestion of infected raw milk, or by contact (with infected animals or with soiled objects', 'through abrasion on the skin). human-to-human transmission is rare.', '– a brucellosis is caused by gram-negative bacilli of the genus brucella: b. melitensis (sheep', 'and goats), b. abortus (cattle), b. suis (pigs) and less commonly, b. canis and b. ovis.', '– a the disease is found worldwide and mainly in rural areas. the true incidence of brucellosis', 'in tropical countries is probably underestimated as it is often undiagnosed.', 'clinical features', 'the clinical signs and associated symptoms are fluctuating and non specific. diagnosis is', 'difficult because of the broad spectrum of clinical manifestations.', 'acute form', '– common form: gradual onset over one to 2 weeks: undulant fever (up to 39-40°c) lasting', '10 to 15 days, night sweats, chills, asthenia, joint and muscle pain. possible sacroileitis,', 'arthritis (knee) and orchitis.', 'in regions where malaria is endemic, the possibility of acute brucellosis should be considered', 'when a high fever persists despite correct anti-malarial treatment.', '– other clinical forms:', '• typhoid-like form: sudden onset with signs of septicaemia; high fever, typhoid state,', 'delirium, abdominal signs.', '• subacute form: mild, non-specific clinical signs that do not lead the patient to seek medical', 'attention. serum test positive.', 'secondary brucellosis', 'prolonged asthenia, focal signs:', '– bone and joint involvement: arthritis of the hip, sacroileitis, spondylitis with sciatalgia', \"(pseudo-pott's disease).\", '– neurobrucellosis: pseudo-tuberculosis meningitis, meningoencephalitis; a complication at', 'vertebral site involving peripheral nerves may cause motor and/or sensory disorders.', 'chronic brucellosis', '– general signs; physical and mental asthenia, sweating and polyalgia.', '– focal signs: slow developing bone, neuromeningeal or visceral foci.', 'laboratory', '– during the acute phase diagnosis can be confirmed by the detection of the pathogen in a blood', 'culture.', '– the rose bengal test (or ring test) can identify specific antibodies. it is a quick, cheap and both', 'specific and sensitive test for the diagnosis of acute and localized forms of brucellosis.', \"– other serological tests (wright's test, elisa, indirect immunfluorescence and coombs’test)\", 'cannot usually be done.', 'chapter 7', '188', 'treatment', 'treatment is based on a combination of 2 antibiotics. since streptomycin and rifampicin are also', 'used in the treatment of tuberculosis, it is essential to rule out the possibility of active tb before', 'starting treatment (patient history, clinical examination and chest x-ray if possible). rifampicin', 'must only be used when indicated below.', 'acute form', '– children over 8 years and adults (except in pregnant or breast-feeding women)', 'doxycycline po ', 'children: 100 to 200 mg once daily or in 2 divided doses for 6 weeks', 'adults: 200 mg once daily or in 2 divided doses for 6 weeks', '+ streptomycin im', 'children: 15 mg/kg once daily for 2 weeks', 'adults: 1 g once daily for 2 weeks', '– children under 8 years', 'cotrimoxazole po: 40 mg smx + 8 mg tmp/kg/day in 2 divided doses for 6 weeks', '+ gentamicin im: 7.5 mg/kg once daily or in 2 divided doses for 2 weeks', 'or rifampicin po: 15 mg/kg once daily for 6 weeks', '– pregnant or breast-feeding women', 'cotrimoxazole po: 1600 mg smx + 320 mg tmp/day in 2 divided doses for 6 weeks', '+ rifampicin po: 600 mg once daily for 6 weeks', 'note: ', 'in pregnant women, the combination of cotrimoxazole + rifampicin can be administered', 'regardless of the stage of pregnancy if treatment is indispensable.', 'administration of vitamin k is recommended to prevent neonatal and maternal haemorrhage.', 'phytomenadione (vial containing 10 mg/ml, 1 ml):', 'to the mother: 10 mg/day po for the 15 days preceding the expected date of delivery', 'to the newborn: 2 mg po as a single dose at birth and again after 4 to 7 days', 'focal brucellosis', '– same treatment regimen as for the acute form, but for a period of 6 weeks to 3 months', 'depending on severity. surgical draining of an abscess of the liver or spleen may be indicated.', '– neurobrucellosis or endocarditis: combination of rifampicin + doxycycline + gentamicin.', 'antibiotic treatment is not effective in the context of chronic, non-focal brucellosis.', 'prevention', '– washing of hands and clothing if in contact with animals.', '– boil milk and avoid eating raw cheese and undercooked meat.', 'bacterial diseases', '189', '7', 'plague', '– a zoonosis caused by the gram-negative bacillus yersinia pestis that mainly affects wild and', 'domestic rodents.', '– plague is transmitted to man by the bite of an infected flea vector or through a break in the', 'skin by contact with a rodent. human-to-human transmission occurs through the bites of', 'human fleas, or, in the case of pneumonic plague, by inhaling infected droplets expelled by', 'coughing.', '– vast foci of infection remain in central and southeast asia, africa, madagascar, and in north', 'and south america.', 'clinical features and progress', 'there are 3 main clinical forms:', '– bubonic plague is the most common form: high fever, chills, headache, associated with one', '(or more) very painful lymph node, usually inguinal (bubo). frequent gastrointestinal signs:', 'abdominal pain, vomiting, diarrhoea, etc. the mortality rate in untreated patients is', 'approximately 50% as a result of septicaemia.', '– septicaemic plague is a complication of untreated bubonic plague and is a fulminant illness.', '– pneumonic plague is a very contagious form: high fever, chills, headache, myalgia associated', 'with paroxysmal coughing, haemoptysis and respiratory distress. this form progresses', 'rapidly, and is fatal unless treated. it occurs either as a complication of bubonic plague or as', 'the result of a primary infection.', 'occasionally, the disease can take the form of meningitic plague.', 'laboratory', '– isolation of y. pestis (direct examination and culture) from lymph node aspirate, blood,', 'sputum, cerebrospinal fluid, depending on the form involved.', '– serodiagnosis: elisa reads positive soon after the onset of the illness.', '– transportation of the samples requires a cold chain (failing that, the temperature must be', 'kept below 30°c).', 'management and treatment', '– when plague is suspected: take samples for cultures and antibiotic sensitivity testing and', 'then treat immediately without waiting for the diagnosis to be confirmed. inform the health', 'authorities as soon as the diagnosis has been confirmed.', '– isolation:', '• patients suffering from bubonic plague do not have to be isolated. treat the patient and', 'his/her bedding and clothing with an insecticide (e.g. permethrin 0.5% powder; see', 'pediculosis, chapter 4). observe elementary rules of hygiene (wash hands, wear gowns,', 'gloves etc.).', '• patients with primary or secondary pneumonic plague must be strictly isolated. their', 'bedding, clothing, sputum and excreta must be disinfected with a chlorinated solution.', 'observe elementary rules of hygiene (wash hands, wear hospital lab coats, gloves etc.)', 'and both the patient and carers should wear facemasks.', 'chapter 7', '190', 'treatment of suspected or confirmed cases', 'if treatment is begun early, recovery is rapid and complete. penicillins, cephalosporins and', 'macrolides should not be used.', 'aminoglycosides, tetracyclines, chloramphenicol and sulphonamides are effective. follow', 'national recommendations. for information:', 'streptomycin im for 10 days', 'children: 30 mg/kg/day in 2 divided doses given at 12 hour-intervals', 'adults: 2 g/day in 2 divided doses given at 12 hour-intervals', 'gentamicin im for 10 days', 'neonates and children under one year: 7.5 mg/kg/day in 2 divided doses', 'children over one year: 6 mg/kg/day in 2 divided doses', 'adults: 3 mg/kg/day in 2 divided doses', 'doxycycline po for 10 days', 'children over 8 years and adults: 200 mg/day, once daily or in 2 divided doses', 'chloramphenicol po or iv for 10 days', 'children from 1 year to less than 13 years: 50 to 100 mg/kg/day in 3 divided doses', 'children ≥ 13 years and adults: 3 g/day in 3 divided doses', 'choice of antibiotics', 'note: in order to prevent the emergence of resistance to streptomycin which is used in the', 'treatment of tuberculosis, it is preferable to use doxycycline or chloramphenicol for the', 'treatment of bubonic plague.', 'chemoprophylaxis of contacts', 'in the event of contact, and within one week after the end of exposure:', 'doxycycline po throughout the period of contact (minimum 5 days of treatment)', 'children over 8 years and adults: 100 to 200 mg/day, once daily or in 2 divided doses', 'or', 'co-trimoxazole po throughout the period of contact (minimum 5 days of treatment)', 'children: 40 mg smx + 8 mg tmp/kg/day in 2 divided doses', 'adults: 1600 mg smx + 320 mg tmp/day in 2 divided doses', 'prevention', '– flea vector control is essential to controlling an epidemic.', '– long-term prevention: environmental sanitation and control of rodent reservoir.', '– vaccination against plague is only indicated for people with a high risk of exposure', '(laboratory technicians handling rodents) and can in no circumstances be used as a method', 'for controlling an epidemic.', 'indications first choice alternative', 'bubonic plague doxycycline chloramphenicol or streptomycin', 'pneumonic plague streptomycin –', 'septicaemic plague streptomycin chloramphenicol', 'meningitic plague chloramphenicol –', 'pregnant or breast-feeding women gentamicin –', 'bacterial diseases', '191', '7', 'leptospirosis', '– a zoonosis caused by spirochetes of the genus leptospira, affecting many domestic and wild', 'animals (particularly rodents and principally rats).', '– leptospirosis is acquired by indirect contact (contact of the skin or mucous membranes with', 'animal urine-contaminated water, e.g. when swimming) and less commonly, by direct', 'contact with infected animals.', 'clinical features', 'diagnosis is difficult because of the broad spectrum of clinical manifestations. a distinction is', 'usually made between the mild form (the most common, usually with a favourable outcome)', 'and the severe form (multiple organ dysfunction syndrome).', '– mild form', '• after an incubation period of one to 3 weeks: influenza-like illness (high fever, chills,', 'headache, myalgias), often combined with gastrointestinal disorders (anorexia, abdominal', 'pain, nausea, vomiting) and possible pulmonary signs (cough, chest pain). other signs:', 'conjunctival haemorrhage, hepatosplenomegaly, and multiple adenopathies. mild', 'jaundice may be present, but this form is usually anicteric.', '• the signs regress after 5 to 6 days, and then reappear, sometimes with meningeal', 'invasion, which may be complicated by encephalitis or myelitis.', \"– severe form or weil's syndrome\", 'the onset of the disease is the same as in mild form. after a few days, acute hepatorenal', 'manifestations with fever, jaundice, oligo-anuric renal failure; diffuse haemorrhagic', 'syndrome (purpura, ecchymoses, epistaxis etc.), pulmonary signs (cough, chest pain,', 'haemoptysis) and cardiac signs (myocarditis, pericarditis).', 'temperature chart and progress of leptospirosis', '! !', '\"#$%$&\\'$!()!*&+,-(.,$%!', '\"#$%$&\\'$!()!/$0+(%0,#$%!', '1$20$#*+3#$!', '456!', '786!', '9! :! 98! 9:! ;8!', \"<*3&.,'$!\", '=>(+$2,*!', '.*?%!', '@&!+a$!-/((.!', '@&!+a$!bcd!', '@&!+a$!3#,&$!', 'chapter 7', '192', 'laboratory', '– isolation through culture of leptospires from blood, cerebrospinal fluid (during the first', 'phase) or urine (during the second phase).', '– serodiagnosis: immunofluorescence or elisa (antibodies are detected from day 8).', '– blood cell count: polymorphonuclear leukocytosis.', '– if meningeal syndrome: lumbar puncture yields a clear fluid, usually with raised leucocyte', 'count and elevated protein level (about 1 g/litre).', '– urine: proteinuria, leukocyturia, possible haematuria and presence of casts.', 'treatment', '– rest and treatment of fever: paracetamol po (chapter 1).', 'acetylsalicylic acid (aspirin) is contraindicated (risk of haemorrhage).', '– antibiotic treatment should be started as soon as possible:', '• moderate form', 'amoxicillin po', 'children: 50 mg/kg/day in 2 divided doses for 7 days', 'adults: 2 g/day in 2 divided doses for 7 days', 'or', 'doxycycline po (except in pregnant or breast-feeding women and children under 8 years)', 'children over 8 years: 100 mg/day in 2 divided doses for 7 days', 'adults: 200 mg/day in 2 divided doses for 7 days', 'or', 'erythromycin po', 'children: 30 to 50 mg/kg/day in 2 or 3 divided doses for 7 days', 'adults: 2 to 3 g/day in 2 or 3 divided doses for 7 days', '• severe form', 'ceftriaxone iva', 'children: 80 to 100 mg/kg once daily for 7 days (max. 2 g/day)', 'adults: 2 g once daily for 7 days', 'prevention', '– avoid bathing in endemic areas.', '– rodent control, environmental sanitation (particularly water).', '– vaccination is restricted to personnel exposed in the course of their work.', 'a for iv administration of ceftriaxone, use only water for injection as solvent.', 'bacterial diseases', '193', '7', 'relapsing fever (borreliosis)', 'relapsing fever (fr) is caused by spirochetes of the genus borrelia, transmitted to humans by', 'arthropod vectors.', 'louse-borne relapsing fever (lbrf)', 'lbrf is caused by borrelia recurrentis. it occurs in epidemic waves when conditions favourable', 'to the transmission of body lice are met: cold climate/season, overcrowding and very poor', 'sanitation (e.g. refugee camps, prisons). endemic foci of lbrf are mainly the sudan and the', 'horn of africa (especially ethiopia). lbrf can be associated with louse-borne typhus (see', 'eruptive rickettsioses). the mortality rate for untreated lbrf ranges from 15 to 40%.', 'clinical features', '– relapsing fever is characterized by febrile episodes separated by afebrile periods of', 'approximately 7 days (4 to 14 days).', '– the initial febrile episode lasts up to 6 days:', '• sudden onset of high fever (> 39°c), severe headache and asthenia, diffuse pain (muscle,', 'joint, back pain), often associated with gastrointestinal disturbances (anorexia, abdominal', 'pain, vomiting, diarrhoea).', '• splenomegaly is common; bleeding signs (e.g. petechiae, subconjunctival haemorrhage,', 'epistaxis, bleeding gums), jaundice or neurological symptoms may be observed.', '• the febrile episode terminates in a crisis with an elevation in temperature, pulse and', 'blood pressure, followed by a fall in temperature and blood pressure, which may last for', 'several hours.', '– following the initial febrile episode, the cycle usually reccurs; each episode is less severe', 'than the previous one and the patient develops temporary immunity.', '– complications:', '• collapse during defervescence, myocarditis, cerebral haemorrhage;', '• during pregnancy: abortion, preterm delivery, in utero foetal death, neonatal death.', 'in practice, in an applicable epidemiological setting (see above), a suspect case of lbrf is,', 'according to the who, a patient with high fever and two of the following symptoms: severe', 'joint pain, chills, jaundice or signs of bleeding (nose or other bleeding) or a patient with high', 'fever who is responding poorly to antimalarial drugs. clothing should be checked for the', 'presence of body lice and nits.', 'laboratory', 'the diagnosis is confirmed by detection of borrelia in thick or thin blood films (giemsa stain).', 'blood samples must be collected during febrile periods. spirochetes are not found in the', 'chapter 7', '194', 'peripheral blood during afebrile periods. in addition, the number of circulating spirochetes', 'tends to decrease with each febrile episode.', 'treatment', '– antibiotic therapy (suspect or confirmed cases and close contacts):', 'doxycycline poa', 'children: 100 mg as a single dose', 'adults: 100 or 200 mg as a single dose', 'or', 'erythromycin po', 'children ≤ 5 years: 250 mg as a single dose', 'children > 5 years and adults: 500 mg as a single dose', '– treatment of pain and fever (paracetamol po) and prevention or treatment of dehydration', 'in the event of associated diarrhoea.', '– elimination of body lice is essential in control of epidemics (see pediculosis, chapter 4).', 'tick-borne relapsing fever (tbrf)', 'tbrfs are caused by different borrelia species. they are endemic in temperate and warm', 'regions of the word, especially in africa (tanzania, drc, senegal, mauritania, mali, the horn of', 'africa) and mainly in rural areas. tbrf is a major cause of morbidity and mortality in children', 'and pregnant women. the mortality rate for untreated tbrf ranges from 2 to 15%.', 'clinical features', 'the clinical manifestations and complications of tbrf are similar to those of lbrf but', 'neurological symptoms (particularly, cranial nerve palsies and lymphocytic meningitis) are', 'more frequent than in lbrf and the number of relapses is higher.', 'the clinical diagnosis is difficult, especially during the first episode: cases occur', 'sporadically rather than in outbreaks; the tick bite is painless and usually unnoticed by', 'the patient; symptoms are very similar to those of malaria, typhoid fever, leptospirosis,', 'certain arbovirosis (yellow fever, dengue) or rickettsiosis, and meningitis.', 'laboratory', '– as for lbrf, the diagnosis is confirmed by detection of borrelia in the patient’s blood.', '– repeat the examination if the first smear is negative despite strong clinical suspicion.', 'a doxycycline is usually contra-indicated in children under 8 years and pregnant women. however, if', 'erythromycin is not available, it may be used for the treatment of lbrf, the administration of a single dose', 'should not cause any adverse effects.', 'bacterial diseases', '195', '7', 'treatment', '– antibiotic therapy:', 'doxycycline po ', 'children over 8 years: 100 mg/day in 2 divided doses for 7 days', 'adults (except pregnant women): 200 mg/day in 2 divided doses for 7 days', 'or', 'erythromycin po ', 'children under 8 years: 50 mg/kg/day in 2 divided doses for 7 days', 'pregnant women: 2 g/day in 2 divided doses for 7 days', '– treatment of pain and fever (paracetamol po) and prevention or treatment of dehydration', 'in the event of associated diarrhoea.', 'antibiotic therapy can trigger a jarisch-herxheimer reaction with high fever, chills, fall in', 'blood pressure and sometimes shock. it is recommended to monitor the patient for', '2 hours after the first dose of antibiotic, for occurrence and management of severe', 'jarisch-herxheimer reaction (symptomatic treatment of shock). jarisch-herxheimer', 'reaction appears to occur more frequently in lbrf than in tbrf.', 'chapter 7', '196', 'eruptive rickettsioses', 'eruptive fevers caused by bacteria of the genus rickettsia and transmitted to man by an', 'arthropod vector. three main groups are distinguished: typhus group, spotted fever group and', 'scrub typhus group.', 'clinical features', 'see next page.', 'laboratory', 'detection of specific igm of each group by indirect immunofluorescence. the diagnosis is', 'confirmed by 2 serological tests at an interval of 10 days. in practice, clinical signs and the', 'epidemiological context are sufficient to suggest the diagnosis and start treatment.', 'treatment', '– symptomatic treatment:', '• hydration (po or iv if the patient is unable to drink).', '• fever: paracetamol po (chapter 1). acetylsalicylic acid (aspirin) is contra- indicated due to', 'the risk of haemorrhage.', '– antibiotic therapya for 5 to 7 days or until 3 days after the fever has disappeared:', 'doxycycline po (except in pregnant or lactating women)', 'children < 45 kg: 4 mg/kg/day in 2 divided doses', 'children ≥ 45 kg and adults: 200 mg/day in 2 divided doses', '– in pregnant or breast-feeding women:', 'josamycin pob: 3 g/day in 3 divided doses for 8 days', '– in a context of epidemic typhus, doxycycline po 200 mg as a single dose is the choice', 'treatment, but there is a risk of recurrence.', 'note: doxycycline is usually contraindicated in pregnant or breast-feeding women. however,', 'the administration of a single dose should not, in theory, provoke adverse effects. check', 'national recommendations.', 'prevention', '– epidemic typhus: control of body lice (see pediculosis, chapter 4).', '– murine typhus: control of fleas and then rats.', '– spotted fevers: avoid tick bites by wearing clothing and using repellents.', '– scrub typhus: use of repellents, chemoprophylaxis with doxycycline po (200 mg once weekly', 'in adults).', 'a unlike borrelioses, antibiotic treatment of rickettsioses does not provoke a jarisch-herxheimer reaction.', 'however, the geographical distribution of borrelioses and rickettsioses may overlap, and thus a reaction may', 'occur due to a possible co-infection (see borreliosis).', 'b only some macrolides can be used. erythromycin is not effective.', 'bacterial diseases', '197', '7', 'c', 'h', 'ap', 'ter 7', '198 clinical features', '– common to all forms:', '• sudden onset of fever (temperature of over 39°c) with severe headache and myalgias.', '• 3 to 5 days later; onset of generalised cutaneous eruption (see below).', '• hypotension; non-dissociated rapid pulse (variable).', '• typhoid state: prostration, omnubilation, confusion and extreme asthenia, particularly marked in typhus forms.', '• inoculation eschar: painless, black crusted lesion surrounded by a erythematous halo at the site of the bite. always check for this significant', 'sign.', '• non-cutaneous signs vary from one form to another, and are atypical and variable (see below).', '– complications can be severe, and sometimes fatal: encephalitis, myocarditis, hepatitis, acute renal failure, haemorrhage etc.', 'group typhus spotted fever scrub typhus', 'form epidemic typhus murine typhus mediterranean', 'spotted fever', 'rocky mountain', 'spotted fever', 'other old-world', 'tick-borne fevers', 'scrub typhus', 'pathogen r. prowasekii r. typhi r. conorii r. rickettsii r. sibirica, r. australis o. tsutsugamushi', 'vector body lice rat fleas ticks ticks ticks mites', 'reservoir man rats dogs rodents rodents, dogs, etc. rodents', 'occurence epidemic endemic endemic endemic endemic sporadic', 'geographical', 'distribution', 'worldwide, conflicts;', 'main sites:', 'burundi/rwanda,', 'ethiopia', 'worldwide', 'around the', 'mediterranean,', 'sub-saharan africa', 'north america,', 'central america,', 'columbia, brazil', 'southern africa,', 'australia, siberia', 'extrême-orient, inde,', 'pacifique sud', 'rash maculopapular maculopapular maculopapular purpural maculopapular macular', 'eschar 0 0 black necrotic area rare black necrotic area black necrotic area', 'typhoid state +++ +++ +/- +/- +/- +++', 'extra-cutaneous', 'signs', 'cough, myalgia,', 'meningeal signs', 'gastrointestinal signs meningeal signs', 'gastrointestinal and', 'neurological signs,', 'hypotension', 'variables meningeal signs', 'case fatality (%) 30 (without treatment) 5 2 5 1 0-30', 'chapter 8: ', 'viral diseases', 'measles', 'poliomyelitis', 'rabies', 'viral hepatitis', 'dengue', 'viral haemorrhagic fevers', 'hiv infection and aids', '8', 'measles', 'measles is a highly contagious acute viral infection, transmitted by the airborne route', '(inhalation of respiratory droplets spread by infected individuals). the disease mainly affects', 'children under 5 years of age and can be prevented by immunization.', 'for more information, refer to the msf handbook management of a measles epidemic.', 'clinical features', 'the average incubation period is 10 days.', 'prodromal or catarrhal phase (2 to 4 days)', '– high fever (39-40°c) with cough, coryza (nasal discharge) and/or conjunctivitis (red and', 'watery eyes).', '– koplik’s spots: tiny bluish-white spots on an erythematous base, found on the inside of the', 'cheek. this sign is specific of measles infection, but may be absent at the time of', \"examination. observation of koplik's spots is not required for diagnosing measles.\", 'eruptive phase (4 to 6 days)', '– on average 3 days after the onset of symptoms: eruption of erythematous, non- pruritic', 'maculopapules, which blanch with pressure. the rash begins on the forehead then spreads', 'downward to the face, neck, trunk (2nd day), abdomen and lower limbs (3rd and 4th day).', '– as the rash progresses, prodromal symptoms subside. in the absence of complications, the', 'fever disappears once the rash reaches the feet. ', '– the rash fades around the 5th day in the same order that it appeared (from the head to the', 'feet).', 'the eruptive phase is followed by skin desquamation during 1 to 2 weeks, very pronounced on', 'pigmented skin (the skin develops a striped appearance).', 'in practice, a patient presenting with fever and erythematous maculopapular rash and at least', 'one of the following signs: cough or coryza or conjunctivitis, is a clinical case of measles.', 'complications', 'most measles cases experience at least one complication:', '– respiratory and ent: pneumonia, otitis media, laryngotracheobronchitis', '– ocular: purulent conjunctivitis, keratitis, xerophthalmia (risk of blindness)', '– gastrointestinal: diarrhoea with or without dehydration, benign or severe stomatitis', '– neurological: febrile seizures; rarely, encephalitis', '– acute malnutrition, provoked or aggravated by measles (post-measles period)', 'pneumonia and dehydration are the most common immediate causes of death.', 'viral diseases', '201', '8', 'http://refbooks.msf.org/msf_docs/en/measles/measles_en.pdf', 'case management', '– admit as inpatient children with at least one major complication:', '• inability to eat/drink/suck, or vomiting', '• altered consciousness or seizures', '• dehydration', '• severe pneumonia (pneumonia with respiratory distress or cyanosis or o2 sat. < 90%)', '• acute laryngotracheobronchitis (croup)a', '• corneal lesions (pain, photophobia, erosion or opacity)', '• severe oral lesions that prevent eating', '• acute malnutrition', '– treat as outpatient children with no major complications, no complications or minor', 'complications:', '• pneumonia without severe signs', '• acute otitis media', '• purulent conjunctivitis (no corneal lesions)', '• diarrhoea without dehydration', '• oral candidiasis that does not interfere with eating', 'if in doubt, keep the child under observation for a few hours.', '– isolation', '• isolation of hospitalised patients', '• measles cases treated as out-patients should be kept at home during this period.', 'treatment', 'supportive and preventive treatment', '– treat fever: paracetamol (fever, chapter 1).', '– make the child drink (high risk of dehydration).', '– give smaller, more frequent meals or breastfeed more frequently (every 2 to 3 hours).', '– clear the nasopharynx (nose-blowing or nasal lavages) to prevent secondary respiratory', 'infection and improve the child’s comfort.', '– clean the eyes with clean water 2 times daily and administer retinol on d1 and d2 (see', 'page 128, chapter 5) to prevent ocular complications.', '– in children under 5 years: amoxicillin po for 5 days as a preventive measure (reduction of', 'respiratory and ocular infections).', '– in the event of watery diarrhoea without dehydration: oral rehydration according to who', 'plan a (appendix 2).', '– insert a nasogastric tube for a few days if oral lesions prevent the child from drinking.', 'treatment of complications', 'see following page.', 'a symptoms (hoarse crying or voice, difficulty breathing, a high-pitched inspiratory wheeze [inspiratory stridor],', 'characteristic \"barking\" cough) are caused by inflammation and narrowing of the larynx. croup is considered', 'benign or “moderate” if the stridor occurs when the child is agitated or crying, but disappears when the child is', 'calm. the child should be monitored during this period, however, because his general and respiratory status', 'can deteriorate rapidly. croup is severe when the stridor persists at rest or is associated with signs of', 'respiratory distress.', 'chapter 8', '202', 'prevention', '– no chemoprophylaxis for contacts.', '– vaccination:', '• the first dose is administered at 9 months of age. in situations where there is high risk of', 'infection (overcrowding, epidemics, malnutrition, infants born to a mother with hiv', 'infection, etc.): administer one dose at 6 months of age (between 6 and 8 months) and', 'one dose at 9 months of age, with an interval of at least 4 weeks between injections.', '• children must receive a second dose before they are 5 years old in order to cover', 'unvaccinated children or children who did not respond to the first dose.', 'treatment of complications', 'severe pneumonia ceftriaxone iv or im + cloxacillin iv then change to amoxicillin/', 'clavulanic acid po (see pages 73-74, chapter 2)', '+ oxygen if cyanosis or o2 saturation < 90%', '+ salbutamol if expiratory wheezing and sibilant rales on auscultation', 'in all cases, close monitoring.', 'pneumonia without', 'severe signs', 'amoxicillin po for 5 days', 'croup inpatient monitoring (risk of worsening). keep the child calm.', 'agitation and crying exacerbate the symptoms.', 'for severe croup:', 'dexamthasone im: 0.6 mg/kg single dose', '+ nebulized epinephrine (adrenaline, 1 mg/ml ampoule): 0.5 ml/kg', '(max. 5 ml)', '+ oxygen if cyanosis or o2 saturation < 90%', 'intensive monitoring until symptoms resolve.', 'acute otitis media see otitis, chapter 2.', 'dehydration rehydration according to who plan b or c.', 'oral candidiasis see stomatitis, chapter 3.', 'purulent', 'conjunctivitis', 'see conjunctivitis, chapter 5.', 'keratitis/', 'keratoconjunctivitis', 'tetracycline 1% eye ointment 2 times daily for 7 days', '+ retinol po one dose on d1, d2 and d8 (see xerophthalmia, chapter 5)', '+ eye protection and tramadol po from 6 months of age (see pain,', 'page 31, chapter 1).', 'no topical corticosteroids.', 'xerophthalmia see xerophthalmia, chapter 5.', 'febrile seizures see seizures, chapter 1.', 'viral diseases', '203', '8', 'poliomyelitis', '– poliomyelitis is an acute viral infection due to a poliovirus (serotypes 1, 2 and 3). human-to-', 'human transmission is direct (faecal-oral) or indirect (ingestion of food and water', 'contaminated by stool). humans are the only reservoir of the virus. in principle the disease', 'can be eradicated by mass vaccination.', '– in endemic areas, epidemics usually affect children under 5 years of age.', 'in non- endemic areas, where vaccination coverage is low, young adults are most commonly', 'affected.', 'clinical features', '– in more than 90% of cases, infection is asymptomatic.', '– non-paralytic form: a non-specific febrile illness with muscle pain, headache, vomiting,', 'backache; no neurological involvement.', 'as spontaneous recovery usually occurs within 10 days, diagnosis is rarely made outside', 'epidemic contexts.', '– paralytic form: in less than 1% of cases, after the non-specific signs, the patient develops', 'rapid onset (from the morning to the evening) asymmetrical acute flaccid paralysis,', 'predominantly of the lower limbs, with ascending progression. the muscles become soft', 'with diminished reflexes. sensation is maintained. the disease is life threatening if paralysis', 'involves the respiratory muscles or muscles of swallowing. initial urinary retention is', 'common. gastrointestinal disturbances (nausea, vomiting, diarrhoea), muscle pain and', 'meningeal symptoms may also occur.', 'laboratory', 'look for the polio virus in stool samples. the virus is excreted for one month after infection,', 'but only intermittently; therefore, 2 samples must be collected with an interval of 48 hours.', 'treatment', '– hospitalise patients with the paralytic form: rest, prevent bed sores in bedridden patients,', 'give analgesics (do not give im injections to patients in the febrile phase), ventilate patients', 'with respiratory paralysis.', '– physiotherapy once the lesions are stable to prevent muscle atrophy and contractures.', '– care for sequelae: physiotherapy, surgery and prosthetics.', 'patients with acute flaccid paralysis (afp)', '– consider all patients with afp as suspected cases of poliomyelitis.', '– confirm the diagnosis by isolating the virus: send the 2 stool samples to a reference', 'laboratory, with a clinical description of the patient. the stool samples must be stored and', 'transported between 0°c and 8°c.', 'chapter 8', '204', 'updated: january 2017', '– while waiting for laboratory confirmation, vaccinate all children under 5 years of age living in', 'the area (from the same village or neighbouring villages), irrespective of their vaccination', 'status.', '– once the case is confirmed, organize a mass vaccination campaign: the area and the age', 'group are determined as a function of epidemiological data.', '– surveillance: for each case of afp there are between 100 and 200 subclinical cases.', 'therefore, active surveillance to detect new cases is essential for epidemic control.', 'prevention', '– 2 types of vaccines exist:', '• a trivalent injectable inactivated poliovirus vaccine (ipv),', '• a bivalent oral live attenuated poliovirus vaccine (bopv).', '– vaccination schedule: depends on the epidemiology of the virus.', 'protocols vary according to the country, follow national recommendations. for information,', 'the who recommends:', '* countries where poliomyelitis is endemic or zones at high risk of importation and subsequent spread of the', 'virus.', '** the 1st dose of bopv is administered at birth, or as soon as possible, to optimise seroconversion rates after', 'subsequent doses and induce mucosal protection.', 'in children who start routine vaccination late (after the age of 3 months ), the dose of ipv is', 'administered together with the 1st dose of bopv, followed by 2 doses of bopv alone', 'administered 4 weeks apart.', 'there is also an ‘ipv only’ schedule: 3 doses administered 4 weeks apart (e.g. at 6, 10 and', '14 weeks) and a booster dose at least 6 months later.', 'ipv should eventually completely replace bopv.', 'schedule', 'primary vaccination', 'endemic or at risk zones* other zones', 'birth 1 dose bopv** –', '6 weeks 1 dose bopv 1 dose bopv', '10 weeks 1 dose bopv 1 dose bopv', '14 weeks 1 dose bopv + 1 dose ivp 1 dose bopv + 1 dose vpi', 'viral diseases', '205', '8', 'rabies', 'rabies is a viral infection of wild and domestic mammals, transmitted to humans by the saliva', 'of infected animals through bites, scratches or licks on broken skin or mucous membranes. any', 'mammal can transmit rabies, but the great majority of human cases are due to dog bites.', 'once symptoms develop, rabies presents as a fatal encephalitis. there is no curative treatment;', 'care is palliative. before symptomatic disease has developed, rabies can effectively be', 'prevented by post- exposure prophylaxis.', 'clinical features', '– the incubation period averages 20 to 90 days from exposure (75% of patients), but can be', 'shorter (in severe exposure, i.e. bites to face, head and hands, multiple bites), or longer (20%', 'of patients develop symptoms between 90 days and 1 year, and 5% more than 1 year after', 'exposure).', '– prodromal phase: itching or paraesthesiae around the site of exposure, and non- specific', 'symptoms (malaise, fever, etc.).', '– neurologic phase:', '• furious form: psychomotor agitation or hydrophobia (throat spasms and panic, triggered', 'by attempting to drink or sight/sound/touch of water) and aerophobia (similar response to', 'a draft of air); sometimes seizures. the patient is calm and lucid between episodes.', '• paralytic form (less common, 20% of cases): progressive ascending paralysis resembling', 'guillain-barré syndrome.', 'diagnosis is often difficult: there may be no history of scratch or bite (exposure through licking)', 'or wounds may have healed; a reliable history may be difficult to obtain.', 'post-exposure prophylaxis', 'risk of rabies virus infection: definition of exposure categories (who)', 'post-exposure prophylaxis is carried out for category ii and iii exposures.', 'a in the case of direct contact with bats, check national recommendations.', 'category i contact with animal, or licks on intact skin no exposure', 'category ii nibbles on exposed skin', 'minor bite(s) or scratch(es) without bleeding', 'minor exposure', 'category iii', 'transdermal bite(s) or scratch(es)', 'licks on broken skin', 'contamination of mucous membranes', 'by animal’s saliva (licks)', 'exposure to bata', 'severe exposure', 'chapter 8', '206', 'treatment of the wound', '– in all cases', 'prolonged cleansing of the wound or contact site to eliminate the virus, as soon as possible', 'after exposure, is of critical importance. for skin: use soap, rinse copiously with running', 'water, remove all foreign material; application of polyvidone iodine 10% or ethanol 70% is an', 'additional precaution which does not take the place of wound washing. for mucous', 'membranes (eye, mouth, etc.): rinse thoroughly with water or 0.9% sodium chloride. local', 'cleansing is indicated even if the patient presents late.', '– according to condition/type of wound', 'in order to avoid inoculating virus deeper into the tissues, wounds are either not sutured at', 'all (e.g. superficial, non-mutilating or puncture wounds), or are left open and re-evaluated in', '48-72 hours, with a view to possible closure. highly contaminated wounds, or wounds that', 'may compromise function, require surgical management (exploration, removal of foreign', 'material, excision of necrotic tissue, copious irrigation with 0.9% sodium chloride or ringer', 'lactate, with local or general anaesthesia). when suturing is unavoidable, rabies immune', 'globulin should be administered several hours or days before wound closure (see below).', 'infected wounds are not sutured and reassessed daily.', 'passive and active immunisation', 'given the variable duration of incubation, administration of vaccine/immune globulin is an', 'urgent priority, even for patients exposed several months previously.', '– administration of rabies immune globulin', 'rabies immune globulin (rig) is indicated for category iii exposuresb, and category ii and iii', 'exposures in immune-compromised patients.', 'rig is intended to neutralize virus in the exposure site. it is given as a single dose on d0, with', 'the first dose of rabies vaccine. ', 'children and adults: human rabies immune globulin, 20 iu/kg, or highly purified equine', 'immune globulin derivative f(ab’)2, 40 iu/kg.', 'infiltrate as much of the dose as possible in and around the wounds(s)c. inject any residual', 'product, using the im route, in a site remote from that used for vaccination. in the event', 'of multiple wounds, dilute the dose 2- to 3-fold with sterile 0.9% sodium chloride to obtain', 'a sufficient quantity to infiltrate all the sites exposed. ', 'if rig is not available on d0, the first dose of rabies vaccine is administered alone. rig can', 'still be given as soon as possible within the next few days. however, rig is no longer', 'recommended when 7 or more days have elapsed since the first dose of vaccine was given,', 'as vaccine-induced immunity will have developed by this time.', 'b unless it can be established that the patient has been correctly vaccinated against rabies before exposure', '(complete pre-exposure vaccination with 3 doses of a ccv).', 'c infiltrate rig, even if the wound has healed. for finger wounds, infiltrate very cautiously to avoid causing a', 'compartment syndrome. when it is not possible to infiltrate the wound (mucous membranes), the entire dose', 'is administered im.', 'viral diseases', '207', '8', '– post-exposure rabies vaccination', 'a complete rabies vaccination series is indicated for category ii and iii exposures. it should', 'be started on d0 and continued to completion if the risk of rabies has not been excludedd.', 'several different types of rabies vaccine are available. vaccines prepared from cell culture', '(ccv), e.g. human diploid cells (hdcv), vero cells (pvrv) or chick embryo cells (pcecv) must', 'replace nerve tissue vaccines (ntv). there are several possible vaccination protocols: check', 'and follow national recommendations. the shortest regimens among those endorsed by the', 'who are shown as examples:', 'post-exposure vaccination regimens', '* incorrect id technique results in failure of pep: if correct id technique cannot be assured, use the im regimen.', 'd either through observation of the captured animal (if domestic) or through laboratory diagnosis of the animal', '(killed). the who recommends a 10-day observation period of the animal, if captured. if no signs of rabies', 'develop during the observation period, the risk of rabies is excluded, and rabies vaccination is discontinued.', 'laboratory diagnosis of the dead animal involves sending the head to a specialised laboratory, which confirms', 'or excludes rabies in the animal. if laboratory diagnosis is negative, risk of rabies is excluded, and rabies', 'vaccination is discontinued.', 'no pre-exposure vaccination', 'or unknown vaccination status', 'or incomplete pre-exposure vaccination', 'or complete pre-exposure vaccination with a ntv', 'complete pre-exposure', 'vaccination', 'with a ccv', 'intramuscular (im)', '2-0-1-1', 'administer in the deltoid muscle', '(anterolateral thigh in children', '< 2 years), never in the gluteal', 'muscle', 'one im dose = 0.5 or 1 ml ', '(depending on the', 'manufacturer)', 'intradermal (id)*', '2-2-2-0-2', 'use only pvrv or pcecv vaccine', 'one id dose = 0.1 ml', 'im or id*', '1-1', 'one im dose = 0.5 or', '1 ml (depending on', 'the manufacturer)', 'one id dose = 0.1 ml', 'd0 2 doses', '(one dose in each arm or thigh)', '2 doses', '(1 dose in each arm)', '1 dose ', 'd3 2 doses', '(1 dose in each arm)', '1 dose', 'd7 1 dose', '(in the arm or thigh)', '2 doses', '(1 dose in each arm)', 'd21 1 dose', '(in the arm or thigh)', 'd28 2 doses', '(1 dose in each arm)', '+ rig on day 0, if indicated no rig', 'chapter 8', '208', 'other measures', '– antibiotic therapy or prophylaxis', '• a 7-day course of antibiotics is indicated for infected wounds (redness, oedema, purulent', 'or serosanguinous drainage, localised cellulitis, lymphangitis, lymphadenopathy, fever). a', 'longer treatment and/or the parenteral route may be indicated in severe infection.', '• antibiotic prophylaxis (5 to 7 days) is recommended for deep puncture wounds, wounds', 'on the face or hands, wounds involving joints, tendons, ligaments or fractures; very', 'contaminated wounds or those requiring debridement; in immune- compromised', 'patients.', '• antibiotic prophylaxis is not recommended for superficial wounds or wounds more than', '24-48 hours old in patients showing no local or general signs of infection.', '• the same dosage is used for both treatment and prophylaxis:', 'amoxicillin/clavulanic acid (co-amoxiclav) poe (dosage expressed in amoxicillin):', '- children < 40 kg: 45 to 50 mg/kg/day in 2 divided doses (if using ratio 8:1 or 7:1) or in', '3 divided doses (if using ratio 4:1)', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', '- children ≥ 40 kg and adults: 1500 to 2000 mg/day depending on the formulation', 'available:', 'ratio 8:1: 2000 mg/day = 2 tablets of 500/62.5 mg 2 times per day', 'ratio 7:1: 1750 mg/day = 1 tablet of 875/125 mg 2 times per day', 'ratio 4:1: 1500 mg/day = 1 tablet of 500/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 375 mg/day.', '– tetanus vaccination and immune globulin', 'verify vaccination status. if unknown or not up-to-date, see tetanus, chapter 7.', 'e co-amoxiclav is the antibiotic of choice. doxycycline (200 mg/day in 2 divided doses) may be used in penicillin-', 'allergic patients, except in pregnant women and children < 8 years.', 'viral diseases', '209', '8', 'viral hepatitis', '– several viral infections of the liver are grouped under the heading of viral hepatitis: hepatitis', 'a, b, c, ∆ (delta) and e.', '– the different hepatitis viruses are present throughout the world, but their prevalence varies', 'by country. hepatitis a and b are common in developing countries where nearly the entire', 'population is infected during childhood or adolescence.', '– the clinical characteristics of all five diseases are similar enough to make differential', 'diagnosis difficult; however, there are epidemiological, immunological and pathological', 'differences. patients with hepatitis b, c and ∆ may later develop chronic liver disease or even', 'hepatocellular carcinoma.', '– the main characteristics of each type of viral hepatitis are summarized in a table on the next', 'page.', 'clinical features', '– asymptomatic forms', 'mild or anicteric forms are the most common, irrespective of the causal virus. the risk of', 'developing later complications from hepatitis b, c and ∆ are the same as for symptomatic', 'patients.', '– classic forms', 'insidious or sudden onset with symptoms of varying intensity: fever, fatigue, nausea,', 'gastrointestinal disturbance, followed by jaundice, dark coloured urine and more or less clay-', 'coloured stool.', '– fulminant forms', 'hepatocellular failure with severe, often fatal, cytolysis. this form is most frequent in', 'hepatitis b patients with secondary infection with the ∆ virus, and in pregnant women', 'infected with hepatitis e during their third trimester (20% mortality).', '– chronic hepatitis', 'hepatitis b, c and ∆ may lead to cirrhosis or hepatoma.', 'main profiles observed in different clinical scenarios ', 'during hbv infection', 'the tests in parentheses are not useful for diagnosis.', 'ag hbs anti-hbsantibodies', 'anti-hbc', 'antibodies', 'anti-hbc', 'igm ag hbe', 'anti-hbe', 'antibodies', 'hbv', 'dna interpretation', '+ (–) (–) + (+) (–) (+) acute hepatitis', '+/– – + – – +/– –', 'acute hepatitis,', 'recovery phase', '– +/– + – – – –', 'post-infectious', 'immunity (cured)', '+ – + +/– + – +', 'chronic hepatitis', '(wild virus)', '– + – – – – –', 'post-vaccination', 'immunity', 'chapter 8', '210', 'v', 'iral d', 'iseases', '211', '8', 'the various forms of viral hepatitis', 'hepatitis a hepatitis b hepatitis c hepatitis ∆ hepatitis e', 'age group most at risk children young adults young adults young adults young adults', 'transmission faecal-oral contaminated', 'food and water', 'transfusion (rare)', 'blood and blood products', 'sexual', 'material contaminated', 'with blood', 'vertical (mother-to-child)', 'blood and blood products', 'sexual: low', 'material contaminated', 'with blood (low)', 'probably vertical', 'blood and blood products', 'sexual', 'material contaminated with', 'blood', 'possibly vertical', 'faecal-oral', 'contaminated food and', 'water', 'incubation period 2 to 6 weeks 4 to 30 weeks', '(average 10 weeks)', '2 to 25 weeks co-infection b/∆: as for', 'hepatitis b', 'secondary infection of', 'hepatitis b: approximately', '5 weeks', '2 to 8 weeks', 'period of', 'communicability', 'precedes signs.', 'brief: < 10 days after the', 'appearance of jaundice', 'most infectious at the', 'end of incubation period.', 'precedes signs and lasts', 'entire active period. can', 'persist in chronic carriers.', 'precedes signs.', 'duration is not well known,', 'probably the same as for', 'hepatitis b. could persist', 'beyond normalisation of', 'transaminases.', 'precedes signs.', 'duration is not well known,', 'probably the same as for', 'hepatitis b.', 'precedes signs.', 'duration is not well', 'known (10 to 15 days', 'after the appearance of', 'jaundice)', 'fulminant forms 0.2 to 0.4% 1 to 3% more rare than in', 'hepatitis b', 'much more common in patients', 'with secondary infection of', 'hepatitis b than in patients', 'with b/∆ co-infection', '20% mortality in', 'pregnant women', 'prognosis no chronic forms chronicity: 0.2 to 10% of', 'which 5 to 15% progress', 'to cirrhosis.', 'hepatoma possible', 'chronicity: up to 50%, of', 'which 10 to 25% progress', 'to cirrhosis.', 'hepatoma possible', 'chronicity: 2 to 5% for patients', 'with b/∆ co- infection; > 90% if', 'secondary infection of', 'hepatitis b (rapid cirrhosis)', 'no chronic forms', 'individual prevention polyvalent', 'immunoglobulin', 'specific anti-hbs', 'immunoglobulin', 'safe sex (condoms)', 'specific anti-hbs', 'immunoglobulin may be', 'effective', 'as for hepatitis b (the ∆ virus', 'can only develop with b)', 'does not exist', 'vaccination anti-hepatitis a anti-hepatitis b does not exist anti-hepatitis b does not exist', 'collective prevention hygiene, sanitation limit transfusion, screen blood prior to transfusion', 'single use of disposable material', 'hygiene, sanitation', 'treatment', '– rest, hydration, no special diet.', '– drug therapy for symptomatic treatment (analgesics, antipyretics, antidiarrhoeals,', 'antiemetics etc.) during the acute phase is contra-indicated as it may aggravate symptoms', 'and the evolution of hepatitis. corticosteroids are not indicated.', 'vaccination', 'only against hepatitis a and b. vaccination against hepatitis b is included in the epi of some', 'countries.', 'im vaccination against hepatitis b:', '– standard schedule', '• newborns, infants', 'in countries where perinatal infection is common: one injection after birth, then at 6 and', '14 weeks', 'where perinatal infection is less common: one injection at 6, 10 and 14 weeks', '• children, adolescents, adults', 'schedule 0-1-6: 2 injections 4 weeks apart, then a 3rd injection 5 months after the', '2nd injection', '– accelerated schedule, when rapid protection is required (imminent departure in highly', 'endemic areas, post-exposure prophylaxis)', 'schedule d0-d7-d21: 3 injections administered during the same month, then a 4th injection', 'one year after the 1st injection', 'chapter 8', '212', 'dengue', '– dengue fever is an arbovirus transmitted to humans by the bite of a mosquito (aedes).', 'transmission by transfusion of contaminated blood and transplacental transmission to the', 'foetus have also been reported.', '– four different serotypes of dengue have been described. infection with one serotype', 'provides a lifelong immunity to that specific serotype, but only partial, short-term immunity', 'to other serotypes. there is no specific antiviral treatment.', '– dengue is a mainly urban disease, present in tropical and subtropical regions, in particular in', 'asia, central and south america and the caribbean. outbreaks have been described in', 'eastern africa.', '– primary infection may be asymptomatic or present as mild dengue fever. subsequent', 'infections increase the risk of severe dengue.', 'clinical features', 'after the incubation period (4 to 10 days), the illness occurs in 3 phases:', '– febrile phase: high fever (39° to 40°c) lasting 2 to 7 days, often accompanied by generalized', 'aches, a maculopapular rash and mild haemorrhagic manifestations.', '– critical phase (between the 3rd and 7th day): decrease in temperature. the majority of', 'patients will have dengue without warning signs and proceed to the recovery phase.', 'certain patients will develop dengue with warning sign(s) or severe dengue.', '– recovery phase: patient improves, vital signs normalise, gastrointestinal symptoms subside and', 'appetite returns. at times, bradycardia and generalized pruritus.', 'a tourniquet test: inflate a blood pressure cuff on the upper arm to a point midway between the systolic and', 'diastolic pressure for 5 min. the test is positive when 20 or more petechiae per 2.5 cm square are observed.', 'symptoms according to severity (adapted from the who)', 'dengue', 'without', 'warning signs', 'fever + 2 of the following symptoms:', '• nausea, vomiting', '• rash resembling measles', '• generalized aches (headache, retro-orbital pain, myalgias, arthralgias)', '• benign mucocutaneous bleeding (petechiae, positive tourniquet testa, epistaxis,', 'gingival bleeding)', '• leucopenia', 'dengue ', 'with warning', 'signs', 'presence of at least one of these symptoms:', '• abdominal pain', '• persistent vomiting', '• fluid accumulation (ascites, pleural effusion)', '• mucosal bleeding', '• hepatomegaly (> 2 cm)', '• agitation or lethargy', '• increasing haematocrit and rapidly dropping platelet count', 'severe dengue • severe plasma leakage with:', '- fluid accumulation (ascites, pleural effusion) + respiratory distress', '- compensated shock: weak and rapid pulse, hypotension, cold extremities,', 'capillary refill time > 2 seconds', '- decompensated shock: pulse and blood pressure unrecordable', '• severe mucocutaneous bleeding', '• multiorgan failure e.g.: hepatic or cardiac failure, obtundation, coma', 'viral diseases', '213', '8', 'major differential diagnoses', 'malaria, influenza, measles, chikungunya, mononucleosis, primary hiv-infection, sepsis,', 'meningococcemia, typhoid fever, viral haemorrhagic fever, leptospirosis.', 'laboratory', 'diagnostic', '– rapid diagnostic test (serum, plasma or whole blood) detects ns1 viral antigen during the', 'febrile phase and igm and igg antibodies during the critical and recovery phases.', '– this test indicates the likely presence of an infection with dengue virus but the results must', 'be confirmed by molecular techniques (pcr) in a reference laboratory.', 'monitoring the haematocrit (hct) and complete blood count', '– the haematocrit (and not the haemoglobin) is the only test that shows haemoconcentration', 'or increased vascular permeability (plasma leakage). the hct reflects disease evolution and', 'suggests therapeutic response.', '– in children and pregnant women and if possible, in all patients, measure a reference hct (hct', '0) at the first visit (during the febrile phase or before the critical phase).', '– measure baseline hct on admission before administering fluid boluses (hct 1) for all patients', 'in groups b and c then monitor hct to determine therapy.', '– an increase in the hct with a rapid drop in the platelet count (≤ 100 000/mm3) is a warning', 'sign.', '– in case of hemodynamic instability or signs of shock:', '• an increased or a persistently high hct (> 50% in men or an increase relative to the', 'previous hct in women and children) indicates severe plasma leakage;', '• a decrease in hct (< 40-45% in men, < 35-40% in women and children 1 year and older,', '< 30-35% in children under 1 year) may indicate a haemorrhage.', '– leukopenia (< 5 000/mm3) is frequent.', 'treatment of patients in group a', 'patients with no warning signs, able to drink sufficiently and with a normal urine output.', '– treat as outpatients, bed rest and good hydration.', '– fever: paracetamol po at the usual doses (see fever, chapter 1), maintaining a strict 6 to 8', 'hour interval between doses. do not prescribe acetylsalicylic acid, ibuprofen or other non-', 'steroidal anti-inflammatory drugs.', '– seek medical attention if: no clinical improvement, persistent vomiting, cold extremities,', 'agitation or lethargy, breathing difficulties or absence of urine output. ', '– if follow-up is impossible or symptoms cannot be monitored at home (patients living far from', 'the health care facility/living alone), hospitalise for observation.', 'treatment of patients in group b', 'patients with warning sign(s) or co-morbidities (e.g. diabetes mellitus, hypertension, cardiac or', 'renal failure, sickle cell anaemia) or at risk populations (pregnant women, infants, the elderly,', 'patients with difficulty drinking).', 'chapter 8', '214', 'in all cases:', '– hospitalise; place the patient under a mosquito net.', '– measure hct 1 and baseline platelet count.', '– avoid invasive procedures (nasogastric tube, im injections) to minimize the risk of bleeding.', '– fever: paracetamol po as in group a. in case of hepatitis, administer with caution and', 'decrease the dose (children: 30 mg/kg/day in 3 divided doses; adults: 1.5 g/day in 3 divided', 'doses; maintaining a strict 8-hour interval between doses).', 'if warning signs or dehydration:', '– place an intravenous line and start hydration with ringer lactate.', '– monitor the hct every 4 to 6 hours until the patient is stabilized.', '– the volume and rate of ringer lactate administration is determined by the vital signs: heart', 'rate (hr), blood pressure (bp) and by the evolution of the hct. see table 1 – group b:', 'dengue with warning signs or dehydration.', '– monitor fluid balance: intake (iv and oral) and output (urine).', '– monitor urine output every 4 hours: administer the volume of iv fluids necessary to ensure', 'that the urine output is at least 1 ml/kg/hour in children and 0.5 ml/kg/hour in adults. if', 'unavailable, ensure that the patient is urinating at least every 4 hours.', 'treatment of patients in group c', 'patients with severe dengue requiring emergency treatment.', 'in all cases:', '– hospitalise in intensive care; place the patient under a mosquito net.', '– administer oxygen (o2) continuously:', '• to maintain the sao2 between 94 and 98% if it is ≤ 90%b or if the patient has cyanosis or', 'respiratory distress;', '• if pulse oxymeter is not available: at least 5 litres/minute or to relieve the hypoxia and', 'improve respiration.', '– before first bolus, measure hct 1, baseline platelets count and blood group, then monitor', 'the hct every 1 to 4 hours until the patient is stabilized.', '– check for the presence of the shock: rapid and weak pulse, low bp or narrow pulse pressure,', 'cold extremities, capillary refill time > 2 seconds.', '– mark the size of the liver with a pen on admission.', '– the volume and rate of ringer lactate or plasma substitute administration is determined by', 'the vital signs (hr, bp) and by the evolution of the hct. see table 2 – group c: dengue with', 'compensated shock or table 3 – group c: dengue with decompensated shock.', '– monitor urine output: same monitoring as in group b.', '– monitor signs of fluid overload (especially in children):', '• increase in rr ≥ 10/minute or tachypnoea; ', '• increase in hr ≥ 20/minute or tachycardia and sao2 < 90%;', '• rales and/or pulmonary oedema (fine crackles);', '• gallop rhythm on cardiac auscultation;', '• increase in liver size;', '• peripheral oedema (e.g. eyelid oedema).', 'b if possible it is better to treat all patients with a sao2 < 95% with oxygen.', 'viral diseases', '215', '8', '– in case of fluid overload, stop the iv infusion if vital signs are stable.', '– in case of respiratory distress with rales, administer furosemide iv (see heart failure, chapter 12)', 'if the patient is not in shock.', '– avoid invasive procedures (nasogastric tube, im injections) to minimize the risk of bleeding.', '– transfuse patients with fresh whole bloodc in case of significant bleeding or if a low hct does', 'not improve with resuscitation. the post-transfusion hct should be interpreted with caution.', '– when the patient improves, stop the iv infusion to avoid fluid overload.', 'prevention', '– individual protection: long sleeves and trousers, repellents, mosquito net (aedes bites during', 'the day).', '– a dengue vaccine is not yet available.', 'c fresh whole blood: that has never been refrigerated, that has never kept at a temperature below 16°c and', 'collected from the donor for less than 6 hours.', 'chapter 8', '216', 'v', 'iral d', 'iseases', '217', '8', 'table 1 – group b: dengue with warning signs or dehydration', 'measure hct 1 then', 'children and adults:', 'ringer lactate', '5-7 ml/kg/h for 1-2 h', '3-5 ml/kg/h for 2-4 h', '2-3 ml/kg/h for 2-4 h or less depending on clinical response', '• re-evaluate the clinical signs (vital signs, capillary refill time, urine output) hourly and measure hct 2 then repeat the hct every 4-6 hours or', 'more if necessary.', '• adjust the rate of the iv infusion in order to maintain a urine output of 1-2 ml/kg/h in children and 0.5 ml/kg/h in adults.', 'hct 2 identical to htc 1', 'or minimally increased', 'children and adults:', 'ringer lactate', '2-3 ml/kg/h for 2-4 h', 'hct 2 increased relative to hct 1 and/or tachycardia and/or hypotension (if shock: see group c)', 'children and adults:', 'ringer lactate', '5-10 ml/kg/h for 1-2 h', 're-evaluate the clinical signs and measure hct 3.', 'htc stable', 'children and adults:', 'ringer lactate', '3-5 ml/kg/h for 2-4 h', '2-3 ml/kg/h or less depending on clinical', 'response', 'hct increased or vital signs unstable', 'children and adults:', 'ringer lactate', '5-10 ml/kg/h for 1-2 h and re-evaluate as', 'above', '• if no improvement treat as a group c patient.', '• if improvement (disappearance of the danger signs, improvement of the urine output or po fluid intake or normalisation of the hct) gradually', 'reduce the rate of iv fluid administration. duration of iv fluid administration: 24-48 h.', 'c', 'h', 'ap', 'ter 8', '218', 'a > 50% in men or increased relative to hct 1 in women and children.', 'b < 40-45% in men, < 35-40% in women and children 1 year and older, < 30-35% in children less than 1 year.', 'table 2 – group c: dengue with compensated shock', '(bp maintained but signs of shock present)', 'measure hct 1 then give ringer lactate (1st bolus) children: 10-20 ml/kg in 1 h', 'adults: 5-10 ml/kg in 1 h', 'if improvement', '(no signs of shock present)', 'reduction of rate:', 'children:', 'ringer lactate', '10 ml/kg/h for 1-2 h', '7 ml/kg/h for 2 h', '5 ml/kg/h for 4 h', '3 ml/kg/h', 'adults:', 'ringer lactate', '5-7 ml/kg/h for 1-2 h', '3-5 ml/kg/h for 2-4 h', '2-3 ml/kg/h for 2-4 h', 'if no improvement (signs of shock present): measure hct 2.', 'hct 2 increases or stays elevateda', 'children: plasma substitute', '10-20 ml/kg in 1 h (2nd bolus)', '10 ml/kg in 1 h', '7 ml/kg in 1h', 'adults: ringer lactate or plasma substitute', '10-20 ml/kg in 1 h (2nd bolus)', 'hct 2 decreasesb', 'look for severe haemorrhage.', 'if improvement', '(no signs of shock present)', 'children:', 'ringer lactate according to', '“reduction of rate in', 'children”', 'adults:', 'ringer lactate 7-10 ml/kg/h', 'for 1-2 h', 'then according to', '“reduction of rate in adults”', 'if no improvement', '(signs of shock present)', 'measure hct 3 and', 'proceed as above from', '“measure hct 2”.', 'no severe haemorrhage', 'children and adults:', 'plasma substitute', '10-20 ml/kg in 1 h', 'evaluate need for transfusion', 'if no improvement.', 'severe haemorrhage', 'transfuse', 'children and adults:', 'fresh whole blood', '10-20 ml/kg', 'verify presence of signs of shock, of fluid overload and measure hct, then reduce the', 'rate as in “reduction of rate” if signs of shock are absent.', '• reduce the rate when the hr and bp normalise. always check for signs of fluid overload.', '• continue for 24-36 h (less if po hydration is tolerated). supplemental boluses of crystalloids or colloids may be necessary in the next 24 h. do', 'not administer iv fluids for more than 48 h.', 'v', 'iral d', 'iseases', '219', '8', 'a if not available, compare to population norms of haematocrit according to age. if these are not know use the following norms as a reference: < 45% in men, < 40% in', 'women and children 1 year or older, < 35% in children less than 1 year.', 'b < 40-45% in men, < 35-40% in women and in children 1 year and older, < 30-35% in children less than 1 year.', 'table 3 – group c: dengue with decompensated shock', '(pulse and blood pressure unrecordable)', 'measure hct 1 then ringer lactate or plasma substitute (if pulse pressure < 10 mmhg or severe hypotension) iv or io :', 'children and adults: 20 ml/kg in 15-30 min (1st bolus)', 'if improvement', '(no signs of shock present)', 'children:', 'plasma substitute', '10 ml/kg in 1 h', 'adults:', 'ringer lactate or plasma', 'substitute', '10 ml/kg in 1 h', 'reduction of rate:', 'ringer lactate', 'children:', '10 ml/kg in 1 h', '7 ml/kg/h for 2 h', '5 ml/kg/h for 4 h', '3 ml/kg/h', 'adults:', '5-7 ml/kg/h for 1-2 h', '3-5 ml/kg/h for 2-4 h', '2-3 ml/kg/h for 2-4 h', 'if no improvement (signs of shock present)', 'compare hct 1 (obtained before the 1st bolus) to hct 0a (obtained during the febrile phase or before the critical phase).', 'hct 1 increases or stays elevated relative to hct 0', 'children and adults:', 'plasma substitute 10-20 ml/kg in 30-60 min (2nd bolus)', 'verify the presence of signs of shock or of fluid overload.', 'hct 1 decreasesb relative to hct 0', 'verify the vital signs and look for signs', 'of severe haemorrhage.', 'if improvement', 'children and', 'adults:', 'plasma substitute', '7-10 ml/kg/h', 'for 1-2 h', 'then', 'children and', 'adults:', 'ringer lactate', 'as in “reduction', 'of rate”', 'if no improvement: measure hct 2 no severe', 'haemorrhage', 'children and adults:', 'plasma substitute', '10-20 ml/kg in', '30-60 min (2nd bolus)', 'transfuse if no', 'improvement.', 'severe', 'haemorrhage', 'transfuse', 'children and', 'adults:', 'fresh whole blood', '10-15 ml/kg', 'if hct 2 < hct 1:', 'severe', 'haemorrhage', 'transfuse', 'children and', 'adults:', 'fresh whole blood', '10-15 ml/kg', 'if hct 2 ≥ hct 1:', 'no severe haemorrhage', 'children and adults:', 'plasma substitute (3rd bolus)', '10-20 ml/kg in 30-60 min', '7-10 ml/kg/h for 1-2 h', 'if improvement', 'children and', 'adults:', 'ringer lactate', 'as in “reduction', 'of rate”', 'if no', 'improvement', 'measure hct 3', 'and proceed as', 'above from', '“measure', 'hct 2”.', 'verify the presence of signs of shock or', 'of fluid overload and measure hct.', 'reduce the iv fluid rate when hr and bp normalise; continue for 24-48 h (or less if po hydration tolerated). supplemental boluses of crystalloids', 'or colloids may be necessary in the next 24 h. do not administer iv fluids for more than 48 h.', 'viral haemorrhagic fevers', '– several diseases with different aetiologies and different modes of transmission are grouped', 'under this term as they present with common clinical signs.', '– dengue haemorrhagic fever is a vhf that is described in a specific chapter (see dengue).', 'clinical features', '– common clinical signs:', '• fever higher than 38.5°c;', '• haemorrhagic symptoms (purpura, epistaxis, haematemesis, melaena, etc.).', '– the clinical signs are often nonspecific; the severity varies depending on the aetiology (see', 'table, page 223).', 'laboratory', '– a sample of whole blood must be send to a reference laboratory for serological diagnosis,', 'with a clinical description of the patient. the sample may also be sent on filter paper. it is', 'easier to transport, but the small volume of blood only allows a limited number of', 'aetiologies to be tested.', '– protective clothing must be worn while taking or handling the sample (gown, gloves, glasses,', 'mask, etc.).', '– the sample must be sent in a triple packaging system for category a infectious substances.', 'management', 'suspicion of haemorrhagic fever (isolated case of fever with haemorrhagic symptoms in an', 'endemic area)', '– isolation: isolation room (or failing that, use screens/partitions); restrict visitors (if a carer is', 'strictly necessary, s/he must be protected with gown, gloves, mask).', '– standard precautions:', 'standard precautions must always be respected. the majority of hospital-acquired infections', 'have occurred due to a lack of respect for these precautions:', '• hand washing;', '• gloves for patient examination and when touching blood, body fluids, secretions,', 'excretions, mucous membranes, non-intact skin;', '• gowns to protect skin and prevent soiling of clothing during consultations and activities', 'that are likely to generate splashes or sprays of blood, body fluids, secretions, or', 'excretions;', '• surgical mask and goggles, or face shield, to protect mucous membranes of the eyes, nose,', 'and mouth during activities that may generate splashes of blood, body fluids, secretions,', 'and excretions;', '• adequate procedures for the routine cleaning and disinfection of objects and surfaces;', '• rubber gloves to handle soiled laundry;', 'chapter 8', '220', '• safe waste management;', '• safe injection practices.', 'confirmed cases of ebola, marburg, lassa, crimean-congo fevers or epidemics of unknown', 'origin', '– strict isolation in a reserved area separate from other patient areas, with a defined circuit for', 'entrance/exit and changing room at the entrance/exit; dedicated staff and equipment/supplies;', 'use of disposable material if possible.', '– standard precautions (as above)', 'plus', '– droplet precautions and contact precautions including personal protective equipment (ppe):', '• two pairs of gloves,', '• double gown or coverall suit,', '• surgical cap or hood, mask, protective glasses,', '• impermeable apron,', '• rubber boots.', 'the ppe is to be worn systematically prior to entry into isolation area, regardless the tasks to', 'be performed (care, cleaning, distribution of meals, etc.) and to be removed before leaving', 'the isolation area.', '– disinfection of surfaces, objects, clothing and bedding with chlorine solution; safe handling', 'and on site disposal of waste and excreta, etc.', '– in the event of a death, do not wash the body. prompt and safe burial of the dead as quickly', 'as possible, using a body bag.', 'confirmed cases of yellow fever or rift valley fever', '– standard precautions.', '– patient under a mosquito net to prevent transmission.', 'for all patients: report to the ministry of health of the country.', 'treatment', '– aetiological treatment: ribavirine for lassa fever and crimean-congo fever.', '– symptomatic treatment:', '• fever: paracetamol (chapter 1). acetylsalicylic acid (aspirin) is contra-indicated.', '• pain: mild (paracetamol), moderate (tramadol), severe (sublingual morphine): see pain,', 'chapter 1).', '• dehydration: oral rehydration salts and/or iv rehydration with ringer lactate, see who', 'protocol (appendix 2).', '• seizures (chapter 1).', '• vomiting: ondansetron po', 'children 6 months to < 2 years: 2 mg once daily', 'children 2 to < 4 years: 4 mg/day in 2 divided doses', 'children 4 to < 12 years: 8 mg/day in 2 divided doses', 'children ≥ 12 years and adults: 8 to 16 mg/day in 2 divided doses', '– for ebola and marburg haemorrhagic fevers: invasive procedures must be strictly limited.', 'health care staff is at risk of contamination when inserting and maintaining iv lines. an iv', 'line must be well secured so that the patient, often confused, cannot pull it out.', 'viral diseases', '221', '8', 'prevention', '– vaccination', '• yellow fever:', 'mass vaccination campaign during an epidemic', 'children from 6 months and adults: a single dose of 0.5 ml im (preferred) or deep sc, in', 'the deltoid muscle. for pregnant women, only administer during an epidemic.', 'routine vaccination (epi)', '• rift valley fever: only during an epidemic.', '– vector control programmes for known vectors.', '– infection control measures are essential in all cases.', 'chapter 8', '222', 'v', 'iral d', 'iseases', '223', '8', '* vhf with epidemic potential', 'cs: common syndrome', 'reservoir/ vector', 'geographical distribution', 'isolation', 'of patients', 'clinical feataures', '(estimated case fatality rate)', 'ebola*', 'marburg', 'bats (?)', 'africa', 'strict', 'isolation', 'cs + sudden onset general malaise, vomiting and diarrhoea', '(60-80%)', 'lassa* rodents', 'central and west africa', 'strict', 'isolation', 'cs + facial oedema, purulent pharyngitis, proteinuria on reagent strip', '(10-25%)', 'junin and machupo*', 'omsk', 'crimean congo*', 'fhsr (hantavirus)*', 'rodents', 'south america', 'ticks', 'europe, asia', 'livestock/ticks', 'africa, asia', 'rodents', 'asia and europe', 'isolation', 'none', 'strict isolation', 'none', 'cs + vomiting, erythema of the face and, depending on the aetiology:', '• periorbital oedema, cervical adenopathy, pharyngitis', '(15-30%)', '• pharyngitis, reddened conjunctivae', '(2-5%)', '• oedema of the soft palate, generalised petechial rash', '(5-20%)', '• proteinuria on reagent strip', '(< 1%)', 'kyasanur small mammals/ticks', 'india', 'none cs + headache, muscle pain, prostration', '(2-10%)', 'rift valley* livestock/mosquitoes', 'africa', 'mosquito nets clinical signs:', '• isolated fever', '• sc (30-50%)', '• encephalitis', '• retinitis and blindness', 'yellow fever* primates/mosquitoes', 'africa, south america', 'mosquito nets cs + jaundice, proteinuria on reagent strip, oliguria, headache', '(10-30%)', 'hiv infection and aids', '– acquired immune deficiency syndrome (aids) is the most advanced stage of infection with', 'human immunodeficiency virus (hiv).', '– two subtypes of hiv have been identified. hiv-1 is more widespread than hiv-2, the latter', 'mainly being found in west africa. hiv-2 is less virulent and less transmissible than hiv-1.', '– hiv weakens the immune system by causing a deficit in cd4 t lymphocytes.', 'evolution of the disease', '– primary infection or acute retroviral syndrome: 50 to 70% of newly infected individuals', 'develop during seroconversion (from 15 days to 3 months post exposure), a viral syndrome', 'with fever, malaise, and lymphadenopathy.', '– asymptomatic hiv infection (after seroconversion): a period of clinical latency, but not viral', 'latency. the time period for progression from hiv infection to the development of severe immune', 'deficiency in western countries is approximately 10 years. this period appears to be shorter in', 'developing countries.', '– symptomatic hiv infection: with progressive destruction of the immune system, common and', 'more severe diseases occur more frequently, and with higher mortality, in seropositive individuals.', '– aids: this stage corresponds to the development of severe opportunistic infections and neoplasms.', 'from a biological point of view, aids is defined as a cd4 count < 200 cells/mm3. without', 'treatment the disease progresses rapidly towards death.', 'the world health organization (who) has proposed a clinical classification of hiv infection in', '4 stages of severity for adults and adolescents and for childrena.', 'laboratory', 'diagnosis of hiv infection', '– the diagnosis is made with serological (detection of antibodies against the virus) or', 'virological (especially in infants) testing.', '– testing should always be done voluntarily with informed consent. ', '– all hiv test results must be strictly confidential in order to avoid discrimination. ', '– the individual should have access to services offering pre-test and post-test counselling,', 'treatment and support.', '– a diagnosis of hiv infection can be made only after at least 2 different test results', '(2 different brands) are clearly positive: the positive result of an initial (highly sensitive) test', 'must be confirmed through use of a second (highly specific) test. in areas where hiv', 'prevalence is low confirmation, diagnosis is made with a three different test.', 'cd4 lymphocyte counts', '– cd4 cell depletion is a marker of the progression of immune depression. the level of the cd4', 'cell count is a predictor of the development of opportunistic infections or neoplasms and can be', 'used to orient their diagnosis, e.g. cerebral toxoplasmosis or cryptococcal meningitis appear', 'when the cd4 count is below 100 cells/mm3 in adults. if clinical symptoms/signs are present', 'suggesting one of these infections, but the cd4 count is greater than or equal to 200 cells/mm3,', 'it is unlikely that that particular infection is present.', 'a who case definitions of hiv for surveillance and revised clinical staging and immunological classification de', 'hiv-related disease in adults and children. world health organization 2007.', 'http://www.who.int/hiv/pub/guidelines/hivstaging150307.pdf', 'chapter 8', '224', 'http://www.who.int/hiv/pub/guidelines/hivstaging150307.pdf', 'opportunistic infections', 'it is important to screen for serious opportunistic infections in those at risk (e.g. testing for', 'cryptococcal antigen for all adults with a cd4 count < 100 cells/mm3 regardless of symptoms).', 'treatment of hiv infection', 'antiretroviral (arv) treatment', 'a multi-drug (at least 3) antiretroviral therapy (art) is the reference treatment. it does not', 'eradicate the virus, but slows the progression of the disease and improves the patient’s clinical', 'state by reducing viral replication and consequently increasing the cd4 cell count to levels', 'beyond the threshold of opportunistic infections.', 'therapeutic classes', 'four major classes arv are used:', '– nrti (nucleoside/nucleotide reverse transcriptase inhibitors): zidovudine (azt), lamivudine', '(3tc), abacavir (abc), tenofovir (tdf), emtricitabine (ftc).', '– nnrti (non-nucleoside reverse transcriptase inhibitors): efavirenz (efv), nevirapine (nvp),', 'etravirine (etr). hiv-2 is naturally resistant to nnrtis.', '– pi (protease inhibitors): atazanavir (atv), lopinavir (lpv), ritonavir (rtv), darunavir (drv).', '– ini (integrase inhibitors): dolutegravir, raltegravir.', 'principles of arv treatment', '– daily triple therapy must be taken for life to prevent the rapid development of resistance. it', 'is important that the patient understands this and that adherence to treatment is optimal.', '– follow the art protocols recommended by national hiv program.', '– the most widely used and easiest regimens to administer are 2 nrti + 1 nnrti: e.g.', 'tdf/3tc/efv.', '– in the event of treatment failure, all 3 drugs should be replaced with a second-line regimen:', '2 other nrtis + 1 pi.', 'other possible combinations exist which are less commonly used or more difficult to manage.', 'criteria for arv treatment', 'as a priority art should be initiated in all patients with who clinical stage 3 or 4 and patients', 'with cd4 < 350 /mm3. however, those with higher cd4 counts can initiate art.', 'monitoring of arv treatment', 'hiv viral load is an essential tool for monitoring the effectiveness of arv. cd4 count is useful', 'for identifying severely immunosuppressed. other tests such as blood count, tests for liver', '(alat) and renal function (creatinine clearance) are not essential, but can be useful in', 'detecting adverse effects.', 'treatment of opportunistic and other infections', 'with progressive immunosuppression, hiv-infected patients who are not receiving triple', 'therapy (or patients on art but with poor adherence) become increasingly susceptible to', 'infections. for conditions of clinical stages 2 and 3, standard treatments are usually effective.', 'patients may benefit from primary prophylaxis against opportunistic infections (see primary', 'prophylaxis). tuberculosis (tb) is the most common serious opportunistic infection. it can be', 'difficult to diagnose in hiv-infected patients however.', 'viral diseases', '225', '8', 'treatment of pain', 'treat all patients for associated pain (see pain, chapter 1).', 'prevention of hiv infection', '– sexual transmission', 'the most reliable method of prevention is the use of male or female condoms.', 'male circumcision decreases significantly the risk of hiv transmission. ', 'early diagnosis and treatment of sexually transmitted infections is essential as they increase', 'the transmission of hiv (see chapter 9).', 'art to hiv positive and adherent partner does protect the negative partner from hiv', 'infection. ', '– occupational transmission (accidental needle stick injuries or injuries with contaminated', 'objects, contact between a patient’s blood and unprotected broken skin or mucous', 'membranes)', 'prevention is based on use of universal precautions to avoid contamination with soiled', 'material or potentially infected body fluids.', 'post-exposure prophylaxis (pep): e.g. in the event of rape or occupational accidental exposure', 'to blood, arv treatment initiated as soon as possible within 72 hours of exposure for a', 'duration of 1 month may reduce the risk of infection.', '– nosocomial transmission', 'prevention of nosocomial hiv infection is based on the rational use of injections and strict', 'respect for hygiene and sterilization and disinfection procedures for medical material.', 'for transfusion: strict respect of indications for transfusion and systematic serological', 'screening of the donor’s blood are the two indispensable precautions in the prevention of', 'hiv transmission through transfusions.', '– transmission in injection drug users', 'needle and syringe exchange programs with disposable needles and syringes for users can', 'reduce the risk.', '– mother-to-child transmission (mtct)', 'the global rate of vertical transmission varies from 20 to 40%. the risk of transmission', 'through breastfeeding is evaluated at approximately 12% and persists for the duration of', 'breastfeeding.', '• in pregnant women: hiv transmission from mother-to-child may be reduced by art. the', 'protocol called option b+ is the internationally preferred protocol. all hiv-infected pregnant', 'women receive lifelong triple-drug therapy, regardless of the cd4 count or clinical stage, both', 'for their own health and to prevent transmission to the child. the most commonly', 'recommended art is tdf/3tc/efv or tdf/ftc/efv. check national recommendations. in', 'addition, arvs are administered to the newborn.', 'programs targeting pregnant women also include other preventive measures such as', 'avoiding artificial rupture of the membranes and systematic episiotomy.', '• in breastfeeding women: exclusive breastfeeding for the first 6 months of life, introduction', 'of complementary (solid) foods at 6 months, gradual cessation of breastfeeding to the age of', '12 months.', 'prevention of opportunistic infections', 'in the absence of arv treatment, all hiv-infected individuals become symptomatic and evolve', 'towards aids. however, some opportunistic infections can be prevented.', 'chapter 8', '226', 'primary prophylaxis', 'for hiv infected patients who have not previously contracted an opportunistic infection, in', 'order to prevent the development of some opportunistic infections.', 'secondary prophylaxis', 'for patients who develop a specific opportunistic infection, in order to prevent recurrence', 'once treatment for the infection is completed.', 'infections primary prophylaxis', 'pneumocystosis ', 'cerebral toxoplasmosis', 'isosporiasis', 'various bacterial infections', 'malaria', 'cotrimoxazole po', 'children: 50 mg smx + 10 mg tmp/kg once daily', 'adults: 800 mg smx + 160 mg tmp once daily', 'infections primary prophylaxis comments', 'pneumocystosis ', 'cotrimoxazole po', 'children: 50 mg smx + 10 mg tmp/kg', 'once daily', 'adults: 800 mg smx + 160 mg tmp', 'once daily', 'alternative', 'dapsone po', 'children: 2 mg/kg once daily without', 'exceeding 100 mg/day', 'adults: 100 mg once daily', 'toxoplasmosis alternative', 'adults: ', 'dapsone po: 200 mg weekly or 50 mg daily', '+ pyrimethamine po: 75 mg weekly', '+ folinic acid po: 25 to 30 mg weekly', 'isosporiasis –', 'penicilliosis', 'histoplasmosis', 'itraconazole po', 'adults: 200 mg once daily', '–', 'cryptococcal', 'meningitis', 'fluconazole po', 'children: 6 mg/kg once daily', 'adults: 200 mg once daily', '–', 'oral or', 'oesophageal', 'candidiasis', 'fluconazole po', 'children: 3 to 6 mg/kg once daily', 'adults: 100 to 200 mg once daily', 'only for frequent and severe', 'recurrences', 'herpes simplex aciclovir po', 'children under 2 years:', '400 mg/day in 2 divided doses', 'children over 2 years and adults:', '800 mg/day in 2 divided doses', 'only for frequent and severe', 'recurrences', 'viral diseases', '227', '8', 'c', 'h', 'ap', 'ter 8', '228 symptoms definitions and aetiologies diagnosis treatment', 'diarrhoea', 'with or', 'without blood', '(also see ', 'chapter 3)', 'diarrhoea is defined as at least', '3 liquid stools per day.', 'aetiologies:', 'parasitic infections', '• isospora belli', '• cryptosporidium', '• microsporidium', '• giardia lamblia', '• entamoeba histolytica', 'bacterial infections', '• shigella', '• salmonella enteritis', '• campylobacter enteritis', 'mycobacterial infections', '• mycobacterium tuberculosis', '(gastrointestinal tb)', '• mycobacterium avium complex', 'helminthiasis', 'strongyloides stercoralis', 'viral infections', 'cytomegalovirus (cmv)', 'other causes', '• kaposi sarcoma', '• lymphoma', '• idiopathic (hiv infection)', '• antiretrovirals (especially', 'lopinavir and ritonavir)', '1. history and clinical', 'examination', '2. microscopic examina-', 'tion of stool for ova', 'and parasites (2 to 3', 'samples)', 'note:', 'i. belli, cryptosporidium,', 'microsporidium, mac and', 'cmv are unlikely if cd4', 'count > 200 cells.', '• persistent (> 2 weeks) or chronic (> 4 weeks) diarrhoea is often associated with', 'weight loss and dehydration.', '• prevention or treatment of dehydration is critical (appendix 2).', '• depending on the results of the stool examinations: give appropriate treatment.', '• if there is no laboratory support:', 'acute bloody diarrhoea', '• first-line treatment:', 'children: azithromycin po: 20 mg/kg once daily for 5 days', 'or ciprofloxacin po: 30 mg/kg/day in 2 divided doses for 7 days', 'adults: ciprofloxacin po: 1 g/day in 2 divided doses for 7 days', '• if amoebiasis suspected: tinidazole or metronidazole po (amoebiasis, chapter 3).', 'non-bloody persistent or chronic diarrhea', 'persistent or chronic diarrhoea suggests advanced immunocompromised state.', 'for patients who qualify for arvs by cd4 count (or unknown cd4 count), arv', 'initiation is urgent and will usually resolve symptoms in 14 to 28 days.', '• isospora belli: cotrimoxazole po', 'children: 80 mg smx + 16 mg tmp/kg/day in 2 divided doses for 10 days', 'followed by 50 mg smx + 10 mg tmp/kg/day in 2 divided doses for 3 weeks', 'adults: 1600 mg smx + 320 mg tmp/day in 2 divided doses for 7 to 10 days', 'followed by 800 mg smx + 160 mg tmp/day in 2 divided doses for 3 weeks', '• cryptosporidium: no specific treatment in hiv-infected patients', '• microsporidium: albendazole po (limited efficacy)', 'children: 20 mg/kg/day (max. 800 mg) in 2 divided doses for 7 days', 'adults: 800 mg/day in 2 divided doses for 2 to 4 weeks', '• helminthiasis: albendazole po', 'children > 6 months but ≤ 10 kg: 200 mg once daily for 3 days', 'children > 6 months and adults: 400 mg once daily for 3 days', '• giardiasis: tinidazole or metronidazole (intestinal protozoan infections, chapter 6).', '• if no improvement (and no contra-indications such as bloody diarrhoea), symptomatic', 'treatment with loperamide po:', 'children < 2 years: contra-indicated', 'children 2 to 5 years: 3 mg/day', 'children 6 to 8 years: 4 mg/day', 'children > 8 years: 6 to 8 mg/day', 'adults: initial dose of 4 mg then 2 mg after each liquid stool (max. 16 mg/day)', 'v', 'iral d', 'iseases', '229', '8', 'symptoms definitions and aetiologies diagnosis treatment', 'diarrhoea', 'with or', 'without blood', '(continued)', 'nutrition ++++', 'children: continue to breastfeed; increase daily calorie intake:', 'children 6-11 months: add 150 kcal/d children 12-23 months: add 200 kcal/d', 'children 2-5 years: add 250 kcal/d children 6-9 years: add 350 kcal/d', 'children 10-14 years: add 400 kcal/d', 'eliminate fresh milk, give porridge prepared with rice water or soup or yoghurts. give', '2.5 ml of oil/meal.', 'any child 0-5 years should receive zinc sulfate (diarrhoea, page 90, chapter 3).', 'adults: increase the calorie and protein intake (at least 2 g protein/kg/day). no food is', 'excluded but avoid raw food, fresh milk and foods high in fibre. encourage small,', 'frequent meals.', 'oral and', 'oesophageal', 'lesions', 'fungal infections', '• oral candidiasis: see', 'stomatitis, chapter 3.', '• oesophageal candidiasis: pain', 'on swallowing, dysphagia.', 'may result in weight loss.', 'viral infections', '• oral hairy leukoplakia', '(keratosis on the lateral sides', 'of the tongue due to the', 'epstein-barr virus)', '• oral and oesophageal herpes', 'aphthous ulcers', 'clinical examination is', 'enough to make a', 'diagnosis.', 'consider all severe oral', 'candidiasis (if the pharynx', 'is involved) as oesophageal', 'candidiasis even in the', 'absence of dysphagia.', '• mild oral candidiasis', 'nystatin po', 'children and adults: 400 000 iu/day in 4 divided doses (1 ml 4 times per day)', 'or miconazole oral gel', 'children 6 months-2 years: 1.25 ml 4 times per day', 'children over 2 years and adults: 2.5 ml 4 times per day', 'the treatment lasts 7 to 14 days.', '• moderate to severe oral candidiasis and oesophageal candidiasis', 'fluconazole po', 'children: 3 to 6 mg/kg once daily', 'adults: 50 to 200 mg once daily', 'up to 400 mg/day if necessary', 'the treatment lasts 7 to 14 days for oral candidiasis and 14 to 21 days for', 'oesophageal candidiasis.', 'candidiasis is an indication for prophylaxis with cotrimoxazole.', '• oral hairy leukoplakia: no treatment', '• oral herpes:', 'analgesics (paracetamol, ibuprofen)', 'for recurrent or extensive forms affecting the oesophagus, add: ', 'aciclovir po', 'children under 2 years: 200 mg 5 times/day for 7 days', 'children over 2 years and adults: 400 mg 5 times/day for 7 days', 'secondary prophylaxis only for patients with frequent recurrences.', 'u', 'p', 'd', 'ated', ': sep', 'tem', 'b', 'er 2016', 'c', 'h', 'ap', 'ter 8', '230 symptoms definitions and aetiologies diagnosis treatment', 'respiratory', 'problems', '(also see', 'chapter 2)', 'cough and/or thoracic pain', 'and/or dyspnoea in a', 'symptomatic hiv infected', 'patient.', 'aetiologies:', 'bacterial infections', '• streptococcus pneumoniae', '• haemophilus influenzae', '• staphylococcus aureus', 'mycobacterial infections', 'm. tuberculosis, mac', 'protozoal infections', 'pneumocystis jiroveci (pcp)', 'fungal infections ', '• cryptococcus neoformans', '• histoplasma capsulatum', '• coccidioides immitis', '• aspergillus spp', '• penicillium marneffei', 'viral infections', 'cmv', 'neoplasms', '• kaposi sarcoma', '• non-hodgkin’s lymphoma', 'others', '• lymphoid interstitial', 'pneumonia', '• pleural effusion (often tb)', '• pericardial effusion (often tb)', '• pneumothorax (may be due', 'to pcp)', '1. history and clinical', 'examination:', 'blood in the sputum?', 'if fever < 7 days, dyspnoea:', 'unlikely tb.', 'if cough > 21 days, weight', 'loss, thoracic pain', '> 15 days, no dyspnoea:', 'likely tb.', 'pulmonary auscultation:', 'bilateral lobar pneumonia?', '2. if possible:', 'a) look for afb in sputum', 'b) chest x-ray ', '• pcp: bilateral interstitial', 'infiltrates', '• tb: miliary shadowing,', 'large heart, pleural', 'effusion, enlarged', 'lymph nodes inside the', 'chest. ', 'notes', '• mac, pcp, cmv and', 'fungal infections are', 'unlikely in patients with', 'a cd4 count', '> 200 cells/mm3.', '• staphylococcal', 'pneumonia is often', 'associated with a', 'pyomyositis or an', 'abscess.', '• for the diagnosis and treatment of upper respiratory tract infections, particularly', 'pneumonia: see chapter 2.', '• if the chest x-ray is consistent with staphylococcal pneumonia: ', 'children: see staphylococcal pneumonia, chapter 2.', 'adults: ceftriaxone im or slow iv 1 g/day once daily + cloxacillin iv 8 g/day in 4 divided', 'doses', '• if the sputum examination is afb+, treat for tb. ', '• if the sputum examination is negative and the chest x-ray is consistent with pcp: ', 'cotrimoxazole po for 21 days', 'children: 100 mg smx + 20 mg tmp/kg/day in 2 divided doses', 'adults: 4800 smx + 960 tmp/day in 3 divided doses', 'note: the symptoms may become worse during the first phase of treatment,', 'effectiveness can only be evaluated after one week of treatment.', 'add prednisolone po for patients with severe pcp with hypoxia:', 'children: start with 2 mg/kg/day then decrease the dose following the adult', 'example', 'adults: 80 mg/day in 2 divided doses for 5 days, then 40 mg/day for 5 days then', '20 mg/day for 10 days', 'secondary prophylaxis is recommended.', '• fungal infections (cryptococcosis, penicilliosis, histoplasmosis):', 'adults: amphotericin b iv: 0.7 to 1 mg/kg/day for 2 weeks (cryptococcosis,', 'penicilliosis) or one to 2 weeks (histoplasmosis), then:', 'fluconazole po: 400 mg/day for 8 weeks (cryptococcosis)', 'itraconazole po: 400 mg/day in 2 divided doses for 10 weeks (penicilliosis)', 'itraconazole po: 600 mg/day in 3 divided doses for 3 days then 200 to 400 mg/day', 'for 12 weeks (histoplasmosis)', 'secondary prophylaxis is recommended.', 'v', 'iral d', 'iseases', '231', '8', 'symptoms definitions and aetiologies diagnosis treatment', 'lymphadenopathy enlarged lymph nodes in a', 'symptomatic hiv-infected', 'patient', 'persistent generalised', 'lymphadenopathy (pgl):', '• 2 or more extra-inguinal sites', '• lymph nodes > 1.5 cm', '• enlarged for 3 or more', 'months pgl is usually due to', 'hiv infection.', 'aetiologies:', 'hiv infection', 'infections', '• tb', '• syphilis', '• histoplasmosis', '• toxoplasmosis', '• cmv', 'neoplasms', '• kaposi sarcoma', '• lymphoma', '1. clinical examination:', 'look for a local cause', '(skin or dental infection', 'etc.); tb or syphilis.', '2. suspected tb: lymph', 'node aspiration, look', 'for afb, chest x-ray', 'note: in hiv infected', 'patients, tb is often', 'extrapulmonary.', '3. suspected syphilis:', 'serology', '4. if all examinations are', 'negative: biopsy is', 'useful to exclude', 'lymphoma, kaposi’s', 'sarcoma and fungal or', 'mycobacterial', 'infections (see notes for', 'patients in stage 1).', '• treat according to the aetiology or empirical treatment with, for example', 'doxycycline po.', '• tb: see the msf handbook tuberculosis.', '• early syphilis:', 'benzathine benzylpenicillin im', 'adults: 2.4 miu as a single dose (1.2 miu in each buttock)', 'or', 'azithromycin po', 'adults: 2 g as a single dose', 'note: in patients in stage 1, no further investigation (other than 1, 2 and 3 in this', 'table) or treatment are required.', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'c', 'h', 'ap', 'ter 8', '232 symptoms definitions and aetiologies treatment', 'skin lesions', '(also see', 'chapter 4)', 'bacterial infections', '• furunculosis', '• impetigo and pyoderma', '• axillary hidradenitis', '• pyomyositis', '• syphilis', 'viral infections', '• herpes zoster', '• herpes simplex', '• genital warts', '• molluscum contagiosum', 'fungal infections', 'candidiasis, dermatophytoses', 'and deep mycoses', '(penicilliosis, cryptococcosis,', 'histoplasmosis, etc.)', 'neoplasms', 'kaposi sarcoma', 'other skin infections', '• chronic prurigo or urticaria', '• severe seborrhoeic', 'dermatitis', '• psoriasis', '• scabies', '• diffuse cutaneous xerosis', 'rash caused by medication', 'bed sores', 'bacterial infections', '• furunculosis, impetigo, chronic folliculitis: see bacterial skin infections, chapter 4.', '• suppurative axillary hidradenitis: local treatment + doxycycline po: 200 mg/day in 1 or 2 divided doses for', '6 weeks (in adults)', '• pyomyositis: antibiotics and surgical drainage, see pyomyositis, chapter 10.', '• primary and secondary syphilis: see chapter 9.', 'viral infections', '• herpes zoster: see herpes simplex and herpes zoster, chapter 4.', 'for necrotic, extensive forms, eruption on the face, ophthalmic zoster, add aciclovir within 48 hours of the', 'onset of lesions:', 'children (iv route): 15 to 30 mg/kg/day in 3 infusions (every 8 hours) for 7 days', 'adults (oral route): 800 mg 5 times daily for 7 days', '• herpes simplex: see herpes simplex and herpes zoster, chapter 4.', '• genital warts: see chapter 9.', 'fungal infections', '• candidiasis: 2% cream miconazole, twice daily', '• dermatophytoses: see superficial fungal infections, chapter 4.', 'treatment of kaposi sarcoma (ks)', '• start promptly art.', 'ks tumours with oedema or ulceration or presence of extensive oral or gastrointestinal or pulmonary ks +/-', 'systemic illness: chemotherapy', 'other skin infections', '• prurigo, urticaria: see other skin disorders, chapter 4.', '• seborrhoeic dermatitis: whitfield’s ointment or 2% miconazole twice daily. for severe inflammation, use a', 'topical corticosteroid in combination with miconazole.', '• xerosis: zinc oxide ointment or calamine lotion', '• psoriasis: corticosteroids and zinc oxide ointment', '• scabies: local treatment. for crusted or profuse scabies, add ivermectin po (see scabies, chapter 4).', 'v', 'iral d', 'iseases', '233', '8', 'symptoms definitions and aetiologies diagnosis treatment', 'neurological', 'disorders in', 'adults', 'aetiologies:', 'infections', '• tb meningitis', '• cryptococcal meningitis', '• cerebral toxoplasmosis', '• neurosyphilis', '• cmv encephalitis', '• hiv encephalopathy', '• progressive multifocal leuko-', 'encephalopathy', '• cerebral malaria', 'neoplasms', 'primary cns lymphoma', 'common causes of headache', 'unrelated to hiv infection:', 'sometimes more frequent in', 'hiv infected patients (sinusitis,', 'problems with accommodation', 'etc.)', 'adverse effects of arvs', 'history and clinical', 'examination:', '• change in mental state', '• focal deficits', '• seizures', '• signs of meningeal', 'irritation', '• raised intercranial', 'pressure', '• motor problems, ataxia', 'in settings where', 'cryptococcal infection is', 'common, screen all', 'adults with cd4 < 100', 'prior to initiation of art,', 'using a rapid crag test on', 'serum or plasma.', 'in endemic areas: check', 'for malaria (if febrile).', 'lumbar puncture (lp) if', 'not contra-indicated.', 'elements in favour of', 'neurosyphilis:', '• vdrl positive in blood', 'and/or csf', '• cells in the csf', '• high protein in the csf', 'positive malaria test: see malaria, chapter 6.', 'for patients with focal signs, treat for toxoplasmosis for 6 weeks:', 'pyrimethamine po: 200 mg in 2 divided doses on the 1st day, then 75 to 100 mg/day', '+ sulfadiazine po: 4 to 6 g/day + folinic acid po: 15 mg/day ', 'or, if not available, cotrimoxazole po at high doses: 50 mg smx + 10 mg tmp/kg/day in 2', 'divided doses for 4 weeks', 'a secondary prophylaxis is recommended.', 'if the lp\\u2008is positive:', '• bacterial meningitis: see chapter 7.', '• tb meningitis: see the msf handbook tuberculosis.', '• cryptococcal meningitis (in order of preference):', 'amphotericin b iv: 0.7-1 mg/kg/d + flucytosine po: 100 mg/kg/d for 2 weeks then', 'fluconazole po: 400-800 mg/d for 8 weeks', 'or amphotericin b iv: 0.7-1 mg/kg/d + fluconazole po: 800 mg/d for 2 weeks then', 'fluconazole po alone: 400-800 mg/d for 8 weeks', 'or amphotericin b iv: 0.7-1 mg/kg/d for 5-7 days + fluconazole po: 800 mg/d for', '10 weeks', 'or fluconazole po: 1200 mg/d + flucytosine po: 100 mg/kg/d for 2 weeks then', 'fluconazole po alone: 800/d for 8 weeks', 'or fluconazole po: 1200 mg/d for 2 weeks then 800 mg/d for 8 weeks', 'during the induction phase: give fluconazole iv (same doses) if the patient cannot', 'take oral treatment; liposomal amphotericin b (3 mg/kg/d, 2 weeks) may be used', 'instead of conventional amphotericin b in case of renal impairment.', 'a secondary prophylaxis is recommended.', 'note: intracranial pressure (icp) is often raised in cryptococcal meningitis. to lower', 'icp, repeated ‘therapeutic’ punctures to drain csf may be necessary at the beginning', 'of treatment.', 'neurosyphilis:', 'benzylpenicillin iv: 12 to 24 miu/day in 6 injections at 4 hour intervals for', '14 days', 'or ceftriaxone iv or im: 2 g once daily for 10 to 14 days', 'headache of unknown origin: symptomatic treatment starting with a step 1 analgesic', '(see pain, chapter 1).', 'updated: october 2016', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'c', 'h', 'ap', 'ter 8', '234 symptoms definitions and aetiologies diagnosis treatment', 'neurological', 'disorders in', 'children', 'aetiologies:', '• bacterial meningitis', '• tb meningitis', '• cryptococcal meningitis', '• cerebral toxoplasmosis', '• cmv meningo-encephalitis', '• cerebral malaria', 'good history taking as', 'only patients with acute', 'episodes benefit from', 'specific aetiological', 'treatment (seizures,', 'meningeal syndrome,', 'focal signs).', 'in endemic areas, check', 'for malaria (if febrile).', 'lumbar puncture (lp) if', 'not contra-indicated.', 'positive malaria test: see malaria, chapter 6.', 'if lp is not possible:', '• treat for bacterial meningitis if patient febrile and/or meningeal syndrome (see', 'chapter 7).', '• treat for toxoplasmosis if focal neurological signs are present:', 'pyrimethamine po: 2 mg/kg/day in 2 divided doses for 2 days then 1 mg/kg/day', '+ sulfadiazine po: 80 mg/kg/d in 2 divided doses + folinic acid po: 10 mg once daily', 'for 8 weeks', 'or, if not available, cotrimoxazole po at high doses: 50 mg smx + 10 mg tmp/kg/day', 'in 2 divided doses for 4 weeks', 'a secondary prophylaxis is recommended.', 'if the lp is positive:', '• bacterial meningitis: see chapter 7.', '• tb meningitis: see the msf handbook tuberculosis.', '• cryptococcal meningitis (in order of preference):', 'amphotericin b iv: 0.7-1 mg/kg/d + flucytosine po: 100 mg/kg/d for 2 weeks then', 'fluconazole po: 6-12 mg/kg/d (max. 800 mg/d) for 8 weeks', 'or amphotericin b v: 0.7-1 mg/kg/d + fluconazole po: 12 mg/kg/d (max. 800 mg/d) for', '2 weeks then fluconazole po alone: 6-12 mg/kg/d for 8 weeks', 'or amphotericin b iv: 0.7-1 mg/kg/d for 5-7 days + fluconazole po: 12 mg/kg/d (max.', '800 mg/d) for 10 weeks', 'or fluconazole po: 12 mg/kg/d (max. 1200 mg/d) + flucytosine po: 100 mg/kg/d for', '2 weeks then fluconazole po alone: 12 mg/kg/d (max. 800 mg/d) for 8 weeks', 'or fluconazole po: 12 mg/kg/d (max. 1200 mg/d) for 2 weeks then 12 mg/kg/d (max.', '800 mg/d) for 8 weeks', 'during the induction phase: give fluconazole iv (same doses) if the child cannot take', 'oral treatment; liposomal amphotericin b (3 mg/kg/d, 2 weeks) may be used instead', 'of conventional amphotericin b in case of renal impairment.', 'a secondary prophylaxis is recommended.', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'v', 'iral d', 'iseases', '235', '8', 'symptoms definitions and aetiologies diagnosis treatment', 'persistent or', 'recurrent fever', 'temperature > 38°c, chronic', '(lasting more than 5 days) or', 'recurrent (multiple episodes in', 'a period of more than 5 days)', 'aetiologies:', 'infections', '• common childhood diseases', '• severe bacterial infections', '(tb, pneumonia, typhoid', 'fever, septicaemia,', 'meningitis, endocarditis, etc.)', '• occult bacterial infections', '(sinusitis, otitis, urinary tract', 'infections)', '• opportunistic infections (tb,', 'mycosis, toxoplasmosis)', '• malaria', 'neoplasms', 'non-hodgkin’s lymphoma', 'hiv infection', 'fever caused by medication', '1. history and clinical', 'examination: look for a', 'ent or urinary', 'infection, tb, skin', 'infection, enlarged', 'lymph nodes etc.', '2. in endemic areas,', 'check for malaria.', '3. suspected tb: look for', 'afb.', '4. chest x-ray, cbc, blood', 'cultures, urinalysis,', 'stool culture, serology,', 'lumbar puncture (lp).', 'if the child is under', 'treatment, consider', 'adverse effects of', 'medication.', 'positive malaria test: see malaria, chapter 6.', 'if testing is not available: in endemic zones, treat malaria.', 'suspected meningitis: treat according to the results of the lp.', 'if lp is not available, treat for bacterial meningitis, see chapter 7.', 'identified or suspected focus of infection: ', '• ent: see chapter 2; urinary: see chapter 9, etc.', '• tb: see the msf handbook tuberculosis.', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'chapter 9: ', 'genito-urinary diseases', 'uro-nephrologic diseases', 'nephrotic syndrome in children', 'urolithiasis', 'acute cystitis', 'acute pyelonephritis', 'acute prostatitis', 'genital infections (gi)', 'urethral discharge', 'abnormal vaginal discharge', 'genital ulcers', 'lower abdominal pain in women', 'upper genital tract infections (ugti)', 'veneral warts', 'major genital infections (summary)', 'metrorrhagia', '9', 'nephrotic syndrome in children', '– nephrotic syndrome (ns) is characterized by the presence of oedema, heavy proteinuria,', 'hypoalbuminemia, and hyperlipidaemia.', '– primary or idiopathic ns is the most common cause of ns in children between 1 and', '10 years. it usually responds to corticosteroids. ', '– secondary ns is associated with infectious diseases (e.g. post-infectious glomerulonephritis,', 'endocarditis, hepatitis b and c, hiv infection, malaria, and schistosomiasis) and may respond', 'to treatment of the underlying cause.', '– children with ns are at increased risk of thromboembolism, severe bacterial infections (in', 'particular, due to s. pneumoniae) and malnutrition. untreated ns may progress to renal', 'failure.', 'clinical features', '– typically, the child presents with soft, pitting and painless oedema, which varies in location', 'based on position and activity. upon awaking, the child has periorbital or facial oedema,', 'which over the day decreases as oedema of the legs increases. as oedema worsens, it may', 'localize to the back or genitals, or become generalized with ascites and pleural effusions.', '– this oedema should be differentiated from the oedema of severe acute malnutrition (sam):', 'in sam, the child presents with bilateral pitting oedema of the feet and lower legs that does', 'not vary with position. oedema extends upwards to hands and face in severe cases. it is', 'usually associated with typical skin and hair changes (see kwashiorkor: severe acute', 'malnutrition, chapter 1).', '– once sam is excluded, the following two criteria must be met to make a clinical diagnosis of', 'primary ns:', '• presence of heavy proteinuria,', 'and', '• absence of associated infections: see hepatitis b and c and hiv infection (chapter 8), malaria', 'and schistosomiasis (chapter 6).', 'laboratory', '– urine', '• measure protein with urinary dipstick on three separate voided urine samples (first voided', 'urine if possible). in ns, proteinuria is equal or greater than +++ or equal or greater than', '300 mg/dl or 30 g/la. ns is excluded if heavy proteinuria is not consistently present.', '• in case of macroscopic haematuria, or microscopic haematuria ≥ +, consider glomerulo -', 'nephritis.', 'a nephrotic range proteinuria in children is defined as urinary protein excretion greater than 50 mg/kg/day.', 'quantitative measurement of protein excretion is normally based on a timed 24-hour urine collection.', 'however, if this test cannot be performed, urine dipstick measurements can be substituted.', 'genito-urinary diseases', '239', '9', '– blood tests (if available)', '• serum albumin concentration less than 30 g/l and hyperlipidaemia.', '• blood urea nitrogen (bun) and creatinine most often in the normal range.', '– perform all necessary laboratory tests to exclude secondary ns.', 'treatment', '– hospitalize the child for initial therapy.', '– corticosteroids (prednisolone or prednisone) are indicated in primary ns.', '– before starting corticosteroid treatment:', '• treat any concomitant acute infections such as pneumonia, peritonitis, sepsis, pharyngitis,', 'or cellulitis.', '• exclude active tuberculosis and/or start antituberculous treatment.', '– corticosteroid treatment', 'see algorithm page 242. total length of initial treatment is 2 to 4 months.', '– nutrition, fluid intake, nursing and follow-up', '• no salt-added diet.', '• do not restrict fluids (risk of thrombosis due to hypercoagulability). if oedema is very', 'severe, fluids may initially be restricted (e.g. 75% of usual intake) while monitoring urine', 'output.', '• encourage child to walk and play to prevent thromboembolism.', '• discharge child when stable, follow-up at least monthly, more frequently if indicated,', 'weight and urine dipstick at each visit.', '• instruct the parent to continue no salt-added diet and to seek medical advice in case of', 'fever, abdominal pain, respiratory distress or signs of thromboembolism.', '– management of infections', 'treat infections as soon as they appear but do not routinely give prophylactic antibiotics.', '– immunization', '• children under 5 years: check that the child has received all epi vaccines including', 'haemophilus influenzae type b, conjugated pneumococcal vaccine and (if in an endemic', 'area) meningococcal a conjugate vaccine. if not, administer catch-up vaccines.', '• children over 5 years: check that the child has received tetanus, measles, pneumococcal', 'conjugate and (if in an endemic area) meningococcal a conjugate vaccine. if not,', 'administer catch-up vaccines.', 'management of complications', '– intravascular volume depletion potentially leading to shock, present despite oedematous', 'appearance', 'signs include decreased urine output with any one of the following: capillary refill ≥ 3 seconds,', 'poor skin perfusion/mottling, cold extremities, low blood pressure (if available).', 'if signs are present, administer human albumin 5% iv: 1 g/kg. if albumin is not available,', 'administer ringer lactate or 0.9% sodium chloride: 10 ml/kg over 30 minutes.', 'if signs of shock are present, see shock, chapter 1.', 'chapter 9', '240', '– respiratory distress due to severe oedema (rare)', 'this is the only situation in which diuretics should be used and only if there are no signs of', 'intravascular volume depletion or after hypovolaemia has been corrected:', 'furosemide po: 1 mg/kg/day in 2 divided doses', 'if not effective, discontinue furosemide. if creatinine is normal, administer spironolactone', 'po: 2 mg/kg/day in 2 divided doses. the dose can be increased to 9 mg/kg/day in resistant', 'cases of ascites.', 'while on diuretics, monitor for dehydration, thromboembolism and hypokalaemia.', 'specialized advice and management (including further investigations such as renal biopsy) are', 'required:', '– in children less than 1 year or more than 10 years,', '– in case of steroid resistant ns,', '– in case of mixed nephrotic and nephritic clinical picture.', 'in case of steroid-resistant ns, when referral is impossible and as a last resort, the following', 'palliative measure may reduce proteinuria and delay renal failure: ', 'enalapril po: 0.2 to 0.6 mg/kg/day in 2 divided doses (start with the lowest dose and increase', 'gradually if necessary until reduction of proteinuria). if available, monitor for hyperkalaemia.', 'however, the prognosis for steroid-resistant ns is poor in the absence of specialized treatment.', 'genito-urinary diseases', '241', '9', 'c', 'h', 'ap', 'ter 9', '242 prednisolonea po: 2 mg/kg once daily in the morning (max. 60 mg/day)', 'monitor proteinuria weekly by urine dipstick. ', 'proteinuria remains ≥ +++ for 4 weeks proteinuria disappears(usually within 1 to 2 weeks)', 'stop prednisolone po and start methylprednisolone iv: 20 mg/kg, or if', 'not available, dexamethasone iv: 5 mg/kg. treat every other day for a', 'total of 3 doses (d1, d3, d5).', 'continue prednisolone po: 2 mg/kg once daily for 4 weeks (max. 6 weeks).', 'then prednisolone po: 2 mg/kg every other day.', 'monitor proteinuria weekly.', 'proteinuria ≥ +++ for 3 conse -', 'cutive days 7 days after above', 'therapy.', 'proteinuria disappears 7 days', 'after above therapy.', 'child has steroid resistant ns', 'refer to specialist.', 'proteinuria remains absent on', 'weekly urine dipstick', 'proteinuria ≥ +++', 'test urine daily. if proteinuria', '≥ +++ for 3 consecutive days,', 'child has relapsedb,c.', 'give prednisolone po: ', '2 mg/kg once daily until', 'proteinuria has disappeared', '(max. 4 weeks).', 'continue prednisolone po: ', '2 mg/kg every other day for', '4 weeks ', 'then taper by 0.5 mg/kg every', 'other week over 6 weeks.', 'monitor urine weekly.', 'proteinuria', 'remains absent', 'on weekly', 'urine dipstick', 'proteinuria', '≥ +++ for', '3 consecutive', 'days', 'stop prednisolone.', 'urine dipstick on', 'follow-up monthly.', 'continue prednisolone po:', '2 mg/kg once daily for 5 days', 'a prednisone is used interchangeably with prednisolone in this algorithm.', 'b if child has relapsed more than once, treat until proteinuria disappears but then taper prednisolone down to 0.5 mg/kg every other day rather than discontinuing entirely', 'and treat for 12 months. continue as long as proteinuria remains negative. if proteinuria recurs, treat as relapse. child has steroid dependent ns.', 'c frequent relapses: 2 or more in the first 6 months or 4 or more in a 12 month period.', 'urolithiasis', 'partial or complete obstruction of the urinary tract by one or more calculi.', 'clinical features', '– acute, sometimes intense, flank or pelvic pain (renal colic).', '– haematuria, may be accompanied by the passage of a calculus.', '– urinalysis: haematuria, leucocyturia may be present.', '– secondary infections may develop: cystitis or pyelonephritis.', 'treatment', '– increase fluid intake: 3 to 4 litres/day', '– analgesics:', '• for moderate pain', 'diclofenac po: 150 mg/day in 3 divided doses for 3 days', '+ hyoscine butylbromide po: 30 to 60 mg/day in 3 divided doses for 3 days', '• for renal colic', 'diclofenac im: 75 mg/injection, 1 or 2 times/day for a maximum of 2 days then change to', 'oral treatment', '+ hyoscine butylbromide im: 10 to 20 mg/injection to be repeated every 8 hours according', 'to the clinical evolution', '– in patients with infection: antibiotic treatment as for pyelonephritis. the effectiveness will', 'depend on the passage of the calculus.', 'genito-urinary diseases', '243', '9', 'acute cystitis', 'cystitis is an infection of the bladder and urethra that affects mainly women and girls from', '2 years of age. escherichia coli is the causative pathogen in 70 to 95% of cases. other', 'pathogens include proteus mirabilis, enterococcus, klebsiella spp and in young women,', 's. saprophyticus.', 'clinical features', '– burning pain on urination and pollakiuria (passing of small quantities of urine more', 'frequently than normal); in children: crying when passing urine; involuntary loss of urine.', 'and', '– no fever (or mild fever), no flank pain; no systemic signs and symptoms in children.', 'it is essential to rule out pyelonephritis. ', \"the symptom 'burning pain on urination' alone is insufficient to make the diagnosis. in the\", 'event of abnormal vaginal discharge, see page 253.', 'laboratory', '– urine dipstick test:', 'perform dipstick analysis for nitrites (which indicate the presence of enterobacteria) and', 'leukocytes (which indicate an inflammation) in the urine.', '• if dipstick analysis is negative for both nitrites and leukocytes, a urinary infection is', 'excluded.', '• if dipstick analysis is positive for nitrites and/or leukocytes, a urinary infection is likely.', '– microscopy/culture: when a dipstick analysis is positive, it is recommended to carry out urine', 'microscopy/culture in order to confirm the infection and identify the causative pathogen,', 'particularly in children and pregnant women.', 'when urine microscopy is not feasible, an empirical antibiotic treatment should be', 'administered to patients with typical signs of cystitis and positive dipstick urinalysis (leucocytes', 'and/or nitrites).', 'note: aside of these results, in areas where urinary schistosomiasis is endemic, consider', 'schistosomiasis in patients with macroscopic haematuria or microscopic haematuria detected', 'by dipstick test, especially in children from 5 to 15 years, even if the patient may suffer from', 'concomitant bacterial cystitis.', 'treatment', 'cystitis in girls ≥ 2 years', 'cefixime po: 8 mg/kg once daily for 3 days', 'or', 'amoxicillin/clavulanic acid po (dose expressed in amoxicillin) 25 mg/kg/day in 2 divided doses', '(with formulation 8:1 or 7:1 or 4:1)', 'note: the dose of clavulanic acid should not exceed 12.5 mg/kg/day (or 375 mg/day).', 'chapter 9', '244', 'cystitis in non pregnant women', '– if dipstick analysis is positive for both nitrites and leukocytes:', 'fosfomycin-trometamine po: 3 g as a single dose', 'or', 'ciprofloxacin po: 500 mg/day in 2 divided doses for 3 days', 'or', 'nitrofurantoin po (except in patients with g6pd deficiency): 300 mg/day in 3 divided doses', 'for 5 days', '– if dipstick analysis is negative for nitrites but positive for leukocytes, the infection may be', 'due to s. saprophyticus. fosfomycin is not active against this pathogen. use ciprofloxacin or', 'nitrofurantoin, as above.', '– whatever the antibiotic used, symptoms may persist for 2 to 3 days despite adequate', 'treatment.', '– in the event of treatment failure (or recurrent cystitis i.e. > 3-4 episodes/year), ciprofloxacin po:', '1 g/day in 2 divided doses for 5 days', '– for patients with recurrent cystitis, consider bladder stones, urinary schistosomiasis, urinary', 'tuberculosis or gonorrhoea (examine the partner).', 'cystitis in pregnant or lactating women', 'fosfomycine-tromethamine po as above', 'or', 'céfixime po: 400 mg/day in 2 divided doses for 5 days', 'or', 'nitrofurantoin po (except in the last month of pregnancy, the first month of breast- feeding and', 'in patients with g6pd deficiency): 300 mg/day in 3 divided doses for 5 to 7 days', 'genito-urinary diseases', '245', '9', 'acute pyelonephritis', 'pyelonephritis is an acute infection of the renal parenchyma, potentially severe, especially in', 'pregnant women, neonates and infants. the pathogens causing pyelonephritis are the same as', 'those causing cystitis (see acute cystitis).', 'clinical features', 'neonates and infants', '– symptoms are not specific: fever, irritability, vomiting, poor oral intake. palpation of the', 'lower abdomen may show abdominal tenderness. the absence of fever does not rule out the', 'diagnosis. on the other hand, fever –with no obvious cause– may be the only manifestation.', '– neonates may present with fever or hypothermia, altered general condition, altered', 'conscious state, pale/grey colour, shock.', 'in practice, a urinary tract infection should be suspected in children with unexplained fever or', 'septic syndrome with no obvious focus of infection.', 'older children and adults', '– signs of cystitis (burning on urination and pollakiuria, etc.)', 'and', '– fever > 38.5°c and flank pain (often unilateral) or abdominal tenderness', 'laboratory', 'see acute cystitis.', 'treatment', '– antibiotic therapy in children', '• children under one month', 'cefotaxime slow iv (3 minutes) for 10 days', 'children 0 to 7 days (< 2 kg): 100 mg/kg/day in 2 divided doses', 'children 0 to 7 days (≥ 2 kg): 150 mg/kg/day in 3 divided doses', 'children 8 days to < 1 month: 150 mg/kg/day in 3 divided doses', 'or', 'ampicillin slow iv (3 minutes) for 10 days', 'children 0 to 7 days (< 2 kg): 100 mg/kg/day in 2 divided doses', 'children 0 to 7 days (≥ 2 kg): 150 mg/kg/day in 3 divided doses', 'children 8 days to < 1 month: 150 mg/kg/day in 3 divided doses', '+ gentamicin slow iv (3 minutes) or infusion (30 minutes) for 5 days', 'children 0 to 7 days (< 2 kg): 3 mg/kg once daily', 'children 0 to 7 days (≥ 2 kg): 5 mg/kg once daily', 'children 8 days to < 1 month: 5 mg/kg once daily', 'chapter 9', '246', '• children over one month', \"ceftriaxone im or slow iva (3 minutes): 50 mg/kg once daily until the child's condition\", 'improves (at least 3 days)', 'then change to oral treatment with:', 'amoxicillin/clavulanic acid po (dose expressed in amoxicillin)', 'children < 40 kg: 45 to 50 mg/kg/day in 2 doses (if using ratio 8:1 or 7:1) or in 3 doses (if', 'using ratio 4:1)', 'children ≥ 40 kg: 1500 to 2000 mg/day in 2 doses (if using ratio 8:1 or 7:1) or in 3 doses (if', 'using ratio 4:1)', 'the dose of clavulanic acid should not exceed 12.5 mg/kg/day or 375 mg/day.', '– antibiotic therapy in adults', '• pyelonephritis with no signs of serious illness', 'ciprofloxacin po: 1 to 1.5 g/day in 2 or 3 divided doses for 7 days', 'or', 'cefixime po: 400 mg/day in 2 divided doses for 10 to 14 days', '• presence of signs of serious illness (vomiting, patient seen late in disease, sepsis) or patient', 'is in poor general condition (e.g. malnutrition, presence of other diseases)', 'ceftriaxone im: 1 g/once daily for at least 3 days, then change to oral treatment with', 'cefixime po: 400 mg/day in 2 divided doses to complete 10 to 14 days of treatment (up to', '21 days depending on clinical response)', '+ gentamicin im: 6 mg/kg once daily for 3 days (if sepsis)', 'or, if not available:', 'ampicillin slow iv (3 minutes): 8 g/day in 3 injections for at least 3 days', '+ gentamicin im: 6 mg/kg once daily for 3 days', 'then change to oral treatment with amoxicillin po: 4 g/day in 2 divided doses to complete', '10 to 14 days of treatment', '– treatment of fever and pain: use paracetamol rather than nsaid (fever, chapter 1).', '– maintain proper hydration (1.5 litre/day in adults), especially in children (risk of', 'dehydration); treat dehydration if present (appendix 2).', '– management of septic shock if needed.', 'a the solvent of ceftriaxone for im injection contains lidocaine. ceftriaxone reconstituted using this solvent must', 'never be administered by iv route. for iv administration, water for injection must always be used.', 'genito-urinary diseases', '247', '9', 'acute prostatitis', 'acute infection of the prostate, most commonly due to gram negative bacteria.', 'clinical features', '– signs of cystitis (burning on urination and urinary frequency) with fever in men, perineal pain', 'is common.', '– very painful rectal examination.', '– urinalysis: leucocyturia and pyuria; haematuria may be present.', 'treatment', 'difficult, the infection may become chronic.', '– increase fluid intake: 3 to 4 litres/day', '– fever and pain (chapter 1)', '– prolonged antibiotic treatment:', 'ciprofloxacin po: 1 g/day in 2 divided doses for 28 days', 'chapter 9', '248', 'genital infections (gi)', 'the diagnosis and treatment of genital infections present several difficulties: clinical features', 'are not specific; many infections are asymptomatic; laboratory tests available in the field are', 'not always reliable; mixed infections are common; partners need to be treated simultaneously', 'in case of sexually transmitted infectionsa and the risk of recurrence or treatment failure is', 'increased in hiv-infected patients.', 'thus, the who has introduced the syndromic management of gi and developed standardised', 'case management flowcharts: based on the identification of consistent groups of signs and', 'symptoms (syndromes), patients are treated for the pathogens/ infectionsb that may cause', 'each syndrome.', 'basic principles of gi management', '– the patient can be effectively treated without laboratory testing. some tests may help in', 'diagnosing vaginal and urethral discharge, but they should never delay treatment (results', 'should be available within one hour).', '– the patient should be treated at his/her first encounter with the health care provider (no', 'patient should be sent home without treatment, e.g. while waiting for laboratory results).', '– single dose regimens are preferred when indicated.', '– in the case of urethral discharge, abnormal vaginal discharge (except candidiasis), genital', 'ulcers (except herpes) and sexually transmitted upper genital tract infection, the sexual', 'partner should receive a treatment. in the case of candidiasis, genital herpes and venereal', 'warts, the partner is treated only if symptomatic.', '– patients with sexually transmitted infections should receive information on their disease(s)', 'and treatment and be counselled on risk reduction and hiv testing. condoms should be', 'provided for the duration of treatment.', 'a genital infections may be sexually transmitted (e.g. gonorrhoea, chlamydia) or not (e.g. most cases of', 'candidiasis).', 'b keep in mind that in schistosoma haematobium endemic areas, genital symptoms may also be due to, or', 'associated with, genitourinary schistosomiasis (see schistosomiasis, chapter 6).', 'look for a genital infection if a patient complains of: see', 'urethral discharge', 'painful or difficult urination (dysuria)', 'urethral discharge', 'abnormal vaginal discharge', 'vulvar itching/burning', 'pain with intercourse (dyspareunia)', 'painful or difficult urination (dysuria)', 'abnormal vaginal discharge', 'genital blisters or sores', 'burning sensation in the vulva or perineum', 'genital ulcers', 'skin growths in the genital (or anal) area venereal warts', 'lower abdominal pain (in women)', 'lower abdominal pain', 'upper genital tract infections', 'genito-urinary diseases', '249', '9', 'special situation: sexual violence', 'taking into consideration the physical, psychological, legal and social consequences of sexual', 'violence, medical care is not limited to the diagnosis and treatment of genital lesions or', 'infections.', 'care includes listening to the victim’s story, a complete physical examination, laboratory tests', 'if available, and completion of a medical certificate (see appendix 3).', 'during the consultation, prophylactic or curative treatments must be proposed to the patient.', '– prophylactic treatment:', '• priority is given to:', 'a) the risk of hiv transmission. start antiretroviral therapy as early as possible if the', 'patient is seen within 48-72 hours after exposure (see hiv infection and aids, chapter 8); ', 'b) the risk of pregnancy resulting from rape. administer emergency contraception as soon', 'as possible, ideally within 72 hours after the rape: levonorgestrel po, one 1.5 mg tablet', 'single dosec; double the dose (3 mg) if the patient is also taking hiv post- exposure', 'prophylaxis or an enzyme-inducing drug (e.g. rifampicin, carbamazepine, some', 'antiretrovirals);', '• prevention of sexually transmitted infections includes a single dose treatment with', 'azithromycin po 2 g + ceftriaxone im 250 mg (or, if ceftriaxone is not available, cefixime po', '400 mg). if necessary, treatment of trichomoniasis may be started later than the other', 'treatments (tinidazole or metronidazole po, 2 g single dose);', '• tetanus prophylaxis and/or vaccination (see tetanus, chapter 7) if there are any wounds;', '• vaccination against hepatitis b (accelerated vaccination schedule, see viral hepatitis,', 'chapter 8).', '– curative treatment:', '• of wounds,', '• of any related pathologies/infections if the assault is not recent.', 'mental health care is necessary irrespective of any delay between the event and the patient', 'arriving for a consultation. care is based on immediate attention (one-on-one reception and', 'listening) and if necessary, follow-up care with a view to detecting and treating any', 'psychological and/or psychiatric sequelae (anxiety, depression, post- traumatic stress disorder,', 'etc.). see chapter 11.', 'c nevertheless, between 72 and 120 hours (5 days) after the rape, emergency contraception is still sufficiently', 'effective to be administered.', 'chapter 9', '250', 'urethral discharge', 'urethral discharge is seen almost exclusively in men. the principal causative organisms are', 'neisseria gonorrhoeae (gonorrhoea) and chlamydia trachomatis (chlamydia).', 'the presence of abnormal discharge should be confirmed by performing a clinical examinationa.', 'in males, the urethra should be milked gently if no discharge is visible. furthermore, specifically', 'check for urethral discharge in patients complaining of painful or difficult urination (dysuria).', 'case management', 'no no', 'yes yes', 'laboratory', '– c. trachomatis cannot easily be identified in a field laboratory. in the absence of validated', 'rapid diagnostic tests, the treatment is empiric.', '– in men, a methylene blue or gram stained smear from a urethral swab may be used to', 'detect gonococci (gram negative intracellular diplococci).', 'a in areas where lymphatic filariasis is endemic, be careful not to confuse purulent urethral discharge with milky', 'or rice-water urine (chyluria) suggestive of lymphatic filariasis.', 'the patient complains', 'of urethral discharge', 'or dysuria', 'take history', 'and examine', 'reassess the patient', 'if symptoms persist', 'another genital', 'condition is present?', 'urethral discharge', 'is present?', 'administer', 'appropriate treatment', 'treat for gonorrhoea', 'and', 'chlamydia', 'genito-urinary diseases', '251', '9', 'treatment of the patient', '– in women: same treatment as cervicitis.', '– in men:', '• if microscopy of a urethral smear has been performed: in the absence of gonococci, treat', 'for chlamydia alone; in the presence of gonococci, treat for chlamydia and gonorrhoea.', '• when no laboratory is available, treat for chlamydia and gonorrhoea as below:', 'if urethral discharge persists or reappears after 7 days:', '– verify that the patient has received an effective treatment (i.e. one of the combinations', 'above).', '– gonococcal resistance is a possibility if another treatment (e.g. cotrimoxazole or kanamycin)', 'has been administered: re-treat for gonorrhoea as above (chlamydia is rarely resistant).', '– if an effective antibiotic therapy has been given, consider trichomoniasis (tinidazole or', 'metronidazole po, 2 g as a single dose); also consider re-infection.', 'treatment of the partner', 'the sexual partner receives the same treatment as the patient, whether or not symptoms are', 'present.', 'treatment for chlamydia treatment for gonorrhoea', 'azithromycin po: 1 g as a single dose plus ceftriaxone im: 250 mg as a single dose', 'our or, if ceftriaxone is not available,', 'doxycycline po: 200 mg/day in cefixime po: 400 mg as a single dose', '2 divided doses for 7 days or', 'spectinomycin im: 2 g as a single dose', 'chapter 9', '252', 'abnormal vaginal discharge', 'abnormal vaginal discharge is defined as discharge that differs from usual with respect to', 'colour/odour/consistency (e.g. discoloured or purulent or malodorous).', 'abnormal discharge is often associated with vulvar pruritus or pain with intercourse', '(dyspareunia), or painful or difficult urination (dysuria) or lower abdominal pain. routinely', 'check for abnormal vaginal discharge in women presenting with these symptoms.', 'abnormal vaginal discharge may be a sign of infection of the vagina (vaginitis) and/or the cervix', '(cervicitis) or upper genital tract infection.', 'the presence of abnormal discharge must be confirmed by performing a clinical examination:', 'inspection of the vulva, speculum exam (checking for cervical/vaginal inflammation or', 'discharge).', 'abdominal and bimanual pelvic examinations should be performed routinely in all women', 'presenting with vaginal discharge to rule out upper genital tract infection (lower abdominal', 'pain and cervical motion tenderness).', 'the principal causative organisms are:', '– in vaginitis: gardnerella vaginalis and other bacteria (bacterial vaginosis), trichomonas', 'vaginalis (trichomoniasis) and candida albicans (candidiasis).', '– in cervicitis: neisseria gonorrhoeae (gonorrhoea) and chlamydia trachomatis (chlamydia).', '– in upper genital tract infections: see page 260. ', 'case management', 'see algorithm, following page.', 'laboratory', '– tests usually available in the field can only identify causes of vaginitis, and thus are of limited', 'usefulness.', 'microscopic examination of a fresh wet smear may show mobile t. vaginalis, yeast cells and', 'hyphae in candidiasis, and “clue cells” in bacterial vaginosis.', '– identification of n. gonorrhoeae by gram stained smear is not sensitive in women and is not', 'recommended.', 'genito-urinary diseases', '253', '9', 'case management', 'no', 'yes', 'yes', 'no', 'yes', 'no', 'yes', 'cervicitis may be difficult to diagnose. when in doubt, administer treatment for cervicitis to', 'women with abnormal vaginal discharge and any of the following risk factors:', '– urethral discharge in the partner', '– context of sexual violence or prostitution', '– new partner or more than one partner in the preceding 3 months', 'take history, examine', 'and assess risk factors', 'abnormal discharge', 'is present?', 'lower abdominal pain', 'or', 'cervical motion tenderness?', 'see', 'lower abdominal pain', 'risk assessment positive', '(see below)', 'or', 'purulent cervical', 'discharge detected?', 'treat for cervicitis', 'and bacterial vaginosis', 'and trichomoniasis', 'treat for bacterial vaginosis', 'and trichomoniasis', 'vulvar oedema, thick', 'discharge, erythema,', 'excoriations present?', 'in addition,', 'treat for', 'candidiasis', 'patient complains', 'of vaginal discharge', 'or vulvar itching/burning, etc.', 'chapter 9', '254', 'look for', 'another genital disorder.', 'if present, treat appropriately.', 'if not, reassure the patient.', 'treatment of the patient', 'cervicitis', 'treat for both chlamydia and gonorrhoea.', 'bacterial vaginosis and trichomoniasis', 'tinidazole po: 2 g as a single dose', 'or metronidazole po: 2 g as a single dose', 'in the case of treatment failure:', 'tinidazole po: 1 g/day in 2 divided doses for 5 days', 'or metronidazole po: 800 to 1000 mg/day in 2 divided doses for 7 days', 'vulvovaginal candidiasis', 'clotrimazole (500 mg vaginal tablet): 1 tablet as a single dose, inserted deep into the vagina at', 'bedtime', 'or, if not available,', 'clotrimazole (100 mg vaginal tablet): one tablet inserted deep into the vagina at bedtime for', '6 days', 'or nystatin (100,000 iu vaginal tablet): one tablet inserted deep into the vagina at bedtime for', '14 days', 'if the patient has extensive vulvar involvement, miconazole 2% cream (2 applications to the', 'vulva daily for 7 days) may be used in combination with the intravaginal treatment above.', 'miconazole cream may complement, but does not replace, treatment with clotrimazole. ', 'treatment of the partner', 'when the patient is treated for vaginitis or cervicitis, the sexual partner receives the same', 'treatment as the patient, whether or not symptoms are present.', 'in the case of vulvovaginal candidiasis, the partner is treated only if symptomatic (itching and', 'redness of the glans/prepuce): miconazole 2%, 2 applications daily for 7 days.', 'non-pregnant women', 'treatment for chlamydia treatment for gonorrhoea', 'azithromycin po: 1 g as a single dose plus ceftriaxone im: 250 mg as a single dose ', 'or or, if ceftriaxone is not available, ', 'doxycycline po: 200 mg/day in cefixime po: 400 mg as a single dose', '2 divided doses for 7 days or', 'spectinomycin im: 2 g as a single dose', 'pregnant women', 'azithromycin po: 1 g as a single dose plus ceftriaxone im: 250 mg as a single dose ', 'or or, if ceftriaxone is not available, ', 'erythromycin po: 2 g/day in cefixime po: 400 mg as a single dose', '2 or 4 divided doses for 7 days', 'genito-urinary diseases', '255', '9', 'genital ulcers', 'genital ulcers, defined as single or multiple vesicular, ulcerative or erosive lesions of the genital', 'tract, with or without inguinal lymphadenopathy, should lead to consideration of sexually', 'transmitted infection.', 'the principal causative organisms are treponema pallidum (syphilis), haemophilus ducreyi', '(chancroid) and herpes simplex (genital herpes). chlamydia trachomatis (lymphogranuloma', 'venereum) and calymmatobacterium granulomatis (donovanosis)a are less frequent.', 'case management', 'i', 'no', 'yes', 'yes', 'no', 'laboratory', 'laboratory testing available in the field is of little value: e.g., in syphilis, a negative rpr or vdrl', 'result does not exclude primary syphilis in early stage, and a positive test may reflect previous', 'infection in a successfully treated patient.', 'a lymphogranuloma venereum is endemic in east and west africa, india, southeast asia, south america and the', 'caribbean. donovanosis is endemic in south africa, papua new guinea, india, brazil and the caribbean.', 'patient complains of genital sore or ulcer', 'take history and examine', 'sore/ulcer/vesicle is present?', 'small painful vesicles,', 'sometimes in clusters,', 'or small ulcers', 'with history of recurrent vesicles?', 'treat for', 'genital herpes', '– treat for syphilis and chancroid', '– in endemic areas, also treat for lymphogranuloma venereum and/or donovanosis', '– refer if necessary', 'chapter 9', '256', 'look for another', 'genital disorder.', 'if present,', 'treat', 'appropriately.', 'if not, reassure', 'the patient.', 'treatment of the patient', 'genital herpes', '– local treatment: clean the area with soap and water.', '– antiviral treatment: aciclovir po', 'in patients with a first episode, treatment may reduce the duration of symptom when given', 'within 5 days after the onset of symptoms: 1200 mg/day in 3 divided doses for 7 days', 'in patients with recurrence, give the same dose for 5 days, but treatment is only effective if', 'initiated during the prodromal phase or within 24 hours after the onset of symptoms.', 'in patients with frequent recurrences (more than 6 episodes/year), see hiv infection and', 'aids, page 227, chapter 8.', '– treatment of pain: paracetamol po (chapter 1).', 'syphilis', 'benzathine benzylpenicillin im: 2.4 mui/injection (half the dose in each buttock). administer a', 'single dose for early syphilis (less than 2 years); one injection per week for 3 weeks for late', 'syphilis (more than 2 years) or if the duration of infection is unknown.', 'or, for penicillin-allergic patients: ', 'azithromycin po: 2 g as a single dose ', 'or', 'erythromycin po: 2 g/day in 2 or 4 divided doses for 14 days ', 'or', 'doxycycline po: 200 mg/day in 2 divided doses for 14 daysb', 'chancroid', 'azithromycin po: 1 g as a single dose ', 'or', 'ceftriaxone im: 250 mg as a single dose ', 'or', 'ciprofloxacin po: 1 g/day in 2 divided doses for 3 daysc', 'or', 'erythromycin po: 2 g/day in 2 or 4 divided doses for 7 days', 'fluctuant lymph nodes may be aspirated through healthy skin as required. do not incise and', 'drain lymph nodes.', 'note: treat simultaneously for syphilis and chancroid as both are frequent, and cannot be', 'correctly distinguished on clinical grounds.', 'lymphogranuloma venereum', 'erythromycin po: 2 g/day in 2 or 4 divided doses for 14 days ', 'or', 'doxycycline po: 200 mg/day in 2 divided doses for 14 daysb', 'fluctuant lymph nodes may be aspirated through healthy skin as required. do not incise and', 'drain lymph nodes.', 'b doxycycline is contra-indicated in pregnant women and breast-feeding women.', 'c ciprofloxacin should be avoided in pregnant women.', 'genito-urinary diseases', '257', '9', 'donovanosis', 'treatment is given until the complete disappearance of the lesions (usually, several weeks;', 'otherwise risk of recurrence):', 'azithromycin po: 1 g the first day then, 500 mg once daily', 'or', 'erythromycin po: 2 g/day in 2 or 4 divided doses', 'or', 'doxycycline po: 200 mg/day in 2 divided dosesd', 'in hiv infected patients, add gentamicin im: 6 mg/kg once daily.', 'treatment of the partner', 'the sexual partner receives the same treatment as the patient, whether or not symptoms are', 'present, except in the case of genital herpes (the partner is treated only if symptomatic).', 'd doxycycline is contra-indicated in pregnant women and breast-feeding women.', 'chapter 9', '258', 'lower abdominal pain in women', 'upper genital tract infection should be suspected in women with lower abdominal pain (see', 'upper genital tract infections).', 'gynaecological examination should be routinely performed:', '– inspection of the vulva, speculum examination: check for purulent discharge or', 'inflammation,', 'and', '– abdominal exam and bimanual pelvic exam: check for pain on mobilising the cervix.', 'case management', 'yes', 'no', 'no no', 'yes yes', 'yes oui oui', 'no', 'yes', '* look for another cause (in particular, gastrointestinal or urinary pathology).', '** look for a pregnancy related pathology (threatened abortion, extra-uterine pregnancy) or a', 'complication (peritonitis, pelvic abscess).', 'patient complains of', 'lower abdominal pain', 'see post-partum/abortum ugti', 'following delivery', 'or abortion?', 'take history', 'and examine', 'any other illness', 'found*?', 'is there cervical motion', 'tenderness', 'or abnormal vaginal', 'discharge?', 'any of the following present?', '– amenorrhoea', '– abnormal vaginal bleeding', '– abdominal guarding or', 'rebound tenderness', 'manage', 'appropriately', 'see upper genital tract', 'infections.', 'review in 3 days.', 'refer patientpatient has improved?', 'request gynaecological/', 'surgical consultation**', 'continue treatment', 'until completed', 'genito-urinary diseases', '259', '9', 'upper genital tract infections (ugti)', 'upper genital tract infections are bacterial infections of the uterus (endometritis) and/or the', 'fallopian tubes (salpingitis), which may be complicated by peritonitis, pelvic abscess or', 'septicaemia.', 'ugti may be sexually transmitted or arise after childbirth or abortion. antibiotic choices are', 'directed by the most common pathogens in each scenario.', 'if peritonitis or pelvic abscess is suspected, request a surgical opinion while initiating antibiotic', 'therapy.', 'clinical features', 'sexually transmitted infections', 'diagnosis may be difficult, as clinical presentation is variable.', '– suggestive symptoms are: abdominal pain, abnormal vaginal discharge, fever, dyspareunia,', 'menometrorrhagia, dysuria.', '– infection is probable when one or more of the above symptoms are associated with one or', 'more of the following signs: cervical motion tenderness, adnexal tenderness, tender', 'abdominal mass.', 'infections after childbirth or abortion', '– most cases present with a typical clinical picture, developing within 2 to 10 days after', 'delivery (caesarean section or vaginal delivery) or abortion (spontaneous or induced):', '• fever, generally high', '• abdominal or pelvic pain', '• malodorous or purulent lochia', '• enlarged, soft and/or tender uterus', '– check for retained placenta.', '– in the early stages, fever may be absent or moderate and abdominal pain may be mild.', 'treatment', '– criteria for hospitalisation include:', '• clinical suspicion of severe or complicated infection (e.g. peritonitis, abscess, septicaemia)', '• diagnostic uncertainty (e.g. suspicion of extra-uterine pregnancy, appendicitis)', '• significant obstacles to ambulatory oral treatment', '• no improvement after 48 hours, or deterioration within 48 hours, of outpatient treatment', '– all other patients may be treated on an ambulatory basis. they should be reassessed', 'routinely on the third day of treatment to evaluate clinical improvement (decrease in pain,', 'absence of fever). if it is difficult to organise routine follow-up, advise patients to return to', 'clinic if there is no improvement after 48 hours of treatment, or sooner if their condition is', 'worsening.', 'chapter 9', '260', 'sexually transmitted infections', '– antibiotic therapy combines 3 antibiotics to cover the most frequent causative organisms:', 'gonococci, chlamydiae, and anaerobes.', '• ambulatory treatment:', 'cefixime po: 400 mg as a single dose or ceftriaxone im: 250 mg as a single dose', '+ doxycycline po: 200 mg/day in 2 divided doses for 14 daysa', '+ metronidazole po: 1 g/day in 2 divided doses for 14 days', '• treatment in hospital:', 'ceftriaxone im: 250 mg/day once daily', '+ doxycycline po: 200 mg/day in 2 divided doses for 14 daysa', '+ metronidazole po or iv: 1 g/day in 2 divided doses or infusions for 14 days ', 'continue triple therapy for 24 to 48 hours after signs and symptoms have improved', '(resolution of fever, decrease in pain), then continue doxycycline (or erythromycin)', '+ metronidazole to complete 14 days of treatment.', '– if an iud is in place, it should be removed (offer another method of contraception).', '– analgesic treatment according to pain intensity.', '– treatment of the partner: single dose treatment for both gonorrhoea and chlamydia (as for', 'urethral discharge), whether or not symptoms are present.', 'infections after childbirth or abortion', '– antibiotic therapy: treatment must cover the most frequent causative organisms: anaerobes,', 'gram negatives and streptococci.', '• ambulatory treatment (early stages only):', 'amoxicillin/clavulanic acid (co-amoxiclav) po for 7 days', 'the dose is expressed in amoxicillin. depending on the formulation of co- amoxiclav', 'available:', 'ratio 8:1: 3000 mg/day = 2 tablets of 500/62.5 mg 3 times per day', 'ratio 7:1: 2625 mg/day = 1 tablet of 875/125 mg 3 times per day', 'the dose of clavulanic acid should not exceed 375 mg/day.', 'or', 'amoxicillin po: 3 g/day in 3 divided doses + metronidazole po: 1.5 g/day in 3 divided doses', 'for 7 days', '• treatment in hospital:', 'amoxicillin/clavulanic acid (co-amoxiclav) iv (dose expressed in amoxicillin): 3 g/day in', '3 injections + gentamicin im: 6 mg/kg once daily', 'or', 'ampicillin iv: 6 g/day in 3 injections', '+ metronidazole iv: 1.5 g/day in 3 infusions', '+ gentamicin im: 6 mg/kg once daily', 'once the patient’s condition has improved and oral treatment can be tolerated, co-', 'amoxiclav or amoxicillin + metronidazole may be given po (as for ambulatory treatment).', 'stop antibiotic therapy 48 hours after resolution of fever and improvement in pain.', 'in penicillin-allergic patients, use clindamycin (2700 mg/day in 3 divided doses or', 'injections) + gentamicin (6 mg/kg once daily).', 'a in pregnant/breastfeeding women: erythromycin po: 2 g/day in 2 to 4 divided doses for 14 days', 'single dose azithromycin is not effective against chlamydia in the treatment of sexually transmitted ugti.', 'genito-urinary diseases', '261', '9', '– in case of placental retention: perform digital curettage or manual vacuum extraction(refer', 'to the msf handbook essential obstetric and newborn care) 24 hours after initiation of', 'antibiotic therapy.', '– analgesic treatment according to pain intensity.', '– if the patient’s condition deteriorates or if fever persists after 48-72 hours of treatment,', 'consider the possibility of complication requiring additional treatment (e.g. pelvic abscess', 'drainage), otherwise change the antibiotic to ceftriaxone + doxycycline + metronidazole as in', 'hospital-based treatment of sexually transmitted ugti.', 'chapter 9', '262', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'veneral warts', 'venereal warts are benign tumours of the skin or mucous membranes due to certain papilloma', 'viruses (hpv).', 'clinical features', '– venereal warts are soft, raised, painless growths, sometimes clustered (cauliflower- like', 'appearance) or macules (flat warts), which are more difficult to discern. warts can be', 'external (vulva, penis, scrotum, perineum, anus) and/or internal (vagina, cervix, urethra,', 'rectum; oral cavity in hiv infected patients).', '– in women, the presence of external warts is an indication for a speculum examination to', 'exclude vaginal or cervical warts. speculum exam may reveal a friable, fungating tumour on the', 'cervix, suggestive of cancer associated with papilloma virusa.', 'treatment', 'choice of treatment depends on the size and location of the warts. treatment may be less', 'effective, and relapses more frequent, in hiv infected patients.', 'external warts < 3 cm and vaginal warts', 'podophyllotoxin 0.5%b solution may be self-applied by the patient, but in the event of vaginal', 'warts, the treatment must be applied by medical staff.', 'explain the procedure to the patient: apply the solution to the warts using an applicator or', 'cotton bud, sparing the surrounding healthy skin, allow to air dry. on vaginal warts, the', 'solution should be allowed to dry before the speculum is withdrawn.', 'apply the solution twice daily, 3 consecutive days per week, for up to 4 weeks. ', 'podophyllum preparations are contra-indicated in pregnantc or breastfeeding women. they', 'should not be applied on cervical, intra-urethral, rectal, oral or extensive warts. improper use', 'may result in painful ulceration.', 'external warts > 3 cm; cervical, intra-urethral, rectal and oral warts; warts in pregnant', 'or breastfeeding women', 'surgical excision or cryotherapy or electrocoagulation.', 'a certain types of hpv may cause cancer. presence of genital warts in women is an indication to screen for pre-', 'cancerous lesions of the cervix, if feasible in the context (visual inspection with acetic acid, or cervical smear, or', 'other available techniques), and to treat any lesions identified (cryotherapy, conisation, etc., according to', 'diagnosis).', 'b podophyllum 10%, 15% or 25% resin is another preparation which is much more caustic, and should be applied', 'only by medical staff. protect the surrounding skin (vaseline or zinc oxide ointment) before applying the resin.', 'wash off with soap and water after 1 to 4 hours. apply once weekly for 4 weeks.', 'c treatment of warts is not an emergency and may be deferred if alternatives to podophyllum preparations are', 'not available. genital warts are not an indication for caesarean section: it is uncommon for warts to interfere', 'with delivery, and the risk of mother-to-child transmission is very low.', 'genito-urinary diseases', '263', '9', 'c', 'h', 'ap', 'ter 9', '264 major genital infections (summary)', 'pathogens/', 'infections clinical features laboratory treatment', 'neisseria', 'gonorrhoeae', '(gonorrhoea)', '• in women:', '– vaginal discharge, cervicitis (mucopurulent cervical', 'discharge), dysuria (50% of infections are asymptomatic);', '– ugti (salpingitis, endometritis).', '• in men: purulent urethral discharge and sometimes', 'dysuria (5 to 50% of infections are asymptomatic).', '• in women: not valid (not sensitive).', '• in men: gram or methylene blue stain:', 'intracellular diplococci and poly -', 'morphonuclear leucocytes (more than', '4 per field).', 'ceftriaxone im: 250 mg as a single dose', 'or, if ceftriaxone is not available, ', 'cefixime po: 400 mg as a single dose', 'treat also for chlamydia.', 'in case of ugti, see page 260.', 'chlamydia', 'trachomatis', '(chlamydia)', '• in women:', '– vaginal discharge, cervicitis, and rarely dysuria (> 50%', 'of infections are asymptomatic);', '– ugti (salpingitis, endometritis).', '• in men: mild urethral discharge and/or dysuria but up to', '90% of infections are asymptomatic.', 'the best method is pcr (not feasible', 'under field conditions).', 'azithromycin po: 1 g as a single dose', 'or doxycycline poa: 200 mg/day for 7 days', 'treat also for gonococcal infection (except when a', 'gram stain in males shows no n. gonorrhoeae).', 'in case of ugti, see page 260.', 'trichomonas', 'vaginalis', '(trichomoniasis)', '• in women: yellow-green vaginal discharge, sometimes', 'foul smelling, vulvar irritation (10 to 50% of infections', 'are asymptomatic).', '• in men: most infections are asymptomatic. can produce', 'balanitis, urethritis with mild discharge and sometimes', 'dysuria.', '• wet mount of fresh vaginal fluid shows', 'motile trichomonas (low sensitivity).', '• ph of urethral/vaginal fluid > 4.5.', 'tinidazole or metronidazole po: 2 g as a single', 'dose', 'bacterial', 'vaginosis', '(gardnerella', 'vaginalis and', 'other associated', 'bacteria)', 'diagnosis is made in the presence of 3 of the following 4 signs:', '• homogenous grey-white adherent vaginal discharge', '• ph of vaginal fluid > 4.5', '• vaginal fluid has an amine (fishy) odour, especially when mixed with 10% koh', '• presence of clue cells in wet mount or gram stain of vaginal fluid', 'tinidazole or metronidazole po: 2 g as a single', 'dose', 'candida', 'albicans', '(candidiasis)', '• mainly seen in women: pruritus and vulvovaginitis,', 'frequently creamy-white vaginal discharge, some- times', 'dysuria.', '• in men: balanitis/balanoposthitis (inflammation of the', 'glans/prepuce, erythema, pruritus, white pustules) and', 'rarely urethritis', '• saline of koh wet mount of fresh vaginal', 'fluid shows budding yeast cells and', 'pseudohyphae.', '• ph of vaginal fluid: normal', '• in women:', 'clotrimazole 500 mg: one vaginal tablet as a single', 'dose', 'or clotrimazole 100 mg: one vaginal tablet/day for', '6 days', 'or nystatin 100,000 iu: one vaginal tablet/day for', '14 days', '• in men:', 'miconazole 2% cream: 2 applications daily for', '7 days', 'g', 'en', 'ito', '-u', 'rin', 'ary d', 'iseases', '265', '9', 'a doxycycline is contra-indicated in pregnant women. it should not be administered to breast-feeding women if the treatment exceeds 7 days (use erythromycin).', 'b ciprofloxacin should be avoided in pregnant women.', 'pathogens/', 'infections clinical features laboratory treatment', 'herpes simplex', 'virus type 2', '(genital herpes)', 'many asymptomatic carriers. multiple vesicles on genitals', 'leading to painful ulcerations. in women, affects vulva,', 'vagina and cervix; in males, penis and sometimes urethra.', 'in primary episodes, fever (30%) and lymphadenopathy', '(50%). recurrences in 1/3 of infections with shorter and', 'milder symptoms.', 'diagnosis by culture, serology and pcr', 'done exclusively at a reference laboratory.', 'analgesics, local disinfection.', 'if available, aciclovir po:', '• primary episode: 1200 mg/day for 7 days, given', 'within 5 days after onset of lesions.', '• recurrent infections: same dose for 5 days, given', 'within 24 hours after onset of lesions.', 'treponema', 'pallidum', '(syphilis)', 'single firm painless genital ulcer, often unnoticed. rpr/vdrl lack sensitivity and specificity,', 'but may be useful for following', 'treatment effectiveness (decrease in', 'titer) or confirming re- infection (rise in', 'titer).', 'treponemic tests (tpha, fta, rapid tests', 'such as sd bioline®) are more sensitive', 'and specific.', 'benzathine benzylpenicillin im:', '2.4 miu/injection, single dose (syphylis < 2 years)', 'or one injection/week for 3 weeks (syphilis > 2 years', 'or unknow duration)', 'or azithromycin 2 g as a single dose ', 'or erythromycin 2 g/day for 14 days ', 'or doxycycline poa: 200 mg/day for 14 days', 'treat also for chancroid.', 'haemophilus', 'ducreyi', '(chancroid)', 'painful single (or multiple) genital ulcer (soft chancre,', 'bleeds easily when touched).', 'painful and voluminous inguinal lymphadenitis in 50%.', 'fistulae develop in 25% of cases.', 'h. ducreyi bacillus is difficult to identify', 'on microscopy or by culture.', 'azithromycin po: 1 g as a single dose', 'or ceftriaxone im: 250 mg as a single dose', 'or ciprofloxacin pob: 1 g/day for 3 days', 'or erythromycin po: 2 g/day for 7 days', 'treat also for syphillis.', 'human', 'papillomavirus', '(venereal warts)', 'soft, raised, painless growths, sometimes clustered', '(acuminate condyloma) or macules (flat warts). warts can', 'be external (vulva, penis, scrotum, perineum, anus) and/or', 'internal (vagina, cervix, urethra, rectum; oral cavity in hiv', 'infected patients).', 'the diagnosis is based on clinical', 'features.', 'it feasible in the context, the presence of', 'genital warts in women in an indication', 'to screen for pre-cancerous lesions of', 'the cervix (visual inspection with acetic', 'acid, or cervical smear, or other available', 'techniques).', '• external warts < 3 cm and vaginal warts:', 'podophyllotoxin 0.5%', '• external warts > 3 cm; cervical, intra- urethral,', 'rectal and oral warts; warts in pregnant or', 'breastfeeding women: surgical excision or', 'cryotherapy or electrocoagulation.', 'metrorrhagia', 'genital bleeding unrelated to the menstrual period. in women of childbearing age, always assess if', 'the bleeding is related to a pregnancy.', 'in all events', '– rapidly assess the severity of bleeding.', '– in the event of heavy haemorrhage or shock or if a surgical intervention (laparotomy,', 'caesarean delivery) is required:', '• start an iv infusion of ringer lactate; monitor vital signs (pulse, bp);', \"• prepare for a possible blood transfusion (determine patient's group, identify potential\", 'donors);', '• if a transfusion is performed, only use blood that has been screened (hiv, hepatitis b and c,', 'syphilis; malaria in endemic zone).', '– in the event of referral to a surgical facility, difficult transport conditions might aggravate the', 'haemorrhage: the patient should be infused and accompanied by family members who are', 'potential blood donors.', '– ultrasound is not imperative but it facilitates certain diagnoses (e.g. ectopic pregnancy,', 'placenta praevia).', '– prevent or treat anaemia (measure haemoglobin if possible).', 'bleeding unrelated to pregnancy', '– clinical examination:', '• speculum examination: determine the origin of the bleeding [vagina, cervix, uterine', 'cavity]; appearance of the cervix; estimation of blood loss;', '• bimanual pelvic examination: look for uterine motion tenderness, increased volume or', 'abnormalities of the uterus.', '– friable, hard, ulcerated, hypertrophic mass on the cervix: possible cervical cancer; surgical', 'treatment is required. while waiting for surgery, tranexamic acid po (3 g/day in 3 divided doses', 'for 3 to 5 days) may be used to reduce bleeding.', '– inflammation of the cervix, light or moderate bleeding, purulent cervical discharge, pelvic', 'pain: consider cervicitis (see abnormal vaginal discharge) or salpingitis (see upper genital', 'tract infections).', '– enlarged, misshapen uterus: uterine fibroids; surgical treatment if large fibroids cause', 'significant bleeding. while waiting for surgery or if surgery is not indicated, treat as a', 'functional uterine bleeding.', '– normal uterus and cervix: possible functional uterine bleeding: tranexamic acid po as above.', 'in situations of repeated bleeding, it can be combined with an nsaid (ibuprofen po: 1200 to', '2400 mg/day maximum, in 3 divided doses for 3 to 5 days) and/or a long-term treatment', 'with oral estroprogestogens or injectable progestogens.', 'note: rule out other causes of vaginal bleeding before diagnosing functional uterine bleeding.', 'consider for example poorly tolerated contraceptive, endometrial cancer in postmenopausal', 'women, genitourinary schistosomiasis in endemic areas (see schistosomiasis, chapter 6).', 'chapter 9', '266', 'bleeding during the first half of pregnancy', 'the two diagnoses to firstly consider are ectopic pregnancy and abortion.', 'ectopic pregnancy', 'pregnancy that develops outside the uterus, very often in a fallopian tube. ectopic pregnancy', 'should be suspected in any woman of reproductive age with pelvic pain and/or metrorrhagia.', 'there are many possible clinical presentations and these can mislead diagnosis towards', 'appendicitis, intestinal obstruction, salpingitis or abortion. the major risk of ectopic pregnancy', 'is rupture, leading to intra abdominal haemorrhage.', 'clinical features and diagnosis', '– amenorrhoea (may be absent) or menstrual irregularity.', '– dark slight bleeding or light to heavy bright red bleeding; or haemorrhagic shock with light', 'bleeding not corresponding to the severity of shock (intra-abdominal haemorrhage).', '– pelvic pain; sometimes distended abdomen, rebound tenderness.', '– on pelvic examination: tender adnexal mass; exquisite pain in the pouch of douglas', '(haemoperitoneum); closed cervix.', '– the diagnosis of pregnancy is confirmed by a positive rapid pregnancy test but a negative', 'urinary test does not rule out an ectopic pregnancy.', '– if ultrasound is available, the presence of an intra-uterine pregnancy eliminates the diagnosis', 'of an ectopic pregnancy. if ultrasound shows an empty uterus together with intra peritoneal', 'effusion, an ectopic pregnancy is likely, especially if the pregnancy test is positive.', 'management', 'if in doubt (negative urinary pregnancy test, no sign of rupture and stable haemodynamic', 'conditions), hospitalise the patient for surveillance, if possible in a surgical facility. otherwise,', 'refer immediately for emergency laparotomy.', 'threatened abortion', 'clinical features', 'in a context of amenorrhoea: slight, bright red bleeding; pelvic pain; closed cervix.', 'management', '– look for foreign bodies or vaginal wound consistent with induced abortion; remove foreign', 'bodies, clean the wound; update tetanus immunization (see tetanus, chapter 7).', '– treat pain: paracetamol or antispasmodics po.', '– place the patient on rest.', 'abortion', 'clinical features', 'slight or significant bright red bleeding; expulsion of the embryo, membranes or products;', 'uterine contractions; open cervix.', 'management', '– look for foreign bodies or vaginal wound consistent with induced abortion; remove foreign', 'bodies, clean the wound; update tetanus immunization (see tetanus, chapter 7).', 'genito-urinary diseases', '267', '9', '– treat pain: paracetamol or antispasmodics po.', '– depending on the stage of pregnancy:', 'before 10 weeks of pregnancy: abortion is likely to be complete. monitor, only intervene in', 'the event of heavy bleeding (aspiration).', 'between 10 and 12/14 weeks of pregnancya: uterine evacuation is often necessary.', '• instrumental method: manual vacuum aspiration is the method of choice (easier to', 'perform, less traumatic and less painful than curettage).', '• medical method: the use of misoprostol as a single dose (400 micrograms sublingually or', '600 micrograms po) may avoid instrumental procedure. there is, however, a risk of failure', 'that increases as the pregnancy progresses. treatment success (that is, an empty uterus)', 'must be verified in the days after the drug is taken. if the medical method fails, the use of', 'an instrumental method is unavoidable.', 'after 12/14 weeks of pregnancy: labour should be allowed to progress, do not rupture the', 'membranes. the placenta is usually evacuated with the foetus. if evacuation is incomplete or in', 'the event of haemorrhage, perform manual removal immediately after the expulsion, before', 'the uterus retracts or the cervix closes. if manual removal is delayed, curettage must be', 'performed which carries a high risk of uterine perforation.', '– in the event of post-abortion infection (pelvic pain, uterine tenderness, foul-smelling vaginal', 'discharge): antibiotic treatment, see upper genital tract infections.', 'bleeding during the second half of pregnancy', 'three conditions –placenta praevia, abruptio placentae, and uterine rupture–can quickly', 'become life-threatening to both mother and child. these conditions must be referred to', 'surgical facilities.', 'when no cause for the bleeding is found, consider the possibility of premature labour.', 'placenta praevia', 'placenta that covers either entirely or partially the internal os of the cervix. placenta praevia', 'may give rise to bleeding during the third trimester and carries a high risk of haemorrhage', 'during delivery.', 'clinical features and diagnosis', '– sudden, painless, slight or significant bright red bleeding.', '– the vaginal exam must be done with extreme care to avoid triggering massive bleeding:', 'uterus is soft; the exam may reveal displacement of the cervix and deformation of the lower', 'uterine segment by the placenta praevia; if the cervix is dilated, the placenta can be felt in', 'the cervix. do not repeat the examination.', '– if ultrasound is available, vaginal examination can be avoided.', 'management', '– if labour has not yet started and bleeding is light: bed rest and monitoring.', '– if labour has started and/or bleeding is heavy: refer to surgical facility.', 'a the gestational age is based on the date of last menstrual period and uterine size. uterine evacuation, using', 'aspiration or misoprostol are usually recommended up to 12 weeks. however, the estimation of gestational', 'age is often approximative. thus, these methods can be used up to an estimated gestational age of 12 to', '14 weeks.', 'chapter 9', '268', 'abruptio placenta', 'haematoma that forms between the placenta and the uterine wall as a result of separation of', 'the placenta, prior to foetal expulsion.', 'clinical features', '– dark slight bleeding, sometimes absent, or shock not always consistent with the external', 'blood loss as bleeding is internal.', '– sudden, severe, continuous abdominal pain.', '– tightly contracted uterus; often, foetal heart sounds absent (foetal death).', '– often occurs in a context of pre-eclampsia.', 'management', 'refer to surgical facility.', 'uterine rupture', 'tear in the uterine wall, in most cases during labour, often related to inappropriate use of', 'oxytocin.', 'clinical features', '– impending rupture: prolonged labour, agitation, alteration of the general state, poor uterine', 'relaxation, continuous abdominal pain, more severe than the contractions.', '– rupture: disappearance of uterine contractions, shock; sometimes, palpation of the dead', 'foetus expelled into the maternal abdomen.', 'management', 'refer to surgical facility for emergency laparotomy.', 'premature labour', 'clinical features', 'cervical changes (effacement and dilatation) and regular uterine contractions before 37 weeks', 'lmp. metrorrhagia are not always present in premature labour. if present, blood loss is usually', 'minimal.', 'management', '– strict bed rest.', '– allow labour to progress in the following cases: gestation is more than 37 weeks; the cervix is', 'more than 3-4 cm dilated; there is significant bleeding; the foetus is distressed or dead; there', 'is amnionitis or pre-eclampsia.', '– otherwise, tocolysis:', 'as first-line treatment, nifedipine po (short-acting capsule): 10 mg by oral route, to be', 'repeated every 15 minutes if uterine contractions persist (maximum 4 doses or 40 mg), then', '20 mg every 6 hours for 48 hours.', 'do not administer by sublingual route (risk of placental hypoperfusion, fœtal deatht), always', 'by oral route.', 'or, if not available,', 'salbutamol iv infusion for 48 hours maximum: dilute 5 mg (10 ampoules of 0.5 mg) in 500 ml of', '5% glucose or 0.9% sodium chloride to obtain a solution of 10 micrograms/ml.', 'start infusion at the rate of 15 to 20 micrograms/minute (30 to 40 drops/minute).', 'genito-urinary diseases', '269', '9', 'if contractions persist, increase the rate by 10 to 20 drops/minute every 30 minutes until', 'uterine contractions cease. do not exceed 45 micrograms/minute (90 drops/minute). ', 'continue for one hour after contractions have ceased, then reduce the rate by half every', '6 hours.', 'monitor maternal pulse regularly, decrease the infusion rate in the event of maternal', 'tachycardia (> 120/minute).', 'do not combine nifedipine and salbutamol.', 'either tocolysis is effective and contractions cease or diminish: in both cases, do not prolong', 'treatment over 48 hours. bed rest until the end of pregnancy.', 'or tocolysis is not effective, contractions persist and labour begins: take necessary steps for a', 'premature birth.', 'post-partum haemorrhage', 'haemorrhage, exceeding the usual 500 ml of a normal placental delivery that occurs in the first', '24 hours (usually immediately) following the delivery of the child. post- partum haemorrhage is', 'mainly due to placental retention and uterine atonia, but may also result from uterine rupture', 'or cervical or vaginal lacerations.', 'management', \"– if systolic bp is < 90 mmhg, elevate the legs (keep or replace the patient's feet in the delivery\", 'table stirrups).', '– sunder general anaesthesia and antibiotic prophylaxis (ampicillin or cefazolin iv, 2 g as a', 'single dose): manual removal of the placenta (if not yet delivered) and systematic manual', 'exploration of the uterus to remove any clots/placental debris and to make sure the uterus', 'has not ruptured.', '– oxytocin: 5 to 10 iu by slow iv injection, and at the same time, start an iv infusion with 20 iu', 'of oxytocin in 1 litre of ringer lactate or 0.9% sodium chloride, to be administered over', '2 hours (160 drops/minute).', '– check for injury to the cervix or vagina using retractors (or speculum).', '– massage of the uterus to expel any clots and aid uterine retraction.', '– insert a urinary catheter to facilitate uterine retraction.', '– continue monitoring (pulse, bp, blood loss). bleeding should diminish and the uterus should', 'remain firm.', 'for more information on the management of pregnancy-related bleeding, refer to the msf', 'handbook, essential obstetric and newborn care.', 'chapter 9', '270', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'chapter 10: ', 'medical and minor surgical', 'procedures', 'dressings', 'treatment of a simple wound', 'burns', 'abscesses', 'pyomyositis', 'leg ulcers', 'necrotising infections of the skin and soft tissues', 'venomous bites and stings', 'dental infections', '10', 'dressings', '– the objective of dressing wounds is to promote healing. the procedure includes cleaning,', 'disinfection and protection of the wound while respecting the rules of hygiene.', '– not all wounds need to be covered by a dressing (e.g. a clean wound that has been sutured', 'for several days; a small dry wound not requiring sutures).', 'material', '– sterile instruments', '• one kocher or pean forceps', '• one dissecting forceps', '• one pair of surgical scissors or one scalpel to excise necrotic tissue and to cut gauze or', 'sutures', 'instruments for one dressing for one patient must be wrapped together in paper or fabric (or', 'can be placed in a metallic box) and sterilised together to limit handling and breaks in', 'asepsis. 5 to 10 compresses may be included in this set.', 'if there are no sterile instruments, a dressing can be done using sterile gloves.', '– renewable supplies', '• sterile compresses', '• non-sterile disposable gloves', '• adhesive tape and/or crepe or gauze bandage', '• sterile 0.9% sodium chloride or sterile water', '• depending on the wound: antiseptic (polyvidone iodine scrub solution, polyvidone iodine', 'dermal solution), paraffin compresses, analgesics', 'organisation of care', 'proper organization of care helps maintain the rules of asepsis and decreases the risk of', 'contamination of the wound or transmission of organisms from one patient to another:', '– assign one room for dressings. it must be cleaned and the waste removed every day. the', 'dressing table must be disinfected after each patient.', '– dressings may be applied at the bedside if the patient’s condition requires. use a clean,', 'disinfected dressing trolley with: on the upper tray, sterile and/or clean material (dressing', 'set, extra compresses, etc.) and on the lower tray, septic material (container for', 'contaminated instruments, sharps disposal container and a container or garbage bag for', 'waste).', '– prepare all the necessary material in a well lit area. if necessary, arrange for an assistant to', 'be present.', '– wear protective glasses if there is a risk of projection from an oozing wound.', '– always proceed from clean to dirty: start with patients with uninfected wounds. if there are', 'multiple dressings for one patient, start with the cleanest wound.', 'medical and minor surgical procedures', '273', '10', 'technique', '– if the procedure may be painful, give an analgesic and wait the necessary time for the drug', 'to take effect before starting the procedure.', '– settle the patient comfortably in an area where his privacy is respected throughout the', 'procedure.', '– explain the procedure to the patient and obtain his co-operation.', '– instruments (or sterile gloves) must be changed between patients.', '– to prevent drug interactions, use the same antiseptic for all care of one patient.', 'removal of an old dressing', '– wash hands (ordinary soap) or disinfect them with an alcohol-based hand rub.', '– put on non-sterile gloves and remove the adhesive tape, bandage and superficial', 'compresses.', '– proceed gently with the last compresses. if they stick to the wound, loosen them with 0.9%', 'sodium chloride or sterile water before removal.', '– observe the soiled compresses. if there is significant discharge, a greenish colour or a foul', 'odour, a wound infection is likely.', '– discard the dressing and the non-sterile gloves in the waste container.', 'observe the wound', '– in the case of an open wound, loss of cutaneous tissue or ulcer, the colour is an indicator of', 'the stage in the healing process:', '• black area = necrosis, wet or dry infected eschar', '• yellow or greenish area = infected tissue and presence of pus', '• red area = granulation, usually a sign of healing (unless there is hypertrophy), however,', 'red edges indicate inflammation or infection', '• pink area = process of epithelisation, the final stage of healing that begins at the edges of', 'the wound', '– in the case of a sutured wound, the existence of local signs of suppuration and pain requires', 'the removal of one or more sutures to avoid the infection spreading. local signs include:', '• red, indurated and painful edges', '• drainage of pus between the sutures, either spontaneously or when pressure is applied on', 'either side of the wound', '• lymphangitis', '• sub-cutaneous crepitations around the wound', 'in any case, if local signs of infection are observed, look for general signs of infection (fever,', 'chills, changes in the overall condition).', 'technique for cleaning and dressing of the wound', '– wash hands again or disinfect them with an alcohol-based hand rub.', '– open the dressing set or box after checking the date of sterilisation and that the wrapping is', 'intact.', '– pick up one of the sterile forceps being careful not to touch anything else.', 'chapter 10', '274', '– pick up the second forceps with the help of the first one.', '– make a swab by folding a compress in 4 using the forceps.', '– clean sutured wound or clean open wound with red granulation:', '• clean with 0.9% sodium chloride or sterile water to remove any organic residue; work', 'from the cleanest to the dirtiest area (use a clean swab for each stroke);', '• dab dry with a sterile compress;', '• re-cover a sutured wound with sterile compresses or an open wound with paraffin', 'compresses; the dressing should extend a few cm beyond the edges of the wound;', '• keep the dressing in place with adhesive tape or a bandage.', '– necrotic or infected open wounds:', '• clean with polyvidone iodine (7.5% scrub solution, 1 part of solution + 4 parts of sterile', '0.9% sodium chloride or sterile water). rinse thoroughly then dab dry with a sterile', 'compress; or if not available, sterile 0.9% sodium chloride or sterile water and apply an', 'antiseptic (10% polyvidone iodine dermal solution).', '• apply sterile vaseline and remove all necrotic tissue at each dressing change until the', 'wound is clean.', '– discard any sharp materials used in an appropriate sharps container and the rest of the', 'waste in a waste container.', '– as quickly as possible, soak the instruments in disinfectant.', '– wash hands again or disinfect them with an alcohol-based hand rub.', 'the principles remain the same if the dressing is done using instruments or sterile gloves.', 'subsequent dressings', '– clean, sutured wound: remove the initial dressing after 5 days if the wound remains painless', 'and odourless, and if the dressing remains clean. the decision to re-cover or to leave the', 'wound uncovered (if it is dry) often depends on the context and local practices.', '– infected, sutured wound: remove one or more sutures and evacuate the pus. change the', 'dressing at least once daily.', '– open, dirty wound: daily cleaning and dressing change.', '– open granulating wound: change the dressing every 2 to 3 days, except if the granulation is', 'hypertrophic (in this case, apply local corticosteroids).', 'medical and minor surgical procedures', '275', '10', 'treatment of a simple wound', '– a simple wound is a break in the continuity of the skin limited in depth at the sub- cutaneous', 'fatty tissue, that does not affect the underlying structures (muscle, bone, joints, major', 'arteries, nerves, tendons) and without significant loss of tissue.', '– the goal of treatment is to assure rapid healing of the wound without complications or', 'sequelae. several basic rules apply:', '• rapidly treat wounds, while maintaining the rules of asepsis and the order of the initial', 'procedures: cleaning-exploration-excision;', '• identify wounds that need to be sutured and those for which suturing would be harmful or', 'dangerous;', '• immediately suture recent, clean, simple wounds (less than 6 hours old) and delay', 'suturing contaminated wounds and/or those more than 6 hours old;', '• prevent local (abscess) or general (gas gangrene; tetanus) infections.', 'material', 'instruments (figures 1a to 1d)', '– one dissecting forceps, one needle-holder, one pair of surgical scissors and one pean or', 'kocher forceps are usually enough.', '– one or two other artery forceps, a pair of farabeuf retractors and a scalpel may be useful for', 'a contused or deep wound.', 'instruments to suture one wound for one patient must be packaged and sterilised together', '(suture box or set) to limit handling and breaks in asepsis.', 'renewable supplies', '– for local anaesthesia: sterile syringe and needle; 1% lidocaine (without epinephrine)', '– sterile gloves, fenestrated sterile towel', '– sterile absorbable and non-absorbable sutures', '– antiseptic and supplies for dressings', '– for drainage: corrugated rubber drain or equivalent, nylon suture', 'technique', '– settle the patient comfortably in an area with good lighting and ensure all the necessary', 'material is prepared.', '– explain the procedure to the patient and ensure his co-operation.', '– if the patient is a young child, arrange to have an assistant hold the child if necessary.', 'chapter 10', '276', 'initial cleaning', '– wear suitable clothing: sterile gloves for all wounds and a gown and protective glasses if', 'there is a risk of projection from a bleeding wound.', '– start by washing the wound, prolong the cleaning if the wound is particularly soiled. use', 'ordinary soap or polyvidone iodine scrub solution and water and rinse.', '– if necessary use a sterile brush. cleaning with running water is preferable to cleaning by', 'immersion.', '– if the wound is infected and the patient has general signs of infection (fever, chills, changes', 'in the overall condition) systemic antibiotic therapy may be required. administer antibiotics', 'at least one hour prior to starting care.', 'exploration', '– wash hands and put on sterile gloves.', '– disinfect the wound and surrounding area with 10% polyvidone iodine.', '– cover the wound with a fenestrated sterile towel.', '– local anaesthetic: infiltrate 1% lidocaine into the edges of the wound and wait at least', '2 minutes for the anaesthetic to take effect.', '– proceed carefully from the superficial to the deepest parts of the wound to explore the', 'extent of the wound, if necessary, aided by an assistant.', '– consider the anatomical location of the wound and look for injury to any underlying', 'structures (the clinical examination of a limb must include evaluation of sensitivity and', 'motor functioning, as well as that of tendons in order to orient surgical exploration):', '• a wound that communicates with a fracture is an open fracture,', '• a wound close to a joint may be a joint wound,', '• a wound on the hands or feet may affect the nerves and/or tendons.', '– look for and remove any foreign bodies.', '– in the event of significant pain or bleeding, the exploration must be completed in an', 'operating room.', 'wound excision', '– the goal of the excision is to remove non-viable tissue, which favours the proliferation of', 'bacteria and infection.', '– the wound may require little or no excision if it is clean. the excision is more extensive if the', 'wound is bruised, irregular or extensive.', '– limit excision of the skin around the wound, particularly in facial wounds.', '– sub-cutaneous fat and tissue of doubtful viability should be generously excised in order to', 'leave only well vascularised tissue.', 'medical and minor surgical procedures', '277', '10', 'immediate suturing of a simple wound', '– immediate suturing may have serious consequences for the patient if precautions to prevent', 'infection and promote healing are not taken.', '– the decision to suture immediately can only be taken after the cleaning, exploration and', 'satisfactory excision, and if the following conditions are met: simple wound, no more than', '6 hours old with no devitalised or contused tissue (the wound may be as long as 24 hours old', 'if on the face, scalp, upper limbs or hands).', '– bites (for local treatment see rabies, chapter 8) and bullet, shell or mine shrapnel wounds', 'should not be immediately sutured.', 'delayed suturing of a simple wound', '– wounds that do not fill the above conditions should not be immediately sutured.', '– after cleaning, exploration and excision a simple dressing is applied to the open wound.', '– further cleaning and removal of any remaining necrotic tissue is completed with daily', 'dressing changes.', '– if after 72 hours there are no signs of local infection, the wound may be sutured.', 'healing by second intention of infected wounds', 'if the wound does not meet the conditions of cleanliness described above, the wound cannot', 'be sutured. it will heal either spontaneously (healing by secondary intention), or will require a', 'skin graft (once the wound is clean) if there is significant loss of tissue.', 'chapter 10', '278', 'figure 1a figure 1b', 'kocher forceps, kelly forceps,', 'straight, toothed curved, non-toothed', 'figure 1c figure 1d', 'small artery forceps, farabeuf retractors', 'curved, non-toothed', 'figures 1', 'basic instruments', 'medical and minor surgical procedures', '279', '10', 'figure 2a', 'always mount a surgical blade using a needle holder.', 'change the blade for each new procedure.', 'figure 2b', 'dissecting forceps should not be held in the palm of the hand, but rather between', 'the thumb and index finger. toothed dissecting forceps should only be used on skin.', 'figure 2c', 'insert the thumb and the ring finger into the handle of a needle holder (or scissors),', 'and stabilize the instrument using the index finger.', 'figures 2 ', 'how to hold instruments', 'chapter 10', '280', 'figure 3a', 'debridement of a contused, ragged wound: straightening of the wound edges with a scalpel.', 'be conservative in facial wounds.', 'figure 3b', 'excision of edges of the aponeurosis to prevent necrosis.', 'figure 3c', 'excision of contused muscle.', 'figures 3', 'wound debridement', 'this should be done sparingly, limited to excision of severely contused', 'or lacerated tissue that is clearly becoming necrotic.', 'medical and minor surgical procedures', '281', '10', 'figure 4a', 'loop the suture around the needle holder in one direction and remember the direction', 'of the loop. grasp the loose end with the needle holder and pull it through the loop', 'to make the first knot. lower the knot so that it closes the wound.', 'figure 4b', 'the second loop should be in the opposite direction.', 'at least 3 knots are needed to make a suture, alternating from one direction to the other.', 'figure 4c figure 4d', 'in principle the first knot lies flat. second knot in the opposite direction.', 'figures 4', 'practising making knots using forceps', 'chapter 10', '282', 'figure 4e figure 4f', 'grasp the loose end with the needle holder.', 'figure 4g', 'first flat knot.', 'slide the knot towards the wound using the hand holding the loose end while holding', 'the other end with the needle holder. tighten the knot without causing tissue ischaemia.', 'figure 4h figure 4i', 'second knot in the opposite direction.', 'figures 4', 'practising making knots using forceps (continued)', 'medical and minor surgical procedures', '283', '10', 'figure 5a figure 5b', 'the suture should be as deep as it is wide.', 'figure 5c figure 5d', 'the suture is too shallow, the edges are invaginated.', 'figure 5e figure 5f', 'poor lining of the edges. do not make the knot directly over the wound.', 'figures 5 ', 'particular problems', 'chapter 10', '284', 'figure 6', 'closing a corner', 'figure 7', 'closure of the skin, simple interrupted sutures with non-absorbable sutures', 'medical and minor surgical procedures', '285', '10', 'burns', 'burns are cutaneous lesions caused by exposure to heat, electricity, chemicals or radiation.', 'they cause significant pain and may threaten survival and/or compromise function.', 'classification of burns', 'severe burns: one or more of the following parameters:', '– involving more than 10% of the body surface area (bsa) in children and 15% in adults', '– inhalation injury (smoke, hot air, particles, toxic gas, etc.)', '– major concomitant trauma (fracture, head injury, etc.)', '– location: face, hands, neck, genitalia/perineum, joints (risk of functional deficit)', '– electrical and chemical burns or burns due to explosions', '– age < 3 years or > 60 years or significant co-morbidities (e.g. epilepsy, malnutrition)', 'minor burns: involving less than 10% of the bsa in children and 15% in adults, in the absence of', 'other risk factors', 'evaluation of burns', 'extent of burns', 'lund-browder table – percentage of body surface area according to age', 'location < 1 year 1-4 years 5-9 years 10-15 years adults', 'head 19 17 13 10 7', 'neck 2 2 2 2 2', 'anterior trunk 13 13 13 13 13', 'posterior trunk 13 13 13 13 13', 'right buttock 2.5 2.5 2.5 2.5 2.5', 'left buttock 2.5 2.5 2.5 2.5 2.5', 'perineum/genitalia 1 1 1 1 1', 'right upper arm 4 4 4 4 4', 'left upper arm 4 4 4 4 4', 'right lower arm 3 3 3 3 3', 'left lower arm 3 3 3 3 3', 'right hand 2.5 2.5 2.5 2.5 2.5', 'left hand 2.5 2.5 2.5 2.5 2.5', 'right thigh 5.5 6.5 8.5 8.5 9.5', 'left thigh 5.5 6.5 8.5 8.5 9.5', 'right leg 5 5 5.5 6 7', 'left leg 5 5 5.5 6 7', 'right foot 3.5 3.5 3.5 3.5 3.5', 'left foot 3.5 3.5 3.5 3.5 3.5', 'chapter 10', '286', 'this table helps to accurately calculate the % of bsa involved according to patient’s age:', 'e.g. burn of the face, anterior trunk, inner surface of the lower arm and circumferential burn of', 'left upper arm in a child 2 years of age: 8.5 + 13 + 1.5 + 4 = 27% bsa.', 'depth of burns', 'apart from first-degree burns (painful erythema of the skin and absence of blisters) and very', 'deep burns (third-degree burns, carbonization), it is not possible, upon initial examination, to', 'determine the depth of burns. differentiation is possible after d8-d10.', 'evaluation for the presence of inhalation injury', 'dyspnoea with chest wall indrawing, bronchospasm, soot in the nares or mouth, productive', 'cough, carbonaceous sputum, hoarseness, etc.', 'treatment of severe burns', '(in hospital)', 'i. initial management', 'on admission', '– ensure airway is patent; high-flow oxygen, even when sao2 is normal.', '– establish intravenous access, through unburned skin if possible (intraosseous access if', 'venous access is not possible).', '– ringer lactate (rl): 20 ml/kg during the first hour, even if the patient is stable.', '– morphine sc: 0.2 mg/kg (step 1 and step 2 analgesics are not effective).', '– in the event of chemical burns: flush with copious amounts of water for 15 to 30 min,', 'avoiding contamination of healthy skin; do not attempt to neutralize the chemical agent.', 'once the patient is stabilized', '– remove clothes if they are not adherent to the burn.', '– take history of the burn injury: mechanism, causative agent, time, etc.', 'superficial burn on d8-d10 deep burn on d8-d10', 'sensation normal or pain insensitive or diminished sensation', 'colour pink, blanches with pressure white, red, brown or black', 'does not blanch with pressure', 'texture smooth and supple firm and leathery', 'appearance minimal fibrinous exudate', 'granulation tissue evident', 'bleeds when incised', 'covered with fibrinous exudate', 'little or no bleeding when incised', 'healing heals spontaneously', 'within 5-15 days', '• very deep burn: always requires', 'surgery (no spontaneous healing)', '• intermediate burn: may heal sponta-', 'neously in 3 to 5 weeks; high risk of', 'infection and permanent sequelae', 'medical and minor surgical procedures', '287', '10', '– assess the burn injury: extent, depth, carbonization; ocular burns, burns at risk of secondary', 'functional deficits; circumferential burns of the extremities, chest or neck. wear face mask', 'and sterile gloves during the examination.', '– assess for associated injuries (fractures, etc.).', '– protect the patient and keep him warm: clean/sterile sheet, survival blanket.', '– insert a urinary catheter if burns involve > 15% of bsa, and in the case of electrical burns or', 'burns of the perineum/genitalia.', '– insert a nasogastric tube if burns involve > 20% of bsa (in the operating room while carrying', 'out dressing procedure).', '– calculate and initiate fluid and electrolyte requirements for the first 24 hours.', '– intensive monitoring: level of consciousness, pulse, blood pressure, pulse oxymetry,', 'respiratory rate (rr) hourly; temperature and urine output every 4 hours.', '– additional testing: haemoglobin, blood group, urine dipstick test.', '– prepare the patient for the first dressing procedure in the operating room.', 'notes:', '– burns do not bleed in the initial stage: check for haemorrhage if haemoglobin level is normal', 'or low.', '– burns alone do not alter the level of consciousness. in the case if altered consciousness,', 'consider head injury, intoxication, postictal state in epileptic patients.', '– clinical manifestations of electrical burns vary significantly according to the type of current.', 'look for complications (arrhythmia, rhabdomyolysis, neurological disorders).', 'ii. general measures during the first 48 hours', 'resuscitative measures', 'intravenous replacement fluid to correct hypovolaemia:', 'fluid and electrolyte requirements during the first 48 hours according to age', '* maintenance fluid: alternate rl and 5% glucose: 4 ml/kg/h for first 10 kg of body weight + 2 ml/kg/h for next', '10 kg + 1 ml/kg/h for each additional kg (over 20 kg, up to 30 kg)', 'note: increase replacement volumes by 50% (3 ml/kg x % bsa for the first 8 hours) in the event', 'of inhalation injury or electrical burn. for burns > 50% bsa, limit the calculation to 50% bsa.', 'this formula provides a guide only and should be adjusted according to systolic arterial', 'pressure (sap) and urine output. avoid fluid overload. reduce replacement fluid volumes if', 'urine output exceeds the upper limit.', 'children < 12 years children ≥ 12 years and adults', '0 - 8 h 2 ml/kg x % bsa of rl', '+ maintenance fluid* per hour x 8 h', '2 ml/kg x % bsa of rl', '8 - 24 h 2 ml/kg x % bsa of rl', '+ maintenance fluid* per hour x 16 h', '2 ml/kg x % bsa of rl', '24 - 48 h daily maintenance iv fluid requirements*', 'minus oral fluids such as milk, broth,', 'gavage feeds (do not include drinking', 'water in the calculation).', '40 ml/kg rl minus oral fluids (do not', 'include drinking water in the calculation).', 'chapter 10', '288', 'target endpoints for iv replacement fluids', 'in patients with oliguria despite adequate fluid replacement:', 'dopamine iv: 5 to 15 µg/kg/min by iv pump', 'or', 'epinephrine iv: 0.1 to 0.5 µg/kg/min by iv pump', 'stop the infusion after 48 hours, if fluid requirements can be met by the oral route or gavage.', 'respiratory care', '– in all cases: continuous inhalation of humidified oxygen, chest physiotherapy.', '– emergency surgical intervention if necessary: tracheotomy, chest escharotomy.', '– do not administer corticosteroids (no effect on oedema; predisposition to infection). no', 'specific treatment for direct bronchopulmonary lesions.', 'analgesia', 'see pain management.', 'nutrition', 'start feeding early, beginning at h8:', '– daily needs in adults', '• calories: 25 kcal/kg + 40 kcal/% scb', '• proteins: 1.5 to 2 g/kg', \"– high energy foods (nrg5, plumpy'nut, f100 milk) are necessary if the bsa is > 20% (normal\", 'food is inadequate).', '– nutritional requirements are administered according to the following distribution:', 'carbohydrates 50%, lipids 30%, proteins 20%.', '– provide 5-10 times the recommended daily intake of vitamins and trace elements.', '– enteral feeds are preferred: oral route or nasogastric tube (necessary if bsa > 20%).', '– start with small quantities on d1, then increase progressively to reach recommended energy', 'requirements within 3 days.', '– assess nutritional status regularly (weigh twice weekly).', '– reduce energy loss: occlusive dressings, warm environment (28-33°c), early grafting;', 'management of pain, insomnia and depression.', 'patients at risk of rhabdomyolysis (deep and extensive burns, electrical burns, crush injuries to', 'the extremities)', 'monitor for myoglobinuria: dark urine and urine dipstick tests. if present, induce alkaline', 'diuresis for 48 hours (20 ml of 8.4% sodium bicarbonate per litre of rl) to obtain an output of', '1 to 2 ml/kg/h. do not administer dopamine or furosemide.', 'non-electrical burns electrical burns', 'children < 1 year children 1-12 years children > 12 years/adults all ages', 'ap (mmhg) sap ≥ 60 sap 70 to 90 + (2 x age) sap ≥ 100 age appropriatesap', 'urine', 'output 1 to 2 ml/kg/h 1 to 1.5 ml/kg/h 0.5 to 1 ml/kg/h 1 to 2 ml/kg/h', 'medical and minor surgical procedures', '289', '10', 'control of infection', 'precautions against infection are of paramount importance until healing is complete. infection', 'is one of the most frequent and serious complications of burns:', '– follow hygiene precautions (e.g. sterile gloves when handling patients).', '– rigorous wound management (dressing changes, early excision).', '– separate “new” patients (< 7 days from burn) from convalescent patients (≥ 7 days from burn).', '– do not administer antibiotherapy in the absence of systemic infection. ', 'infection is defined by the presence of at least 2 of 4 following signs: temperature > 38.5°c', 'or < 36°c, tachycardia, tachypnoea, elevation of white blood cell count by more than 100%', '(or substantial decrease in the number of white blood cells).', '– in the event of systemic infection, start empiric antibiotic treatment:', 'cefazolin iv', 'children > 1 month: 75 mg/kg/day in 3 divided doses', 'adults : 6 g/day in 3 divided doses', '+ ciprofloxacin po', 'children > 1 month: 30 mg/kg/day in 2 divided doses', 'adults: 1.5 g/day in 3 divided doses', '– local infection, in the absence of signs of systemic infection, requires topical treatment with', 'silver sulfadiazine.', 'other treatments', '– omeprazole iv from d1', 'children: 1 mg/kg once daily', 'adults: 40 mg once daily', '– tetanus immunization/prophylaxis (see tetanus, chapter 7).', '– thromboprophylaxis: nadroparin sc beginning 48 to 72 hours post-injury. high risk dosing', 'protocol if the bsa is > 50% and/or in the event of high-voltage electrical injury; moderate', 'risk dosing protocol if the bsa is 20 to 50% and/or in the event of burns of the lower limbs.', '– physiotherapy from d1 (prevention of contractures), analgesia is necessary.', '– intentional burns (suicide attempt, aggression): appropriate psychological follow-up.', 'iii. local treatment', 'regular dressing changesa prevent infection, decrease heat and fluid losses, reduce energy', 'loss, and promote patient comfort. dressings should be occlusive, assist in relieving pain,', 'permit mobilisation, and prevent contractures.', '– basic principles', '• rigorous adherence to the principles of asepsis.', '• dressing changes require morphine administration in the non-anaesthetised patient.', '• the first dressing procedure is performed in the operating room under general anaesthesia,', 'the following in an operating room under general anaesthesia or at the bedside with', 'morphine.', '– technique', '• at the time of the first dressing procedure, shave any hairy areas (armpit, groin, pubis) if', 'burns involve the adjacent tissues; scalp (anteriorly in the case of facial burns, entirely in', 'the case of cranial burns). cut nails.', '• clean the burn with polyvidone iodine scrub solution (1 volume of 7.5% pvi + 4 volumes of', '0.9% sodium chloride or sterile water). scrub gently with compresses, taking care to avoid', 'bleeding.', 'a open technique « naked burn patient under a mosquito net » and water immersion therapy are obsolete and', 'should no longer be used.', 'chapter 10', '290', '• remove blisters with forceps and scissors.', '• rinse with 0.9% sodium chloride or sterile water.', '• dry the skin by blotting with sterile compresses.', '• apply silver sulfadiazine directly by hand (wear sterile gloves) in a uniform layer of 3-5 mm', 'to all burned areas (except eyelids and lips).', '• apply a greasy dressing (jelonet® or petrolatum gauze) using a to-and-fro motion (do not', 'use circular dressings).', '• cover with a sterile compresses, unfolded into a single layer. never encircle a limb with a', 'single compress.', '• wrap with a crepe bandage, loosely applied.', '• elevate extremities to prevent oedema; immobilise in extension.', '– frequency: routinely every 48 hours; daily in the event of superinfection or in certain areas', '(e.g. perineum).', '– monitoring', '• distal ischaemia of the burned limb is the main complication during the first 48 hours.', 'assess for signs of ischaemia: cyanosis or pallor of the extremity, dysaesthesia, hyperalgia,', 'impaired capillary refill.', '• monitor daily: pain, bleeding, progression of healing and infection.', 'iv. surgical care', '– emergency surgical interventions', '• escharotomy: in the case of circumferential burns of arms, legs or fingers, in order to avoid', 'ischaemia, and circumferential burns of chest or neck that compromise respiratory', 'movements.', '• tracheotomy: in the event of airway obstruction due to oedema (e.g. deep cervicofacial', 'burns). tracheotomy can be performed through a burned area.', '• tarsorrhaphy: in the event of ocular or deep eyelid burns.', '• surgery for associated injuries (fractures, visceral lesions, etc.).', '– burn surgery', '• excision-grafting of deep burns, in the operating room, under general anaesthesia,', 'between d5 and d6: excision of necrotic tissue (eschar) with simultaneous grafting with', 'autografts of thin skin. this intervention entails significant bleeding risk, do not involve', 'more than 15% of bsa in the same surgery.', '• if early excision-grafting is not feasible, default to the process of sloughing- granulation-re-', 'epithelisation. sloughing occurs spontaneously due to the action of sulfadiazine/', 'petrolatum gauze dressings and, if necessary, by mechanical surgical debridement of', 'necrotic tissue. this is followed by granulation, which may require surgical reduction in the', 'case of hypertrophy. the risk of infection is high and the process is prolonged (> 1 month).', 'v. pain management', 'all burns require analgesic treatment. pain intensity is not always predictable and regular', 'assessment is paramount: use a simple verbal scale (svs) in children > 5 years and adults and', 'nfcs or flacc scales in children < 5 years (see pain, chapter 1).', 'morphine is the treatment of choice for moderate to severe pain. development of tolerance is', 'common in burn patients and requires dose augmentation. adjuvant treatment may', 'complement analgesic medication (e.g. massage therapy, psychotherapy).', 'medical and minor surgical procedures', '291', '10', 'continuous pain (experienced at rest)', '– moderate pain:', 'paracetamol po: 60 mg/kg/day in 4 divided doses', '+ tramadol po: 4 to 8 mg/kg/day in 4 divided doses', '– moderate to severe pain:', 'paracetamol po: 60 mg/kg/day in 4 divided doses', '+ slow release morphine po: 1 to 2 mg/kg/day in 2 divided doses at 12 hour-interval. in', 'patients with severe burns, oral drugs are poorly absorbed in the digestive tract during the', 'first 48 hours. morphine must be administered by sc route: 0.2 mg/kg every 4 hours.', 'acute pain experienced during care', 'analgesics are given in addition to those given for continuous pain.', '– significant medical interventions and extensive burns: general anaesthesia in an operating', 'room.', '– limited non-surgical interventions (dressings, painful physiotherapy):', '• mild to moderate pain, 60 to 90 minutes before giving care:', 'codeine po or tramadol po (see pain, page 31, chapter 1) rarely allows treatment to be', 'completed comfortably. in the event of treatment failure, use morphine.', '• moderate or severe pain, 60 to 90 minutes before giving care:', 'immediate release morphine po: initial dose of 0.5 to 1 mg/kg. the effective dose is usually', 'around 1 mg/kg, but there is no maximum dose.', 'or morphine sc: initial dose of 0.2 to 0.5 mg/kg. the effective dose is usually around', '0.5 mg/kg, but there is no maximum dose.', 'note: doses given are for adults.', 'for paracetamol, dosing is the same in children.', 'for tramadol and codeine, dosing is the same in children > 6 months.', 'for morphine, dosing is the same in children > 1 year, should be halved in children less than', '1 year, and quartered in infants less than 3 months.', '– pain management using morphine during dressing changes at the bedside requires:', '• a trained nursing team.', '• availability of immediate release oral morphine and naloxone.', '• close monitoring: level of consciousness, rr, pulse, sao2, every 15 min for the first hour', 'following dressing change, then routine monitoring.', '• assessment of pain intensity and sedation during the intervention and for 1 hour', 'thereafter.', '• necessary equipment for ventilation by mask and manual suction.', '• gentle handling of the patient at all times.', '– adjustment of morphine doses for subsequent dressings:', '• if pain intensity (svs) is 0 or 1: continue with the same dose.', '• if svs score ≥ 2: increase the dose by 25 to 50%. if pain control remains inadequate, the', 'dressing change should be carried out in the operating room under anaesthesia.', '– take advantage of the residual analgesia following dressing changes to carry out', 'physiotherapy.', '– as a last resort (morphine unavailable and no facilities to give general anaesthesia), in a safe', 'setting (trained staff, resuscitation equipment, recovery room), adding ketamine im at', 'analgesic doses (0.5 to 1 mg/kg) reinforces the analgesic effect of the paracetamol', '+ tramadol combination given before a dressing change.', 'chapter 10', '292', 'updated: april 2017', 'chronic pain (during the rehabilitation period)', '– the treatment is guided by self-evaluation of pain intensity, and utilises paracetamol and/or', 'tramadol. patients may develop neuropathic pain (see pain, page 34, chapter 1).', '– all other associated pain (physiotherapy, mobilization) should be treated as acute pain.', 'minor burns', '(outpatient treatment)', '– wound care: dressings with silver sulfadiazine or petrolatum gauze (except for first- degree', 'superficial burns).', '– pain: paracetamol ± tramadol usually suffices.', 'medical and minor surgical procedures', '293', '10', 'abscesses', 'an abscess is a collection of pus in the soft tissues most commonly due to staphylococcus', 'aureus.', 'during the suppurative stage, a ‘ripe’ abscess is red, inflamed, painful, shiny and swollen. it is', 'usually fluctuant on palpation and may be fistulated. at this stage, the abscess cavity is', 'inaccessible to antibiotics and surgical drainage is the only effective treatment.', 'during the early indurated stage, that precedes the suppurative stage medical treatment may', 'be effective.', 'treatment', 'indurated stage', '– antibiotic therapy:', 'amoxicillin po', 'children: 80 mg/kg/day in 3 divided doses', 'adults: 3000 mg/day in 3 divided doses', '+ metronidazole po', 'children: 30 to 50 mg/kg/day in 3 divided doses', 'adults: 1500 mg/day in 3 divided doses', 'or', 'amoxicillin/clavulanic acid (co-amoxiclav) po, only if formulations in a ratio 8:1 or 7:1 are', 'available. the dose is expressed in amoxicillin:', 'children < 40 kg: 80 mg/kg/day in 2 to 3 divided doses', 'children ≥ 40 kg and adults: 2500 to 3000 mg/day in 3 divided doses depending on', 'formulation available:', '• ratio 8:1 : 3000 mg/day = 2 tablets of 500/62.5 mg, 3 times/day', '• ratio 7:1 : 2625 mg/day = 1 tablet of 875/125 mg, 3 times/day', '– adapt analgesics to the pain level (see pain, chapter 1).', '– apply compresses soaked with warm water 2 to 3 times/day.', 'if there is improvement after 48 hours: continue antibiotic treatment for 5 days to complete', '7 days of treatment.', 'if there is no improvement after 48 hours of correct treatment: treat surgically.', 'suppurative stage', 'surgical drainage', 'material', '– sterile scalpel handle and blade', '– sterile curved, non-toothed artery forceps (kelly type)', '– sterile gloves', '– antiseptic', '– 5 or 10 ml syringe', '– non-absorbable sutures', '– sterile corrugated drain', 'chapter 10', '294', 'anaesthesia', 'with the exception of paronychia, local anaesthesia of the abscess is usually impossible.', 'general anaesthesia may be indicated, using:', 'ketamine im: 10 mg/kg', 'technique', 'incision (figure 8a)', '– hold the scalpel between the thumb and middle finger of the dominant hand, the index', 'finger presses on the handle. hold the abscess between the thumb and index finger of the', 'other hand. the scalpel blade should be perpendicular to the skin.', '– the incision is made in a single stroke along the long axis of the abscess. the incision must be', 'long enough for a finger to be inserted.', '– be cautious when excising an abscess located over a blood vessel (carotid, axillary, humeral,', 'femoral, popliteal).', 'figure 8a', 'incision with a scalpel', 'digital exploration (figure 8b)', '– explore the cavity with the index finger, breaking down all loculi (a single cavity should', 'remain), evacuate the pus and explore to the edges of the cavity.', '– the exploration also allows an assessment of the extent of the abscess, the depth, and', 'location with respect to underlying structures (arterial pulsation) or any possible contact', 'with underlying bone. in this last case, seek surgical advice.', 'figure 8b', 'exploration of the cavity, breaking down any loculi', 'washing', 'abundant washing of the cavity using a syringe filled with antiseptic solution.', 'medical and minor surgical procedures', '295', '10', 'drainage (figure 8c)', 'insert a drain (or, failing that a gauze wick) into the base of the cavity. if possible, fix it to the', 'edge of the incision with a single suture. the drain is withdrawn progressively and then, after 3', 'to 5 days removed completely.', 'figure 8c', 'drain fixed to the skin', 'special sites ', 'breast abscesses', '(figures 9a to 9d)', '– breast abscesses are usually superficial, but deep ones, when they occur, are more difficult', 'to diagnose and drain.', 'indurated stage: medical treatment', '– antibiotic treatment (see above)', '– apply a constrictive bandage, stop breast-feeding from the infected breast; express milk', 'using a breast pump to avoid engorgement.', 'suppurative stage: surgical drainage', '– incision:', '• radial for superficial abscesses,', '• peri-areolar for abscesses near the nipple,', '• submammary for deep abscesses.', '– gentle exploration with a finger.', '– wash abundantly with a syringe filled with an antiseptic solution.', '– insert a corrugated drain.', 'figure 9a figure 9b', 'locations of breast abscesses incisions: radial, peri-areolar, submammary', 'chapter 10', '296', 'figure 9c figure 9d', 'submammary incision gentle exploration with a finger, ', 'breaking down any loculi', 'parotid abscess', 'there is a risk of severing the facial nerve when incising a parotid abscess. the incision should', 'be horizontal along the lower margin of the abscess.', 'figure 10', 'incision of a parotid abscess', 'medical and minor surgical procedures', '297', '10', 'pyomyositis', '– pyomyositis is an infection of the muscle, almost always due to staphylococcus aureus. it', 'most commonly affects the muscles of the limbs and torso. these infections may occur', 'simultaneously in multiple sites.', '– during the early indurated stage, while the muscle is swollen, hot and painful, medical', 'treatment may be effective. during the suppurative stage, when the abscess has formed,', 'surgical drainage is the only effective treatment.', 'treatment', 'indurated stage', '– immobilise the limb.', '– antibiotic therapy as for other abscesses (see abscesses).', '– adapt analgesics to the pain level (see pain, chapter 1).', '– apply compresses soaked in 70% alcohol, 2 times/day (maximum of 3 times/day to prevent', 'burns to the skin).', 'suppurative stage', 'treatment of pyomyositis is by incision following the rules for incision of abscesses (see page 295).', 'muscle abscesses are often deeper than other abscesses. as a result, needle aspiration with a large', 'bore needle may be necessary to locate the abscess; it yields thick pus. needle aspiration is', 'insufficient treatment even if pus is evacuated.', 'material and anaesthesia', 'as for abscesses.', 'technique', '– generous incision along the axis of the limb, over the site of the abscess and avoiding', 'underlying neurovascular stuctures; incise the skin, subcutaneous tissues and muscular', 'fascia with a scalpel (figure 11a).', '– dissect the muscle fibres with non-toothed forceps (kelly type) or round tipped scissors.', 'insert the instrument into the muscle until the purulent cavity is reached. during insertion,', 'keep the instrument closed and perpendicular to the muscle fibres. withdraw gently with the', 'scissors or forceps slightly open, keeping instrument perpendicular to the fibres (figure 11b).', '– use a forefinger to explore the cavity, break down any loculi and evacuate the pus (figure 11c).', '– wash abundantly with antiseptic solution.', '– insert a large drain.', '– fix the drain to the edge of the wound using a single suture. remove the drain on about the', '5th day (figure 11d).', 'chapter 10', '298', 'figure 11a figure 11b', 'long incision dissection of the muscle using', 'kelly forceps, insert closed then withdraw', 'with the instrument slightly open', 'figure 11c figure 11d', 'exploration and evacuation of pus drain fixed to the skin', 'with the finger', 'figures 11', 'surgical drainage of a pyomyositis', 'special site', 'myositis of the psoas muscle: if the abscess is on the right side, the clinical signs are the same', 'as for appendicitis with pain in the right iliac area. transfer the patient to a surgical centre.', 'medical and minor surgical procedures', '299', '10', 'leg ulcers', '– leg ulcers are chronic losses of cutaneous tissue. they are common in tropical regions,', 'resulting from varied aetiologies:', '• vascular: venous and/or arterial insufficiency,', '• bacterial: leprosy, buruli ulcer (mycobacterium ulcerans), phagedenic ulcer, yaws, syphilis,', '• parasitic: dracunculiasis (guinea-worm disease), leishmaniasis,', '• metabolic: diabetes,', '• traumatic: trauma is often a precipitating factor combined with another underlying cause/', '– the history of the disease and a complete clinical examination (paying particular attention to', 'the neurological examination to determine if there is a peripheral neuropathy caused by', 'leprosy or diabetes) usually leads to an aetiological diagnosis.', '– all ulcers may become complicated with either local or regional secondary infections', '(abscess, lymphadenopathy, adenitis, osteomyelitis, erysipela, pyodermitis), generalised', 'infection (septicaemia), tetanus and after many years of evolution, skin cancer.', 'daily local treatment', '– bathe the leg for 10 to 15 minutes in nadcc or chloramine and rinse in boiled water.', '– remove any necrotic (black) and fibrinous (yellowish) tissue using compresses or excise the', 'tissue with a scalpel.', '– apply:', '• to a clean ulcer, with little discharge: 10% polyvidone iodine and vaseline;', '• to a dirty ulcer, with little discharge: silver sulfadiazine;', '• to an oozing ulcer: 10% polyvidone iodine alone;', '• o multiple or extensive ulcers with no discharge: silver sulfadiazine (monitor for systemic', 'adverse effects);', '• to multiple or extensive oozing ulcers: diluted polyvidone iodine (1/4 of 10% polyvidone', '+ 3/4 of 0.9% nacl or clean water) for one minute then rinse with 0.9% nacl or clean', 'water to reduce the risk of transcutaneous iodine absorption.', '– cover with a dry sterile dressing.', 'systemic treatment', '– treatment with analgesics in the event of pain: adapt the level and dosage to the individual', '(see pain, chapter 1).', '– give systemic antibiotics in case of:', '• secondary infection (see bacterial skin infections, chapter 4).', 'chapter 10', '300', '• phagedenic ulcer (in the early stages, antibiotics may be useful. they are often ineffective', 'in the chronic stages):', 'doxycycline po (except in children under 8 years and pregnant or lactating women) ', 'children over 8 years: 4 mg/kg once daily', 'adults: 200 mg once daily', 'or', 'metronidazole po', 'children: 30 mg/kg/day in 3 divided doses', 'adults: 1.5 g/day in 3 divided doses', 'if after 7 days, antibiotherapy is effective, change to oral treatment by using phenoxy -', 'methylpenicillin po in the same dosages (or continue the treatment with doxycycline or', 'metronidazole as above).treatment duration varies according to the clinical evolution.', '– treat the cause.', '– complementary therapy:', '• elevate the legs in cases of venous and/or lymphatic insufficiency.', '• give tetanus prophylaxis if appropriate (see tetanus, chapter 7).', '• skin graft if the ulcer is extensive, clean, red and flat. skin grafts are often necessary after', 'surgical excision to heal phagedenic and buruli ulcers.', 'medical and minor surgical procedures', '301', '10', 'updated: october 2016', 'necrotising infections of the skin and soft', 'tissues', '– these infections are characterized by the invasion of the soft tissues: skin, subcutaneous', 'tissue, superficial or deep fascia, muscles. they include necrotizing cellulitis, necrotizing', 'fasciitis, myonecrosis, gas gangrene, etc.', '– the clinical presentation depends on the causative organism and the stage of progression.', 'group a streptococcus is frequently isolated as are staphylococcus aureus, enterobacteriaceae', 'and anaerobic bacteria including clostridium spp.', '– the delay in treatment of a minor wound and certain types of wounds such as gunshot', 'wounds or stabbings, open fractures or non-sterile intramuscular injections/circumcisions,', 'favour the development of a necrotizing infection. the risk factors for a necrotizing infection', 'are immunosuppression, diabetes, malnutrition and advanced age in adults and malnutrition,', 'varicella and omphalitis in children.', '– a necrotizing infection is a surgical emergency and has a poor prognosis.', 'clinical features', '– early in the infection, it may be difficult to differentiate necrotizing infections from non-', 'necrotizing infections. initial signs and symptoms of erythema, swelling and pain can', 'resemble cellulitis. location depends on the portal of entry.', '– lesions progress rapidly despite antibiotic therapy, with the development of the typical signs', 'of a necrotizing infection: pain disproportionate to appearance and tense oedema outside', 'the area of erythema, followed by haemorrhagic blisters and necrosis (cold bluish or blackish', 'hypoaesthetic macules).', '– signs of late infection: crepitus on palpation and fetid odour (gas gangrene).', '– necrotizing infections are associated with signs of a severe systemic infection: altered', 'mental status, hypotension and shock.', 'laboratory', '– if available, the following tests can help identify an early necrotizing infection: white blood', 'cell count > 15 000/mm³ or < 4000/mm³; serum creatinine > 141 μmol/l; serum glucose', '> 10 mmol/l (180 mg/dl) or < 3.3 mmol/l (60 mg/dl).', '– obtain specimens for bacterial culture in the operating room and blood cultures if possible.', 'treatment', 'prompt surgical management accompanied by iv antibiotic therapy may at times reduce the', 'high mortality. in case of septic shock, stabilize the patient prior to surgical transfer.', '– emergency surgical treatment:', '•  debridement, drainage, wide excision of necrotic tissue and rapid amputation if necessary.', '•  surgical re-evaluation within 24 to 36 hours to check for eventual progression of the', 'necrosis and need for further debridement.', 'chapter 10', '302', 'medical and minor surgical procedures', '303', '10', '– triple antibiotic therapy for at least 10 to 14 days or more depending on clinical response:', 'amoxicillin/clavulanic acid (co-amoxiclav) slow iv injection (3 minutes) or iv infusion (30 minutes)a', 'children less than 3 months: 100 mg/kg/day in 2 divided doses', 'children ≥ 3 months and < 40 kg: 150 mg/kg/day in 3 divided doses (max. 6 g/day)', 'children ≥ 40 kg and adults: 6 g/day in 3 divided doses', 'or', 'ceftriaxone slow iv (3 minutes) or iv infusion (30 minutes)b', 'children 1 month and over: 100 mg/kg once daily', 'adults: 2 g once daily', '+', 'clindamycin iv infusion (30 minutes)c', 'neonates 0 to 7 days (< 2 kg): 10 mg/kg/day in 2 divided doses', 'neonates 0 to 7 days (≥ 2 kg): 15 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (< 2 kg): 15 mg/kg/day in 3 divided doses', 'neonates 8 days to < 1 month (≥ 2 kg): 30 mg/kg/day in 3 divided doses', 'children 1 month and over: 40 mg/kg/day in 3 divided doses (max. 2700 mg/day)', 'adults: 2700 mg/day in 3 divided doses', '+ ', 'gentamicin slow iv injection (3 minutes) or iv infusion (30 minutes)c', 'neonates 0 to 7 days (< 2 kg): 3 mg/kg once daily', 'neonates 0 to 7 days (≥ 2 kg): 5 mg/kg once daily', 'neonates 8 days to < 1 month: 5 mg/kg once daily', 'children 1 month and over and adults: 6 mg/kg once daily', 'stop gentamicin after 48 hours if on surgical second look there is no evidence of progression of', 'necrosis or if cultures do not grow pseudomonas aeruginosa.', '– other treatments:', '•  deep vein thrombosis prophylaxis;', '•  appropriate management of pain (see pain, chapter 1);', '•  early nutritional support.', 'a dilute each dose of amoxicillin/clavulanic acid in 5 ml/kg of 0.9% sodium chloride in children less than 20 kg and', 'in a bag of 100 ml of 0.9% sodium chloride in children over 20 kg and in adults. do not dilute in glucose.', 'b for administration by iv route, ceftriaxone powder should to be reconstituted in water for injection only. for', 'administration by iv infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose', 'in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg', 'and in adults.', 'c dilute each dose of clindamycin or gentamicin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less', 'than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'updated: september 2017', 'venomous bites and stings', 'snake bites and envenomation', '– more than 50% of the bites are dry bites, i.e. no envenomation occurred. in the event that', 'venom is injected, the severity of envenomation depends on the species, the amount of', 'venom injected, the location of the bite (bites on the head and neck are the most dangerous)', 'and the weight, general condition and age of the individual (more serious in children).', '– it is rare that the snake involved is identified. however, observation of the clinical signs may', 'orient diagnosis and management. two major syndromes are identified:', '• neurological disorders that evolve towards respiratory muscle paralysis and coma are', 'common manifestations of elapid envenomation (cobra, mamba, etc.);', '• extensive local lesions (intense pain, inflammation with oedema and necrosis) and', 'coagulation abnormalities are common manifestations of viperid or crotalid (rattle snake)', 'envenomation.', 'clinical manifestations and management of bites and envenomations are described in the', 'following page.', '– early diagnosis and monitoring of coagulation abnormalities is based on whole blood clotting', 'tests performed in a dry tube (at the patient’s arrival and then every 4 to 6 hours for the first', 'day).', 'take 2 to 5 ml of whole blood, wait 30 minutes and examine the tube:', '• complete clotting: no coagulation abnormality', '• incomplete clotting or no clotting: coagulation abnormality, susceptibility to bleedinga', 'in the event of coagulation abnormalities, continue to monitor once daily until coagulation', 'returns to normal.', '– aetiological treatment is based on the administration of snake antivenom serum, only if', 'there are clear clinical manifestations of envenomation or coagulation abnormalities are', 'observed.', 'antivenom sera are effective, but rarely available (verify local availability) and difficult to', 'store. antivenom serum should be administered as early as possible: by iv infusion (in 0.9%', 'sodium chloride) if using a poorly purified serum; by slow iv in the event of severe', 'envenomation if the serum is known to be well purified. repeat antivenom serum', 'administration after 4 or 6 hours if the symptoms of envenomation persist.', 'for all patients, be prepared for an anaphylactic reaction, which, despite its potential', 'severity (shock), is usually more easily controlled than coagulation disorders or', 'serious neurological disorders.', '– in asymptomatic patients (bites without signs of envenomation and with normal', 'coagulation), monitoring must continue for at least 12 hours (24 hours preferred).', 'a there can be a considerable delay between the decrease in coagulation factors (less than 30 minutes after the', 'bite) and the first signs of bleeding (other than bleeding at the site of the bite and/or the development of sero-', 'sanguinous blisters), which may appear only 3 days after the bite. conversely, bleeding may resolve prior to', 'normalization of coagulation parameters.', 'chapter 10', '304', 'clinical signs and treatment', 'a tourniquets, incision-suction and cauterisation are ineffective and may be dangerous.', 'b do not use acetylsalicylic acid (aspirin).', '– in case of clinical evidence of infection only: drainage of any abscess; amoxicillin/clavulanic', 'acid (co-amoxiclav) for 7 to 10 days in case of cellulitis.', 'infections are relatively rare, and most often associated with traditional treatment or with', 'nosocomial transmission after unnecessary or premature surgery.', 'time since', 'bite clinical manifestations', 'possible', 'aggressor treatment', 'bite', '0 fang marks', 'pain at the site of bite', '? strict rest, immobilisation of the limb with a', 'splint to slow the diffusion of venoma.', 'wound cleansing.', 'tetanus prophylaxis (tetanus, chapter 7).', 'observe for manifestations of envenomation.', 'a the dispensary level, prepare patient', 'evacuation to a referral centre.', 'envenomation', '10-30 minutes hypotension, myosis,', 'excessive salivation and', 'sweating, dysphagia,', 'dyspnoea', 'local paraesthesia, paresis', 'elapids insert a peripheral iv line.', 'iv antivenom serum as soon as possible.', 'inflammatory syndrome:', 'intense pain, extensive', 'regional oedema', 'viperids', 'crotalids', 'insert a peripheral iv line.', 'iv antivenom serum as soon as possible.', 'analgesicsb.', 'iv or pob anti-inflammatories.', '30 minutes-', '5 hours', 'cobra syndrome: bilateral', 'eyelid drooping, trismus,', 'respiratory muscle paralysis', 'shock', 'elapids intubation and assisted ventilation.', 'see shock, chapter 1.', '30 minutes-', '48 hours', 'haemorrhagic syndome:', 'epistaxis, purpura,', 'haemolysis or disseminated', 'intra-vascular coagulation', 'shock', 'viperids', 'crotalids', 'monitor coagulation (blood clotting test in a', 'dry tube).', 'transfusion of fresh blood in the event of', 'severe anaemia.', 'see shock, chapter 1.', '6 hours', 'or more', 'no signs or changes in', 'coagulation (non-venomous', 'snakes or snake bite', 'without envenomation)', '? reassure the patient.', 'send him home after 12 hours.', 'tissue necrosis remove blisters, clean; daily (non occlusive)', 'dressings.', 'surgical intervention for necrosis,', 'depending on the extent, after the lesions', 'stabilise (minimum 15 days).', 'medical and minor surgical procedures', '305', '10', 'scorpion stings and envenomation', '– in most cases, the sting causes local effects including: pain, oedema, erythema. management', 'includes strict rest, wound cleansing, analgesics po, and tetanus prophylaxis (see tetanus,', 'chapter 7). in patients with significant pain, infiltrate the area around the sting with local', 'anaesthetic (1% lidocaine). observe for 12 hours.', '– general signs appear in the event of severe envenomation: hypertension, excessive', 'salivation and sweating, hyperthermia, vomiting, diarrhoea, muscle pain, respiratory', 'difficulties, seizures; rarely, shock.', '– aetiological treatment:', 'the use of scorpion antivenom sera is controversial (most of them are not very effective;', 'they may be poorly tolerated due to insufficient purification).', 'in practice, in countries where scorpion envenomations are severe (north africa, the middle', 'east, central america and amazonia), check local availability of antivenom sera and follow', 'national recommendations.', 'the criteria for administration are the severity of the envenomation, the age of the patient', '(more severe in children) and the time elapsed since the sting. this should not exceed 2 to', '3 hours. if the time elapsed is more than 2 or 3 hours, the benefit of antivenom serum is', 'poor in comparison with the risk of anaphylaxis (in contrast to envenomation by snakes).', '– symptomatic treatment:', '• in the event of vomiting, diarrhoea or excessive sweating: prevention of dehydration (oral', 'rehydration salts), especially in children.', '• in the event of muscle pain: 10% calcium gluconate slow iv (children: 5 ml/injection,', 'adults: 10 ml/injection, administered over 10 to 20 minutes).', '• in the event of seizures: diazepam may be used with caution; the risk of respiratory', 'depression is increased in envenomated patients (see seizures, chapter 1).', 'spider bites and envenomation', '– treatment is usually limited to wound cleansing, strict rest, analgesics po and tetanus', 'prophylaxis (see tetanus, chapter 7).', '– severe envenomations are rare. there are two main clinical syndromes:', '• neurotoxic syndrome (black widow spider): severe muscle pain, tachycardia, hypertension,', 'nausea, vomiting, headache, excessive sweating. the signs develop for 24 hours and then', 'resolve spontaneously over a few days.', '• necrotic syndrome (recluse spider): local tissue lesions, possible necrosis and ulceration;', 'mild general signs (fever, chills, malaise and vomiting) which usually resolve over a few', 'days. if present, haemolysis may sometimes be life threatening.', 'as well as the general measures listed above, treatment includes administration of', '10% calcium gluconate by slow iv in the event of muscle spasms (children: 5 ml/injection,', 'adults: 10 ml/injection, administered over 10 to 20 minutes).', 'incision and debridement of necrotic tissue are not recommended (not useful; may impair', 'healing).', 'chapter 10', '306', 'hymenoptera stings (honeybees, wasps and hornets)', '– local care: remove the embedded sting (bee), clean with soap and water; if pruriginous,', 'apply calamine lotion.', '– analgesics if necessary (paracetamol po).', '– in the event of an anaphylactic reaction:', 'epinephrine (adrenaline) im', 'use undiluted epinephrine solution (1:1000 = 1 mg/ml) and a 1 ml syringe graduated in', '0.01 ml in children:', 'children under 6 years: 0.15 ml', 'children from 6 to 12 years: 0.3 ml ', 'children over 12 years and adults: 0.5 ml', 'for children, if 1 ml syringe is not available, use a diluted solution, i.e. add 1 mg epinephine', 'to 9 ml of 0.9% sodium chloride to obtain a 0.1 mg/ml solution (1:10 000): ', 'children under 6 years: 1.5 ml', 'children from 6 to 12 years: 3 ml ', 'repeat after 5 minutes if no clinical improvement.', 'use iv epinephrine (for doses, see anaphylactic shock, page 17, chapter 1) in patients with', 'circulatory collapse or those who deteriorate despite receiving im epinephrine.', 'medical and minor surgical procedures', '307', '10', 'dental infections', 'infection arising as a secondary complication of an inflammation of the dental pulp. the', 'severity and the treatment of dental infections depend on their evolution: localised to the', 'infected tooth, extended to adjacent anatomical structures or diffuse infections.', 'clinical features and treatment', 'infection localised to a tooth and its surroundings (acute dental abscess)', '– intense and continuous pain.', '– on examination: swelling limited to the gum surrounding the infected tooth. purulent', 'exudate may be present draining either through the root canal, or through the periodontal', 'ligament (loosening the tooth) or through a gingival fistula. there are no signs of the', 'infection extending to adjacent anatomical structures nor general signs of infection.', '– treatment:', '• treatment is only surgical (the source of infection is inaccessible to antibiotics): root canal', 'therapy (disinfection of the root canal) if possible or extraction of the tooth.', '• pain: paracetamol or ibuprofen po (see pain, chapter 1).', 'infections extending to adjacent anatomical structures (acute dento-alveolar abscess)', 'local spreading of an acute dental abscess into the surrounding bone and tissue.', '– painful gingival and buccal swelling with warm and tender skin, developing into a ripe abscess:', 'intense pain, with trismus, particularly if the infection is in a posterior tooth, presence of', 'general signs (fever, fatigue, cervical lymphadenopathy).', '– in patients with acute gangrenous cellulitis (crepitations on palpation), treat as an infection', 'extending into the cervico-facial tissues (see below).', '– treatment:', '• first surgical: incision and drainage of the pus or extraction of the tooth.', '• then antibiotic treatment for 5 days following the procedure: amoxicillin po', 'children: 50 mg/kg/day in 2 divided doses', 'adults: 2 g/day in 2 divided doses', 'notes:', 'if the dental procedure has to be delayed (local anaesthesia not possible due to', 'inflammation, significant trismus), start with antibiotic treatment, but the dental', 'procedure must be completed in the following days.', 'if there is no improvement within 48 to 72 hours after the dental procedure, do not', 'change antibiotic, but start a new procedure on the tooth.', '• pain: paracetamol or ibuprofen po (see pain, chapter 1).', 'infections extending into the cervico-facial tissues', '– extremely serious cellulitis, with rapidly spreading cervical or facial tissue necrosis and signs', 'of septicaemia.', '– treatment:', '• treatment in an intensive care unit.', '• high dose antibiotic treatment (see necrotising infections of the skin and soft tissues).', '• extraction of the tooth.', 'chapter 10', '308', 'chapter 11: ', 'mental/psychical disorders in adults', 'anxiety', 'insomnia', 'agitation', 'mental confusion', 'post-traumatic stress disorder', 'depression', 'psychotic disorders', 'acute psychotic episode', 'chronic psychoses', 'bipolar disorder', '11', 'anxiety', 'a patient suffering from anxiety has:', '– psychical symptoms: pervasive worries, e.g. fear of having a serious illness, fear with no', 'clearly-defined object or phobias;', '– behavioural changes: nervousness, avoidance behaviour;', '– physical symptoms: e.g., dry mouth, “lump in the throat,” nonspecific complaints (e.g.', 'feeling of malaise, hot flashes or chills, diffuse pain).', 'anxiety is a common feature in depression, post-traumatic stress disorder and psychosis). it', 'can also occur in isolation, not associated with any other mental disorders. anxiety disorders', 'often occur immediately after a difficult life event.', 'management', 'try to determine the source of the anxiety and reassure the patient. if necessary, use simple', 'relaxation techniques to alleviate the symptomsa.', 'if symptoms are exacerbated (e.g., tachycardia, feeling of suffocation, fear of dying or “going', 'crazy,” agitation, or conversely, prostration), it may be necessary to administer diazepam: 5 to', '10 mg po or 10 mg im, to be repeated after one hour if required.', 'severe anxiety may justify a short courseb (one to two weeks max.) of diazepam po: 5 to', '10 mg/day in 2 divided doses; reducing the dose by half in the last few days of treatment.si if', 'symptoms recur after treatment discontinuation, do not resume diazepam.', 'haloperidol po at very low dose and for a short period of time (1 mg/day in 2 divided for', 'maximum 2 to 4 weeks) may be used for its anxiolytic properties if a treatment is still needed.', 'however, before prescribing haloperidol, re-evaluate for possible depression or post-traumatic', 'stress disorder (see post-traumatic stress disorder and depression).', 'for generalised anxiety, an antidepressant with anxiolytic properties is preferred (paroxetine', 'po: 10 to 20 mg maximum once daily at bedtime), to be continued for 2 to 3 months after', 'symptoms resolve then, stop gradually over 2 weeks.', 'for recurring attacks (panic disorder), clomipramine po may be prescribed to prevent', 'recurrences: 25 mg once daily, to be gradually increased to 75 mg once daily. continue for 2 to', '3 months after symptoms resolve then, stop gradually (over 3 to 4 weeks) while monitoring the', 'patient for recurrence of symptoms.', 'a for example, in case of hyperventilation, use a technique that controls the respiratory rate: get the patient in a', 'comfortable position with his eyes closed. help him focus on his breathing so that it becomes calmer and more', 'regular, with three-phase breathing cycles: inhalation (count to three), exhalation (count to three), pause', '(count to three), etc.', 'b treatment should be short as benzodiazepines can cause dependence and tolerance.', 'mental/psychical disorders in adults', '311', '11', 'insomnia', 'complaints may be: difficulty falling or remaining asleep, waking up too early in the morning,', 'nightmares, or daytime fatigue.', 'management', 'if the insomnia is related to an organic cause, treat the cause (e.g., administer analgesics for', 'pain).', 'if the insomnia is related to the use of alcohol, drugs or a medicationa, management depends', 'on the substance responsible.', 'if the insomnia is related to a particular life event (e.g. bereavement), a short term treatment', 'with a sedating antihistamine (adults: promethazine po, 25 mg once daily at bedtime for 8 to 10', 'days) may be useful.', 'if the insomnia persists, re-evaluate the patient. insomnia is a common feature in depression,', 'post-traumatic stress disorder and anxiety disorders. in such cases, the underlying disorder', 'should be addressed.', 'a the main drugs known to cause sleep problems are corticosteroids, beta blockers, levodopa/carbidopa,', 'levothyroxin (if overdosage), phenytoin, fluoxetine and clomipramine.', 'chapter 11', '312', 'updated: september 2017', 'agitation', 'patients with anxiety or psychotic or personality disorders, or mental confusion may have', 'periods of psychomotor agitation.', 'agitation is also common in acute intoxication (alcohol/drugs) and withdrawal syndrome (e.g.', 'delirium tremens or abrupt interruption of antidepressant therapy).', 'it may be accompanied by oppositional behaviour, violence or fleeing.', 'management', 'clinical evaluation is best performed in pairs, in a calm setting, with or without the person’s', 'family/friends, depending on the situation.', 'it may be necessary to administer diazepam 10 mg po to reduce the agitation and conduct the', 'clinical exam.', 'if the patient is violent or dangerous, urgent sedation is required: diazepam im 10 mg, to be', 'repeated after 30 to 60 minutes if necessary.', 'physical restraint may be required in certain circumstances. however, its use should be view as', 'a temporary measure, always in combination with sedation and close medical supervision.', 'determine whether or not the patient is confused; look for an underlying cause, e.g.,', 'neurological, metabolic, etc. (see mental confusion). management depends on the underlying', 'cause.', 'if the agitation is associated with anxiety, see anxiety; if associated with psychotic disorders,', 'see psychotic disorders.', 'alcoholic patients can experience withdrawal symptoms within 6 to 24 hours after they stop', 'drinking. in the early phase (pre-delirium tremens), the manifestations include irritability, a general', 'feeling of malaise, profuse sweating and shaking. withdrawal syndrome should be taken into', 'consideration in patients who are hospitalised and therefore forced to stop drinking abruptly.', 'at a more advanced stage (delirium tremens), agitation is accompanied by fever, mental', 'confusion and visual hallucinations (zoopsia).', 'pre-dt symptoms can be prevented or treated with: diazepam po (40 mg/day in 4 divided', 'doses 6 hours apart for 1 to 3 days, then reduce and stop over 7 days) + oral hydration (3 litres', 'of water/day) + thiamine im (100 mg/day for at least 3 days).', 'in post-operative patients, start with the parenteral route: diazepam slow iv, 5 to 10 mg', '4 times daily (for precautions, see delirium tremens below) + iv hydration (2 to 4 litres 0.9%', 'sodium chloride/24 hours) + thiamine im as above.', 'in case of delirium tremens (dt):', '– admit the patient to an intensive care unit.', '– administer diazepam iv: 10 to 20 mg 4 to 6 times/day, under close supervision with', 'ventilation equipment near at hand. the goal is to achieve mild sedation without provoking', 'respiratory depression. the doses and duration of the treatment are adapted according to', 'the clinical progress.', '– add chlorpromazine im if necessary: 25 to 50 mg 1 to 3 times/day.', '– iv hydration: 2 to 4 litres 0.9% sodium chloride/24 hours.', '– administer thiamine im: 100 mg/day for at least 3 days.', '– monitor vital signs and blood glucose levels.', 'mental/psychical disorders in adults', '313', '11', 'mental confusion', 'the clinical picture includes:', '– disorientation in time and space;', '– impaired consciousness;', '– concentration problems;', '– memory impairment.', 'these symptoms develop rapidly (hours or days), and often fluctuate during the course of the', 'day.', 'agitation, delusions, behavioural disorders and hallucinations (often visual) may complicate the', 'picture.', 'mental confusion almost always has an organic cause:', '– infectious: meningitis, cerebral malaria, encephalitis, septicaemia, syphilis, aids, etc.', '– metabolic: hyper/hypoglycaemia, electrolyte imbalance, niacin or b1 deficiencies, etc.', '– endocrine: thyroid disorders', '– neurological: epilepsy, raised intracranial pressure, head trauma, meningeal haemorrhage,', 'brain tumour, etc.', 'also consider treatment adverse effects (corticosteroids, opioid analgesics, psychotropic drugs,', 'etc.), use of toxic substances (alcohol/drugs), or withdrawal from these substances (see', 'delirium tremens, previous page).', 'management', 'mental confusion requires hospitalisation. treat the underlying cause.', 'chapter 11', '314', 'post-traumatic stress disorder', 'an event is “traumatic” when someone has been directly confronted with death, either by', 'seeing another person being killed or seriously injured as the result of violence, or by', 'experiencing serious harm, such as a threat to his/her life or physical integrity (e.g. rape,', 'torture). these events cause feelings of helplessness and horror.', 'immediate, transitory disorders (prostration, disorientation, fleeing, automatic behaviours,', 'etc.) are to be distinguished from secondary, long-lasting problems that appear several weeks', 'or months after the event: post-traumatic stress, often associated with depression', '(depression), or sometimes acute psychosis (psychotic disorders), even in people with no', 'history of psychotic symptoms.', 'post-traumatic stress disorder (ptsd) is characterised by three types of psychological response,', 'generally seen in combination:', '– persistent re-experiencing', 'the patient describes:', '• images, thoughts or perceptions related to the traumatic experience, which intrude', 'despite efforts to block them out, including at night in the form of distressing dreams;', '• flashbacks during which the patient “relives” parts of the traumatic scene.', '– avoidance', 'the patient tries to avoid:', '• places, situations and people that might be associated with the trauma;', '• having thoughts or feelings related to the trauma; patients may use alcohol, drugs or any', 'psychotropic agents for this purpose.', '– increased arousal', 'constant state of alert, exaggerated startle response, anxiety, insomnia, poor concentration.', 'the patient may develop somatic symptoms such as hypertension, sweating, shaking,', 'tachycardia, headache, etc.).', 're-experiencing is highly distressing and causes disorders that may worsen over time; people', 'isolate themselves, behave differently, stop fulfilling their family/social obligations, and', 'experience diffuse pain and mental exhaustion.', 'management', 'psychological intervention is essential to reduce the suffering, disabling symptoms and social', 'handicaps resulting from ptsd.', 'it is important to reassure the patient that his symptoms are a comprehensible response to a', 'very abnormal event. sessions should be conducted with tact. the patient should be', 'encouraged to talk about his experience. avoid over active explorations of the patient’s', 'emotions: leave it to the patient to decide how far he wants to go.', 'associated symptoms (anxiety or insomnia), if persistent, can be relieved by symptomatic', 'treatment (diazepam) for no more than two weeksa.', 'if the patient has severe symptoms (obsessive thoughts, pronounced arousal, etc.), the', 'pharmacological treatment is paroxetine po (see anxiety).', 'a benzodiazepines can lead to dependence and tolerance. they should be used only for severe conditions and for', 'a limited amount of time.', 'mental/psychical disorders in adults', '315', '11', 'depression', 'depression is characterised by a set of symptoms lasting at least two weeks and causing a', 'change from the patient’s previous functioning.', 'the classic diagnostic criteria for a major depressive episode are:', '– pervasive sadness and/or a lack of interest or pleasure in activities normally found', 'pleasurable', 'and', '– at least four of the following signs:', '• significant loss of appetite or weight', '• insomnia, especially early waking (or, more rarely, hypersomnia)', '• psychomotor agitation or retardation', '• significant fatigue, making it difficult to carry out daily tasks', '• diminished ability to make decisions or concentrate', '• feeling of guilt or worthlessness, loss of self-confidence or self-esteem', '• feeling of despair', '• thoughts of death, suicidal ideation or attempt', 'the features of depression can vary, however, from one culture to anothera. for example, the', 'depressed patient may express multiple somatic complaints rather than psychological distress.', 'depression may also manifest itself as an acute psychotic disorder in a given cultural context.', 'management', 'when faced with symptoms of depression, consider an underlying organic cause (e.g.,', 'hypothyroidism or parkinson’s disease) or adverse effects from medical treatment', '(corticosteroids, cycloserine, efavirenz, levodopa, etc.). look for a triggering event (e.g. rape,', 'recent childbirth and post-partum depression).', 'depressive symptoms are the most common psychical disorders in patients with severe chronic', 'infectious diseases such as hiv infection or tuberculosis. these symptoms should not be', 'neglected, especially as they have a negative impact on adherence to treatment.', 'symptoms of depression are usual right after a major loss (bereavement, exile, etc.). they', 'gradually subside, in most cases, with support from relatives. psychological support may be', 'useful.', 'pharmacological treatment is justified if there is a risk of suicide or in the event of severe or', 'long-lasting problems with significant impact on daily life, or if psychological follow-up alone is', 'not enough.', 'before prescribing, make sure that a 6-month treatment and follow-up (psychological support,', 'adherence and response) is possible.', 'a hence the importance of working with an “informant” (in the anthropological sense of the word) when dealing', 'with unfamiliar cultural contexts.', 'chapter 11', '316', 'preferably use a serotonin reuptake inhibitor (sri), particularly in elderly patients:', 'paroxetine po: 20 mg once daily in the evening', 'or', 'fluoxetine po: 20 mg once daily in the morning; use with caution in patients with severe anxiety', 'disorders or who are immobilised (e.g., wounded).', 'if the depression is accompanied by severe anxiety, use amitriptyline po instead: start with', '25 mg once daily and gradually increase over one week to 75 mg once daily (150 mg/day', 'maximum).', 'be careful with tricyclic antidepressants, as the therapeutic dose is close to the lethal dose. in', 'elderly patients, reduce the dose by half.', 'depression is less frequent in pregnancy than in the postpartum period. in situations where', 'antidepressants are required, use paroxetine rather than fluoxetine if the woman plans to', 'breastfeed. in the event of pregnancy in a woman under antidepressants, re- evaluate the', 'need to continue the treatment. if the treatment is still necessary, refer to the table below.', 'monitor newborns for signs of toxicity or withdrawal symptoms during the first few days of life.', 'antidepressant therapy', 'if sris are unavailable or poorly tolerated, clomipramine po may also be use: start with 25 mg', 'once daily at bedtime, and gradually increase over one week to 75 mg once daily (150 mg/day', 'maximum).', 'there is a delay of 2 to 3 weeks before antidepressant effect occurs. during this period, anxiety', 'may be exacerbated and the risk of suicide increased, especially with fluoxetine and', 'clomipramine. diazepam po (5 to 10 mg/day in 2 divided doses) may be given for the first two', 'weeks of treatment.', 'during the first month, the patient should be followed weekly. during this period, do not give', 'more tablets than the quantity required for each week.', 'all serious depression carries the risk for suicide. talking to patients about this will not increase', 'the risk of suicide attempt. on the contrary – depressed people are often anxious and', 'ambivalent about suicide and feel relieved when able to talk about it.', 'week/month', 'fluoxetine ', '(mg/day)', 'paroxetine', '(mg/day)', 'amitriptyline', '(mg/day)', 'w1 w2 w3 m1 w1 w2 w3 m1 w1 w2 w3 m1', 'adults 20 20 20 40 20 20 20 40 25 50 75 100', '> 60 years idem idem 25 25 50 75', 'increase at m1 (end of the first month) only if still necessary.', 'breastfeeding avoid can be used', 'can be used;', 'monitor the infant (risk of', 'drowsiness).', 'pregnancy can be used', 'can be used;', 'reduce the dose at the', 'end of pregnancy.', 'mental/psychical disorders in adults', '317', '11', 'if major symptoms have not resolved at all after a month at a normally-effective dose, refer the', 'patient to a psychiatrist, if possible; if not, try a different antidepressant2b.', 'the treatment should always be stopped gradually (over a 2-week period for sris, and a', '4-week period for tricyclics). inform the patient about problems associated with abrupt', 'treatment discontinuation (very common with paroxetine).', 'b in case of treatment failure with an sri: if the patient is under paroxetine, reduce the dose over a two-week', 'period to avoid withdrawal symptoms, then wait 2 to 4 days before starting the tricyclic antidepressant. if the', 'patient is under fluoxetine, stop fluoxetine (withdrawal symptoms are unlikely) and wait at least 10 to 14 days', 'before starting the tricyclic antidepressant.', 'chapter 11', '318', 'psychotic disorders', 'psychoses are characterised by delusions. the patient is convinced of things that are not real,', 'based on intuition, interpretation or hallucinations – especially auditory ones. ', 'delusions are often accompanied by behaviour disorders, for example agitation, prostration,', 'mutism, opposition, and fleeing.', 'management includes psychosocial support and antipsychotic medication.', 'treatment efficacy and the prognosis depend in large part on the quality of the relationship', 'established with the patient and his family.', 'keeping the patient at home with outpatient follow-up is preferred if the patient is not a', 'danger to himself or others, and if the family is capable of managing the disorder.', 'the meaning of psychoses varies with the cultural contexta. for example, psychotic disorders', 'may be attributed to charms or to ancestor intervention. therapeutic approach should take', 'those beliefs into account. patient are usually already under “traditional” treatments, this', 'should not be seen as an obstacle to conventional medical treatment.', 'acute psychotic episode', 'an acute psychotic episode can be a one-time occurrence, usually of sudden onset, or can', 'occur repeatedly or may be the early phase of chronic psychosis. it can occur following a life', 'event (e.g., loss, acute stress or trauma). in postpartum psychosis, the delusions centre on the', 'mother-child relationship.', 'before prescribing antipsychotic medication, consider the possibility of an underlying organic', 'cause (see mental confusion) or use of toxic substances.', 'antipsychotic therapy is the same as that for chronic psychoses (risperidone or haloperidol, see', 'following page) and should last at least 3 months. after 3 months, if the patient is stable, stop', 'the treatment gradually over 4 weeks, monitoring for potential relapse.', 'for severe anxiety or agitation, an short-course anxiolytic or sedative treatment (see page 321)', 'may be added to the antipsychotic treatment, at the beginning of treatment.', 'chronic psychoses', 'the chronic psychoses (schizophrenia, paranoid psychosis, etc.) are defined by specific clinical', 'characteristics and their long-term nature.', 'in schizophrenia, delusions are accompanied by dissociation; the patient seems odd, his speech', 'and thoughts are incoherent, his behaviour unpredictable and his emotional expression', 'discordant. such patients are often very anxious. delusions of persecution are common.', 'a hence the importance of working with an “informant” (in the anthropological sense of the word) when dealing', 'with unfamiliar cultural contexts.', 'mental/psychical disorders in adults', '319', '11', 'the goal of the treatment is to reduce psychological suffering and disabling symptoms,', 'particularly on the relational level. it offers real benefits, even if chronic symptoms persist', '(tendency toward social isolation, possible relapses and periods of increased behavioural', 'problems, etc.).', 'the treatment should last at least one year, with a gradual dose reduction. low dose may be', 'maintained for longer periods if necessary.', 'uncertainty about the possibility of follow-up at one year or beyond is no reason not to treat.', 'however, it is better not to start pharmacological treatment for patients who have no', 'family/social support (e.g., homeless), provided they do not have severe behavioural disorders.', 'start treatment at a low dose:', 'risperidone po: 2 mg in 2 divided doses on d1, then 4 mg/day in 2 divided doses as of d2. if', 'insufficient, increase to 6 mg/day (8 mg/day maximum).', 'or', 'haloperidol pob: 5 mg/day in 2 divided doses; if insufficient, 10 mg/day in 2 divided doses. not', 'to exceed 20 mg/day.', 'antipsychotic therapy', 'in elderly patients, reduce the dose by half, whichever medication is used.', 'extrapyramidal effects, which are more common with haloperidol than with risperidone, can', 'be counteracted by adding biperiden po: 2 to 4 mg/day in 2 divided doses.', 'psychoses (first acute episode or decompensation of a chronic psychosis) are much less', 'common during pregnancy than postpartum. in the event of pregnancy in a woman taking', 'antipsychotics, re-evaluate the need to continue the treatment. if treatment is still necessary,', 'refer to the table above. monitor the newborn for extrapyramidal symptoms during the first', 'few days of life.', 'for postpartum psychosis, if the woman is breastfeeding, risperidone should be preferred to', 'haloperidol.', 'b if available haloperidol decanoate im (long-acting form) can be used in the long-term treatment of psychoses in', 'patients stabilised on oral therapy (100 mg every 4 weeks).', 'week/month', 'risperidone', '(mg/day)', 'haloperidol', '(mg/day)', 'd1 w1-w2 w3 m1 w1 w2 w3 m1', 'adults 2 4 4 to 6 4 to 6 5 5 5 to 10 5 to 15', '> 60 years 1 2 2 to 4 2 to 4 2 2 2 to 5 2 to 10', 'increase only if necessary.', 'breastfeeding can be used.', 'avoid;', 'if absolutely necessary, administer less', 'than 5 mg/day.', 'pregnancy monitor the newborn for the first fewdays of life.', 'monitor the newborn for the first few', 'days of life if the mother received high', 'doses during the 3rd trimester.', 'chapter 11', '320', 'for severe anxiety or agitation, the following can be added, for a short period, at the beginning', 'of the antipsychotic treatment:', '– an anxiolytic, if the patient is anxious:', 'diazepam po: 5 to 15 mg/day in 2 or 3 divided doses for a few days', 'only use the injectable form in severe anxiety (diazepam im: 10 mg, to be repeated once', 'after one or two hours, if necessary), then change to diazepam po as above.', '– another, more sedating, antipsychotic if the patient is agitated:', 'chlorpromazine po: 75 to 150 mg/day in 3 divided doses for a few days', '– for very severe agitation, violence or opposition:', 'haloperidol + chlorpromazine im: 25 mg, to be repeated once after one or two hours, if', 'necessary.', 'in such cases, continue with haloperidol po rather than risperidone (and if necessary,', 'continue chlorpromazine po as above for a few days).', 'bipolar disorder', 'bipolar disorder is characterised by alternating manic and depressive episodesc, generally', 'separated by “normal” periods lasting several months or years.', 'manic episodes are characterised by elation, euphoria and hyperactivity accompanied by', 'insomnia, grandiose ideas, and loss of social inhibitions (sexual, in particular). ', 'depressive episodes are often severe, with significant risk of suicide.', 'pharmacologically:', '– manic episodes are treated with risperidone po: start at a low dose of 2 mg once daily;', 'increase if necessary in steps of 1 mg/day (maximum dose 6 mg/day) for 3 to 6 weeks. the', 'medication should be stopped gradually, monitoring for possible relapse.', '– depressive episodes are treated as depression (see depression).', '– the primary treatment for bipolar disorder is a long-term mood stabiliser (lithium or', 'carbamazepine).', 'c “unipolar forms” are characterized by recurring episodes of depression.', 'mental/psychical disorders in adults', '321', '11', 'chapter 12: ', 'other conditions', 'sickle cell disease', 'hypertension', 'heart failure in adults', 'endemic goitre and iodine deficiency', '12', 'sickle cell disease', '– homozygous sickle cell disease (scd) is a life-threatening genetic disorder of haemoglobin', '(hb). the abnormal hb (hbs) results in the distortion of red blood cells into a sickle shape', 'leading to increased destruction (haemolysis), an increase in blood viscosity and obstruction', 'of capillaries (vaso-occlusion).', '– scd is common in sub-saharan africa (1 to 3% of births), on the american continent, in india', 'and in the mediterranean basin.', 'clinical features', '– symptoms generally begin after 6 months of age.', '– major signs: recurrent painful crises, chronic anaemia, splenomegaly and frequently, growth', 'retardation and malnutrition in children.', '– serious acute life threatening complications such as stroke, overwhelming infections and', 'acute chest syndrome.', '– in populations in whom the disease is frequent, diagnosis is suggested by a family history of', 'similar clinical signs.', 'major acute manifestations', 'painful vaso-occlusive crises (voc)', '– children under 2 years present with the hand-foot syndrome or dactylitis (acute pain and', 'swelling in the hands or feet).', '– children older than 2 years and adults present with acute pain affecting the back, chest,', 'abdomen (can resemble an acute abdomen) and extremities.', '– young children may have non-specific signs of a voc: refusal to walk, irritability, lack of', 'appetite, crying, whimpering or moaning when touched, etc.', '– look for an associated infection that might have precipitated the voc.', '– in case of bony pain in a single location, unresponsive to analgesics (or a persistent limp in a', 'child) associated with fever and erythema or swelling, consider an osteomyelitis.', 'fever', 'look for infection: in particular pneumonia, cellulitis, meningitis, osteomyelitis and sepsis (patients', 'are particularly susceptible to infections especially due to pneumococcus, meningococcus and', 'haemophilus influenzae); malaria.', 'acute severe anaemia', '– the chronic anaemia is often complicated by acute severe anaemia with gradually appearing', 'fatigue, pallor of the conjunctivae and palms, shortness of breath, tachycardia, syncope or', 'heart failure.', '– the acute anaemia can be due to:', '• acute severe haemolysis often secondary to malaria: fever, haemoglobinuria (dark urine)', 'and yellow conjunctivae.', '• splenic sequestration (trapping of blood cells in the spleen), mostly in children 1 to 4 years:', 'sudden enlargement of the spleen, severe left upper quadrant pain, thrombocytopenia.', 'can lead to shock.', 'other conditions', '325', '12', '• aplastic crisis (transient suspension of red blood cell production by the bone marrow):', 'impalpable spleen and absence of reticulocytes.', 'stroke', '– most often ischaemic (due to vaso-occlusion in cerebral vessels) but a stroke can also be', 'haemorrhagic.', '– sudden loss of motor function or aphasia, in children and in adults.', '– signs can resemble meningitis and cerebral malaria: headache, photophobia, vomiting, stiff', 'neck, alteration of consciousness and neurologic signs or rarely seizures.', 'acute chest syndrome (acs)', '– chest pain, tachypnoea, respiratory distress, hypoxia; fever (more frequent in children);', 'pulmonary infiltrate on chest x-ray. often proceeded by a voc.', '– complications: multiorgan failure (lung, liver, kidney).', 'priapism', 'painful prolonged erection in the absence of sexual stimulation, also occurring in young boys.', 'risk of necrosis and irreversible erectile dysfunction.', 'laboratory and other examinations', 'diagnosis', '– hb electrophoresis confirms the diagnosis but is often unavailable.', '– if not available, a positive emmel test (or sickling test) in the presence of clinical signs of', 'sickle cell disease supports the diagnosis.', 'other examinations', 'tests indications', 'haemoglobin • at the time of diagnosis and annually (frequently 7 to 9 g/dl).', '• in case of voc, fever, acute anaemia (≤ 5 g/dl or drop in hb ≥ 2 g/dl', 'below the patient’s baseline), stroke, acs.', '• for monitoring of transfused patients.', 'platelets • at the time of diagnosis and annually.', '• in case of acute anaemia (thrombocytopenia - platelet count ≤ 100 000/mm3', 'if splenic sequestration).', 'urine dipstick • look for a urinary tract infection in case of fever.', '• look for haemoglobinuria in case of acute severe anaemia.', 'malaria test in case of voc, fever, acute anaemia or stroke.', 'lumbar', 'puncture', 'in case of fever with meningeal signs or unexplained coma.', 'other', '(if available)', '• complete blood count and reticulocyte count.', '• blood culture in case of fever.', '• x-ray if suspicion of pneumonia, osteomyelitis, acs.', 'chapter 12', '326', 'management of major acute manifestations', 'painful vaso-occlusive crisis (voc)', '– moderate pain (at home):', '• generous oral hydration (water, soup, juice, coconut water): minimum 100 ml/kg/day in', 'children and 50 ml/kg/day in adults (2.5 to 3 litres/day);', '• warm compresses (application of cold is contra-indicated);', '• level 1 (paracetamol and ibuprofen) and level 2 (tramadol) analgesics;', '• if pain is not controlled at home within 24 hours, seek medical attention.', '– severe pain or pain not controlled at home (in hospital):', '• iv hydration (appendix 1b) and po; monitor for fluid overload, discontinue iv fluids', 'progressively after 24 to 48 hours;', '• level 3 analgesics (morphine);', '• do not give routine antibiotics in the absence of fever; do not transfuse for voc.', 'for the treatment of pain according to intensity, see pain (chapter 1).', 'fever and infection', '– admit to hospital:', '• all children less than 2 years;', '• in case of fever ≥ 38.5°c in children and ≥ 39.5°c in adults; patients who are critically ill', 'appearinga or have acute anaemia.', '– po or iv hydration (appendix 1a).', '– treat malaria if present.', '– treat bacterial infections according to cause.', '– treat all patients with respiratory symptoms for pneumonia and acs.', '– in case of osteomyelitis:', 'ceftriaxone slow ivb injection (3 minutes) or iv infusion (30 minutes)', 'children < 40 kg: 100 mg/kg/day in 2 divided doses', 'children ≥ 40 kg and adults: 4 g/day in 2 divided doses', '+ cloxacillin iv infusion (60 minutes)c', 'children < 40 kg: 200 mg/kg/day in 4 divided doses', 'children ≥ 40 kg and adults: 12 g/day in 4 divided doses', 'administer iv therapy for at least 14 days. then if the patient has improved, change to the', 'oral route for an additional 14 days of treatment with a combination of:', 'ciprofloxacin po', 'children < 35 kg: 30 mg/kg/day in 2 divided doses', 'children ≥ 35 kg and adults: 1 g/day in 2 divided doses', '+ amoxicillin/clavulanic acid po (see next page)', '– if the source of infection is unknown:', 'ceftriaxone im or slow ivb injection (3 minutes) or iv infusion (30 minutes)', 'children < 20 kg: 50 mg/kg once daily (max. 2 g/day)', 'children ≥ 20 kg and adults: 1 to 2 g once daily', 'a critically ill appearing child: weak grunting or crying, drowsy and difficult to arouse, does not smile,', 'disconjugate or anxious gaze, pallor or cyanosis, general hypotonia.', 'b for administration by iv route, ceftriaxone powder should to be reconstituted in water for injection only. for', 'administration by iv infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose', 'in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg', 'and in adults.', 'c cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. then dilute each dose of', 'cloxacillin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of 100 ml of', ' 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.', 'other conditions', '327', '12', 'after 48 hours re-evaluate the patient:', '• if the patient is improving (afebrile, can drink), change to:', 'amoxicillin/clavulanic acid (co-amoxiclav) po for 7 to 10 days. the dose is expressed in', 'amoxicillin:', 'children < 40 kg: 80 to 100 mg/kg/day in 2 or 3 divided doses (use formulations in a ratio', 'of 8:1 or 7:1 exclusivelyd)', 'children ≥ 40 kg and adults:', 'ratio 8:1: 3000 mg/day (= 2 tab of 500/62.5 mg 3 times per day)', 'ratio 7:1: 2625 mg/day (= 1 tab of 875/125 mg 3 times per day)', 'patients over 2 years without acute anaemia can continue treatment as outpatients.', 'patients under 2 years or with acute anaemia or who cannot be monitored and treated at', 'home by their family should complete po antibiotic therapy in hospital.', '• if the patient is not improving, continue ceftriaxone until the patient is afebrile, then,', 'change to po treatment. monitor for acute anaemia.', 'acute severe haemolysis (in hospital)', '– treat malaria if present.', '– transfuse packed red blood cellse,f if hb < 5 g/dl or drop of 2 g/dl below the patient’s', 'baseline. target a hb level of 9 g/dl.', '• start with 10 to 15 ml/kg in 3 to 4 hours. for information, 10 ml/kg of packed red blood', 'cells usually raise the hb by 2.5 g/dl.', '• repeat the hb. if a 2nd transfusion is needed, check for signs of fluid overload before', 'starting the transfusion.', '• measure hb and perform urine dipstick in the following days. further transfusions may be', 'necessary if haemolysis is ongoing.', 'aplastic crisis (in hospital)', '– treat an associated bacterial infection if present.', '– transfuse as for haemolysis. repeat the hb every other day. an increasing reticulocyte count', 'and a gradual increase of the hb indicate improvement. follow patient until they have', 'reached their baseline hb.', 'splenic sequestration (in hospital)', '– treat hypovolaemic shock if present.', '– monitor the size of the spleen.', '– transfuse if hb < 5 g/dl, target a hb level of 7 to 8 g/dl maximum.', '– administer ceftriaxone as above.', '– after clinical improvement, monitor for relapse (follow the size of the spleen).', 'note: splenectomy is contra-indicated (high operative mortality).', 'stroke (in hospital)', '– the treatment of choice for ischaemic stroke is an exchange transfusion to lower the', 'concentration of hbs. transfer the patient to a specialized facility for further management', '(including prophylactic therapy to prevent recurrences with transfusion program, hydroxyurea).', '– if the patient is awaiting transfer or if transfer is not possible:', '• oxygen continuously, at least 5 litres/minute or to maintain the o2 saturation (sao2)', 'between 94 and 98%.', '• treat seizures if present.', '• transfuse if the hb ≤ 9 g/dl. target hb of 10 g/dl.', '• after the transfusion provide iv hydration (appendix 1a).', 'd if the only formulation of co-amoxiclav available is 4:1, the dose is 50 mg/kg/day. ', 'e always inquire how many transfusions a patient has previously received (risk of iron overload).', 'f do not transfuse whole blood if possible (risk of fluid overload).', 'chapter 12', '328', 'acute chest syndrome (in hospital)', '– measure sao2 and administer oxygen as in stroke.', '– iv hydration (appendix 1a) while monitoring for fluid overload.', '– antibiotics:', 'ceftriaxone slow ivg injection (3 minutes) or iv infusion (30 minutes) for 7 to 10 days', 'children < 20 kg: 50 mg/kg once daily (max. 2 g/day)', 'children ≥ 20 kg and adults: 1 to 2 g once daily', '+ azithromycin poh for 5 days', 'children: 10 mg/kg once daily (max. 500 mg/day)', 'adults: 500 mg on d1 then 250 mg from d2 to d5', '– transfuse if symptoms are unresponsive to antibiotics and hb < 9 g/dl.', '– if wheezing is present treat with:', 'salbutamol aerosol (100 micrograms/puff)', 'children and adults: 2 to 4 puffs with a spacer every 10 to 30 minutes as needed', '– encourage deep breathing (incentive spirometry hourly).', '– treat pain (see pain, chapter 1).', 'priapism', '– po and iv hydration (appendix 1b), encourage urination, apply warm compresses, treat pain.', '– erection > 4 hours: consider transfusion and refer to surgery.', 'prevention of complications', 'certain complications can be avoided with appropriate health education of patients/families,', 'routine preventive care and regular follow-up.', 'education of patients (including children) and families', 'g for administration by iv route, ceftriaxone powder should to be reconstituted in water for injection only. for', 'administration by iv infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose', 'in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg', 'and in adults.', 'h if azithromycin is not available, erythromycin po for 10 to 14 days: children: 30 to 50 mg/kg/day in 2 or 3 divided', 'doses; adults: 2 to 3 g/day in 2 or 3 divided doses', 'basic knowledge', '• disease chronic, necessarily transmitted by both parents, non-contagious.', '• treatment routine (next page) and symptomatic (pain).', '• monitoring size of the spleen, temperature, baseline hb.', 'major precipitating factors of a painful crisis and how to prevent them', '• cold wear warm clothing, avoid bathing in cold water.', '• excessive heat for example, avoid going out at mid-day.', '• tight clothing wear wide comfortable clothing without elastics.', '• dehydration drink plenty of fluids.', '• excessive effort moderate physical activity is beneficial.', '• infections follow routine treatments (including vaccination).', 'principal complications requiring the patient to seek urgent medical advice', '• pain unresponsive to analgesia after 24 hours or severe from the start.', '• any fever (do not treat at home).', '• respiratory problems (cough, difficulty breathing, chest pain).', '• diarrhoea/vomiting and inability to drink.', '• dehydration (dark, infrequent urine).', '• anaemia (pale or yellow conjunctivae, pale palms, enlarged spleen).', 'other conditions', '329', '12', 'routine preventive care', '– prevention of pneumococcal infections', 'phenoxymethylpenicillin (penicillin v) po until age 15 years (imperatively until 5 years):', 'children < 1 year: 125 mg/day in 2 divided doses', 'children 1 to < 5 years: 250 mg/day in 2 divided doses', 'children 5 to 15 years: 500 mg/day in 2 divided doses', '– immunization', 'ensure that the child’s immunisations are up to date; if not, administer catch up vaccines:', '– to support red blood cell production', 'folic acid poi (life-long treatment)', 'children < 1 year: 2.5 mg once daily', 'children ≥ 1 year and adults: 5 mg once daily', '– malaria chemoprophylaxis (if malaria prevalence ≥ 5%)', 'mefloquine po', 'children 6 months to 5 years and > 5 kg: 5 mg base/kg once weekly', 'do not use to treat malaria.', '– provide nutritional support at hospital discharge.', 'routine follow-up of patients', '– between crises, for information:', '• children under 5 years: every 1 to 3 months;', '• children over 5 years: every 3 to 6 months.', '– after a crisis: as often as necessary, according to the clinical course.', 'i iron is contraindicated in patients who have received multiple transfusions. avoid combined preparations of', 'iron and folic acid.', 'ch', 'ild', 're', 'n', '< ', '5 ', 'ye', 'ar', 's', '• hepatitis b, polio, dtp, measles, h. influenzae type b (3 doses)', '• pneumococcal conjugate vaccine, pcv13, or if unavailable pcv7 (3 to 4 doses)', '• meningococcal conjugate vaccine in endemic areas', '• at 2 years: pneumococcal 23-valent polysaccharide vaccine, at least 8 weeks', 'after the last pcv13 or pcv7', 'ch', 'ild', 're', 'n', '> ', '5 ', 'ye', 'ar', 's • hepatitis b, polio, dt or td according to age, measles, h. influenzae type b (1 dose)', '• pneumococcal conjugate vaccine pcv13 or pcv7 (3 to 4 doses)', '• meningococcal conjugate vaccine in endemic areas', 'chapter 12', '330', 'hypertension', '– adult essential hypertension is defined as a systolic pressure greater than or equal to 160 mmhg', 'and/or a diastolic pressure greater than or equal to 90 mmhg.', 'the elevation must be constant: blood pressure must be measured twice at rest during three', 'consecutive consultations over a period of three months.', 'hypertension is a risk factor for stroke (cerebrovascular accident or cva), heart failure, renal', 'failure and atherosclerosis.', '– hypertension in pregnancy is defined as a systolic pressure greater than or equal to 140 mmhg', 'or a diastolic pressure greater than or equal to 90 mmhg (with the patient seated and at rest).', 'it may be isolated or associated with proteinuria or oedema in the case of pre-eclampsia.', 'hypertension in pregnancy is a risk factor for eclampsia, placental abruption and premature', 'delivery.', 'treatment of adult essential hypertension', '– in patients with medication-induced hypertension (oral contraceptives, hydrocortisone, mao', 'inhibitors, nsaid etc.), stop or change the treatment.', '– otherwise, start with diet and exercise modification: reduce salt intake, lose any excess', 'weight, and increase the level of physical activity.', '– if despite these measures the blood pressure remains consistently above 160/100 mmhg (or', '140/80 mmhg for a diabetic patient or following a cva), an anti-hypertensive medication may', 'be added.', '– start with monotherapy. the optimal dose depends on the patient; reduce by half the initial', 'dose for elderly patients.', '– the three classes of anti-hypertensives used as initial therapya are the thiazide diuretics, the', 'beta-blockers and the angiotensin converting enzyme (ace) inhibitors. for information:', '– the treatment must be taken regularly. abrupt cessation of beta-blocker treatment may', 'cause adverse effects (malaise, angina)b. only prescribe a treatment if it can be followed by a', 'patient under regular surveillance.', 'a the diuretics, beta-blockers, and ace inhibitors have shown their capacity to prevent the complications of', 'hypertension. they are preferred to other anti-hypertensives, notably calcium channel blockers (nifedipine).', 'b furthermore, a sudden stop to treatment with centrally acting anti-hypertensives (e.g. methyldopa, clonidine)', 'may cause a rebound effect.', 'indications initial treatment', 'uncomplicated hypertension thiazide diuretic or beta-blocker', 'patient over 65 years thiazide diuretic', 'diabetic patient thiazide diuretic', 'complicated hypertension:', 'following a cva', 'following a myocardial infarction', 'heart failure', 'renal failure', 'thiazide diuretic', 'beta-blocker', 'ace inhibitor', 'ace inhibitor', 'other conditions', '331', '12', 'the objective is to reduce the blood pressure to below 160/90 mmhg (or 140/90 mmhg for', 'diabetic patients) while producing the fewest possible adverse effects.', 'for uncomplicated hypertension:', '• start with a thiazide diuretic: hydrochlorothiazide po, 25 to 50 mg once daily.', '• if the patient is not improving after 4 weeks, or if treatment is not tolerated: check', 'compliance, and then if there are no contra-indications (asthma, uncontrolled heart', 'failure), change to a beta-blocker: atenolol po, 50 to 100 mg once daily.', '• if the treatment is still of little or no benefit: recheck compliance, and then consider', 'combined therapy (thiazide diuretic + beta-blocker or thiazide diuretic + ace inhibitor).', 'note: if enalaprilc is used as monotherapy (see table of indications), start with 5 mg once daily,', 'then increase the dose every 1 to 2 weeks, according to blood pressure, up to 10 to 40 mg once', 'daily or in 2 divided doses. in elderly patients, patients taking a diuretic or patients with renal', 'impairment: start with 2.5 mg once daily as there is a risk of hypotension and/or acute renal', 'impairment.', 'specific case: treatment of hypertensive crisis', 'an occasional rise in blood pressure usually passes without problems, whereas aggressive', 'treatment, notably with sublingual nifedipine, can have serious consequences (syncope, or', 'myocardial, cerebral, or renal ischaemia).', '– in patients with hypertensive crisis:', '• reassure the patient and place him at rest.', '• if despite these measures the blood pressure remains elevated, the addition of furosemide po', '(20 mg once daily) may, in certain cases, gradually reduce the blood pressure in 24 to', '48 hours and prevent eventual complications.', '– in patients with hypertensive crisis complicated by acute pulmonary oedema:', '• the objective is not to normalise the blood pressure at any price, but to treat the', 'pulmonary oedema (see acute heart failure).', '• start or adjust the baseline treatment once the crisis is resolved.', 'treatment of hta in pregnancy and pre-eclampsia', 'assess regularly: bp, weight, oedema, proteinuria, and uterine height.', 'for isolated hypertension (without proteinuria)', '– rest and observation, normal sodium and caloric intake.', '– antihypertensive treatment if the systolic bp is ≥ 160 mmhg or the diastolic bp is', '≥ 110 mmhg:', 'methyldopa po: 500 to 750 mg/day in 2 to 3 divided doses for 2 days then increase gradually', 'by 250 mg increments every 2 to 3 days, up to the usual dose of 1.5 g/day. do not exceed', '3 g/day.', 'or', 'labetalol po: 200 mg/day in 2 divided doses then increase by 100 to 200 mg increments up to', 'the usual dose of 400 to 800 mg/day. if higher daily doses are required, administer in', '3 divided doses. do not exceed 2.4 g/day.', 'do not stop treatment abruptly, reduce doses gradually.', 'diuretics and angiotensin converting enzyme inhibitors are contra-indicated in the treatment', 'of hypertension in pregnancy.', 'c enalapril (10 to 40 mg once daily or in 2 divided doses) may be replaced by captopril (100 mg/day in 2 divided', 'doses).', 'chapter 12', '332', 'for moderate pre-eclampsia (hypertension + proteinuria)', '– rest and observation, normal sodium and caloric intake.', '– antihypertensive treatment if the systolic bp is ≥ 160 mmhg or the diastolic bp is', '≥ 110 mmhg, as above.', '– after 37 weeks, if there is a true intrauterine growth retardation: delivery, vaginally or by', 'caesarean section depending on the cervical assessment. if there is no clear growth', 'retardation, induce delivery as soon as the cervix is favourable.', 'for severe pre-eclampsia (hypertension + massive proteinuria + major oedema)', '– refer to a surgical centre for urgent delivery within 24 hours, vaginally or by caesarean', 'section depending on the cervical assessment and the foetus condition.', '– while waiting for delivery, observation, normal sodium and caloric intake.', '– antihypertensive treatment if the systolic bp is ≥ 160 mmhg or the diastolic bp is', '≥ 110 mmhg, as above. if the treatment cannot be administered by oral route, use:', 'hydralazine by iv infusion:', 'dilute 100 mg (5 vials of hydralazine, 5 ml) in 500 ml of 0.9% sodium chloride or ringer', 'lactate, to obtain a solution containing 200 micrograms/ml.', 'initial dose: 200 to 300 micrograms/minute; maintenance dose: 50 to 150 micrograms/minute.', 'administer by increasing the rate up to 20 drops/minute (max. 30 drops/minute), check bp', 'every 5 minutes.', 'as soon as hypertension is controlled, decrease progressively the rate (15 drops/ minute,', 'then 10, then 5) until stopping infusion. an abrupt discontinuation may provoke a', 'hypertensive crisis.', 'or hydralazine by slow, diluted iv injection:', 'dilute 20 mg (1 vial hydralazine, 1 ml) in 9 ml of 0.9% sodium chloride to obtain a solution', 'containing 2 mg/ml.', 'administer 5 mg (2.5 ml of the diluted solution) over 2 to 4 minutes. check bp for', '20 minutes. if bp is not controlled after 20 minutes, administer the same dose. continue', 'repeating if necessary, waiting 20 minutes between each injection, without exceeding a', 'cumulative dose of 20 mg.', 'or labetalol (100 mg in 20 ml ampoule, 5 mg/ml) slow iv:', 'one dose of 20 mg (4 ml) over at least one minute. check bp 5 and 10 minutes after', 'injection. if bp is not controlled, administer another dose of 20 mg and check bp. additional', 'doses of 40 mg then 80 mg may be administered every 10 minutes until bp is controlled. do', 'not exceed a cumulative dose of 300 mg.', 'do not exceed recommended doses and administration rate. during administration, monitor', 'maternal bp and pulse, as well as foetal heart rate. an overdose or too rapid administration', 'may provoke an abrupt fall in maternal bp with placental hypoperfusion and foetal death.', 'diastolic bp must never fall below 90 mmhg. in the event of hypotension, use ringer lactate', 'to maintain the diastolic bp ≥ 90 mmhg.', '– to reduce the risk of eclampsia prior to delivery:', 'magnesium sulfate (see seizures, page 23, chapter 1). continue for 24 hours following', 'delivery.', 'other conditions', '333', '12', 'for eclampsia', '– urgent delivery within 12 hours, vaginally or by caesarean section depending on the cervical', 'assessment and the foetus condition.', '– antihypertensive treatment if the systolic bp is ≥ 160 mmhg or the diastolic bp is', '≥ 110 mmhg, as above.', '– magnesium sulfate (see seizures, page 23, chapter 1). continue for 24 hours following', 'delivery or following the last seizure.', '– nursing, hydration, monitor urinary output (insert a urinary catheter); oxygen (4 to', '6 litres/minute).', 'for more information, refer to the msf handbook, essential obstetric and newborn care.', 'chapter 12', '334', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'heart failure in adults', 'heart failure is defined as the inability of the myocardium to provide normal haemodynamic', 'function.', 'left-sided heart failure (often secondary to coronary or valvular heart disease, and/or arterial', 'hypertension) is the most common form.', 'there are two types:', '– chronic heart failure with insidious onset,', '– acute heart failure, which is life threatening, presents either as acute pulmonary oedema or', 'as cardiogenic shock.', 'clinical features', '– left-sided heart failure secondary to left ventricular failure:', '• fatigue and/or progressive dyspnoea, occurs on exertion and then at rest (accentuated by', 'the decubitus position, preventing the patient from lying down);', '• acute pulmonary oedema: acute dyspnoea, laryngeal crackles, cough, frothy sputum,', 'anxiety, pallor, varied degrees of cyanosis, feeble rapid pulse, wet rales in both lung fields,', 'muffled heart sounds, often with cardiac gallop.', '– right-sided heart failure secondary to right ventricular failure:', '• oedema of the lower limbs, jugular venous distention, hepatomegaly, hepatojugular', 'reflux;', '• ascites in advanced stages.', 'rarely isolated, this is often a consequence of left ventricular failure.', '– global heart failure secondary to failure of both ventricles:', '• left and right-sided signs. signs of right ventricular failure are often the most prominent.', 'treatment of acute heart failure (acute pulmonary oedema and', 'cardiogenic shock)', 'first case: blood pressure is maintained', '– place the patient in the semi-reclined position with legs lowered.', '– give high-flow oxygen', '– reduce pulmonary pressure with combination furosemide + morphine + rapidly-acting', 'nitrate derivatives:', 'furosemide iv (onset of action in 5 minutes and peak effect in 30 minutes): ', '40 to 80 mg/injection, to be repeated every 2 hours according to clinical evolution; monitor', 'blood pressure and urine output', '+ morphine: according to severity 3 to 5 mg by slow iv injection or 5 to 10 mg by sc injection', '+ glyceryl trinitrate sublingual: 0.25 to 0.5 mg. monitor blood pressure. repeat after', '30 minutes if necessary, only if the systolic blood pressure remains above 100 mmhg.', '– in certain serious cases, if none of these drugs are available, bleed off 300 to 500 ml of blood', 'over 5 to 10 minutes from the basilic vein (in the elbow fold) and monitor the blood pressure.', 'second case: blood pressure collapsed', 'see cardiogenic shock, page 19, chapter 1.', 'other conditions', '335', '12', 'treatment of chronic heart failure', 'the objective is to improve the prognosis and quality of life.', 'dietary modification', 'reduce salt intake to limit fluid retention, normal fluid intake (except in the case of anasarca:', '750 ml/24 hours).', 'treatment of fluid retention', '– initial therapy: furosemide po', 'during congestive episodes: 40 to 120 mg once daily. when the congestive episode is', 'controlled, reduce the dose to 20 mg once daily.', '– the dose can be increased (up to 240 mg/day). if these doses are still ineffective, adding', 'hydrochlorothiazide po (25 to 50 mg/day for several days) may be considered.', '– in case of treatment failure and in the absence of severe renal impairment, furosemide may', 'be combined with spironolactone po: 25 mg once daily.', '– if present, drainage of pleural effusions by needle aspiration.', 'note: the risks of administering diuretics include: dehydration, hypotension, hypo- or', 'hyperkalaemia, hyponatremia, and renal impairment. clinical monitoring (hydration, blood', 'pressure) and if possible metabolic monitoring (serum electrolytes and creatinine), should be', 'done regularly, especially if giving high doses or in elderly patients.', 'baseline treatment', '– angiotensin converting enzyme (ace) inhibitors are the first line treatment. start with low', 'doses, especially in patients with low blood pressure, renal impairment, hyponatremia, or', 'concurrent diuretic treatment.', 'enalapril po: 2.5 mg once daily for the first week, then double the dose each week until', 'the effective dose is reached, usually around 10 to 20 mg once daily or in 2 divided doses', \"(max. 40 mg/day). increases in the dose are made while monitoring the patient's blood\", 'pressure (the systolic pressure should remain above 90 mmhg) and blood chemistry (there is a', 'risk of hyperkalemiaa and renal impairment).', 'in patients treated with diuretics, reduce the dose of the diuretic if possible while', 'introducing ace inhibitors.', 'if the patient is taking high doses of diuretics, reduce the initial dose of enalapril to half (risk', 'of symptomatic hypotension).', 'do not combine ace inhibitors and spironolactone (risk of severe hyperkalemia).', '– if the patient has stabilised with enalapril, introduce bisoprolol po if possible: start with', '1.25 mg/day and increase according to the table below, as long as the drug is well tolerated', '(monitor cardiac frequency, blood pressure, signs of worsening heart failure).', 'a moderate hyperkalaemia is frequent, but of no concern if it remains below 5.5 meq/l.', 'weeks daily dose', 'week 1 1.25 mg once daily', 'week 2 2.5 mg once daily', 'week 3 3.75 mg once daily', 'week 4 to 8 5 mg once daily', 'week 9 to 12 7.5 mg once daily', 'from week 13 10 mg once daily (max. 10 mg/day)', 'chapter 12', '336', 'updated: january 2017', '– digitalis glycosides are only indicated in patients with proven atrial fibrillation (ecg).', 'if there are no contra-indications (bradycardia, unidentified rhythm disturbances): ', 'digoxin po: 0.5 to 1 mg in 3 or 4 divided doses on the first day, then 0.25 mg once daily', 'the therapeutic dose is close to the toxic dose. do not exceed the indicated dose and give half', 'the dose, or even a quarter (on alternate days) to elderly or malnourished patients and to', 'patients with renal impairment.', '– with global and left-sided heart failure, the nitrate derivatives may be used in case of signs', 'of intolerance to ace inhibitors (chronic cough, renal impairment, severe hypotension).', 'isosorbide dinitrate po: start with 10 to 15 mg/day in 2 or 3 divided doses and increase to the', 'effective dose, usually around 15 to 60 mg/day. very high doses (up to 240 mg/day) may be', 'necessary.', '– whatever the treatment prescribed, monitoring should be regular: checking clinical', 'improvement and treatment tolerance:', '• clinical monitoring consists of evaluating the weight, blood pressure, pulse (rhythm', 'disturbances) and the progress of signs (dyspnoea, oedema, etc.);', '• laboratory monitoring is adapted according to the treatment.', 'treatment of specific aetiologies', 'see hypertension and anaemia (chapter 1).', 'cardiovascular or “wet” beriberi from vitamin b1 deficiency', 'thiamine im or iv', 'children: 25 to 50 mg/day for several days', 'adults: 50 to 100 mg/day for several days', 'then change to oral treatment with thiamine po', 'children and adults: 3 to 5 mg once daily for 4 to 6 weeks', 'acute rheumatic fever', '– primary prophylaxis', 'benzathine benzylpenicillin im', 'children under 30 kg: 600 000 iu as a single dose', 'children 30 kg and over and adults: 1.2 miu as a single dose', '– anti-inflammatory treatment', 'start with acetylsalicylic acid po: 50 to 100 mg/kg/day', 'if the fever or cardiac signs persist, replace with a corticosteroid:', 'prednisolone po', 'children: 1 to 2 mg/kg/day', 'adults: 60 to 120 mg/day', 'continue this treatment for 2 to 3 weeks after normalisation of the erythrocyte sedimentation', 'rate (esr), then decrease the doses progressively (over 2 weeks).', 'to avoid a relapse, resume the acetylsalicylic acid treatment in parallel with the decrease in', 'prednisolone dose. the acetylsalicylic acid treatment is continued for 2 to 3 weeks after the', 'corticosteroids are fully stopped.', '– secondary prophylaxis', 'prophylactic treatment lasts for several years (until 18 years old, even until 25 years in the', 'case of cardiac effects; for life in the case of chronic valvular damage).', 'benzathine benzylpenicillin im', 'children under 30 kg: 600 000 iu, one injection every 4 weeks', 'children 30 kg and over and adults: 1.2 miu, one injection every 4 weeks', 'other conditions', '337', '12', 'updated: january 2017', 'endemic goitre and iodine deficiency', '– goitre is an enlargement of the thyroid gland. endemic goitre occurs in iodine- deficient', 'areas. goitre can also be caused or aggravated by the regular consumption of goitrogens', 'such as manioc, cabbage, turnips, millet etc.', '– goitre is an adaptive process: iodine is essential for the production of thyroid hormones;', 'iodine deficiency impairs thyroid hormone synthesis; to compensate, the thyroid gland', 'increases in volume. thyroid function usually remains normal.', '– as well as the development of goitre, iodine deficiency in pregnant women has serious', 'consequences for the child (foetal and perinatal mortality, physical and mental retardation,', 'cretinism). these risks must be prevented by providing iodine supplementation in iodine-', 'deficient areas.', 'clinical features', '– the who proposes a simplified classification based on the significance of goitre: ', 'group 0: normal thyroid, no palpable or visible goitre', 'group 1: enlarged thyroid, palpable but not visible when the neck is in the normal position', 'group 2: thyroid clearly visible when the neck is in the normal position', '– possible mechanical complications (rare): compression, deviation of the trachea or of the', 'oesophagus.', 'prevention and treatment', 'the objective of prevention is to reduce the consequences of iodine deficiency in neonates and', 'children. supplying iodised salt through national programmes is the recommended method of', 'prevention.', 'for prevention in populations living in iodine deficient areas where iodised salt is not available', 'and for curative treatment of patients with goitre: use iodised oil, according to national', 'protocols. for information (according to the who):', 'population', 'oral iodised oil', 'as a single yearly dose', '(190 mg capsule)', 'children under 1 year 1 capsule', 'children from 1 to < 6 years 2 capsules', 'children from 6 to 15 years 3 capsules', 'pregnant or lactating women or women of childbearing age 2 capsules', 'chapter 12', '338', 'updated: september 2016', 'curative and preventive single-doses are the same. oral treatment is preferred. the target', 'populations are pregnant and breastfeeding women, women of childbearing age and children.', 'in children, goitre disappears after several months. it disappears more slowly (or never) in', 'adults despite restoration of normal thyroid function in 2 weeks. surgery is only indicated for', 'patients with local mechanical dysfunction.', 'other conditions', '339', '12', 'updated: september 2016', 'appendices', '1a. normal daily maintenance iv fluids in children > 1 month', '1b. 1.5 x daily maintenance iv fluids in children > 1 month', '2. assessment and treatment of diarrhoea - the interagency emergency health kit', 'annex 2 (who)', '3. practical advice for writing medical certificates in the event of sexual violence', 'appendices', 'appendix 1a. normal daily maintenance iv fluids ', 'in children > 1 month', 'indications', 'basic hydration needsa for patients unable to drink sufficiently. after 48 hours, it is essential to', 'provide nutrition to the patient orally or by nasogastric tube and to gradually reduce iv fluids.', 'this protocol should not be used for surgical or burns patients, those with renal, cardiac', 'disease or diabetic ketoacidosis.', 'fluid to be administered', 'the fluid of choice in children is ringer lactate-glucose 5% (rl-g5%). use a premixed solution if', 'available. if not, add 50 ml of g50% to 500 ml of rl or 100 ml of g50% to 1000 ml of rl. if rl is', 'not available, use 0.9% sodium chloride instead.', 'for ease of prescription and administration, the daily volumes and rates in drops per minute', 'have been rounded off.', '* in a paediatric infusion set, the number of drops per minute is equal to the number of ml per hour.', 'for example: 15 drops/min = 15 ml/hour', 'a daily needs are calculated according the following formula:', 'children 0-10 kg: 100 ml/kg per day', 'children 11-20 kg: 1000 ml + (50 ml/kg for every kg over 10 kg) per day', 'children > 20 kg: 1500 ml + (20-25 ml/kg for every kg over 20 kg) per day', 'adults: 2 litres per day', 'weight volume/24 hours rate* (paediatric infusion set 1 ml = 60 drops)', '3 to < 4 kg 350 ml/24 h 16 drops/min', '4 to < 5 kg 450 ml/24 h 18 drops/min', '5 to < 6 kg 550 ml/24 h 22 drops/min', '6 to < 7 kg 650 ml/24 h 26 drops/min', '7 to < 8 kg 750 ml/24 h 30 drops/min', '8 to < 9 kg 850 ml/24 h 36 drops/min', '9 to < 11 kg 950 ml/24 h 40 drops/min', '11 to < 14 kg 1100 ml/24 h 46 drops/min', '14 to < 16 kg 1200 ml/24 h 50 drops/min', '16 to < 18 kg 1300 ml/24 h 54 drops/min', '18 to < 20 kg 1400 ml/24 h 58 drops/min', 'weight volume/24 hours', 'rate*', '(paediatric infusion set', '1 ml = 60 drops)', 'rate', '(standard infusion set', '1 ml = 20 drops)', '20 to < 22 kg 1500 ml/24 h 62 drops/min 20 drops/min', '22 to < 26 kg 1600 ml/24 h 66 drops/min 22 drops/min', '26 to < 30 kg 1700 ml/24 h 70 drops/min 24 drops/min', '30 to < 35 kg 1800 ml/24 h 74 drops/min 26 drops/min', '≥ 35 kg 2000 ml/24 h 82 drops/min 28 drops/min', 'appendix 1a', '343', 'appendices', 'appendix 1b. 1.5 x daily maintenance iv fluids ', 'in children > 1 month', 'indications', 'increased hydration (more than maintenance fluids) is indicated in certain exceptional', 'situations such as in sickle cell patients with painful vaso-occlusive crises (unless acute chest', 'syndrome is suspected) and priapism.', 'do not administer these volumes for more than 24 hours; encourage early oral hydration and', 'simultaneously, gradually reduce iv fluids. monitor for signs of fluid overload.', 'fluid to be administered', 'the fluid of choice in children is ringer lactate-glucose 5%. for preparation, see appendix 1a.', 'for ease of prescription and administration, the daily volumes and rates in drops per minute', 'have been rounded off.', '1.5 x maintenance fluids', 'weight volume/24 hours rate (paediatric infusion set 1 ml = 60 drops)', '3 to < 4 kg 550 ml/24 h 22 drops/min', '4 to < 5 kg 650 ml/24 h 26 drops/min', '5 to < 6 kg 850 ml/24 h 34 drops/min', '6 to < 7 kg 950 ml/24 h 40 drops/min', '7 to < 8 kg 1100 ml/24 h 46 drops/min', '8 to < 9 kg 1250 ml/24 h 52 drops/min', '9 to < 11 kg 1450 ml/24 h 60 drops/min', '11 to < 14 kg 1650 ml/24 h 68 drops/min', '14 to < 16 kg 1800 ml/24 h 76 drops/min', '16 to < 18 kg 1950 ml/24 h 82 drops/min', '18 to < 20 kg 2100 ml/24 h 86 drops/min', 'weight volume/24 hours', 'rate', '(paediatric infusion set', '1 ml = 60 drops)', 'rate', '(standard infusion set', '1 ml = 20 drops)', '20 to < 22 kg 2200 ml/24 h 92 drops/min 30 drops/min', '22 to < 26 kg 2400 ml/24 h 100 drops/min 34 drops/min', '26 to < 30 kg 2600 ml/24 h 108 drops/min 36 drops/min', '30 to < 35 kg 2800 ml/24 h – 38 drops/min', '≥ 35 kg 3000 ml/24 h – 42 drops/min', 'appendix 1b', '344', 'appendix 2', '345', 'appendices', 'assessment and treatment of diarrhoea ', 'annex 2: ', 'assessment and treatment of diarrhoea53 ', 'a-2.1 assessment of diarrhoeal patients for dehydration ', 'table 1: assessment of diarrhoea patients for dehydration ', ' a b c ', '1. look at: ', 'conditiona ', 'eyesb ', 'thirst ', 'well, alert ', 'normal ', 'drinks normally, not ', 'thirsty ', 'restless, irritable ', 'sunken ', 'thirsty, drinks eagerly ', 'lethargic or unconscious  ', 'sunken ', 'drinks poorly or not able to ', 'drink ', '2. feel: ', 'skin pinchc ', 'goes back quickly ', 'goes back slowly ', 'goes back very slowly ', '3. decide: the patient has ', 'no signs of ', 'dehydration ', 'if the patient has two or ', 'more signs in b, there is ', 'some dehydration ', 'if the patient has two or ', 'more signs in c, there is ', 'severe dehydration ', '4. treat: use treatment plan a weigh the patient, if ', 'possible, and use ', 'treatment plan b ', 'weigh the patient and use ', 'treatment plan c ', 'urgently ', \"a being lethargic and sleepy are not the same. a lethargic child is not simply asleep: the child's \", 'mental state is dull and the child cannot be fully awakened; the child may appear to be drifting ', 'into unconsciousness. ', 'b in some infants and children the eyes normally appear somewhat sunken. it is helpful to ask ', 'the mother if the child’s eyes are normal or more sunken than usual. ', 'c the skin pinch is less useful in infants or children with marasmus or kwashiorkor or in obese ', 'children. ', '53  department of child and adolescent health and development. the treatment of diarrhoea - a manual for ', 'physicians and other senior health workers. geneva: world health organization; 2005.  ', 'appendix 2', '346', 'the interagency emergency health kit', 'a-2.2  treatment of acute diarrhoea (without blood) ', 'treatment plan a: treat diarrhoea at home ', 'use this plan to teach the mother how to:', ' prevent dehydration at home by giving the child more fluid than usual;', ' prevent malnutrition by continuing to feed the child, and why these actions are', 'important;', ' recognize signs indicating that the child should be taken to a health worker.', 'the four rules of treatment plan a:', 'rule 1: ', 'give the child more fluids than usual, to prevent dehydration ', ' use recommended home fluids. these include: ors solution, salted drinks (e.g. salted', 'rice water or a salted yogurt drink), vegetable or chicken soup with salt.', ' avoid fluids that do not contain salt, such as: plain water, water in which a cereal has', 'been cooked (e.g. unsalted rice water), unsalted soup, yoghurt drinks without salt,', 'green coconut water, weak tea (unsweetened), unsweetened fresh fruit juice. other', 'fluids to avoid are those with stimulant, diuretic or purgative effects, for example:', 'coffee, some medicinal teas or infusions.', ' be aware of fluids that are potentially dangerous and should be avoided during', 'diarrhoea. especially important are drinks sweetened with sugar, which can cause', 'osmotic diarrhoea and hypernatraemia. some examples are: commercial carbonated', 'beverages, commercial fruit juices, sweetened tea.', ' use ors solution for children as described in the box below. (note: if the child is under', '6 months and not yet taking solid food, give ors solution or water.)', 'give as much as the child or adult wants until diarrhoea stops. use the amounts shown', 'below for ors as a guide. describe and show the amount to be given after each stool is', 'passed, using a local measure.', 'age amount of ors to be given ', 'after each loose stool ', 'amount of ors to ', 'provide for use at home ', ' 24 months 50-100 ml 500 ml/day ', '2 - 10 years 100-200 ml 1l/day ', '10 years as much as wanted 2l/day ', 'show the mother how to mix ors and show her how to give ors.', ' give a teaspoonful every 1 2 minutes for a child under 2 years.', ' give frequent sips from a cup for older children.', 'appendix 2', '347', 'appendices', 'assessment and treatment of diarrhoea ', ' if the child vomits, wait 10 minutes. then give the solution more slowly (for example, a', 'spoonful every 2 3 minutes).', ' if diarrhoea continues after the ors packets are used up, tell the mother to give other', 'fluids as described in the first rule above or return for more ors.', 'rule 2:  ', 'give supplemental zinc sulfate 20 mg tab to the child, every day for 10 ', 'to 14 days ', 'zinc sulfate can be given as dispersible tablets. by giving zinc sulfate as soon as diarrhoea', 'starts, the duration and severity of the episode as well as the risk of dehydration will be', 'reduced. by continuing zinc sulfate supplementation for 10 to 14 days, the zinc lost during', 'diarrhoea is fully replaced and the risk of the child having new episodes of diarrhoea in the', 'following 2 to 3 months is reduced.', 'rule 3:  ', 'continue to feed the child, to prevent malnutrition ', ' breastfeeding should always be continued.', ' the infant s usual diet should be continued during diarrhoea and increased afterwards;', ' food should never be withheld and the child s usual food should not be diluted;', ' most children with watery diarrhoea regain their appetite after dehydration is', 'corrected;', ' milk:', ' infants of any age who are breastfed should be allowed to breast feed as often and', 'as long as they want. infants will often breastfeed more than usual, encourage this;', ' infants who are not breastfed, should be given their usual milk feed (formula) at', 'least every three hours, if possible by cup.', ' infants below 6 months of age who take breast milk and other foods should', 'receive increased breastfeeding. as the child recovers and the supply and the', 'supply of breast milk increases, other foods should be decreased.', ' a child who is at least 6 months old or is already taking soft foods should be', 'given cereals, vegetables and other foods, in addition to milk. if the child is over 6', 'months and such foods are not yet being given, they should be started during the', 'diarrhoea episode or soon after it stops.', ' recommended food should be culturally acceptable, readily available. milk should', 'be mixed with a cereal and if possible, 1 2 teaspoonfuls of vegetable oil should be', 'added to each serving of cereal. if available, meat, fish or egg should be given.', ' foods rich in potassium, such as bananas, green coconut water and fresh fruit juice', 'are beneficial;', ' offer the child food every three or four hours (six times a day);', ' after the diarrhoea stops, continue to give the same energy rich food, and', 'give one more meal than usual each day for at least two weeks.', 'appendix 2', '348', 'the interagency emergency health kit', 'rule 4:  ', 'take the child to a health worker if there are signs of dehydration or ', 'other problems ', 'the mother should take her child to a health worker if the child:', ' starts to pass many watery stools', ' vomits repeatedly', ' becomes very thirsty', ' is eating or drinking very poorly', ' develops a fever', ' has blood in the stool; or', ' does not get better in three days', 'treatment plan b: oral rehydration therapy for children with some ', 'dehydration ', 'table 2:  ', 'guidelines for treating children and adults with some dehydration ', 'approximate amount of ors solution to give in the first 4 hours ', 'age* <4 mths 4-11 mths 12-23mths  2-4 years 5-14 years 15 years ', 'weight  < 5 kg 5-7.9 kg 8-10.9 kg 11-15.9 kg 16-29.9 kg 30 kg ', 'quantity 200-400 ml 400-600 ml 600-800 ml 800 ml-1.2 l  1.2-2 l 2.2-4 l ', 'in local ', 'measure ', \"use the patient's age only when you do not know the weight. the approximate amount of \", 'ors required (in ml) can also be calculated by multiplying the patient’s weight in kg by 75.  ', ' if the patient wants more ors than shown, give more. ', ' encourage the mother to continue breastfeeding her child. ', 'note: during the initial stages of therapy, while still dehydrated, adults can consume up to ', '750 ml per hour, if necessary, and children up to 20 ml per kg body weight per hour.', 'how to give ors solution ', ' teach a family member to prepare and give ors solution.', ' use a clean spoon or cup to give ors solution to infants and young children. feeding', 'bottles should not be used.', ' use droppers or syringes to put small amounts of ors solution into mouths of babies.', ' children under 2 years of age, should get a teaspoonful every 1 2 minutes; older', 'children (and adults) may take frequent sips directly from a cup.', ' check from time to time to see if there are problems.', ' if the child vomits, wait 5 10 minutes and then start giving ors again, but more', 'slowly, for example, a spoonful every 2 3 minutes.', 'appendix 2', '349', 'appendices', 'assessment and treatment of diarrhoea ', ' if the child’s eyelids become puffy, stop the ors and give plain water or breast milk.', 'give ors according to plan a when the puffiness is gone.', 'monitoring the progress of oral rehydration therapy ', ' check the child frequently during rehydration.', ' ensure that ors solution is being taken satisfactorily and the signs of dehydration are', 'not worsening.', ' after four hours, reassess the child fully following the guidelines in table 1 and decide', 'what treatment to give.', ' if signs of severe dehydration have appeared, shift to treatment plan c.', ' if signs indicating some dehydration are still present, repeat treatment plan b. at the', 'same time offer food, milk and other fluids as described in treatment plan a, and', 'continue to reassess the child frequently.', ' if there are no signs of dehydration, the child should be considered fully rehydrated.', 'when rehydration is complete:', ' skin pinch is normal;', ' thirst has subsided;', ' urine is passed;', ' child becomes quiet, is no longer irritable and often falls asleep.', ' teach the mother how to treat her child at home with ors solution and food following', 'treatment plan a. give her enough ors packets for 2 days.', ' also teach her the signs that mean she should bring her child back to see a health', 'worker.', 'if oral rehydration therapy must be interrupted ', 'if the mother and child must leave before the rehydration with ors solution is completed:', ' show her how much ors to give to finish the 4 hour treatment at home.', ' give her enough ors packets to complete the four hour treatment and to continue oral', 'rehydration for two more days, as shown in treatment plan b.', ' show her how to prepare ors solution.', ' teach her the four rules in treatment plan a for treating her child at home.', 'when oral rehydration fails ', ' if signs of dehydration persist or reappear, refer the child.', 'giving zinc sulfate ', ' begin to give supplemental zinc sulfate tablets, as in treatment plan a, as soon as the', 'child is able to eat following the initial four hour rehydration period.', 'giving food ', ' except for breast milk, food should not be given during the initial four hour', 'rehydration period.', 'appendix 2', '350', 'the interagency emergency health kit', ' children continued on treatment plan b longer than four hours should be given some', 'food every 3 4 hours as described in treatment plan a.', ' all children older than 6 months should be given some food before being sent home.', 'this helps to emphasize to mothers the importance of continued feeding during', 'diarrhoea.', 'appendix 2', '351', 'appendices', 'assessment and treatment of diarrhoea ', 'treatment plan c: for patients with severe dehydration  ', 'follow the arrows. if the answer is “yes” go across. if “no” go down. ', 'can you give intravenous ', '(iv) fluids immediately? yes ', 'start iv fluids immediately. if the patient can drink, ', 'give ors by mouth while the drip is set up. give ', '100 ml/kg ringer’s lactate solution (or if not ', 'available normal saline), divided as follows: ', 'age first give ', '30 ml/kg in: ', 'then give ', '70 ml/kg in: ', 'infants  ', '(under 12 months) ', '1 hour* ', '5 hours ', 'older 30 minutes* 2 ½ hours ', 'no ', '*  repeat once if radial pulse is still very weak or non-', 'detectable.', ' reassess the patient every 1-2 hours. if ', 'hydration is not improving, give the iv drip ', 'more rapidly. ', ' also give ors (about 5 ml/kg/hour) as soon ', 'as the patient can drink: usually after 2-4 ', 'hours (infants) or 1-2 hours (older patients). ', ' after 6 hours (infants) or 3 hours (older ', 'patients), evaluate the patient using the ', 'assessment chart. then choose the ', 'appropriate plan (a, b or c) to continue ', 'treatment. ', 'is iv treatment available ', 'nearby  ', '(within 30 minutes)? ', 'yes  send the patient immediately for iv ', 'treatment. ', ' if the patient can drink, provide the mother ', 'with ors solution and show her how to give it ', 'during the trip to receive iv treatment. ', 'no ', 'are you trained to use a ', 'naso-gastric tube (ng) for ', 'rehydration? ', 'yes  start rehydration by tube with ors solution: ', 'give 20 ml/kg/hour for 6 hours (total of ', '120 ml/kg). ', ' reassess the patient every 1-2 hours: ', ' if there is repeated vomiting or increased ', 'abdominal distension, give the fluid more slowly. ', ' if hydration is not improved after 3 hours, send ', 'the patient for iv therapy. ', 'no  after 6 hours, reassess the patient and ', 'choose the appropriate treatment plan. ', 'can the patient drink? ', 'yes  start rehydration by mouth with ors ', 'solution, giving 20 ml/kg/hour for 6 hours ', '(total of 120 ml/kg). ', ' reassess the patient every 1-2 hours: ', ' if there is repeated vomiting, give the fluid more ', 'slowly - if hydration is not improved after 3 hours ', 'send the patient for iv therapy. ', 'no  after 6 hours, reassess the patient and choose ', 'the appropriate treatment plan. ', 'urgent: send the patient ', 'for iv or ng treatment. ', 'nb: if possible, observe the patient for at least six hours after rehydration to be sure the mother ', 'can maintain hydration giving ors solution by mouth. if the patient is over two years old and there ', 'is cholera in your area, give an appropriate oral antibiotic after the patient is alert.', 'appendix 3', '352', 'appendix 3. practical advice for writing medical', 'certificates in the event of sexual violence', 'physicians are often the first to be confronted with the consequences of violence. victims are', 'sometimes afraid to report to the authorities concerned, particularly when the population', 'affected is vulnerable (refugees, prisoners, civilian victims of war etc.). in such a situation, the', 'physician should try to determine if the event was isolated or part of larger scale violence (e.g.', 'systematic rape).', 'faced with sexual violence, the physician is obliged to complete a medical certificate for the', 'benefit of the victim, irrespective of the country in which (s)he is practising.', 'the certificate is individual (for the benefit of the individual or their beneficiaries) and confidential', '(it falls within professional confidentiality). the examples of certificates presented in the', 'following pages are written for sexual violence, but the approach is the same for all forms of', 'intentional violence.', 'all medical certificates must include:', '– the identity of the signing physician.', '– the identity of the victim (except for certificates passed on to hcr or to icrc without the', 'consent of the victim, see below).', '– the complete date and the time of the examination.', '– the statement of the victim in his/her own words.', '– the findings of the clinical examination.', '– the samples taken and the examinations carried out.', 'notes:', '• the name of the victim (except for certificates passed on to hcr or to icrc without the', 'consent of the victim, see below), the name of the physician and his/her signature, as well as', 'the date of the examination must appear on each page.', '• a copy containing the victim’s name is given to the victim for future legal use. keep a copy of', 'the medical certificate (or, if the case should arise, of the mandatory reporta) in the patient', 'record, archived to allow future authentication of the certificate given to the victim.', 'what the practitioner should not do:', '– rephrase the words of the victim as the practitioner ’s own.', '– endorse the identity of the aggressor nor the nature of the crime, this must be left to the', 'legal authorities.', '– conclude that there was no sexual violence in the absence of lesions on clinical examination.', 'examples of medical certificates for adults and children (see following pages).', 'with the consent of the victim, the physician gives a copy of the certificate containing the', 'victim’s name:', '– to hcr (to the protection officer only) if the victim is a refugee or displaced, so that', 'protection measures may be put in place for the individual;', '– to icrc if the victim is a victim of war or a prisoner.', 'without the consent of the victim, the physician may give a copy of the certificate to hcr or', 'icrc, but without revealing the identity of the victim (concretely, the sections “family name,', 'first name and precise address” should not appear).', 'a in principle, legal reporting of sexual violence against children under 15 years is mandatory. the only exception', 'is if there is a risk that reporting may further harm the situation of the child. consider each case individually.', 'appendix 3', '353', 'appendices', 'medical certificate for an adult', 'i, the undersigned, ............................................................................. (family name, first name), doctor of', 'medicine, certify that i have examined on ............................................ (hour, day, month, year), at', 'his/her request, mr, mrs, miss .......................................................................... (family name, first name),', 'born on the ............................................. (day, month, year), living at ......................................................', '.......................................................................................................................................... (precise address).', 's)he declares that (s)he has been the victim of sexual assault on ................................................ (hour, day,', 'month, year) at ............................................... (place) by .............................................................................', '(one/several aggressors, known/unknown, armed/non-armed).).', 'during the interview, (s)he stated:', '“ .....................................................................................................................................................................', '.....................................................................................................................................................................', '..................................................................................................................................................................... ”', 'mr, mrs, miss .............................................................. presents the following clinical signs:', '– on general examination: ..........................................................................................................................', '(describe the behaviour: prostrated, excited, calm, frightened, mute, tearful, etc.)', '– on somatic examination: .........................................................................................................................', '...................................................................................................................................................................', '...................................................................................................................................................................', '(describe precisely all lesions observed on the entire body: signs of abrasion, cuts, scratches, bites,', 'strangulation, swelling, burns etc. indicate the site, the extent, the number, the character (old or', 'recent), the severity etc.)', '– on genital examination: ...........................................................................................................................', '...................................................................................................................................................................', '(traumatic lesions, genital infection, etc.)', '– on anal examination: ...............................................................................................................................', '(detectable traumatic lesions etc.)', '– examinations completed (particularly samples taken): ...........................................................................', 'in conclusion (optional)', '☐ this patient presents physical signs and an emotional reaction compatible with the assault of which', '(s)he claims to have been victim.', '☐ the use of constraint and threat during the assault, or the time period between the date of the', 'assault and the date of the medical consultation, can explain the absence of signs of physical', 'violence on this patient. ', 'this document is established with the consent of the patient and may be used for legal purpose.', 'signature of physician', 'appendix 3', '354', 'medical certificate for a child', 'i, the undersigned, ............................................................. (family name, first name), doctor of', 'medicine, certify that i have examined on ......................................................... (hour, day, month, year),', '............................................................... (child’s family name, first name), born on the ..............................', '(day, month, year), living at ..........................................................................................................................', '.......................................................................... (precise address of the parents or residence of the child),', 'at the request of ................................................... (father, mother, legal representative), who declares', 'that the child was the victim of sexual assault on .............................................. (hour, day, month, year)', 'at ................................................................ (place).', 'during the interview, the child told me:', '“ .....................................................................................................................................................................', '......................................................................................................................................................................”', '(quote as faithfully as possible the words of the child without interpreting them)', 'during the interview, ............................................. (name of the person accompanying the child) stated:', '“ .....................................................................................................................................................................', '..................................................................................................................................................................... ”', 'this child presents the following clinical signs:', '– on general examination: ..........................................................................................................................', '(describe the behaviour: prostrated, excited, calm, frightened, mute, tearful, etc.)', '– on somatic examination: .........................................................................................................................', '...................................................................................................................................................................', '...................................................................................................................................................................', '(describe precisely all lesions observed on the entire body: signs of abrasion, cuts, scratches, bites,', 'strangulation, swelling, burns etc. indicate the site, the extent, the number, the character (old or', 'recent), the severity etc.)', '– on genital examination: ...........................................................................................................................', '...................................................................................................................................................................', '(is the hymen intact or not (if not, did it occur recently or in the past), traumatic lesions, genital', 'infection etc.)', '– on anal examination: ...............................................................................................................................', '(detectable traumatic lesions etc.)', '– examinations completed (particularly samples taken): ...........................................................................', 'in conclusion (optional)', '☐ this patient presents physical signs and an emotional reaction compatible with the assault of which', '(s)he claims to have been victim.', '☐ the use of constraint and threat during the assault, or the time period between the date of the', 'assault and the date of the medical consultation, can explain the absence of signs of physical', 'violence on this patient. ', 'this document is established with the consent of .................................................................. (father,', 'mother or legal representative) and may be used for legal purpose.', 'signature of physician', 'main references', 'websites consulted between february 2013 and may 2016', 'bmj group. bmj best practice.', 'british medical association and pharmaceutical society of great britain. british national', 'formulary.', 'centers for disease control and prevention.', 'http://www.cdc.gov/diseasesconditions/', 'cochrane library.', 'la revue prescrire.', 'martindale. the complete drug reference. the pharmaceutical press.', 'world health organization.', 'http://www.who.int/publications/en/', 'uptodate. evidence-based clinical decision support resource.', 'who publications available on line and used in this edition', 'who. hospital care for children. guidelines for the management of common childhood', 'illnesses. 2015.', 'http://apps.who.int/iris/bitstream/10665/81170/1/9789241548373_eng.pdf?ua=1', 'who. who model formulary for children. geneva, 2010.', 'http://www.who.int/selection_medicines/list/wmfc_2010.pdf', 'who. daily iron and folic acid supplementation in pregnant women. geneva, 2012.', 'http://apps.who.int/iris/bitstream/10665/77770/1/9789241501996_eng.pdf?ua=1', 'who. yaws - fact sheet. 2016.', 'http://www.who.int/mediacentre/factsheets/fs316/en/', 'who. guidelines for the treatment of malaria. geneva, 2015.', 'http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1', 'who. meningitis outbreak response in sub-saharan africa. geneva, 2015.', 'http://apps.who.int/iris/bitstream/10665/144727/1/who_hse_ped_ced_14.5_eng.pdf?ua=1', '&ua=1', 'who. handbook for clinical management of dengue. geneva, 2012.', 'http://www.wpro.who.int/mvp/documents/handbook_for_clinical_management_of_dengue.pdf', 'who. rapid advice: diagnosis, prevention and management of cryptococcal disease in hiv-', 'infected adults, adolescents and children. geneva, 2011.', 'http://apps.who.int/iris/bitstream/10665/44786/1/9789241502979_eng.pdf', '.', 'main references', '355', 'http://apps.who.int/iris/bitstream/10665/44786/1/9789241502979_eng.pdf', 'http://www.wpro.who.int/mvp/documents/handbook_for_clinical_management_of_dengue.pdf', 'http://apps.who.int/iris/bitstream/10665/144727/1/who_hse_ped_ced_14.5_eng.pdf?ua=1&ua=1', 'http://apps.who.int/iris/bitstream/10665/144727/1/who_hse_ped_ced_14.5_eng.pdf?ua=1&ua=1', 'http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1', 'http://www.who.int/mediacentre/factsheets/fs316/en/', 'http://apps.who.int/iris/bitstream/10665/77770/1/9789241501996_eng.pdf?ua=1', 'http://www.who.int/selection_medicines/list/wmfc_2010.pdf', 'http://apps.who.int/iris/bitstream/10665/81170/1/9789241548373_eng.pdf?ua=1', 'http://www.who.int/publications/en/', 'http://www.cdc.gov/diseasesconditions/', 'index', '356', 'a', 'abortion.............................................................267', 'abortion, threatened.........................................267', 'abruptio placenta ..............................................269', 'abscesses ...........................................................294', 'abscess, acute dental ........................................308', 'abscess, acute dento-alveolar ...........................308', 'abscess, amoebic liver .........................................94', 'abscess, breast ..................................................296', 'abscess, parotid.................................................297', 'abscess, peritonsillar ...........................................54', 'acute flaccid paralysis........................................204', 'agitation ............................................................313', 'aids....................................................................224', 'amoebiasis......................................................89,94', 'anaemia ...............................................................36', 'ankylostomiase..................................................163', 'anthrax, cutaneous............................................115', 'anxiety ...............................................................311', 'ascariasis............................................................163', 'asthma ................................................................80', 'asthma attack ......................................................80', 'asthma, acute ......................................................80', 'asthma, chronic ...................................................82', 'b', 'bejel ...................................................................118', 'beri-beri .............................................................337', 'bipolar disorder .................................................321', 'bites, venomous.................................................304', 'borreliosis ..........................................................194', 'bronchiolitis .........................................................69', 'bronchitis, acute ..................................................67', 'bronchitis, chronic ...............................................67', 'brucellosis ..........................................................188', 'burns..................................................................286', 'c', 'campylobacter ...................................................228', 'candidiasis, oral and oropharyngeal.............98,229', 'candidiasis, vaginal .....................................253,264', 'carbuncles .........................................................112', 'cataract..............................................................137', 'cellulitis..............................................................113', 'cellulitis, periorbital and orbital ........................134', 'certificates, medical (sexual violence)...............352', 'cervicitis.............................................................255', 'cestodes ............................................................161', 'chagas’s disease ................................................151', 'chancroid....................................................256,265', 'chlamydia ............................................251,253,264', 'cholera.................................................................90', 'confusion, mental..............................................314', 'conjunctivitis .....................................................129', 'conjunctivitis, neonatal .....................................130', 'croup ...................................................................58', 'cryptococcosis ............................................230,233', 'cryptosporidiosis ........................................156,228', 'cyclosporiasis.....................................................156', 'cysticercosis.......................................................162', 'cystitis, acute.....................................................244', 'd', 'dehydration, who protocol ..............................345', 'delirium tremens ...............................................313', 'dengue ..............................................................213', 'dental abscess, acute.........................................308', 'dental infections................................................308', 'dento-alveolar abscess, acute ...........................308', 'depression .........................................................316', 'dermatitis, diaper ..............................................109', 'dermatitis, seborrheic ................................123,232', 'dermatology ......................................................103', 'dermatophytoses ..............................................110', 'diarrhoea, acute ..................................................89', 'diarrhoea, parasitic............................................156', 'diffuse cervico-facial infections .........................308', 'diphtheria ............................................................55', 'diphyllobothriasis ..............................................161', 'donovanosis.......................................................258', 'dressings............................................................273', 'duodenum disorders ...........................................95', 'dysenterie................................................92,94,218', 'dyspepsia.............................................................97', 'e', 'eclampsia ......................................................23,334', 'ectopic pregnancy..............................................267', 'eczema...............................................................123', 'endometritis ......................................................260', 'enterobiasis .......................................................164', 'envenomation....................................................304', 'epiglottitis ............................................................59', 'epilepsy ................................................................22', 'erysipelas ...........................................................113', 'ethmoiditis ...........................................................50', 'f', 'fever .............................................................25,235', 'fever, relapsing..................................................194', 'fever, viral haemorrhagic ..................................220', 'fever, yellow......................................................220', 'filariasis .............................................................166', 'filariasis, lymphatic............................................170', 'flukes .................................................................158', 'folic acid deficiency .............................................38', 'fungal infections, superficial .............................109', 'furuncles............................................................112', 'index', 'g', 'gastric and duodenal ulcers ................................95', 'gastro-oesophageal reflux...................................95', 'gastrointestinal bleeding.....................................96', 'genital infections........................................249,264', 'genital ulcers .....................................................256', 'giardiasis.......................................................89,156', 'goitre, endemic .................................................338', 'gonorrhoea..........................................251,253,264', 'h', 'haemolytic, anaemia ...........................................37', 'haemorrhagic disease of the newborn,', 'prophylaxis...................................................189', 'haemorrhagic fevers, viral.................................220', 'hansen’s disease................................................119', 'heart failure in adults ........................................335', 'hepatitis, viral ....................................................210', 'herpes, genital ............................................257,265', 'herpes, oral...................................................98,229', 'herpes simplex...................................................122', 'herpes zoster .....................................................122', 'hidradenitis axillary ...........................................232', 'histoplasmosis ...................................................230', 'hiv infection ......................................................224', 'hydatid cyst .......................................................162', 'hymenolepiasis..................................................161', 'hypertension .....................................................331', 'hypoglycaemia.....................................................25', 'i', 'impetigo.............................................................111', 'infections, genital .......................................249,264', 'infections, necrotising........................................302', 'infections, upper genital tract ...........................260', 'insomnia ............................................................312', 'iodine deficiency................................................338', 'iron deficiency .....................................................37', 'isosporiasis..................................................156,218', 'iv fluids, 1.5 x daily maintenance ......................344', 'iv fluids, normal daily maintenance ..................343', 'k', 'kala-azar ............................................................153', 'keratoconjunctivitis, viral epidemic...................131', 'kwashiorkor .........................................................39', 'l', 'labour, premature.............................................269', 'laryngotracheitis .................................................58', 'laryngotracheobronchitis ....................................58', 'leg ulcers ...........................................................300', 'leishmaniases ....................................................153', 'leprosy...............................................................119', 'leptospirosis ......................................................192', 'leukoplakia, oral ................................................229', 'lice .....................................................................107', 'loiasis..........................................................136,168', 'louse-borne relapsing fever ..............................194', 'lower abdominal pain in women ......................259', 'lumbar puncture ...............................................176', 'lymphadenopathy, persistent generalised........231', 'lymphogranuloma venereum............................257', 'm', 'malaria...............................................................141', 'malnutrition.........................................................39', 'marasmus ............................................................39', 'measles ..............................................................201', 'meningitis, bacterial ..........................................175', 'meningitis, parasitic...........................................233', 'mental confusion...............................................314', 'metrorrhagia......................................................266', 'microsporidium ..................................................228', 'myositis of the psoas .........................................299', 'n', 'necrotising infections of the skin and', 'soft tissues ...................................................302', 'nematode infections .........................................163', 'nephrotic syndrome in children ........................239', 'neurosyphilis .....................................................233', 'o', 'oedema, acute pulmonary ................................335', 'onchocerciasis ............................................136,166', 'opistorchiasis.....................................................158', 'otitis externa, acute ............................................62', 'otitis media, acute...............................................62', 'otitis media, chronic suppurative........................64', 'p', 'pain ......................................................................28', 'pain, evaluation scales .........................................29', 'pain, lower abdominal in women ......................259', 'panic disorder ....................................................311', 'papilloma viruses ........................................263,265', 'paragonimiasis ...................................................158', 'paralysis, acute flaccid .......................................204', 'pediculosis .........................................................107', 'pellagra ..............................................................124', 'penicilliosis.........................................................230', 'perforation, gastric ..............................................96', 'pertussis...............................................................65', 'pharyngitis, acute ................................................52', 'pinta...................................................................118', 'placenta praevia.................................................268', 'plague ................................................................190', 'pneumocystosis .................................................230', 'pneumonia, acute ................................................71', 'pneumonia, persistent.........................................77', 'poliomyelitis.......................................................204', 'post-partum haemorrhage ................................270', 'index', '357', 'index', '358', 'post-traumatic stress disorder...........................315', 'pre-delirium tremens.........................................313', 'pre-eclampsia ....................................................332', 'premature labour...............................................269', 'prostatitis, acute ................................................248', 'protozoan infections, intestinal .........................156', 'psoa, myositis ....................................................299', 'psoriasis and hiv................................................232', 'psychoses, chronic .............................................319', 'psychotic disorders ............................................319', 'psychotic episode, acute....................................319', 'pterygium...........................................................136', 'pulmonary oedema, acute.................................335', 'pulmonary tuberculosis .......................................85', 'pyelonephritis, acute .........................................246', 'pyodermitis ........................................................111', 'pyomyositis ........................................................298', 'r', 'rabies.................................................................506', 'relapsing fever...................................................194', 'relapsing fever, louse-borne .............................194', 'relapsing fever, tick-borne ................................195', 'rheumatic fever, acute......................................337', 'rhinitis .................................................................49', 'rhinopharyngitis ..................................................49', 'rickettsioses, eruptive .......................................197', 'river blindness............................................136,166', 's', 'salpingitis ...........................................................260', 'scabies ...............................................................104', 'scarlet fever .........................................................99', 'schistosomiases .................................................159', 'schizophrenia.....................................................319', 'scurvy.................................................................100', 'seborrheic dermatitis .................................123,232', 'seizures ................................................................21', 'shigellosis........................................................89,92', 'shingles ..............................................................122', 'shock....................................................................15', 'shock, anaphylactic..............................................16', 'shock, cardiogenic ...............................................15', 'shock, haemorrhagic ...........................................16', 'shock, hypovolaemic ...........................................15', 'shock, septic ........................................................15', 'sickle cell disease...............................................325', 'sinusitis, acute .....................................................50', 'skin infections, bacterial ....................................111', 'sleeping sickness................................................148', 'staphylococcal pneumonia ...........................78,230', 'stings, venomous...............................................304', 'stomach disorders ...............................................95', 'stomatitis.............................................................98', 'strongyloidiasis ..................................................164', 'sutures ...............................................................278', 'syphilis ........................................................257,265', 't', 'taeniasis ............................................................161', 'tetanus ..............................................................180', 'threatened abortion..........................................267', 'tick-borne relapsing fever .................................195', 'toxoplasmosis, cerebral .............................233,234', 'tracheitis, bacterial..............................................60', 'trachoma ...........................................................132', 'transfusion, blood ...............................................37', 'treponematoses, endemic ................................117', 'trichinellosis ......................................................165', 'trichomoniasis ............................................253,264', 'trichuriasis .........................................................163', 'trypanosomiasis, african ...................................148', 'trypanosomiasis, american ...............................151', 'tuberculosis, pulmonary......................................85', 'typhoid fever .....................................................186', 'typhus................................................................197', 'u', 'ulcers, gastric and duodenal................................95', 'ulcers, genital ....................................................256', 'ulcers, leg ..........................................................300', 'upper airway obstruction, acute .........................47', 'upper genital tract infections ............................260', 'urethral discharge .............................................251', 'urolithiasis .........................................................243', 'urticaria .............................................................124', 'uterine rupture..................................................269', 'v', 'vaginal discharge, abnormal..............................253', 'vaginitis .............................................................253', 'venoms ..............................................................304', 'violence, sexual ..........................................250,352', 'vitamin a deficiency ..........................................127', 'vitamin c deficiency ..........................................100', 'w', 'warts, veneral.............................................263,265', 'whooping cough..................................................65', 'wound, simple...................................................276', 'x', 'xerophthalmia ...................................................127', 'xerosis, diffuse cutaneous .................................232', 'y', 'yaws...................................................................118', 'yellow fever .......................................................220', 'in the same collection', 'essential drugs - practical guidelines', 'english, french, spanish, arabic', 'essential obstetric and newborn care', 'english, french, arabic', 'tuberculosis', 'english, french', 'management of a measles epidemic', 'english, french', 'public health engineering in emergency situations', 'english, french', 'rapid health assessment of refugee or displaced populations', 'english only', 'http://refbooks.msf.org/msf_docs/en/rapid_health/rapid_health_en.pdf', 'http://refbooks.msf.org/msf_docs/en/public_health/public_health_en.pdf', 'http://refbooks.msf.org/msf_docs/en/measles/measles_en.pdf', 'http://refbooks.msf.org/msf_docs/en/tuberculosis/tuberculosis_en.pdf', 'http://refbooks.msf.org/msf_docs/en/obstetrics/obstetrics_en.pdf', 'http://refbooks.msf.org/msf_docs/en/essential_drugs/ed_en.pdf', 'belgium médecins sans frontières/artsen zonder grenzen', \"46 rue de l'arbre bénit, 1050 brussels\", 'tel.: +32 (0)2 474 74 74', 'fax: +32 (0)2 474 75 75', 'e-mail: info@msf.be', 'france médecins sans frontières', '8 rue saint-sabin, 75544 paris cedex 11', 'tel.: +33 (0)1 40 21 29 29', 'fax: +33 (0)1 48 06 68 68', 'e-mail: office@paris.msf.org', 'netherlands artsen zonder grenzen', 'plantage middenlaan 14, 1018 dd amsterdam', 'tel.: +31 (0)20 52 08 700', 'fax: +31 (0)20 62 05 170', 'e-mail: office@amsterdam.msf.org', 'spain medicos sin fronteras', 'nou de la rambla 26, 08001 barcelona', 'tel.: +34 933 046 100', 'fax: +34 933 046 102', 'e-mail: oficina@barcelona.msf.org', 'switzerland médecins sans frontières', '78 rue de lausanne - case postale 116 - 1211\\u2008geneva 27', 'tel.: +41 (0)22 849 84 84', 'fax: +41 (0)22 849 84 88', 'e-mail: office-gva@geneva.msf.org', 'achevé d’imprimer en france par isi, 93210 la plaine saint-denis', 'juin 2016', '\\tmsf-clinical guidelines', '\\tforeword\\t', '\\thow to use this manual\\t', '\\ttable of contents\\t', '\\tintroduction\\t', '\\tchapter 1: a few symptoms and syndromes', '\\tshock', '\\tseizures', '\\thypoglycaemia', '\\tfever', '\\tpain', '\\tanaemia', '\\tsevere acute malnutrition', '\\tchapter 2: respiratory diseases', '\\tacute upper airway obstruction\\t', '\\trhinitis and rhinopharyngitis (common cold)\\t', '\\tacute sinusitis\\t', '\\tacute pharyngitis\\t', '\\tdiphtheria\\t', '\\tother upper respiratory tract infections\\t', '\\tlaryngotracheitis and laryngotracheobronchitis (croup)\\t', '\\tepiglottitis\\t', '\\tbacterial tracheitis\\t', '\\totitis\\t', '\\tacute otitis externa\\t', '\\tacute otitis media (aom)\\t', '\\tchronic suppurative otitis media (csom)\\t', '\\twhooping cough (pertussis)\\t', '\\tbronchitis\\t', '\\tacute bronchitis\\t', '\\tchronic bronchitis\\t', '\\tbronchiolitis\\t', '\\tacute pneumonia\\t', '\\tpneumonia in children under 5 years of age\\t', '\\tpneumonia in children over 5 years and adults\\t', '\\tpersistent pneumonia\\t', '\\tstaphylococcal pneumonia\\t', '\\tasthma\\t', '\\tasthma attack (acute asthma)\\t', '\\tchronic asthma\\t', '\\tpulmonary tuberculosis\\t', '\\tchapter 3: gastrointestinal disorders', '\\tacute diarrhoea\\t', '\\tshigellosis\\t', '\\tamoebiasis\\t', '\\tdisorders of the stomach and duodenum\\t', '\\tgastro-oesophageal reflux\\t', '\\tgastric and duodenal ulcers in adults\\t', '\\tdyspepsia\\t', '\\tstomatitis\\t', '\\toral and oropharyngeal candidiasis\\t', '\\toral herpes\\t', '\\tother infectious causes\\t', '\\tstomatitis from scurvy (vitamin c deficiency)\\t', '\\tother lesions resulting from a nutritional deficiency\\t', '\\tchapter 4: skin diseases', '\\tdermatology\\t', '\\tscabies\\t', '\\tlice (pediculosis)\\t', '\\tsuperficial fungal infections\\t', '\\tbacterial skin infections\\t', '\\timpetigo\\t', '\\terysipelas and cellulitis\\t', '\\tcutaneous anthrax\\t', '\\tendemic treponematoses\\t', '\\tleprosy (hansen’s disease)\\t', '\\therpes simplex and herpes zoster\\t', '\\therpes simplex\\t', '\\therpes zoster (shingles)\\t', '\\tother skin disorders\\t', '\\teczema (dermatitis)\\t', '\\tseborrheic dermatitis\\t', '\\turticaria\\t', '\\tpellagra\\t', '\\tchapter 5: eye diseases', '\\txerophthalmia (vitamin a deficiency)\\t', '\\tconjunctivitis\\t', '\\tneonatal conjunctivitis\\t', '\\tviral epidemic keratoconjunctivitis\\t', '\\ttrachoma\\t', '\\tperiorbital and orbital cellulitis\\t', '\\tother pathologies\\t', '\\tonchocerciasis\\t', '\\tloiasis\\t', '\\tpterygium\\t', '\\tcataract\\t', '\\tchapter 6: parasitic diseases', '\\tmalaria\\t', '\\thuman african trypanosomiasis\\t', '\\tamerican trypanosomiasis\\t', '\\tleishmaniases\\t', '\\tintestinal protozoan infections (parasitic diarrhoea)\\t', '\\tflukes\\t', '\\tschistosomiases\\t', '\\tcestodes ', '\\tnematode infections\\t', '\\tfilariasis\\t', '\\tonchocerciasis\\t', '\\tloiasis\\t', '\\tlymphatic filariasis (lf)\\t', '\\tchapter 7: bacterial diseases', '\\tbacterial meningitis\\t', '\\ttetanus\\t', '\\ttyphoid fever\\t', '\\tbrucellosis\\t', '\\tplague\\t', '\\tleptospirosis\\t', '\\trelapsing fever (borreliosis)\\t', '\\tlouse-borne relapsing fever (lbrf)\\t', '\\ttick-borne relapsing fever (tbrf)\\t', '\\teruptive rickettsioses\\t', '\\tchapter 8: viral diseases', '\\tmeasles\\t', '\\tpoliomyelitis\\t', '\\trabies\\t', '\\tviral hepatitis\\t', '\\tdengue\\t', '\\tviral haemorrhagic fevers\\t', '\\thiv infection and aids', '\\tchapter 9: genito-urinary diseases', '\\tnephrotic syndrome in children\\t', '\\turolithiasis\\t', '\\tacute cystitis\\t', '\\tacute pyelonephritis\\t', '\\tacute prostatitis\\t', '\\tgenital infections (gi)\\t', '\\turethral discharge\\t', '\\tabnormal vaginal discharge\\t', '\\tgenital ulcers\\t', '\\tlower abdominal pain in women\\t', '\\tupper genital tract infections (ugti)\\t', '\\tveneral warts\\t', '\\tmajor genital infections (summary)\\t', '\\tmetrorrhagia\\t', '\\tchapter 10: medical and minor surgical procedures', '\\tdressings\\t', '\\ttreatment of a simple wound\\t', '\\tburns\\t', '\\tabscesses\\t', '\\tpyomyositis\\t', '\\tleg ulcers\\t', '\\tnecrotising infections of the skin and soft tissues\\t', '\\tvenomous bites and stings\\t', '\\tdental infections\\t', '\\tchapter 11: mental/psychical disorders in adults', '\\tanxiety\\t', '\\tinsomnia\\t', '\\tagitation\\t', '\\tmental confusion\\t', '\\tpost-traumatic stress disorder\\t', '\\tdepression\\t', '\\tpsychotic disorders\\t', '\\tacute psychotic episode\\t', '\\tchronic psychoses\\t', '\\tbipolar disorder\\t', '\\tchapter 12: other conditions', '\\tsickle cell disease\\t', '\\thypertension\\t', '\\theart failure in adults\\t', '\\tendemic goitre and iodine deficiency\\t', '\\tappendices', '\\tappendix 1a. normal daily maintenance iv fluids in children > 1 month', '\\tappendix 1b. 1.5 x daily maintenance iv fluidsin children > 1 month', '\\tappendix 2. assessment and treatment of diarrhoea (who)', '\\tappendix 3. practical advice for writing medical certificates in the event of sexual violence\\t', '\\tmain references\\t', '\\tindex\\t', '\\tcollection', '\\tmsf addresses']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "msf_str = ' '.join(rawList)     #Join list of sentences into string\n",
        "for c in string.punctuation:\n",
        "    msf_str = msf_str.replace(c, \"\")  #remove punctuations\n",
        "len(msf_str)                                  "
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "A6w1WTX5THDR",
        "outputId": "9d16b9b0-7f5e-4ec3-f1ed-b75ae99a4293"
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "640363"
            ]
          },
          "metadata": {},
          "execution_count": 11
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open(\"msf2016.txt\", \"w\") as text_file:\n",
        "    text_file.write(msf_str)                                       #write string as text file"
      ],
      "metadata": {
        "id": "K8q2Y8sbTIog"
      },
      "execution_count": 12,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "msf_model = fasttext.train_unsupervised('msf2016.txt', \n",
        "                                        epoch=50,\n",
        "                                        dim=300,\n",
        "                                        lr= 0.01,\n",
        "                                        wordNgrams = 5 )    #train model using fasttext\n",
        "msf_model.save_model('msf_model.bin')    #save trained model"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Kx9qENSUTKQM",
        "outputId": "2af9c463-2a6d-42a3-e451-69c6e14741ba"
      },
      "execution_count": 16,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "CPU times: user 3min 49s, sys: 6.59 s, total: 3min 56s\n",
            "Wall time: 4min\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "fasttext_trained_model = FastText.load_fasttext_format('msf_model.bin') "
      ],
      "metadata": {
        "id": "UXDJAdAuTXAO"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "fasttext_trained_model.wv.vocab"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "OUWekUo9Tb4k",
        "outputId": "b03c2d94-8853-4f24-cbb6-48728085fa92"
      },
      "execution_count": 20,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'the': <gensim.models.keyedvectors.Vocab at 0x7f2da498be90>,\n",
              " 'of': <gensim.models.keyedvectors.Vocab at 0x7f2da498bed0>,\n",
              " 'in': <gensim.models.keyedvectors.Vocab at 0x7f2da498bb90>,\n",
              " 'and': <gensim.models.keyedvectors.Vocab at 0x7f2da4722410>,\n",
              " 'to': <gensim.models.keyedvectors.Vocab at 0x7f2da4722e50>,\n",
              " 'or': <gensim.models.keyedvectors.Vocab at 0x7f2da4722a90>,\n",
              " '–': <gensim.models.keyedvectors.Vocab at 0x7f2da4722c50>,\n",
              " 'is': <gensim.models.keyedvectors.Vocab at 0x7f2da4722d50>,\n",
              " 'a': <gensim.models.keyedvectors.Vocab at 0x7f2da4722990>,\n",
              " 'for': <gensim.models.keyedvectors.Vocab at 0x7f2da4722710>,\n",
              " 'treatment': <gensim.models.keyedvectors.Vocab at 0x7f2da4714090>,\n",
              " '•': <gensim.models.keyedvectors.Vocab at 0x7f2da47140d0>,\n",
              " 'with': <gensim.models.keyedvectors.Vocab at 0x7f2da4714150>,\n",
              " '2': <gensim.models.keyedvectors.Vocab at 0x7f2da4714190>,\n",
              " 'if': <gensim.models.keyedvectors.Vocab at 0x7f2da4714210>,\n",
              " 'children': <gensim.models.keyedvectors.Vocab at 0x7f2da4714290>,\n",
              " 'be': <gensim.models.keyedvectors.Vocab at 0x7f2da4714310>,\n",
              " '3': <gensim.models.keyedvectors.Vocab at 0x7f2da4714350>,\n",
              " '1': <gensim.models.keyedvectors.Vocab at 0x7f2da4714390>,\n",
              " 'as': <gensim.models.keyedvectors.Vocab at 0x7f2da4714410>,\n",
              " 'doses': <gensim.models.keyedvectors.Vocab at 0x7f2da4714490>,\n",
              " 'days': <gensim.models.keyedvectors.Vocab at 0x7f2da4714510>,\n",
              " 'are': <gensim.models.keyedvectors.Vocab at 0x7f2da4714590>,\n",
              " 'po': <gensim.models.keyedvectors.Vocab at 0x7f2da4714610>,\n",
              " 'not': <gensim.models.keyedvectors.Vocab at 0x7f2da4714690>,\n",
              " 'divided': <gensim.models.keyedvectors.Vocab at 0x7f2da4714710>,\n",
              " 'adults': <gensim.models.keyedvectors.Vocab at 0x7f2da4714790>,\n",
              " 'on': <gensim.models.keyedvectors.Vocab at 0x7f2da5484a90>,\n",
              " 'by': <gensim.models.keyedvectors.Vocab at 0x7f2da4722110>,\n",
              " '5': <gensim.models.keyedvectors.Vocab at 0x7f2da4722890>,\n",
              " 'dose': <gensim.models.keyedvectors.Vocab at 0x7f2da47223d0>,\n",
              " '10': <gensim.models.keyedvectors.Vocab at 0x7f2da4722d90>,\n",
              " 'may': <gensim.models.keyedvectors.Vocab at 0x7f2da4722f10>,\n",
              " 'mg': <gensim.models.keyedvectors.Vocab at 0x7f2da4722f90>,\n",
              " 'chapter': <gensim.models.keyedvectors.Vocab at 0x7f2da4722790>,\n",
              " '4': <gensim.models.keyedvectors.Vocab at 0x7f2da47222d0>,\n",
              " 'iv': <gensim.models.keyedvectors.Vocab at 0x7f2da4722a10>,\n",
              " 'at': <gensim.models.keyedvectors.Vocab at 0x7f2da4722350>,\n",
              " 'patient': <gensim.models.keyedvectors.Vocab at 0x7f2da47229d0>,\n",
              " '6': <gensim.models.keyedvectors.Vocab at 0x7f2da4722b90>,\n",
              " 'patients': <gensim.models.keyedvectors.Vocab at 0x7f2da47227d0>,\n",
              " 'daily': <gensim.models.keyedvectors.Vocab at 0x7f2da4722150>,\n",
              " 'infection': <gensim.models.keyedvectors.Vocab at 0x7f2da4722b50>,\n",
              " 'an': <gensim.models.keyedvectors.Vocab at 0x7f2da4722490>,\n",
              " 'pain': <gensim.models.keyedvectors.Vocab at 0x7f2da4722690>,\n",
              " 'years': <gensim.models.keyedvectors.Vocab at 0x7f2da47225d0>,\n",
              " 'signs': <gensim.models.keyedvectors.Vocab at 0x7f2da4722550>,\n",
              " 'kg': <gensim.models.keyedvectors.Vocab at 0x7f2da4722510>,\n",
              " 'clinical': <gensim.models.keyedvectors.Vocab at 0x7f2da47221d0>,\n",
              " 'fever': <gensim.models.keyedvectors.Vocab at 0x7f2da4722290>,\n",
              " 'see': <gensim.models.keyedvectors.Vocab at 0x7f2da4722050>,\n",
              " 'once': <gensim.models.keyedvectors.Vocab at 0x7f2da554d950>,\n",
              " 'hours': <gensim.models.keyedvectors.Vocab at 0x7f2da554da50>,\n",
              " 'should': <gensim.models.keyedvectors.Vocab at 0x7f2da547d7d0>,\n",
              " 'mgkgday': <gensim.models.keyedvectors.Vocab at 0x7f2da547d1d0>,\n",
              " 'severe': <gensim.models.keyedvectors.Vocab at 0x7f2da547df10>,\n",
              " 'after': <gensim.models.keyedvectors.Vocab at 0x7f2da548a8d0>,\n",
              " 'acute': <gensim.models.keyedvectors.Vocab at 0x7f2da4716e10>,\n",
              " 'mgday': <gensim.models.keyedvectors.Vocab at 0x7f2da4716f90>,\n",
              " '7': <gensim.models.keyedvectors.Vocab at 0x7f2da4716f50>,\n",
              " 'no': <gensim.models.keyedvectors.Vocab at 0x7f2da4716ed0>,\n",
              " 'infections': <gensim.models.keyedvectors.Vocab at 0x7f2da4716e50>,\n",
              " 'symptoms': <gensim.models.keyedvectors.Vocab at 0x7f2da4716710>,\n",
              " 'from': <gensim.models.keyedvectors.Vocab at 0x7f2da4716950>,\n",
              " 'it': <gensim.models.keyedvectors.Vocab at 0x7f2da4716790>,\n",
              " 'over': <gensim.models.keyedvectors.Vocab at 0x7f2da47162d0>,\n",
              " 'than': <gensim.models.keyedvectors.Vocab at 0x7f2da4716050>,\n",
              " 'skin': <gensim.models.keyedvectors.Vocab at 0x7f2da4716a10>,\n",
              " 'blood': <gensim.models.keyedvectors.Vocab at 0x7f2da4716b50>,\n",
              " '20': <gensim.models.keyedvectors.Vocab at 0x7f2da4716b10>,\n",
              " '8': <gensim.models.keyedvectors.Vocab at 0x7f2da4716bd0>,\n",
              " 'weeks': <gensim.models.keyedvectors.Vocab at 0x7f2da4716310>,\n",
              " '12': <gensim.models.keyedvectors.Vocab at 0x7f2da4716590>,\n",
              " 'months': <gensim.models.keyedvectors.Vocab at 0x7f2da47164d0>,\n",
              " 'risk': <gensim.models.keyedvectors.Vocab at 0x7f2da47163d0>,\n",
              " 'can': <gensim.models.keyedvectors.Vocab at 0x7f2da4716090>,\n",
              " 'child': <gensim.models.keyedvectors.Vocab at 0x7f2da47161d0>,\n",
              " 'oral': <gensim.models.keyedvectors.Vocab at 0x7f2da4716150>,\n",
              " '50': <gensim.models.keyedvectors.Vocab at 0x7f2da498b890>,\n",
              " 'that': <gensim.models.keyedvectors.Vocab at 0x7f2da498bf50>,\n",
              " 'then': <gensim.models.keyedvectors.Vocab at 0x7f2da498b810>,\n",
              " 'ml': <gensim.models.keyedvectors.Vocab at 0x7f2da498b8d0>,\n",
              " 'other': <gensim.models.keyedvectors.Vocab at 0x7f2da498bf10>,\n",
              " 'more': <gensim.models.keyedvectors.Vocab at 0x7f2da498b750>,\n",
              " '100': <gensim.models.keyedvectors.Vocab at 0x7f2da5490f90>,\n",
              " 'single': <gensim.models.keyedvectors.Vocab at 0x7f2da5490610>,\n",
              " '30': <gensim.models.keyedvectors.Vocab at 0x7f2da54900d0>,\n",
              " 'use': <gensim.models.keyedvectors.Vocab at 0x7f2da5490450>,\n",
              " 'one': <gensim.models.keyedvectors.Vocab at 0x7f2da5490190>,\n",
              " 'under': <gensim.models.keyedvectors.Vocab at 0x7f2da5490d50>,\n",
              " 'h': <gensim.models.keyedvectors.Vocab at 0x7f2da5490650>,\n",
              " 'mgkg': <gensim.models.keyedvectors.Vocab at 0x7f2da5490850>,\n",
              " 'during': <gensim.models.keyedvectors.Vocab at 0x7f2da5490ed0>,\n",
              " 'im': <gensim.models.keyedvectors.Vocab at 0x7f2da5490ad0>,\n",
              " 'possible': <gensim.models.keyedvectors.Vocab at 0x7f2da5490f50>,\n",
              " 'respiratory': <gensim.models.keyedvectors.Vocab at 0x7f2da5490bd0>,\n",
              " 'b': <gensim.models.keyedvectors.Vocab at 0x7f2da5490990>,\n",
              " 'minutes': <gensim.models.keyedvectors.Vocab at 0x7f2da5490550>,\n",
              " 'diseases': <gensim.models.keyedvectors.Vocab at 0x7f2da5490110>,\n",
              " '15': <gensim.models.keyedvectors.Vocab at 0x7f2da5490790>,\n",
              " 'women': <gensim.models.keyedvectors.Vocab at 0x7f2da5490890>,\n",
              " 'etc': <gensim.models.keyedvectors.Vocab at 0x7f2da47147d0>,\n",
              " 'when': <gensim.models.keyedvectors.Vocab at 0x7f2da4714850>,\n",
              " 'treat': <gensim.models.keyedvectors.Vocab at 0x7f2da47148d0>,\n",
              " 'first': <gensim.models.keyedvectors.Vocab at 0x7f2da4714950>,\n",
              " 'm': <gensim.models.keyedvectors.Vocab at 0x7f2da4714990>,\n",
              " 'g': <gensim.models.keyedvectors.Vocab at 0x7f2da47149d0>,\n",
              " '≥': <gensim.models.keyedvectors.Vocab at 0x7f2da4714a10>,\n",
              " 'antibiotic': <gensim.models.keyedvectors.Vocab at 0x7f2da4714a90>,\n",
              " 'diagnosis': <gensim.models.keyedvectors.Vocab at 0x7f2da4714b10>,\n",
              " 'gday': <gensim.models.keyedvectors.Vocab at 0x7f2da4714b90>,\n",
              " 'only': <gensim.models.keyedvectors.Vocab at 0x7f2da4714c10>,\n",
              " 'bacterial': <gensim.models.keyedvectors.Vocab at 0x7f2da4714c90>,\n",
              " 'has': <gensim.models.keyedvectors.Vocab at 0x7f2da4714d10>,\n",
              " 'every': <gensim.models.keyedvectors.Vocab at 0x7f2da4714d90>,\n",
              " 'case': <gensim.models.keyedvectors.Vocab at 0x7f2da4714e10>,\n",
              " 'diarrhoea': <gensim.models.keyedvectors.Vocab at 0x7f2da4714e90>,\n",
              " 'there': <gensim.models.keyedvectors.Vocab at 0x7f2da4714f10>,\n",
              " 'administer': <gensim.models.keyedvectors.Vocab at 0x7f2da4714f90>,\n",
              " 'all': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3050>,\n",
              " 'lesions': <gensim.models.keyedvectors.Vocab at 0x7f2da46f30d0>,\n",
              " 'this': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3150>,\n",
              " 'but': <gensim.models.keyedvectors.Vocab at 0x7f2da46f31d0>,\n",
              " 'o': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3210>,\n",
              " 'features': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3290>,\n",
              " 'must': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3310>,\n",
              " 'available': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3390>,\n",
              " 'often': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3410>,\n",
              " 'cases': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3490>,\n",
              " 'therapy': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3510>,\n",
              " 'water': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3590>,\n",
              " '25': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3610>,\n",
              " 'infusion': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3690>,\n",
              " '200': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3710>,\n",
              " 'event': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3790>,\n",
              " 'd': <gensim.models.keyedvectors.Vocab at 0x7f2da46f37d0>,\n",
              " 'necessary': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3850>,\n",
              " 'most': <gensim.models.keyedvectors.Vocab at 0x7f2da46f38d0>,\n",
              " 'do': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3950>,\n",
              " 'chronic': <gensim.models.keyedvectors.Vocab at 0x7f2da46f39d0>,\n",
              " 'shock': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3a50>,\n",
              " 'eg': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3ad0>,\n",
              " 'usually': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3b50>,\n",
              " 'present': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3bd0>,\n",
              " 'medical': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3c50>,\n",
              " 's': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3c90>,\n",
              " 'sodium': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3d10>,\n",
              " 'disease': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3d90>,\n",
              " 'due': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3e10>,\n",
              " 'less': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3e90>,\n",
              " 'malaria': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3f10>,\n",
              " '09': <gensim.models.keyedvectors.Vocab at 0x7f2da46f3f90>,\n",
              " 'common': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4050>,\n",
              " 'wound': <gensim.models.keyedvectors.Vocab at 0x7f2da46f40d0>,\n",
              " '40': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4150>,\n",
              " 'ceftriaxone': <gensim.models.keyedvectors.Vocab at 0x7f2da46f41d0>,\n",
              " 'age': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4250>,\n",
              " 'who': <gensim.models.keyedvectors.Vocab at 0x7f2da46f42d0>,\n",
              " 'hiv': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4350>,\n",
              " 'following': <gensim.models.keyedvectors.Vocab at 0x7f2da46f43d0>,\n",
              " 'glucose': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4450>,\n",
              " 'e': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4490>,\n",
              " 'give': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4510>,\n",
              " 'oedema': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4590>,\n",
              " 'acid': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4610>,\n",
              " 'failure': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4690>,\n",
              " 'without': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4710>,\n",
              " 'c': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4750>,\n",
              " '14': <gensim.models.keyedvectors.Vocab at 0x7f2da46f47d0>,\n",
              " 'administration': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4850>,\n",
              " 'surgical': <gensim.models.keyedvectors.Vocab at 0x7f2da46f48d0>,\n",
              " 'day': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4950>,\n",
              " 'pregnant': <gensim.models.keyedvectors.Vocab at 0x7f2da46f49d0>,\n",
              " 'used': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4a50>,\n",
              " 'viral': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4ad0>,\n",
              " 'chloride': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4b50>,\n",
              " 'fluid': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4bd0>,\n",
              " '24': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4c50>,\n",
              " 'administered': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4cd0>,\n",
              " 'dehydration': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4d50>,\n",
              " 'which': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4dd0>,\n",
              " 'injection': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4e50>,\n",
              " 'route': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4ed0>,\n",
              " 'month': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4f50>,\n",
              " 'associated': <gensim.models.keyedvectors.Vocab at 0x7f2da46f4fd0>,\n",
              " 'discharge': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5090>,\n",
              " 'above': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5110>,\n",
              " 'according': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5190>,\n",
              " 'genital': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5210>,\n",
              " 'andor': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5290>,\n",
              " 'management': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5310>,\n",
              " 'least': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5390>,\n",
              " 'examination': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5410>,\n",
              " 'same': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5490>,\n",
              " 'pneumonia': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5510>,\n",
              " 'each': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5590>,\n",
              " 'page': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5610>,\n",
              " 'mlkg': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5690>,\n",
              " '9': <gensim.models.keyedvectors.Vocab at 0x7f2da46f56d0>,\n",
              " '60': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5750>,\n",
              " 'using': <gensim.models.keyedvectors.Vocab at 0x7f2da46f57d0>,\n",
              " 'solution': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5850>,\n",
              " 'per': <gensim.models.keyedvectors.Vocab at 0x7f2da46f58d0>,\n",
              " 'cause': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5950>,\n",
              " 'before': <gensim.models.keyedvectors.Vocab at 0x7f2da46f59d0>,\n",
              " 'rate': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5a50>,\n",
              " 'have': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5ad0>,\n",
              " 'endemic': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5b50>,\n",
              " 'times': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5bd0>,\n",
              " 'high': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5c50>,\n",
              " 'between': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5cd0>,\n",
              " 'complications': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5d50>,\n",
              " 'laboratory': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5dd0>,\n",
              " 't': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5e10>,\n",
              " 'any': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5e90>,\n",
              " 'stage': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5f10>,\n",
              " '48': <gensim.models.keyedvectors.Vocab at 0x7f2da46f5f90>,\n",
              " 'tab': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8050>,\n",
              " 'monitor': <gensim.models.keyedvectors.Vocab at 0x7f2da46f80d0>,\n",
              " 'avoid': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8150>,\n",
              " '0': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8190>,\n",
              " 'disorders': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8210>,\n",
              " 'slow': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8290>,\n",
              " 'local': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8310>,\n",
              " 'transmission': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8390>,\n",
              " 'bleeding': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8410>,\n",
              " 'start': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8490>,\n",
              " 'pregnancy': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8510>,\n",
              " 'p': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8550>,\n",
              " 'urine': <gensim.models.keyedvectors.Vocab at 0x7f2da46f85d0>,\n",
              " 'secondary': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8650>,\n",
              " 'n': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8690>,\n",
              " 'prevention': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8710>,\n",
              " 'condition': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8790>,\n",
              " 'herpes': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8810>,\n",
              " 'until': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8890>,\n",
              " 'given': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8910>,\n",
              " 'burns': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8990>,\n",
              " 'test': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8a10>,\n",
              " 'meningitis': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8a90>,\n",
              " 'abdominal': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8b10>,\n",
              " 'these': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8b90>,\n",
              " 'tuberculosis': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8c10>,\n",
              " 'd1': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8c90>,\n",
              " 'effective': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8d10>,\n",
              " 'also': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8d90>,\n",
              " 'care': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8e10>,\n",
              " 'complete': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8e90>,\n",
              " 'asthma': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8f10>,\n",
              " 'pressure': <gensim.models.keyedvectors.Vocab at 0x7f2da46f8f90>,\n",
              " 'year': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9050>,\n",
              " 'max': <gensim.models.keyedvectors.Vocab at 0x7f2da46f90d0>,\n",
              " 'continue': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9150>,\n",
              " 'does': <gensim.models.keyedvectors.Vocab at 0x7f2da46f91d0>,\n",
              " 'recommended': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9250>,\n",
              " 'seizures': <gensim.models.keyedvectors.Vocab at 0x7f2da46f92d0>,\n",
              " 'abscess': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9350>,\n",
              " 'improvement': <gensim.models.keyedvectors.Vocab at 0x7f2da46f93d0>,\n",
              " 'frequent': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9450>,\n",
              " 'up': <gensim.models.keyedvectors.Vocab at 0x7f2da46f94d0>,\n",
              " 'consider': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9550>,\n",
              " 'increase': <gensim.models.keyedvectors.Vocab at 0x7f2da46f95d0>,\n",
              " 'areas': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9650>,\n",
              " 'lower': <gensim.models.keyedvectors.Vocab at 0x7f2da46f96d0>,\n",
              " 'vaginal': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9750>,\n",
              " 'reduce': <gensim.models.keyedvectors.Vocab at 0x7f2da46f97d0>,\n",
              " 'general': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9850>,\n",
              " 'presence': <gensim.models.keyedvectors.Vocab at 0x7f2da46f98d0>,\n",
              " 'normal': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9950>,\n",
              " 'upper': <gensim.models.keyedvectors.Vocab at 0x7f2da46f99d0>,\n",
              " 'period': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9a50>,\n",
              " 'amoxicillin': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9ad0>,\n",
              " 'clean': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9b50>,\n",
              " 'weight': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9bd0>,\n",
              " 'check': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9c50>,\n",
              " 'anaemia': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9cd0>,\n",
              " 'severity': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9d50>,\n",
              " 'look': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9dd0>,\n",
              " 'into': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9e50>,\n",
              " 'pulmonary': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9ed0>,\n",
              " 'loss': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9f50>,\n",
              " 'level': <gensim.models.keyedvectors.Vocab at 0x7f2da46f9fd0>,\n",
              " 'hepatitis': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc090>,\n",
              " 'hct': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc110>,\n",
              " 'paracetamol': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc190>,\n",
              " 'they': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc210>,\n",
              " 'few': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc290>,\n",
              " 'ratio': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc310>,\n",
              " 'diazepam': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc390>,\n",
              " 'deficiency': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc410>,\n",
              " 'cough': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc490>,\n",
              " 'phase': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc510>,\n",
              " 'tetanus': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc590>,\n",
              " 'vaccination': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc610>,\n",
              " 'malnutrition': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc690>,\n",
              " 'body': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc710>,\n",
              " 'time': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc790>,\n",
              " 'absence': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc810>,\n",
              " 'prevent': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc890>,\n",
              " 'indicated': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc910>,\n",
              " 'vomiting': <gensim.models.keyedvectors.Vocab at 0x7f2da46fc990>,\n",
              " 'forms': <gensim.models.keyedvectors.Vocab at 0x7f2da46fca10>,\n",
              " 'infected': <gensim.models.keyedvectors.Vocab at 0x7f2da46fca90>,\n",
              " 'within': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcb10>,\n",
              " 'infants': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcb90>,\n",
              " 'sterile': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcc10>,\n",
              " 'been': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcc90>,\n",
              " 'depending': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcd10>,\n",
              " 'contact': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcd90>,\n",
              " 'hydration': <gensim.models.keyedvectors.Vocab at 0x7f2da46fce10>,\n",
              " 'symptomatic': <gensim.models.keyedvectors.Vocab at 0x7f2da46fce90>,\n",
              " 'several': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcf10>,\n",
              " 'significant': <gensim.models.keyedvectors.Vocab at 0x7f2da46fcf90>,\n",
              " 'area': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd050>,\n",
              " 'doxycycline': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd0d0>,\n",
              " 'figure': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd150>,\n",
              " 'always': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd1d0>,\n",
              " 'specific': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd250>,\n",
              " 'form': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd2d0>,\n",
              " 'very': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd350>,\n",
              " 'tract': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd3d0>,\n",
              " 'rapid': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd450>,\n",
              " 'difficult': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd4d0>,\n",
              " 'painful': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd550>,\n",
              " 'heart': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd5d0>,\n",
              " 'change': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd650>,\n",
              " '400': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd6d0>,\n",
              " '05': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd750>,\n",
              " 'appendix': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd7d0>,\n",
              " 'haemorrhage': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd850>,\n",
              " 'breastfeeding': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd8d0>,\n",
              " 'cloxacillin': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd950>,\n",
              " 'neonates': <gensim.models.keyedvectors.Vocab at 0x7f2da46fd9d0>,\n",
              " 'drugs': <gensim.models.keyedvectors.Vocab at 0x7f2da46fda50>,\n",
              " 'onset': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdad0>,\n",
              " 'd2': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdb50>,\n",
              " 'however': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdbd0>,\n",
              " 'essential': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdc50>,\n",
              " 'distress': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdcd0>,\n",
              " 'chest': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdd50>,\n",
              " '500': <gensim.models.keyedvectors.Vocab at 0x7f2da46fddd0>,\n",
              " 'two': <gensim.models.keyedvectors.Vocab at 0x7f2da46fde50>,\n",
              " 'dropsmin': <gensim.models.keyedvectors.Vocab at 0x7f2da46fded0>,\n",
              " 'such': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdf50>,\n",
              " 'wounds': <gensim.models.keyedvectors.Vocab at 0x7f2da46fdfd0>,\n",
              " 'dry': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff090>,\n",
              " 'moderate': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff110>,\n",
              " 'africa': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff190>,\n",
              " 'ringer': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff210>,\n",
              " 'rehydration': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff290>,\n",
              " 'ulcers': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff310>,\n",
              " 'prophylaxis': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff390>,\n",
              " 'include': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff410>,\n",
              " 'health': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff490>,\n",
              " 're': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff510>,\n",
              " 'fluids': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff590>,\n",
              " 'lactate': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff610>,\n",
              " 'gentamicin': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff690>,\n",
              " 'primary': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff710>,\n",
              " 'gastrointestinal': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff790>,\n",
              " 'below': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff7d0>,\n",
              " 'monitoring': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff850>,\n",
              " 'group': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff8d0>,\n",
              " 'through': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff950>,\n",
              " 'early': <gensim.models.keyedvectors.Vocab at 0x7f2da46ff9d0>,\n",
              " 'sometimes': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffa50>,\n",
              " 'initial': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffad0>,\n",
              " 'dressing': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffb50>,\n",
              " 'urinary': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffbd0>,\n",
              " 'note': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffc50>,\n",
              " 'eye': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffcd0>,\n",
              " 'both': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffd50>,\n",
              " 'treated': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffdd0>,\n",
              " 'serious': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffe50>,\n",
              " 'mild': <gensim.models.keyedvectors.Vocab at 0x7f2da46ffed0>,\n",
              " 'warts': <gensim.models.keyedvectors.Vocab at 0x7f2da46fff50>,\n",
              " 'apply': <gensim.models.keyedvectors.Vocab at 0x7f2da46fffd0>,\n",
              " '150': <gensim.models.keyedvectors.Vocab at 0x7f2da4702090>,\n",
              " '000': <gensim.models.keyedvectors.Vocab at 0x7f2da4702110>,\n",
              " 'increased': <gensim.models.keyedvectors.Vocab at 0x7f2da4702190>,\n",
              " 'red': <gensim.models.keyedvectors.Vocab at 0x7f2da4702210>,\n",
              " 'hour': <gensim.models.keyedvectors.Vocab at 0x7f2da4702290>,\n",
              " 'morphine': <gensim.models.keyedvectors.Vocab at 0x7f2da4702310>,\n",
              " 'depression': <gensim.models.keyedvectors.Vocab at 0x7f2da4702390>,\n",
              " 'duration': <gensim.models.keyedvectors.Vocab at 0x7f2da4702410>,\n",
              " 'well': <gensim.models.keyedvectors.Vocab at 0x7f2da4702490>,\n",
              " 'their': <gensim.models.keyedvectors.Vocab at 0x7f2da4702510>,\n",
              " 'except': <gensim.models.keyedvectors.Vocab at 0x7f2da4702590>,\n",
              " 'table': <gensim.models.keyedvectors.Vocab at 0x7f2da4702610>,\n",
              " 'place': <gensim.models.keyedvectors.Vocab at 0x7f2da4702690>,\n",
              " 'face': <gensim.models.keyedvectors.Vocab at 0x7f2da4702710>,\n",
              " 'required': <gensim.models.keyedvectors.Vocab at 0x7f2da4702790>,\n",
              " 'ors': <gensim.models.keyedvectors.Vocab at 0x7f2da4702810>,\n",
              " 'r': <gensim.models.keyedvectors.Vocab at 0x7f2da4702850>,\n",
              " 'caused': <gensim.models.keyedvectors.Vocab at 0x7f2da47028d0>,\n",
              " 'tissue': <gensim.models.keyedvectors.Vocab at 0x7f2da4702950>,\n",
              " '11': <gensim.models.keyedvectors.Vocab at 0x7f2da47029d0>,\n",
              " 'bp': <gensim.models.keyedvectors.Vocab at 0x7f2da4702a50>,\n",
              " 'stop': <gensim.models.keyedvectors.Vocab at 0x7f2da4702ad0>,\n",
              " 'candidiasis': <gensim.models.keyedvectors.Vocab at 0x7f2da4702b50>,\n",
              " '75': <gensim.models.keyedvectors.Vocab at 0x7f2da4702bd0>,\n",
              " 'food': <gensim.models.keyedvectors.Vocab at 0x7f2da4702c50>,\n",
              " 'syndrome': <gensim.models.keyedvectors.Vocab at 0x7f2da4702cd0>,\n",
              " 'lice': <gensim.models.keyedvectors.Vocab at 0x7f2da4702d50>,\n",
              " 'epidemic': <gensim.models.keyedvectors.Vocab at 0x7f2da4702dd0>,\n",
              " 'count': <gensim.models.keyedvectors.Vocab at 0x7f2da4702e50>,\n",
              " 'contraindicated': <gensim.models.keyedvectors.Vocab at 0x7f2da4702ed0>,\n",
              " 'cannot': <gensim.models.keyedvectors.Vocab at 0x7f2da4702f50>,\n",
              " 'erythromycin': <gensim.models.keyedvectors.Vocab at 0x7f2da4702fd0>,\n",
              " 'obstruction': <gensim.models.keyedvectors.Vocab at 0x7f2da4703090>,\n",
              " 'otitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4703110>,\n",
              " 'te': <gensim.models.keyedvectors.Vocab at 0x7f2da4703190>,\n",
              " 'especially': <gensim.models.keyedvectors.Vocab at 0x7f2da4703210>,\n",
              " 'pulse': <gensim.models.keyedvectors.Vocab at 0x7f2da4703290>,\n",
              " 'proteinuria': <gensim.models.keyedvectors.Vocab at 0x7f2da4703310>,\n",
              " 'suspected': <gensim.models.keyedvectors.Vocab at 0x7f2da4703390>,\n",
              " 'history': <gensim.models.keyedvectors.Vocab at 0x7f2da4703410>,\n",
              " '90': <gensim.models.keyedvectors.Vocab at 0x7f2da4703490>,\n",
              " 'particularly': <gensim.models.keyedvectors.Vocab at 0x7f2da4703510>,\n",
              " 'muscle': <gensim.models.keyedvectors.Vocab at 0x7f2da4703590>,\n",
              " 'mlkgh': <gensim.models.keyedvectors.Vocab at 0x7f2da4703610>,\n",
              " 'positive': <gensim.models.keyedvectors.Vocab at 0x7f2da4703690>,\n",
              " 'antibiotics': <gensim.models.keyedvectors.Vocab at 0x7f2da4703710>,\n",
              " 'where': <gensim.models.keyedvectors.Vocab at 0x7f2da4703790>,\n",
              " 'parasitic': <gensim.models.keyedvectors.Vocab at 0x7f2da4703810>,\n",
              " 'intestinal': <gensim.models.keyedvectors.Vocab at 0x7f2da4703890>,\n",
              " 'consciousness': <gensim.models.keyedvectors.Vocab at 0x7f2da4703910>,\n",
              " 'exceed': <gensim.models.keyedvectors.Vocab at 0x7f2da4703990>,\n",
              " 'ml24': <gensim.models.keyedvectors.Vocab at 0x7f2da4703a10>,\n",
              " '35': <gensim.models.keyedvectors.Vocab at 0x7f2da4703a90>,\n",
              " 'leprosy': <gensim.models.keyedvectors.Vocab at 0x7f2da4703b10>,\n",
              " 'adult': <gensim.models.keyedvectors.Vocab at 0x7f2da4703b90>,\n",
              " 'conjunctivitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4703c10>,\n",
              " 'while': <gensim.models.keyedvectors.Vocab at 0x7f2da4703c90>,\n",
              " 'azithromycin': <gensim.models.keyedvectors.Vocab at 0x7f2da4703d10>,\n",
              " 'minor': <gensim.models.keyedvectors.Vocab at 0x7f2da4703d90>,\n",
              " 'virus': <gensim.models.keyedvectors.Vocab at 0x7f2da4703e10>,\n",
              " 'analgesics': <gensim.models.keyedvectors.Vocab at 0x7f2da4703e90>,\n",
              " 'procedures': <gensim.models.keyedvectors.Vocab at 0x7f2da4703f10>,\n",
              " 'ciprofloxacin': <gensim.models.keyedvectors.Vocab at 0x7f2da4703f90>,\n",
              " 'confirmed': <gensim.models.keyedvectors.Vocab at 0x7f2da4706050>,\n",
              " 'combination': <gensim.models.keyedvectors.Vocab at 0x7f2da47060d0>,\n",
              " 'transfusion': <gensim.models.keyedvectors.Vocab at 0x7f2da4706150>,\n",
              " 'prolonged': <gensim.models.keyedvectors.Vocab at 0x7f2da47061d0>,\n",
              " 'ivermectin': <gensim.models.keyedvectors.Vocab at 0x7f2da4706250>,\n",
              " 'criteria': <gensim.models.keyedvectors.Vocab at 0x7f2da47062d0>,\n",
              " 'rest': <gensim.models.keyedvectors.Vocab at 0x7f2da4706350>,\n",
              " 'line': <gensim.models.keyedvectors.Vocab at 0x7f2da47063d0>,\n",
              " 'renal': <gensim.models.keyedvectors.Vocab at 0x7f2da4706450>,\n",
              " 'metronidazole': <gensim.models.keyedvectors.Vocab at 0x7f2da47064d0>,\n",
              " 'causes': <gensim.models.keyedvectors.Vocab at 0x7f2da4706550>,\n",
              " 'agitation': <gensim.models.keyedvectors.Vocab at 0x7f2da47065d0>,\n",
              " 'u': <gensim.models.keyedvectors.Vocab at 0x7f2da4706610>,\n",
              " 'scabies': <gensim.models.keyedvectors.Vocab at 0x7f2da4706690>,\n",
              " 'even': <gensim.models.keyedvectors.Vocab at 0x7f2da4706710>,\n",
              " 'temperature': <gensim.models.keyedvectors.Vocab at 0x7f2da4706790>,\n",
              " 'hypoglycaemia': <gensim.models.keyedvectors.Vocab at 0x7f2da4706810>,\n",
              " 'delivery': <gensim.models.keyedvectors.Vocab at 0x7f2da4706890>,\n",
              " 'transmitted': <gensim.models.keyedvectors.Vocab at 0x7f2da4706910>,\n",
              " 'add': <gensim.models.keyedvectors.Vocab at 0x7f2da4706990>,\n",
              " 'ampicillin': <gensim.models.keyedvectors.Vocab at 0x7f2da4706a10>,\n",
              " 'patient’s': <gensim.models.keyedvectors.Vocab at 0x7f2da4706a50>,\n",
              " 'ear': <gensim.models.keyedvectors.Vocab at 0x7f2da4706ad0>,\n",
              " 'those': <gensim.models.keyedvectors.Vocab at 0x7f2da4706b50>,\n",
              " 'hands': <gensim.models.keyedvectors.Vocab at 0x7f2da4706bd0>,\n",
              " 'cutaneous': <gensim.models.keyedvectors.Vocab at 0x7f2da4706c50>,\n",
              " 'order': <gensim.models.keyedvectors.Vocab at 0x7f2da4706cd0>,\n",
              " 'vitamin': <gensim.models.keyedvectors.Vocab at 0x7f2da4706d50>,\n",
              " 'cell': <gensim.models.keyedvectors.Vocab at 0x7f2da4706dd0>,\n",
              " 'hypertension': <gensim.models.keyedvectors.Vocab at 0x7f2da4706e50>,\n",
              " 'output': <gensim.models.keyedvectors.Vocab at 0x7f2da4706ed0>,\n",
              " 'assessment': <gensim.models.keyedvectors.Vocab at 0x7f2da4706f50>,\n",
              " 'oxygen': <gensim.models.keyedvectors.Vocab at 0x7f2da4706fd0>,\n",
              " 'd3': <gensim.models.keyedvectors.Vocab at 0x7f2da4708090>,\n",
              " 'choice': <gensim.models.keyedvectors.Vocab at 0x7f2da4708110>,\n",
              " 'volume': <gensim.models.keyedvectors.Vocab at 0x7f2da4708190>,\n",
              " 'dengue': <gensim.models.keyedvectors.Vocab at 0x7f2da4708210>,\n",
              " 'occur': <gensim.models.keyedvectors.Vocab at 0x7f2da4708290>,\n",
              " 'develop': <gensim.models.keyedvectors.Vocab at 0x7f2da4708310>,\n",
              " 'uterine': <gensim.models.keyedvectors.Vocab at 0x7f2da4708390>,\n",
              " 'improved': <gensim.models.keyedvectors.Vocab at 0x7f2da4708410>,\n",
              " 'measles': <gensim.models.keyedvectors.Vocab at 0x7f2da4708490>,\n",
              " 'take': <gensim.models.keyedvectors.Vocab at 0x7f2da4708510>,\n",
              " 'hospital': <gensim.models.keyedvectors.Vocab at 0x7f2da4708590>,\n",
              " 'illness': <gensim.models.keyedvectors.Vocab at 0x7f2da4708610>,\n",
              " 'frequently': <gensim.models.keyedvectors.Vocab at 0x7f2da4708690>,\n",
              " 'attack': <gensim.models.keyedvectors.Vocab at 0x7f2da4708710>,\n",
              " 'poor': <gensim.models.keyedvectors.Vocab at 0x7f2da4708790>,\n",
              " 'mouth': <gensim.models.keyedvectors.Vocab at 0x7f2da4708810>,\n",
              " 'tablet': <gensim.models.keyedvectors.Vocab at 0x7f2da4708890>,\n",
              " 'plan': <gensim.models.keyedvectors.Vocab at 0x7f2da4708910>,\n",
              " 'drainage': <gensim.models.keyedvectors.Vocab at 0x7f2da4708990>,\n",
              " 'inflammation': <gensim.models.keyedvectors.Vocab at 0x7f2da4708a10>,\n",
              " 'bites': <gensim.models.keyedvectors.Vocab at 0x7f2da4708a90>,\n",
              " 'dilute': <gensim.models.keyedvectors.Vocab at 0x7f2da4708b10>,\n",
              " 'insert': <gensim.models.keyedvectors.Vocab at 0x7f2da4708b90>,\n",
              " 'purulent': <gensim.models.keyedvectors.Vocab at 0x7f2da4708c10>,\n",
              " 'anxiety': <gensim.models.keyedvectors.Vocab at 0x7f2da4708c90>,\n",
              " 'tb': <gensim.models.keyedvectors.Vocab at 0x7f2da4708d10>,\n",
              " 'tests': <gensim.models.keyedvectors.Vocab at 0x7f2da4708d90>,\n",
              " 'coamoxiclav': <gensim.models.keyedvectors.Vocab at 0x7f2da4708e10>,\n",
              " 'measure': <gensim.models.keyedvectors.Vocab at 0x7f2da4708e90>,\n",
              " '80': <gensim.models.keyedvectors.Vocab at 0x7f2da4708f10>,\n",
              " 'close': <gensim.models.keyedvectors.Vocab at 0x7f2da4708f90>,\n",
              " 'tube': <gensim.models.keyedvectors.Vocab at 0x7f2da4709050>,\n",
              " 'bag': <gensim.models.keyedvectors.Vocab at 0x7f2da47090d0>,\n",
              " 'never': <gensim.models.keyedvectors.Vocab at 0x7f2da4709150>,\n",
              " '250': <gensim.models.keyedvectors.Vocab at 0x7f2da47091d0>,\n",
              " 'stools': <gensim.models.keyedvectors.Vocab at 0x7f2da4709250>,\n",
              " 'refer': <gensim.models.keyedvectors.Vocab at 0x7f2da47092d0>,\n",
              " 'persistent': <gensim.models.keyedvectors.Vocab at 0x7f2da4709350>,\n",
              " 'conditions': <gensim.models.keyedvectors.Vocab at 0x7f2da47093d0>,\n",
              " 'mainly': <gensim.models.keyedvectors.Vocab at 0x7f2da4709450>,\n",
              " 'rr': <gensim.models.keyedvectors.Vocab at 0x7f2da47094d0>,\n",
              " 'timesday': <gensim.models.keyedvectors.Vocab at 0x7f2da4709550>,\n",
              " 'soon': <gensim.models.keyedvectors.Vocab at 0x7f2da47095d0>,\n",
              " 'week': <gensim.models.keyedvectors.Vocab at 0x7f2da4709650>,\n",
              " 'adverse': <gensim.models.keyedvectors.Vocab at 0x7f2da47096d0>,\n",
              " 'l': <gensim.models.keyedvectors.Vocab at 0x7f2da4709710>,\n",
              " 'salbutamol': <gensim.models.keyedvectors.Vocab at 0x7f2da4709790>,\n",
              " 'neurological': <gensim.models.keyedvectors.Vocab at 0x7f2da4709810>,\n",
              " 'syphilis': <gensim.models.keyedvectors.Vocab at 0x7f2da4709890>,\n",
              " 'cellulitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4709910>,\n",
              " 'young': <gensim.models.keyedvectors.Vocab at 0x7f2da4709990>,\n",
              " 'effects': <gensim.models.keyedvectors.Vocab at 0x7f2da4709a10>,\n",
              " 'drops': <gensim.models.keyedvectors.Vocab at 0x7f2da4709a90>,\n",
              " 'milk': <gensim.models.keyedvectors.Vocab at 0x7f2da4709b10>,\n",
              " 'emergency': <gensim.models.keyedvectors.Vocab at 0x7f2da4709b90>,\n",
              " 'persist': <gensim.models.keyedvectors.Vocab at 0x7f2da4709c10>,\n",
              " 'life': <gensim.models.keyedvectors.Vocab at 0x7f2da4709c90>,\n",
              " 'second': <gensim.models.keyedvectors.Vocab at 0x7f2da4709d10>,\n",
              " 'mother': <gensim.models.keyedvectors.Vocab at 0x7f2da4709d90>,\n",
              " '81': <gensim.models.keyedvectors.Vocab at 0x7f2da4709e10>,\n",
              " 'abnormal': <gensim.models.keyedvectors.Vocab at 0x7f2da4709e90>,\n",
              " 'deep': <gensim.models.keyedvectors.Vocab at 0x7f2da4709f10>,\n",
              " 'pharyngitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4709f90>,\n",
              " 'considered': <gensim.models.keyedvectors.Vocab at 0x7f2da470c050>,\n",
              " 'gdl': <gensim.models.keyedvectors.Vocab at 0x7f2da470c0d0>,\n",
              " 'individual': <gensim.models.keyedvectors.Vocab at 0x7f2da470c150>,\n",
              " 'manual': <gensim.models.keyedvectors.Vocab at 0x7f2da470c1d0>,\n",
              " 'certain': <gensim.models.keyedvectors.Vocab at 0x7f2da470c250>,\n",
              " 'iodine': <gensim.models.keyedvectors.Vocab at 0x7f2da470c2d0>,\n",
              " 'dipstick': <gensim.models.keyedvectors.Vocab at 0x7f2da470c350>,\n",
              " '71': <gensim.models.keyedvectors.Vocab at 0x7f2da470c3d0>,\n",
              " 'context': <gensim.models.keyedvectors.Vocab at 0x7f2da470c450>,\n",
              " 'cervical': <gensim.models.keyedvectors.Vocab at 0x7f2da470c4d0>,\n",
              " 'f': <gensim.models.keyedvectors.Vocab at 0x7f2da470c510>,\n",
              " 'peripheral': <gensim.models.keyedvectors.Vocab at 0x7f2da470c590>,\n",
              " 'some': <gensim.models.keyedvectors.Vocab at 0x7f2da470c610>,\n",
              " 'rabies': <gensim.models.keyedvectors.Vocab at 0x7f2da470c690>,\n",
              " 'syringe': <gensim.models.keyedvectors.Vocab at 0x7f2da470c710>,\n",
              " 'repeat': <gensim.models.keyedvectors.Vocab at 0x7f2da470c790>,\n",
              " 'iu': <gensim.models.keyedvectors.Vocab at 0x7f2da470c810>,\n",
              " 'repeated': <gensim.models.keyedvectors.Vocab at 0x7f2da470c890>,\n",
              " 'x': <gensim.models.keyedvectors.Vocab at 0x7f2da470c8d0>,\n",
              " 'drug': <gensim.models.keyedvectors.Vocab at 0x7f2da470c950>,\n",
              " 'distribution': <gensim.models.keyedvectors.Vocab at 0x7f2da470c9d0>,\n",
              " 'expressed': <gensim.models.keyedvectors.Vocab at 0x7f2da470ca50>,\n",
              " 'asymptomatic': <gensim.models.keyedvectors.Vocab at 0x7f2da470cad0>,\n",
              " 'yes': <gensim.models.keyedvectors.Vocab at 0x7f2da470cb50>,\n",
              " 'occurs': <gensim.models.keyedvectors.Vocab at 0x7f2da470cbd0>,\n",
              " 'updated': <gensim.models.keyedvectors.Vocab at 0x7f2da470cc50>,\n",
              " 'maintain': <gensim.models.keyedvectors.Vocab at 0x7f2da470ccd0>,\n",
              " 'exposure': <gensim.models.keyedvectors.Vocab at 0x7f2da470cd50>,\n",
              " 'systemic': <gensim.models.keyedvectors.Vocab at 0x7f2da470cdd0>,\n",
              " 'y': <gensim.models.keyedvectors.Vocab at 0x7f2da470ce10>,\n",
              " 'difficulty': <gensim.models.keyedvectors.Vocab at 0x7f2da470ce90>,\n",
              " 'smx': <gensim.models.keyedvectors.Vocab at 0x7f2da470cf10>,\n",
              " 'home': <gensim.models.keyedvectors.Vocab at 0x7f2da470cf90>,\n",
              " 'amoxicillinclavulanic': <gensim.models.keyedvectors.Vocab at 0x7f2da470cfd0>,\n",
              " 'airway': <gensim.models.keyedvectors.Vocab at 0x7f2da470e090>,\n",
              " 'disorder': <gensim.models.keyedvectors.Vocab at 0x7f2da470e110>,\n",
              " 'loa': <gensim.models.keyedvectors.Vocab at 0x7f2da470e190>,\n",
              " 'injections': <gensim.models.keyedvectors.Vocab at 0x7f2da470e210>,\n",
              " 'parasite': <gensim.models.keyedvectors.Vocab at 0x7f2da470e290>,\n",
              " 'hb': <gensim.models.keyedvectors.Vocab at 0x7f2da470e310>,\n",
              " 'sexual': <gensim.models.keyedvectors.Vocab at 0x7f2da470e390>,\n",
              " 'febrile': <gensim.models.keyedvectors.Vocab at 0x7f2da470e410>,\n",
              " 'cervix': <gensim.models.keyedvectors.Vocab at 0x7f2da470e490>,\n",
              " 'clindamycin': <gensim.models.keyedvectors.Vocab at 0x7f2da470e510>,\n",
              " 'haemorrhagic': <gensim.models.keyedvectors.Vocab at 0x7f2da470e590>,\n",
              " 'next': <gensim.models.keyedvectors.Vocab at 0x7f2da470e610>,\n",
              " 'based': <gensim.models.keyedvectors.Vocab at 0x7f2da470e690>,\n",
              " 'major': <gensim.models.keyedvectors.Vocab at 0x7f2da470e710>,\n",
              " '300': <gensim.models.keyedvectors.Vocab at 0x7f2da470e790>,\n",
              " 'reaction': <gensim.models.keyedvectors.Vocab at 0x7f2da470e810>,\n",
              " 'loiasis': <gensim.models.keyedvectors.Vocab at 0x7f2da470e890>,\n",
              " 'national': <gensim.models.keyedvectors.Vocab at 0x7f2da470e910>,\n",
              " 'mgml': <gensim.models.keyedvectors.Vocab at 0x7f2da470e990>,\n",
              " 'epinephrine': <gensim.models.keyedvectors.Vocab at 0x7f2da470ea10>,\n",
              " 'remove': <gensim.models.keyedvectors.Vocab at 0x7f2da470ea90>,\n",
              " 'low': <gensim.models.keyedvectors.Vocab at 0x7f2da470eb10>,\n",
              " 'cyanosis': <gensim.models.keyedvectors.Vocab at 0x7f2da470eb90>,\n",
              " 'rapidly': <gensim.models.keyedvectors.Vocab at 0x7f2da470ec10>,\n",
              " 'leishmaniasis': <gensim.models.keyedvectors.Vocab at 0x7f2da470ec90>,\n",
              " 'eyes': <gensim.models.keyedvectors.Vocab at 0x7f2da470ed10>,\n",
              " 'remains': <gensim.models.keyedvectors.Vocab at 0x7f2da470ed90>,\n",
              " 'i': <gensim.models.keyedvectors.Vocab at 0x7f2da470edd0>,\n",
              " 'prednisolone': <gensim.models.keyedvectors.Vocab at 0x7f2da470ee50>,\n",
              " '800': <gensim.models.keyedvectors.Vocab at 0x7f2da470eed0>,\n",
              " 'example': <gensim.models.keyedvectors.Vocab at 0x7f2da470ef50>,\n",
              " 'another': <gensim.models.keyedvectors.Vocab at 0x7f2da470efd0>,\n",
              " 'hand': <gensim.models.keyedvectors.Vocab at 0x7f2da470f090>,\n",
              " 'impetigo': <gensim.models.keyedvectors.Vocab at 0x7f2da470f110>,\n",
              " 'intake': <gensim.models.keyedvectors.Vocab at 0x7f2da470f190>,\n",
              " 'iron': <gensim.models.keyedvectors.Vocab at 0x7f2da470f210>,\n",
              " 'reduction': <gensim.models.keyedvectors.Vocab at 0x7f2da470f290>,\n",
              " 'syndromes': <gensim.models.keyedvectors.Vocab at 0x7f2da470f310>,\n",
              " 'asia': <gensim.models.keyedvectors.Vocab at 0x7f2da470f390>,\n",
              " 'including': <gensim.models.keyedvectors.Vocab at 0x7f2da470f410>,\n",
              " 'despite': <gensim.models.keyedvectors.Vocab at 0x7f2da470f490>,\n",
              " 'control': <gensim.models.keyedvectors.Vocab at 0x7f2da470f510>,\n",
              " '41': <gensim.models.keyedvectors.Vocab at 0x7f2da470f590>,\n",
              " 'manifestations': <gensim.models.keyedvectors.Vocab at 0x7f2da470f610>,\n",
              " 'gloves': <gensim.models.keyedvectors.Vocab at 0x7f2da470f690>,\n",
              " 'stool': <gensim.models.keyedvectors.Vocab at 0x7f2da470f710>,\n",
              " 'contaminated': <gensim.models.keyedvectors.Vocab at 0x7f2da470f790>,\n",
              " 'membranes': <gensim.models.keyedvectors.Vocab at 0x7f2da470f810>,\n",
              " 'immediately': <gensim.models.keyedvectors.Vocab at 0x7f2da470f890>,\n",
              " 'mmhg': <gensim.models.keyedvectors.Vocab at 0x7f2da470f910>,\n",
              " 'cm': <gensim.models.keyedvectors.Vocab at 0x7f2da470f990>,\n",
              " 'extensive': <gensim.models.keyedvectors.Vocab at 0x7f2da470fa10>,\n",
              " 'south': <gensim.models.keyedvectors.Vocab at 0x7f2da470fa90>,\n",
              " 'genitourinary': <gensim.models.keyedvectors.Vocab at 0x7f2da470fb10>,\n",
              " 'nasal': <gensim.models.keyedvectors.Vocab at 0x7f2da470fb90>,\n",
              " 'different': <gensim.models.keyedvectors.Vocab at 0x7f2da470fc10>,\n",
              " 'left': <gensim.models.keyedvectors.Vocab at 0x7f2da470fc90>,\n",
              " 'ensure': <gensim.models.keyedvectors.Vocab at 0x7f2da470fd10>,\n",
              " 'vaccine': <gensim.models.keyedvectors.Vocab at 0x7f2da470fd90>,\n",
              " 'small': <gensim.models.keyedvectors.Vocab at 0x7f2da470fe10>,\n",
              " 'neck': <gensim.models.keyedvectors.Vocab at 0x7f2da470fe90>,\n",
              " 'found': <gensim.models.keyedvectors.Vocab at 0x7f2da470ff10>,\n",
              " 'type': <gensim.models.keyedvectors.Vocab at 0x7f2da470ff90>,\n",
              " 'headache': <gensim.models.keyedvectors.Vocab at 0x7f2da4712050>,\n",
              " 'alternative': <gensim.models.keyedvectors.Vocab at 0x7f2da47120d0>,\n",
              " 'ointment': <gensim.models.keyedvectors.Vocab at 0x7f2da4712150>,\n",
              " 'routine': <gensim.models.keyedvectors.Vocab at 0x7f2da47121d0>,\n",
              " 'saturation': <gensim.models.keyedvectors.Vocab at 0x7f2da4712250>,\n",
              " 'urethral': <gensim.models.keyedvectors.Vocab at 0x7f2da47122d0>,\n",
              " 'chlamydia': <gensim.models.keyedvectors.Vocab at 0x7f2da4712350>,\n",
              " 'soft': <gensim.models.keyedvectors.Vocab at 0x7f2da47123d0>,\n",
              " 'rarely': <gensim.models.keyedvectors.Vocab at 0x7f2da4712450>,\n",
              " 'episode': <gensim.models.keyedvectors.Vocab at 0x7f2da47124d0>,\n",
              " 'o2': <gensim.models.keyedvectors.Vocab at 0x7f2da4712550>,\n",
              " 'aids': <gensim.models.keyedvectors.Vocab at 0x7f2da47125d0>,\n",
              " 'episodes': <gensim.models.keyedvectors.Vocab at 0x7f2da4712650>,\n",
              " 'tablets': <gensim.models.keyedvectors.Vocab at 0x7f2da47126d0>,\n",
              " 'gradually': <gensim.models.keyedvectors.Vocab at 0x7f2da4712750>,\n",
              " 'underlying': <gensim.models.keyedvectors.Vocab at 0x7f2da47127d0>,\n",
              " 'obtain': <gensim.models.keyedvectors.Vocab at 0x7f2da4712850>,\n",
              " 'direct': <gensim.models.keyedvectors.Vocab at 0x7f2da47128d0>,\n",
              " 'around': <gensim.models.keyedvectors.Vocab at 0x7f2da4712950>,\n",
              " 'decrease': <gensim.models.keyedvectors.Vocab at 0x7f2da47129d0>,\n",
              " 'followed': <gensim.models.keyedvectors.Vocab at 0x7f2da4712a50>,\n",
              " 'mental': <gensim.models.keyedvectors.Vocab at 0x7f2da4712ad0>,\n",
              " 'onchocerciasis': <gensim.models.keyedvectors.Vocab at 0x7f2da4712b50>,\n",
              " 'multiple': <gensim.models.keyedvectors.Vocab at 0x7f2da4712bd0>,\n",
              " 'v': <gensim.models.keyedvectors.Vocab at 0x7f2da4712c10>,\n",
              " 'hygiene': <gensim.models.keyedvectors.Vocab at 0x7f2da4712c90>,\n",
              " '≤': <gensim.models.keyedvectors.Vocab at 0x7f2da4712cd0>,\n",
              " 'erythema': <gensim.models.keyedvectors.Vocab at 0x7f2da4712d50>,\n",
              " 'nutritional': <gensim.models.keyedvectors.Vocab at 0x7f2da4712dd0>,\n",
              " 'plague': <gensim.models.keyedvectors.Vocab at 0x7f2da4712e50>,\n",
              " 'position': <gensim.models.keyedvectors.Vocab at 0x7f2da4712ed0>,\n",
              " 'back': <gensim.models.keyedvectors.Vocab at 0x7f2da4712f50>,\n",
              " 'men': <gensim.models.keyedvectors.Vocab at 0x7f2da4712fd0>,\n",
              " 'recurrent': <gensim.models.keyedvectors.Vocab at 0x7f2da4715090>,\n",
              " 'out': <gensim.models.keyedvectors.Vocab at 0x7f2da4715110>,\n",
              " '01': <gensim.models.keyedvectors.Vocab at 0x7f2da4715190>,\n",
              " 'limbs': <gensim.models.keyedvectors.Vocab at 0x7f2da4715210>,\n",
              " 'ie': <gensim.models.keyedvectors.Vocab at 0x7f2da4715290>,\n",
              " 'will': <gensim.models.keyedvectors.Vocab at 0x7f2da4715310>,\n",
              " 'overload': <gensim.models.keyedvectors.Vocab at 0x7f2da4715390>,\n",
              " 'mgkgd': <gensim.models.keyedvectors.Vocab at 0x7f2da4715410>,\n",
              " 'isolation': <gensim.models.keyedvectors.Vocab at 0x7f2da4715490>,\n",
              " 'results': <gensim.models.keyedvectors.Vocab at 0x7f2da4715510>,\n",
              " 'sinusitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4715590>,\n",
              " 'keep': <gensim.models.keyedvectors.Vocab at 0x7f2da4715610>,\n",
              " 'negative': <gensim.models.keyedvectors.Vocab at 0x7f2da4715690>,\n",
              " 'rare': <gensim.models.keyedvectors.Vocab at 0x7f2da4715710>,\n",
              " 'cardiac': <gensim.models.keyedvectors.Vocab at 0x7f2da4715790>,\n",
              " 'open': <gensim.models.keyedvectors.Vocab at 0x7f2da4715810>,\n",
              " 'cold': <gensim.models.keyedvectors.Vocab at 0x7f2da4715890>,\n",
              " 'alone': <gensim.models.keyedvectors.Vocab at 0x7f2da4715910>,\n",
              " 'erythematous': <gensim.models.keyedvectors.Vocab at 0x7f2da4715990>,\n",
              " 'rash': <gensim.models.keyedvectors.Vocab at 0x7f2da4715a10>,\n",
              " 'clothing': <gensim.models.keyedvectors.Vocab at 0x7f2da4715a90>,\n",
              " 've': <gensim.models.keyedvectors.Vocab at 0x7f2da4715b10>,\n",
              " 'lesion': <gensim.models.keyedvectors.Vocab at 0x7f2da4715b90>,\n",
              " 'bite': <gensim.models.keyedvectors.Vocab at 0x7f2da4715c10>,\n",
              " 'long': <gensim.models.keyedvectors.Vocab at 0x7f2da4715c90>,\n",
              " 'nasogastric': <gensim.models.keyedvectors.Vocab at 0x7f2da4715d10>,\n",
              " 'last': <gensim.models.keyedvectors.Vocab at 0x7f2da4715d90>,\n",
              " 'needed': <gensim.models.keyedvectors.Vocab at 0x7f2da4715e10>,\n",
              " 'corticosteroids': <gensim.models.keyedvectors.Vocab at 0x7f2da4715e90>,\n",
              " 'clavulanic': <gensim.models.keyedvectors.Vocab at 0x7f2da4715f10>,\n",
              " 'simple': <gensim.models.keyedvectors.Vocab at 0x7f2da4715f90>,\n",
              " 'procedure': <gensim.models.keyedvectors.Vocab at 0x7f2da4718050>,\n",
              " 'media': <gensim.models.keyedvectors.Vocab at 0x7f2da47180d0>,\n",
              " 'white': <gensim.models.keyedvectors.Vocab at 0x7f2da4718150>,\n",
              " 'contacts': <gensim.models.keyedvectors.Vocab at 0x7f2da47181d0>,\n",
              " 'cotrimoxazole': <gensim.models.keyedvectors.Vocab at 0x7f2da4718250>,\n",
              " 'about': <gensim.models.keyedvectors.Vocab at 0x7f2da47182d0>,\n",
              " 'breast': <gensim.models.keyedvectors.Vocab at 0x7f2da4718350>,\n",
              " 'forceps': <gensim.models.keyedvectors.Vocab at 0x7f2da47183d0>,\n",
              " 'feeding': <gensim.models.keyedvectors.Vocab at 0x7f2da4718450>,\n",
              " 'simplex': <gensim.models.keyedvectors.Vocab at 0x7f2da47184d0>,\n",
              " 'fluconazole': <gensim.models.keyedvectors.Vocab at 0x7f2da4718550>,\n",
              " 'his': <gensim.models.keyedvectors.Vocab at 0x7f2da47185d0>,\n",
              " 'bronchitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4718650>,\n",
              " 'useful': <gensim.models.keyedvectors.Vocab at 0x7f2da47186d0>,\n",
              " 'supervision': <gensim.models.keyedvectors.Vocab at 0x7f2da4718750>,\n",
              " 'maintenance': <gensim.models.keyedvectors.Vocab at 0x7f2da47187d0>,\n",
              " 'rectal': <gensim.models.keyedvectors.Vocab at 0x7f2da4718850>,\n",
              " 'status': <gensim.models.keyedvectors.Vocab at 0x7f2da47188d0>,\n",
              " 'head': <gensim.models.keyedvectors.Vocab at 0x7f2da4718950>,\n",
              " 'containing': <gensim.models.keyedvectors.Vocab at 0x7f2da47189d0>,\n",
              " 'infectious': <gensim.models.keyedvectors.Vocab at 0x7f2da4718a50>,\n",
              " 'relapsing': <gensim.models.keyedvectors.Vocab at 0x7f2da4718ad0>,\n",
              " 'cd4': <gensim.models.keyedvectors.Vocab at 0x7f2da4718b50>,\n",
              " 'sign': <gensim.models.keyedvectors.Vocab at 0x7f2da4718bd0>,\n",
              " 'follow': <gensim.models.keyedvectors.Vocab at 0x7f2da4718c50>,\n",
              " '45': <gensim.models.keyedvectors.Vocab at 0x7f2da4718cd0>,\n",
              " 'site': <gensim.models.keyedvectors.Vocab at 0x7f2da4718d50>,\n",
              " 'appear': <gensim.models.keyedvectors.Vocab at 0x7f2da4718dd0>,\n",
              " 'rs': <gensim.models.keyedvectors.Vocab at 0x7f2da4718e50>,\n",
              " 'en': <gensim.models.keyedvectors.Vocab at 0x7f2da4718ed0>,\n",
              " 'central': <gensim.models.keyedvectors.Vocab at 0x7f2da4718f50>,\n",
              " 'coma': <gensim.models.keyedvectors.Vocab at 0x7f2da4718fd0>,\n",
              " 'dyspnoea': <gensim.models.keyedvectors.Vocab at 0x7f2da471a090>,\n",
              " 'se': <gensim.models.keyedvectors.Vocab at 0x7f2da471a110>,\n",
              " 'foreign': <gensim.models.keyedvectors.Vocab at 0x7f2da471a190>,\n",
              " 'followup': <gensim.models.keyedvectors.Vocab at 0x7f2da471a210>,\n",
              " 'activity': <gensim.models.keyedvectors.Vocab at 0x7f2da471a290>,\n",
              " 'partner': <gensim.models.keyedvectors.Vocab at 0x7f2da471a310>,\n",
              " 'drink': <gensim.models.keyedvectors.Vocab at 0x7f2da471a390>,\n",
              " 'america': <gensim.models.keyedvectors.Vocab at 0x7f2da471a410>,\n",
              " 'determine': <gensim.models.keyedvectors.Vocab at 0x7f2da471a490>,\n",
              " 'victim': <gensim.models.keyedvectors.Vocab at 0x7f2da471a510>,\n",
              " 'resistance': <gensim.models.keyedvectors.Vocab at 0x7f2da471a590>,\n",
              " 'ns': <gensim.models.keyedvectors.Vocab at 0x7f2da471a610>,\n",
              " 'mortality': <gensim.models.keyedvectors.Vocab at 0x7f2da471a690>,\n",
              " '125': <gensim.models.keyedvectors.Vocab at 0x7f2da471a710>,\n",
              " 'violence': <gensim.models.keyedvectors.Vocab at 0x7f2da471a790>,\n",
              " 'secretions': <gensim.models.keyedvectors.Vocab at 0x7f2da471a810>,\n",
              " 'response': <gensim.models.keyedvectors.Vocab at 0x7f2da471a890>,\n",
              " 'interval': <gensim.models.keyedvectors.Vocab at 0x7f2da471a910>,\n",
              " 'plasma': <gensim.models.keyedvectors.Vocab at 0x7f2da471a990>,\n",
              " 'worms': <gensim.models.keyedvectors.Vocab at 0x7f2da471aa10>,\n",
              " 'lymph': <gensim.models.keyedvectors.Vocab at 0x7f2da471aa90>,\n",
              " 'immunisation': <gensim.models.keyedvectors.Vocab at 0x7f2da471ab10>,\n",
              " 'wash': <gensim.models.keyedvectors.Vocab at 0x7f2da471ab90>,\n",
              " 'ulcer': <gensim.models.keyedvectors.Vocab at 0x7f2da471ac10>,\n",
              " 'stomatitis': <gensim.models.keyedvectors.Vocab at 0x7f2da471ac90>,\n",
              " 'mucous': <gensim.models.keyedvectors.Vocab at 0x7f2da471ad10>,\n",
              " 'older': <gensim.models.keyedvectors.Vocab at 0x7f2da471ad90>,\n",
              " 'croup': <gensim.models.keyedvectors.Vocab at 0x7f2da471ae10>,\n",
              " '13': <gensim.models.keyedvectors.Vocab at 0x7f2da471ae90>,\n",
              " 'cystitis': <gensim.models.keyedvectors.Vocab at 0x7f2da471af10>,\n",
              " 'contagious': <gensim.models.keyedvectors.Vocab at 0x7f2da471af90>,\n",
              " 'amoebiasis': <gensim.models.keyedvectors.Vocab at 0x7f2da471b050>,\n",
              " 'support': <gensim.models.keyedvectors.Vocab at 0x7f2da471b0d0>,\n",
              " 'visceral': <gensim.models.keyedvectors.Vocab at 0x7f2da471b150>,\n",
              " 'made': <gensim.models.keyedvectors.Vocab at 0x7f2da471b1d0>,\n",
              " 'fungal': <gensim.models.keyedvectors.Vocab at 0x7f2da471b250>,\n",
              " 'abscesses': <gensim.models.keyedvectors.Vocab at 0x7f2da471b2d0>,\n",
              " 'tolerated': <gensim.models.keyedvectors.Vocab at 0x7f2da471b350>,\n",
              " 'total': <gensim.models.keyedvectors.Vocab at 0x7f2da471b3d0>,\n",
              " 'serum': <gensim.models.keyedvectors.Vocab at 0x7f2da471b450>,\n",
              " 'room': <gensim.models.keyedvectors.Vocab at 0x7f2da471b4d0>,\n",
              " 'excision': <gensim.models.keyedvectors.Vocab at 0x7f2da471b550>,\n",
              " 'human': <gensim.models.keyedvectors.Vocab at 0x7f2da471b5d0>,\n",
              " 'depends': <gensim.models.keyedvectors.Vocab at 0x7f2da471b650>,\n",
              " 'bilateral': <gensim.models.keyedvectors.Vocab at 0x7f2da471b6d0>,\n",
              " 'zoster': <gensim.models.keyedvectors.Vocab at 0x7f2da471b750>,\n",
              " 'main': <gensim.models.keyedvectors.Vocab at 0x7f2da471b7d0>,\n",
              " 'species': <gensim.models.keyedvectors.Vocab at 0x7f2da471b850>,\n",
              " 'short': <gensim.models.keyedvectors.Vocab at 0x7f2da471b8d0>,\n",
              " 'schistosomiasis': <gensim.models.keyedvectors.Vocab at 0x7f2da471b950>,\n",
              " 'regular': <gensim.models.keyedvectors.Vocab at 0x7f2da471b9d0>,\n",
              " 'w': <gensim.models.keyedvectors.Vocab at 0x7f2da471ba10>,\n",
              " 'nausea': <gensim.models.keyedvectors.Vocab at 0x7f2da471ba90>,\n",
              " 'sputum': <gensim.models.keyedvectors.Vocab at 0x7f2da471bb10>,\n",
              " 'dressings': <gensim.models.keyedvectors.Vocab at 0x7f2da471bb90>,\n",
              " 'absent': <gensim.models.keyedvectors.Vocab at 0x7f2da471bc10>,\n",
              " 'bsa': <gensim.models.keyedvectors.Vocab at 0x7f2da471bc90>,\n",
              " 'its': <gensim.models.keyedvectors.Vocab at 0x7f2da471bd10>,\n",
              " 'compresses': <gensim.models.keyedvectors.Vocab at 0x7f2da471bd90>,\n",
              " 'longer': <gensim.models.keyedvectors.Vocab at 0x7f2da471be10>,\n",
              " '375': <gensim.models.keyedvectors.Vocab at 0x7f2da471be90>,\n",
              " 'benign': <gensim.models.keyedvectors.Vocab at 0x7f2da471bf10>,\n",
              " 'tachycardia': <gensim.models.keyedvectors.Vocab at 0x7f2da471bf90>,\n",
              " 'correct': <gensim.models.keyedvectors.Vocab at 0x7f2da471e050>,\n",
              " 'aetiologies': <gensim.models.keyedvectors.Vocab at 0x7f2da471e0d0>,\n",
              " 'puffs': <gensim.models.keyedvectors.Vocab at 0x7f2da471e150>,\n",
              " 'sudden': <gensim.models.keyedvectors.Vocab at 0x7f2da471e1d0>,\n",
              " 'accompanied': <gensim.models.keyedvectors.Vocab at 0x7f2da471e250>,\n",
              " 'set': <gensim.models.keyedvectors.Vocab at 0x7f2da471e2d0>,\n",
              " 'anaesthesia': <gensim.models.keyedvectors.Vocab at 0x7f2da471e350>,\n",
              " 'albendazole': <gensim.models.keyedvectors.Vocab at 0x7f2da471e3d0>,\n",
              " 'material': <gensim.models.keyedvectors.Vocab at 0x7f2da471e450>,\n",
              " 'development': <gensim.models.keyedvectors.Vocab at 0x7f2da471e4d0>,\n",
              " 'result': <gensim.models.keyedvectors.Vocab at 0x7f2da471e550>,\n",
              " 'sulfate': <gensim.models.keyedvectors.Vocab at 0x7f2da471e5d0>,\n",
              " 'twice': <gensim.models.keyedvectors.Vocab at 0x7f2da471e650>,\n",
              " 'confusion': <gensim.models.keyedvectors.Vocab at 0x7f2da471e6d0>,\n",
              " 'blister': <gensim.models.keyedvectors.Vocab at 0x7f2da471e750>,\n",
              " 'zinc': <gensim.models.keyedvectors.Vocab at 0x7f2da471e7d0>,\n",
              " 'either': <gensim.models.keyedvectors.Vocab at 0x7f2da471e850>,\n",
              " 'psychotic': <gensim.models.keyedvectors.Vocab at 0x7f2da471e8d0>,\n",
              " 'taken': <gensim.models.keyedvectors.Vocab at 0x7f2da471e950>,\n",
              " '2016': <gensim.models.keyedvectors.Vocab at 0x7f2da471e9d0>,\n",
              " 'breathing': <gensim.models.keyedvectors.Vocab at 0x7f2da471ea50>,\n",
              " 'defined': <gensim.models.keyedvectors.Vocab at 0x7f2da471ead0>,\n",
              " 'lead': <gensim.models.keyedvectors.Vocab at 0x7f2da471eb50>,\n",
              " 'physical': <gensim.models.keyedvectors.Vocab at 0x7f2da471ebd0>,\n",
              " 'usual': <gensim.models.keyedvectors.Vocab at 0x7f2da471ec50>,\n",
              " 'amphotericin': <gensim.models.keyedvectors.Vocab at 0x7f2da471ecd0>,\n",
              " 'information': <gensim.models.keyedvectors.Vocab at 0x7f2da471ed50>,\n",
              " 'number': <gensim.models.keyedvectors.Vocab at 0x7f2da471edd0>,\n",
              " 'quinine': <gensim.models.keyedvectors.Vocab at 0x7f2da471ee50>,\n",
              " 'sickle': <gensim.models.keyedvectors.Vocab at 0x7f2da471eed0>,\n",
              " 'improve': <gensim.models.keyedvectors.Vocab at 0x7f2da471ef50>,\n",
              " 'dental': <gensim.models.keyedvectors.Vocab at 0x7f2da471efd0>,\n",
              " 'dermatitis': <gensim.models.keyedvectors.Vocab at 0x7f2da4721090>,\n",
              " 'measures': <gensim.models.keyedvectors.Vocab at 0x7f2da4721110>,\n",
              " 'maximum': <gensim.models.keyedvectors.Vocab at 0x7f2da4721190>,\n",
              " 'name': <gensim.models.keyedvectors.Vocab at 0x7f2da4721210>,\n",
              " 'healing': <gensim.models.keyedvectors.Vocab at 0x7f2da4721290>,\n",
              " 'adequate': <gensim.models.keyedvectors.Vocab at 0x7f2da4721310>,\n",
              " 'family': <gensim.models.keyedvectors.Vocab at 0x7f2da4721390>,\n",
              " 'soap': <gensim.models.keyedvectors.Vocab at 0x7f2da4721410>,\n",
              " 'hypotension': <gensim.models.keyedvectors.Vocab at 0x7f2da4721490>,\n",
              " 'weekly': <gensim.models.keyedvectors.Vocab at 0x7f2da4721510>,\n",
              " 'benzylpenicillin': <gensim.models.keyedvectors.Vocab at 0x7f2da4721590>,\n",
              " 'necrotic': <gensim.models.keyedvectors.Vocab at 0x7f2da47215d0>,\n",
              " 'envenomation': <gensim.models.keyedvectors.Vocab at 0x7f2da4721650>,\n",
              " 'addition': <gensim.models.keyedvectors.Vocab at 0x7f2da47216d0>,\n",
              " 'lymphadenopathy': <gensim.models.keyedvectors.Vocab at 0x7f2da4721750>,\n",
              " 'detected': <gensim.models.keyedvectors.Vocab at 0x7f2da47217d0>,\n",
              " '2000': <gensim.models.keyedvectors.Vocab at 0x7f2da4721850>,\n",
              " 'important': <gensim.models.keyedvectors.Vocab at 0x7f2da47218d0>,\n",
              " 'clear': <gensim.models.keyedvectors.Vocab at 0x7f2da4721950>,\n",
              " 'scalp': <gensim.models.keyedvectors.Vocab at 0x7f2da47219d0>,\n",
              " 'spontaneously': <gensim.models.keyedvectors.Vocab at 0x7f2da4721a50>,\n",
              " 'superficial': <gensim.models.keyedvectors.Vocab at 0x7f2da4721ad0>,\n",
              " 'er': <gensim.models.keyedvectors.Vocab at 0x7f2da4721b50>,\n",
              " 'right': <gensim.models.keyedvectors.Vocab at 0x7f2da4721bd0>,\n",
              " 'filariasis': <gensim.models.keyedvectors.Vocab at 0x7f2da4721c50>,\n",
              " 'tabblister': <gensim.models.keyedvectors.Vocab at 0x7f2da4721cd0>,\n",
              " 'stridor': <gensim.models.keyedvectors.Vocab at 0x7f2da4721d50>,\n",
              " 'ay': <gensim.models.keyedvectors.Vocab at 0x7f2da4721dd0>,\n",
              " 'liver': <gensim.models.keyedvectors.Vocab at 0x7f2da4721e50>,\n",
              " 'night': <gensim.models.keyedvectors.Vocab at 0x7f2da4721ed0>,\n",
              " 'crying': <gensim.models.keyedvectors.Vocab at 0x7f2da4721f50>,\n",
              " 'continuous': <gensim.models.keyedvectors.Vocab at 0x7f2da4721fd0>,\n",
              " 'reconstituted': <gensim.models.keyedvectors.Vocab at 0x7f2da4723090>,\n",
              " 'insomnia': <gensim.models.keyedvectors.Vocab at 0x7f2da4723110>,\n",
              " 'microfilaraemia': <gensim.models.keyedvectors.Vocab at 0x7f2da4723190>,\n",
              " 'pruritus': <gensim.models.keyedvectors.Vocab at 0x7f2da4723210>,\n",
              " 'ill': <gensim.models.keyedvectors.Vocab at 0x7f2da4723290>,\n",
              " 'death': <gensim.models.keyedvectors.Vocab at 0x7f2da4723310>,\n",
              " 'against': <gensim.models.keyedvectors.Vocab at 0x7f2da4723390>,\n",
              " 'presents': <gensim.models.keyedvectors.Vocab at 0x7f2da4723410>,\n",
              " 'appropriate': <gensim.models.keyedvectors.Vocab at 0x7f2da4723490>,\n",
              " 'elderly': <gensim.models.keyedvectors.Vocab at 0x7f2da4723510>,\n",
              " '2017': <gensim.models.keyedvectors.Vocab at 0x7f2da4723590>,\n",
              " 'taking': <gensim.models.keyedvectors.Vocab at 0x7f2da4723610>,\n",
              " 'still': <gensim.models.keyedvectors.Vocab at 0x7f2da4723690>,\n",
              " 'become': <gensim.models.keyedvectors.Vocab at 0x7f2da4723710>,\n",
              " 'orbital': <gensim.models.keyedvectors.Vocab at 0x7f2da4723790>,\n",
              " 'ed': <gensim.models.keyedvectors.Vocab at 0x7f2da4723810>,\n",
              " 'sp': <gensim.models.keyedvectors.Vocab at 0x7f2da4723890>,\n",
              " 'ap': <gensim.models.keyedvectors.Vocab at 0x7f2da4723910>,\n",
              " 'drain': <gensim.models.keyedvectors.Vocab at 0x7f2da4723990>,\n",
              " 'tachypnoea': <gensim.models.keyedvectors.Vocab at 0x7f2da4723a10>,\n",
              " 'eating': <gensim.models.keyedvectors.Vocab at 0x7f2da4723a90>,\n",
              " 'cerebral': <gensim.models.keyedvectors.Vocab at 0x7f2da4723b10>,\n",
              " 'testing': <gensim.models.keyedvectors.Vocab at 0x7f2da4723b90>,\n",
              " 'limited': <gensim.models.keyedvectors.Vocab at 0x7f2da4723c10>,\n",
              " 'detection': <gensim.models.keyedvectors.Vocab at 0x7f2da4723c90>,\n",
              " 'mgd': <gensim.models.keyedvectors.Vocab at 0x7f2da4723d10>,\n",
              " 'extremities': <gensim.models.keyedvectors.Vocab at 0x7f2da4723d90>,\n",
              " 'progress': <gensim.models.keyedvectors.Vocab at 0x7f2da4723e10>,\n",
              " 'altered': <gensim.models.keyedvectors.Vocab at 0x7f2da4723e90>,\n",
              " 'weak': <gensim.models.keyedvectors.Vocab at 0x7f2da4723f10>,\n",
              " 'newborn': <gensim.models.keyedvectors.Vocab at 0x7f2da4723f90>,\n",
              " 'paralysis': <gensim.models.keyedvectors.Vocab at 0x7f2da4726050>,\n",
              " 'ocular': <gensim.models.keyedvectors.Vocab at 0x7f2da47260d0>,\n",
              " 'progressively': <gensim.models.keyedvectors.Vocab at 0x7f2da4726150>,\n",
              " 'intensity': <gensim.models.keyedvectors.Vocab at 0x7f2da47261d0>,\n",
              " 'commonly': <gensim.models.keyedvectors.Vocab at 0x7f2da4726250>,\n",
              " 'msf': <gensim.models.keyedvectors.Vocab at 0x7f2da47262d0>,\n",
              " 'arm': <gensim.models.keyedvectors.Vocab at 0x7f2da4726350>,\n",
              " 'subcutaneous': <gensim.models.keyedvectors.Vocab at 0x7f2da47263d0>,\n",
              " 'sugar': <gensim.models.keyedvectors.Vocab at 0x7f2da4726450>,\n",
              " 'opportunistic': <gensim.models.keyedvectors.Vocab at 0x7f2da47264d0>,\n",
              " 'jaundice': <gensim.models.keyedvectors.Vocab at 0x7f2da4726550>,\n",
              " 'starting': <gensim.models.keyedvectors.Vocab at 0x7f2da47265d0>,\n",
              " 'critically': <gensim.models.keyedvectors.Vocab at 0x7f2da4726650>,\n",
              " 'meningeal': <gensim.models.keyedvectors.Vocab at 0x7f2da47266d0>,\n",
              " 'therapeutic': <gensim.models.keyedvectors.Vocab at 0x7f2da4726750>,\n",
              " 'how': <gensim.models.keyedvectors.Vocab at 0x7f2da47267d0>,\n",
              " 'tramadol': <gensim.models.keyedvectors.Vocab at 0x7f2da4726850>,\n",
              " 'three': <gensim.models.keyedvectors.Vocab at 0x7f2da47268d0>,\n",
              " 'end': <gensim.models.keyedvectors.Vocab at 0x7f2da4726950>,\n",
              " 'field': <gensim.models.keyedvectors.Vocab at 0x7f2da47269d0>,\n",
              " 'lymphatic': <gensim.models.keyedvectors.Vocab at 0x7f2da4726a50>,\n",
              " 'burn': <gensim.models.keyedvectors.Vocab at 0x7f2da4726ad0>,\n",
              " 'routinely': <gensim.models.keyedvectors.Vocab at 0x7f2da4726b50>,\n",
              " 'surgery': <gensim.models.keyedvectors.Vocab at 0x7f2da4726bd0>,\n",
              " 'isolated': <gensim.models.keyedvectors.Vocab at 0x7f2da4726c50>,\n",
              " 'bacteria': <gensim.models.keyedvectors.Vocab at 0x7f2da4726cd0>,\n",
              " 'method': <gensim.models.keyedvectors.Vocab at 0x7f2da4726d50>,\n",
              " 'typhoid': <gensim.models.keyedvectors.Vocab at 0x7f2da4726dd0>,\n",
              " 'influenzae': <gensim.models.keyedvectors.Vocab at 0x7f2da4726e50>,\n",
              " 'immediate': <gensim.models.keyedvectors.Vocab at 0x7f2da4726ed0>,\n",
              " 'non': <gensim.models.keyedvectors.Vocab at 0x7f2da4726f50>,\n",
              " 'preferred': <gensim.models.keyedvectors.Vocab at 0x7f2da4726fd0>,\n",
              " 'problems': <gensim.models.keyedvectors.Vocab at 0x7f2da4728090>,\n",
              " 'admission': <gensim.models.keyedvectors.Vocab at 0x7f2da4728110>,\n",
              " 'hat': <gensim.models.keyedvectors.Vocab at 0x7f2da4728190>,\n",
              " 'provide': <gensim.models.keyedvectors.Vocab at 0x7f2da4728210>,\n",
              " 'notes': <gensim.models.keyedvectors.Vocab at 0x7f2da4728290>,\n",
              " 'sexually': <gensim.models.keyedvectors.Vocab at 0x7f2da4728310>,\n",
              " 'reactions': <gensim.models.keyedvectors.Vocab at 0x7f2da4728390>,\n",
              " 'trauma': <gensim.models.keyedvectors.Vocab at 0x7f2da4728410>,\n",
              " 'foods': <gensim.models.keyedvectors.Vocab at 0x7f2da4728490>,\n",
              " 'pallor': <gensim.models.keyedvectors.Vocab at 0x7f2da4728510>,\n",
              " 'abortion': <gensim.models.keyedvectors.Vocab at 0x7f2da4728590>,\n",
              " 'recovery': <gensim.models.keyedvectors.Vocab at 0x7f2da4728610>,\n",
              " 'cells': <gensim.models.keyedvectors.Vocab at 0x7f2da4728690>,\n",
              " 'outpatient': <gensim.models.keyedvectors.Vocab at 0x7f2da4728710>,\n",
              " 'topical': <gensim.models.keyedvectors.Vocab at 0x7f2da4728790>,\n",
              " 'greater': <gensim.models.keyedvectors.Vocab at 0x7f2da4728810>,\n",
              " 'conjunctiva': <gensim.models.keyedvectors.Vocab at 0x7f2da4728890>,\n",
              " 'rinse': <gensim.models.keyedvectors.Vocab at 0x7f2da4728910>,\n",
              " 'causing': <gensim.models.keyedvectors.Vocab at 0x7f2da4728990>,\n",
              " 'incision': <gensim.models.keyedvectors.Vocab at 0x7f2da4728a10>,\n",
              " 'minimum': <gensim.models.keyedvectors.Vocab at 0x7f2da4728a90>,\n",
              " 'reference': <gensim.models.keyedvectors.Vocab at 0x7f2da4728b10>,\n",
              " 'factors': <gensim.models.keyedvectors.Vocab at 0x7f2da4728b90>,\n",
              " 'further': <gensim.models.keyedvectors.Vocab at 0x7f2da4728c10>,\n",
              " 'precautions': <gensim.models.keyedvectors.Vocab at 0x7f2da4728c90>,\n",
              " 'treatments': <gensim.models.keyedvectors.Vocab at 0x7f2da4728d10>,\n",
              " 'uterus': <gensim.models.keyedvectors.Vocab at 0x7f2da4728d90>,\n",
              " 'withdrawal': <gensim.models.keyedvectors.Vocab at 0x7f2da4728e10>,\n",
              " 'culture': <gensim.models.keyedvectors.Vocab at 0x7f2da4728e90>,\n",
              " 'suppurative': <gensim.models.keyedvectors.Vocab at 0x7f2da4728f10>,\n",
              " 'protection': <gensim.models.keyedvectors.Vocab at 0x7f2da4728f90>,\n",
              " 'technique': <gensim.models.keyedvectors.Vocab at 0x7f2da472a050>,\n",
              " 'seen': <gensim.models.keyedvectors.Vocab at 0x7f2da472a0d0>,\n",
              " 'later': <gensim.models.keyedvectors.Vocab at 0x7f2da472a150>,\n",
              " 'handbook': <gensim.models.keyedvectors.Vocab at 0x7f2da472a1d0>,\n",
              " 'inhaled': <gensim.models.keyedvectors.Vocab at 0x7f2da472a250>,\n",
              " 'blindness': <gensim.models.keyedvectors.Vocab at 0x7f2da472a2d0>,\n",
              " 'tympanic': <gensim.models.keyedvectors.Vocab at 0x7f2da472a350>,\n",
              " '600': <gensim.models.keyedvectors.Vocab at 0x7f2da472a3d0>,\n",
              " 'rhinopharyngitis': <gensim.models.keyedvectors.Vocab at 0x7f2da472a450>,\n",
              " 'diffuse': <gensim.models.keyedvectors.Vocab at 0x7f2da472a490>,\n",
              " 'resolve': <gensim.models.keyedvectors.Vocab at 0x7f2da472a510>,\n",
              " '70': <gensim.models.keyedvectors.Vocab at 0x7f2da472a590>,\n",
              " 'make': <gensim.models.keyedvectors.Vocab at 0x7f2da472a610>,\n",
              " 'eggs': <gensim.models.keyedvectors.Vocab at 0x7f2da472a690>,\n",
              " 'index': <gensim.models.keyedvectors.Vocab at 0x7f2da472a710>,\n",
              " 'samples': <gensim.models.keyedvectors.Vocab at 0x7f2da472a790>,\n",
              " 'pelvic': <gensim.models.keyedvectors.Vocab at 0x7f2da472a810>,\n",
              " '36': <gensim.models.keyedvectors.Vocab at 0x7f2da472a890>,\n",
              " 'solvent': <gensim.models.keyedvectors.Vocab at 0x7f2da472a910>,\n",
              " 'dropsminute': <gensim.models.keyedvectors.Vocab at 0x7f2da472a990>,\n",
              " 'state': <gensim.models.keyedvectors.Vocab at 0x7f2da472aa10>,\n",
              " 'ter': <gensim.models.keyedvectors.Vocab at 0x7f2da472aa90>,\n",
              " 'stages': <gensim.models.keyedvectors.Vocab at 0x7f2da472ab10>,\n",
              " 'requires': <gensim.models.keyedvectors.Vocab at 0x7f2da472ab90>,\n",
              " '95': <gensim.models.keyedvectors.Vocab at 0x7f2da472ac10>,\n",
              " 'removal': <gensim.models.keyedvectors.Vocab at 0x7f2da472ac90>,\n",
              " 'miconazole': <gensim.models.keyedvectors.Vocab at 0x7f2da472ad10>,\n",
              " 'regions': <gensim.models.keyedvectors.Vocab at 0x7f2da472ad90>,\n",
              " 'fresh': <gensim.models.keyedvectors.Vocab at 0x7f2da472ae10>,\n",
              " 'rule': <gensim.models.keyedvectors.Vocab at 0x7f2da472ae90>,\n",
              " 'limb': <gensim.models.keyedvectors.Vocab at 0x7f2da472af10>,\n",
              " 'rifampicin': <gensim.models.keyedvectors.Vocab at 0x7f2da472af90>,\n",
              " 'warm': <gensim.models.keyedvectors.Vocab at 0x7f2da472c050>,\n",
              " 'down': <gensim.models.keyedvectors.Vocab at 0x7f2da472c0d0>,\n",
              " 'require': <gensim.models.keyedvectors.Vocab at 0x7f2da472c150>,\n",
              " 'visual': <gensim.models.keyedvectors.Vocab at 0x7f2da472c1d0>,\n",
              " '1500': <gensim.models.keyedvectors.Vocab at 0x7f2da472c250>,\n",
              " 'spread': <gensim.models.keyedvectors.Vocab at 0x7f2da472c2d0>,\n",
              " 'cleaning': <gensim.models.keyedvectors.Vocab at 0x7f2da472c350>,\n",
              " 'urgent': <gensim.models.keyedvectors.Vocab at 0x7f2da472c3d0>,\n",
              " 'tinidazole': <gensim.models.keyedvectors.Vocab at 0x7f2da472c450>,\n",
              " 'presenting': <gensim.models.keyedvectors.Vocab at 0x7f2da472c4d0>,\n",
              " 'external': <gensim.models.keyedvectors.Vocab at 0x7f2da472c550>,\n",
              " 'appearance': <gensim.models.keyedvectors.Vocab at 0x7f2da472c5d0>,\n",
              " 'drowsiness': <gensim.models.keyedvectors.Vocab at 0x7f2da472c650>,\n",
              " 'effect': <gensim.models.keyedvectors.Vocab at 0x7f2da472c6d0>,\n",
              " 'mlhour': <gensim.models.keyedvectors.Vocab at 0x7f2da472c750>,\n",
              " '02': <gensim.models.keyedvectors.Vocab at 0x7f2da472c7d0>,\n",
              " 'generalised': <gensim.models.keyedvectors.Vocab at 0x7f2da472c850>,\n",
              " 'new': <gensim.models.keyedvectors.Vocab at 0x7f2da472c8d0>,\n",
              " ...}"
            ]
          },
          "metadata": {},
          "execution_count": 20
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"Words associated with dizziness in our model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"dizziness\"], topn=5)))\n",
        "print(\"Words associated with paracetamol in our model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"paracetamol\"], topn=5)))\n",
        "print(\"Words associated with in our pain model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"pain\"], topn=5)))\n",
        "print(\"Words associated with in our gastroenteritis model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"gastroenteritis\"], topn=5)))\n",
        "print(\"Words associated with in our malaria model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"malaria\"], topn=5)))\n",
        "print(\"Words associated with in our sepsis model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"sepsis\"], topn=5)))\n",
        "print(\"Words associated with in our ciprofloxacin model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"ciprofloxacin\"], topn=5)))\n",
        "print(\"Words associated with in our adverse effect model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"adverse effect\"], topn=5)))\n",
        "print(\"Words associated with in our ulcer model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"ulcer\"], topn=5)))\n",
        "print(\"Words associated with in our insulin model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"insulin\"], topn=5)))\n",
        "print(\"Words associated with in our diabetes model{}\\n\" .format(fasttext_trained_model.wv.most_similar([\"diabetes\"], topn=5)))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RTuuw5cgTfj0",
        "outputId": "ebfd27fc-682c-45f5-a888-95a1c6ba1d69"
      },
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Words associated with dizziness in our model[('drowsiness', 0.9514392614364624), ('worsen', 0.9291642904281616), ('hoarse', 0.9247850179672241), ('disappears', 0.9113582968711853), ('exercise', 0.9102153778076172)]\n",
            "\n",
            "Words associated with paracetamol in our model[('ibuprofen', 0.9093706011772156), ('tramadol', 0.8766424655914307), ('nsaid', 0.87250816822052), ('analgesic', 0.8481435775756836), ('antipyretics', 0.840915322303772)]\n",
            "\n",
            "Words associated with in our pain model[('painful', 0.9087786674499512), ('paracetamol', 0.8303413391113281), ('abdomen', 0.8216066360473633), ('tenderness', 0.8064980506896973), ('anorexia', 0.8059426546096802)]\n",
            "\n",
            "Words associated with in our gastroenteritis model[('gas', 0.9424405097961426), ('dyspepsia', 0.9311060905456543), ('gastrooesophageal', 0.9091954231262207), ('gastrointestinal', 0.9085849523544312), ('epistaxis', 0.8995848894119263)]\n",
            "\n",
            "Words associated with in our malaria model[('serology', 0.8736555576324463), ('pathology', 0.8588211536407471), ('bloody', 0.8512060642242432), ('anaemia', 0.8492456674575806), ('pathogenic', 0.8484177589416504)]\n",
            "\n",
            "Words associated with in our sepsis model[('asepsis', 0.9082221984863281), ('bacterial', 0.8838688731193542), ('osteomyelitis', 0.8694989085197449), ('sinusitis', 0.8625711798667908), ('xerosis', 0.8469935655593872)]\n",
            "\n",
            "Words associated with in our ciprofloxacin model[('penicillinallergic', 0.9624035358428955), ('clindamycin', 0.9560341238975525), ('cefalexin', 0.9522636532783508), ('erythromycin', 0.9465685486793518), ('azithromycin', 0.9412065744400024)]\n",
            "\n",
            "Words associated with in our adverse effect model[('effects', 0.9706249237060547), ('adverse', 0.9694200754165649), ('effect', 0.9427394866943359), ('effectiveness', 0.9228652715682983), ('effective', 0.8882338404655457)]\n",
            "\n",
            "Words associated with in our ulcer model[('ulcers', 0.9499408602714539), ('warts', 0.8571841716766357), ('soft', 0.8487341403961182), ('superficial', 0.845543622970581), ('venereal', 0.8340305089950562)]\n",
            "\n",
            "Words associated with in our insulin model[('globulin', 0.9121487140655518), ('immunoglobulin', 0.8960134387016296), ('schedule', 0.8900580406188965), ('insufficient', 0.880337119102478), ('again', 0.8757722973823547)]\n",
            "\n",
            "Words associated with in our diabetes model[('metabolic', 0.9247081279754639), ('delirium', 0.8950856924057007), ('diagnoses', 0.8902453184127808), ('potentially', 0.8888338804244995), ('etc', 0.8799620270729065)]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/gensim/models/keyedvectors.py:2018: RuntimeWarning: invalid value encountered in true_divide\n",
            "  (self.vectors_ngrams / sqrt((self.vectors_ngrams ** 2).sum(-1))[..., newaxis]).astype(REAL)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Visualization of PCA https://stackabuse.com/python-for-nlp-working-with-facebook-fasttext-library/"
      ],
      "metadata": {
        "id": "EBKlT7FcVRvf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "semantically_similar_words = {words: [item[0] for item in fasttext_trained_model.wv.most_similar([words], topn=5)]\n",
        "                  for words in ['paracetamol','Nurse' ,'pain', 'adverse effect', 'dizziness',\"diabetes\"]}\n",
        "\n",
        "for k,v in semantically_similar_words.items():\n",
        "    print(k+\":\"+str(v))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wqrWUO08VTKy",
        "outputId": "71d73514-684f-419f-a5ef-604980994355"
      },
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "paracetamol:['ibuprofen', 'tramadol', 'nsaid', 'analgesic', 'antipyretics']\n",
            "Nurse:['course', 'benefit', 'importance', 'delay', 'support']\n",
            "pain:['painful', 'paracetamol', 'abdomen', 'tenderness', 'anorexia']\n",
            "adverse effect:['effects', 'adverse', 'effect', 'effectiveness', 'effective']\n",
            "dizziness:['drowsiness', 'worsen', 'hoarse', 'disappears', 'exercise']\n",
            "diabetes:['metabolic', 'delirium', 'diagnoses', 'potentially', 'etc']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "all_similar_words = sum([[k] + v for k, v in semantically_similar_words.items()], [])\n",
        "\n",
        "print(all_similar_words)\n",
        "print(type(all_similar_words))\n",
        "print(len(all_similar_words))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "o_kKOcIJVVmn",
        "outputId": "ffe4faf1-5df5-437a-c923-6e5f048cbca1"
      },
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['paracetamol', 'ibuprofen', 'tramadol', 'nsaid', 'analgesic', 'antipyretics', 'Nurse', 'course', 'benefit', 'importance', 'delay', 'support', 'pain', 'painful', 'paracetamol', 'abdomen', 'tenderness', 'anorexia', 'adverse effect', 'effects', 'adverse', 'effect', 'effectiveness', 'effective', 'dizziness', 'drowsiness', 'worsen', 'hoarse', 'disappears', 'exercise', 'diabetes', 'metabolic', 'delirium', 'diagnoses', 'potentially', 'etc']\n",
            "<class 'list'>\n",
            "36\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "word_vectors = fasttext_trained_model[all_similar_words]\n",
        "\n",
        "pca = PCA(2)\n",
        "\n",
        "p_comps = pca.fit_transform(word_vectors)\n",
        "word_names = all_similar_words\n",
        "\n",
        "plt.figure(figsize=(18, 10))\n",
        "plt.scatter(p_comps[:, 0], p_comps[:, 1], c='b')\n",
        "\n",
        "for word_names, x, y in zip(word_names, p_comps[:, 0], p_comps[:, 1]):\n",
        "    plt.annotate(word_names, xy=(x+0.06, y+0.03), xytext=(0, 0), textcoords='offset points')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 627
        },
        "id": "CdYk7GxbVaUW",
        "outputId": "fcb881bf-ec28-404e-a363-9395e2ca823c"
      },
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/ipykernel_launcher.py:1: DeprecationWarning: Call to deprecated `__getitem__` (Method will be removed in 4.0.0, use self.wv.__getitem__() instead).\n",
            "  \"\"\"Entry point for launching an IPython kernel.\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1296x720 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "ZNiJiPmgVcBi"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}